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Abstract 	  
How cellular ATP/ADP ratios and reactive oxygen species 
affect AMPK signalling 
Elizabeth Clare Hinchy 	  
Mitochondria are key generators of cellular ATP, vital to complex life. 
Historically, mitochondrial generation of reactive oxygen species (ROS) was 
considered to be an unregulated process, produced by dysfunctional 
mitochondria. More recently, mitochondrial ROS generated by complex I, 
particularly by the process of reverse electron transfer (RET), has emerged as a 
potentially biologically relevant signal that is tightly-regulated and dependent on 
mitochondrial status. ROS production by RET is reported to play a role in the 
innate immune response and lifespan extension in fruit flies. One way in which 
mitochondrial ROS may behave as a signal is by altering the activity of AMP-
activated protein kinase (AMPK), a key metabolic sensor and regulator of cell 
metabolism, which is activated when cellular ATP levels decrease during 
energy demand. Mitochondria can signal to AMPK via the magnitude of the 
cellular ATP/AMP and ATP/ADP ratios, which alter in response to mitochondrial 
function. Our view is mitochondria may also signal to AMPK via ROS. Important 
studies have helped to clarify the role of exogenous or cytosolic ROS in AMPK 
regulation. However, the effects of mitochondrial ROS on AMPK activity, 
specifically that generated by complex I, remain unclear and is the main focus 
of this thesis. I characterized the effects of exogenous H2O2 on cellular AMPK 
activity, ATP/ADP ratios and cellular redox state in a cell model. I then 
compounded this with selective mitochondria generated ROS by the 
mitochondria-targeted redox-cycler, MitoParaquat (MPQ). AMPK activity 
appeared to correlate with decreasing cell ATP/ADP ratios, indicating that both 
sources of ROS primarily activate AMPK in an AMP/ADP-dependent 
mechanism. In parallel, I developed an approach for analyzing the redox state 
of candidate proteins, an important step in determining if a protein is directly 
regulated by ROS. I also initiated development of a cell model for studying the 
downstream effects of mitochondrial ROS production by RET, by expressing 
alternative respiratory enzymes in a mammalian cell line.  
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ΔP    proton motive force 
ΔpH   pH gradient 
Δψ   membrane potential 
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CoA-SH  coenzyme A 
CPT 1   carnitine/palmitoyl-transferase 1 
Cyt c   cytochrome c 
DMEM  Dulbecco's Modified Eagle’s Medium 
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e-   electron 
Eh   reduction potential 
ETC   electron transport chain 
FADH2  flavin adenine dinucleotide (reduced) 
FBS   foetal bovine serum 
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FMN   flavin mononucleotide 
FOXO   forkhead box O 
FRT   flp recombination target 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GLUT   glucose transporter 
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Gpx   glutathione peroxidase 
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GR   glutathione reductase 
Grx   glutaredoxin 
GS   glycogen synthase 
GSH   glutathione (reduced) 
GST   glutathione-S-transferase 
GTP   guanosine-5’-triphosphate 
HEK   human embryonic kidney 
HIF-1α  hypoxia-inducible factor-1α 
HMGR  HMG-CoA reductase 
ICDH   isocitrate dehydrogenase 
IMM   inner mitochondrial membrane 
IMS   intermembrane space 
KEAP1  kelch-like ECH-associated protein 1 
LKB1   liver kinase B1 
MAVS   mitochondrial antiviral signalling 
MnSOD  manganese superoxide dismutase 
MPTP   mitochondrial permeability transition pore 
MQ H2O  Milli-Q H2O 
mTORC  mammalian target of rapamycin complex  
mtDNA  mitochondrial DNA 
NDI1   single subunit yeast NADH dehydrogenase 
NEM   N-ethylmaleimide 
NES   nuclear export sequence 
NO•   nitric oxide 
NRF   nuclear respiratory factor  
OCR   oxygen consumption rate 
OMM   outer mitochondrial membrane 
OXPHOS  oxidative phosphorylation 
PAGE   polyacrylamide gel electrophoresis 
PBS   phosphate buffered saline 
PCA   perchloric acid 
PEP   phosphoenolpyruvate 
PGC1a peroxisome proliferator-activated receptor gamma 
coactivator 1-α 
Pi   phosphate 
PFK   phosphofructokinase 
PK   pyruvate kinase 
PP   protein phosphatase 
PPi   pyrophosphate 
Pr   protein 
Prx   peroxiredoxin 
PTM   post-translational modification 
PVDF   polyvinylidene difluoride 
RE   restriction enzyme 
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RET   reverse electron transfer 
ROS   reactive oxygen species 
rpm   revolutions per minute  
RT   room temperature 
RX   electrophile 
SDH   succinate dehydrogenase 
SDS   sodium dodecyl sulfate 
SOD   superoxide dismutase 
SREBP1c  sterol regulatory element-binding protein 1c 
ST-loop  serine/threonine rich loop 
T2D   type 2 diabetes 
TA   tris-acetate buffer 
TBS   tris buffered saline 
TCEP   tris (2-carboxyethyl)phosphine hydrochloride 
Tet   tetracycline 
TH   transhydrogenase 
TIM   translocase of the inner membrane 
TOM   translocase of the outer membrane 
Trx   thioredoxin 
TrxR/TR  thioredoxin reductase 
Tx100   triton X-100  
Q   ubiquinone 
QH2   ubiquinol 
VDAC   voltage-dependent anion channel 
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1.1 General introduction 	  
Mitochondria are subcellular organelles found in nearly all eukaryotic cells and are 
the site of ATP production by oxidative phosphorylation (OXPHOS) as well as 
many other functions. Mitochondria are considered to have evolved over 2 billion 
years ago when an oxygen-utilising α-proteobacteria formed a symbiotic 
relationship with and was engulfed by an archaeal or early eukaryotic cell (Gray, 
2012, Lane and Martin, 2010). Over time, many of the genes of the engulfed, 
oxygen-utilising cell transferred into the genome of the host cell, resulting in a non-
autonomous, sub-cellular, oxygen-metabolising organelle providing an efficient 
source of energy to the host cell. The engulfed organelle maintained some of its 
own genes and so retained some ability, via gene expression, to adapt and 
maintain its proton motive force (ΔP), crucial for survival. It is thought the 
advantageous bioenergetics of the relationship between the endosymbiont and the 
host cell enabled the host cell genome to increase vastly in complexity and thus 
flexibility, and that this advancement facilitated the evolution of complex life as we 
know it (Lane and Martin, 2010). Thus, for the vast majority of eukaryotic cells, 
survival is dependent on fully functioning mitochondria that can respond rapidly to 
changes in the environment to provide a stable energy supply in response to 
changing energy demands.  
 
Mitochondria can acutely respond to short-term energy demand by increasing or 
decreasing ATP synthesis by OXPHOS, dependent on the magnitude of the ΔP 
(Brown, 1992, Murphy and Brand, 1987, Chance and Williams, 1956, Mitchell, 
1961). However, the level of mitochondrial ATP production in cells is also 
dependent on electron supply to the mitochondrial respiratory complexes (required 
for generation of the ΔP) and the quantity of mitochondria in the cell. Adapting 
these variables to the energy demand requires communication between the 
mitochondria and the other cell sub-compartments. For example, substrate 
availability for the citric acid cycle (CAC) and fatty acid oxidation, which occur in the 
mitochondria and provide electrons to the respiratory complexes, is initially 
Chapter 1 – Introduction  
	   3	  
controlled by hormone effects on storage tissues, e.g. adipose tissue or liver. Then 
once taken up by the target cell, the supply of the substrate to mitochondria is 
further controlled by many processes in the cytosol. Furthermore, mitochondrial 
biogenesis (i.e. the growth and division of pre-existing mitochondria) requires 
increased transcription of mitochondrial genes encoded by mitochondrial DNA and 
also those encoded by the nucleus (Lane and Martin, 2010). To facilitate 
communication between mitochondria and the rest of the cell, eukaryotic cells have 
evolved energy-sensing systems that can rewire whole cellular metabolism to 
maintain a stable energy supply with varying energy demand. AMP-activated 
protein kinase (AMPK) plays a key role in energy sensing and is considered to be 
one of the cell’s master regulators of energy metabolism (Carling et al., 2011, 
Hardie et al., 2012, Garcia and Shaw, 2017, Hardie et al., 2016). AMPK senses 
energy demand as an increase in cellular AMP and ADP relative to ATP and then 
adapts a broad range of cellular processes to promote ATP production and inhibit 
ATP expenditure.   AMPK can regulate mitochondrial ATP production in the short-
term by increasing electron supply for OXPHOS (e.g. by promoting fatty acid 
oxidation and cellular glucose uptake), and AMPK can also bring about long-term 
adaptation by affecting transcription factors controlling mitochondrial gene 
expression from both mitochondrial and nuclear genomes.  
 
Communication between mitochondria and AMPK is vital to sustain complex life. 
Mitochondria are key producers of cellular ATP so can signal to AMPK, which 
senses and responds to changes in the adenine nucleotide pool. Mitochondria are 
also important producers of reactive oxygen species (ROS), which, if generated in 
excess, can overwhelm the many antioxidant defences within the mitochondrial 
matrix and lead to oxidative damage and eventual cell death (Smith et al., 2012). 
However, there is a growing view that the production of ROS from mitochondria 
can act as a redox signal to the rest of the cell. ROS produced particularly by 
reverse electron transport (RET) is now suggested by us and several other labs to 
be a potential signal during periods of metabolic adaptation, as RET is tightly 
regulated and responsive to mitochondrial status (Chouchani et al., 2014, Mills et 
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al., 2016, Scialo et al., 2016, Chouchani et al., 2016). As ROS, such as H2O2, can 
modify protein function by oxidising cysteine thiols, ROS has been investigated as 
an alternative regulator of AMPK activity, perhaps signaling to AMPK to upregulate 
antioxidant defense systems in the cell (Zaha et al., 2016, Jager et al., 2007, Qi 
and Young, 2015, Kim et al., 2011, Greer et al., 2007). While several important 
papers have helped to clarify the role of exogenously-generated or cytosolic ROS 
in AMPK activity (Zmijewski et al., 2010, Auciello et al., 2014, Shao et al., 2014), 
less clear is the role of mitochondrial ROS (Emerling et al., 2009, Mungai et al., 
2011, Hart et al., 2015), particularly that produced by RET, in the regulation of 
AMPK.  
 
In the next sections I outline the general principles of mitochondrial energy 
metabolism, mitochondrial ROS production and redox signalling, before focusing 
on AMPK - a vital link between mitochondria and the rest of the cell.  
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1.2 Structure and functions of mitochondria 
1.2.1 Mitochondrial architecture and dynamics 
Evidence of the endosymbiotic theory is apparent in the architecture of the 
mitochondrion. Mitochondria are composed of two phospholipid bilayers: the outer 
and inner membranes, which have distinct components and functions. The outer 
mitochondrial membrane (OMM) shows similarity to other eukaryotic cell 
membranes, while the inner mitochondrial membrane (IMM) shares characteristics 
with a bacterial cell membrane, such as the presence of cardiolipin (Cavalier-
Smith, 2006). The OMM contacts the cytosol, is permeable to small molecules (< 5 
kDa) and contains channels and transport proteins (e.g. translocase of the outer 
membrane (TOM)) to facilitate the inward transfer of proteins synthesised outside 
the mitochondria (Mannella, 1992, Wiedemann and Pfanner, 2017). The OMM has 
many other functions, including roles in cell death, mitochondrial fission and fusion, 
mitophagy, inflammation and other cell processes (Friedman and Nunnari, 2014, 
Arnoult et al., 2011). The IMM is more protein-dense than the OMM, being the site 
of the respiratory complexes I – IV and the FOF1-ATP synthase, (which are mainly 
responsible for ATP production by oxidative phosphorylation) as well as carrier and 
transport proteins for metabolites or externally synthesised proteins (e.g. 
translocases of the inner membrane (TIMs)) (Wiedemann and Pfanner, 2017). The 
IMM is highly folded into sub-structures called cristae, which greatly increases the 
surface area of the IMM and maximises the area available for oxidative 
phosphorylation.  
 
The OMM and IMM are separated by an inter-membrane space (IMS), a distinct 
compartment in which lies Cytochrome c (Cyt c), which is involved in electron 
transfer along the respiratory chain but is also released from the IMS into the 
cytoplasm along with other proteins during apoptosis. The IMS also contains other 
proteins, e.g. Cu/Zn superoxide dismutase (SOD), which is responsible for 
detoxification of superoxide, a potentially harmful by-product of oxygen metabolism 
(Herrmann and Riemer, 2010). 
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The IMM surrounds a protein-rich mitochondrial matrix in which lie projections of 
some of the respiratory complexes and FOF1-ATP synthase, as well as many other 
enzymes responsible for metabolic and redox-reactions (e.g. enzymes of the CAC, 
amino acid and fatty acid metabolism and ROS metabolism). The matrix is also the 
site of many copies of the simplified mitochondrial genome (and gene transcription 
and translation machinery), which shares characteristics with the bacterial genome 
and is further evidence of the endosymbiotic origin of mitochondria (Lane and 
Martin, 2010). The mammalian mitochondrial DNA (MtDNA) is a circular, double-
stranded 16,569 bp genome (Gustafsson et al., 2016). It encodes 37 genes: 22 for 
transfer RNAs, 2 for ribosomal RNAs and 13 for polypeptides. All the 13 
polypeptides encoded by mammalian MtDNA are components of respiratory chain 
complexes (I, III and IV) or FOF1-ATP synthase, while complex II is entirely 
encoded by nuclear DNA. The other respiratory complexes and FOF1-ATP 
synthase also contain subunits encoded by the nuclear genome and all other 
proteins in the mitochondria are entirely encoded by the nuclear genome.  
 
Mitochondria used to be depicted in textbooks as individual rod-shaped structures 
(Figure 1.1). However, it is now clear that mitochondria are present as a dynamic, 
fused and elongated network (Lee and Yoon, 2016). Mitochondria exist in a 
constant state of fission and fusion that facilitates changes in morphology and 
serves as a quality control mechanism for identifying dysfunctional mitochondria 
and targeting them for degradation by mitophagy. The volume and network of 
mitochondria in the cell can also vary rapidly depending on the function and 
metabolic demands of the cell (Jornayvaz and Shulman, 2010, Zong et al., 2002, 
Civitarese et al., 2007).  
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Figure 1.1: Mitochondrial morphology. (A) Cartoon image of the mitochondrion (Lodish and 
Darnell, 1995). (B) Electron micrograph of the mitochondrion (Frey and Mannella, 2000).  
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1.2.2 Oxidative phosphorylation 	  
Oxidative phosphorylation (OXPHOS) is an energy-transducing process in which 
ATP is formed during aerobic respiration by the phosphorylation of ADP by FOF1-
ATP synthase. Energy for this ATP synthesis is provided by an electrochemical 
proton potential gradient known as the proton motive force (ΔP) that is generated 
across the IMM, first outlined by Mitchell in his chemiosmotic hypothesis (Mitchell, 
1961). The ΔP is composed of a pH gradient (ΔpH) (more basic in the matrix) and 
membrane potential (ΔΨ) (more negative in the matrix).  When glucose, amino 
acids and fatty acids are oxidised, electrons are first passed to the electron carriers 
NADH or FADH2 and then passed along respiratory complexes that make up the 
electron transport chain (ETC), each with increasing reduction potential (Eh) (i.e. 
more oxidising) (Sazanov, 2015). In addition, ubiquinone (Q) in the IMM and Cyt C 
in the IMS also act as electron carriers.  Finally, electrons are passed to the 
terminal electron acceptor, O2, which is reduced to H2O at complex IV. This 
electron transport is an exergonic process and provides energy to complexes I, III 
and IV to pump protons from the matrix to the IMS against the electrochemical 
proton gradient, establishing the ΔP. The ΔP then drives H+ back down the 
gradient into the matrix via FOF1-ATP synthase, which uses the energy to 
phosphorylate ADP to form ATP (Watt et al., 2010). In this way substrate oxidation 
is coupled to ATP synthesis by electron transfer to O2 and the ΔP.  
 
Aerobic respiration involves several interconnecting metabolic pathways that 
converge on electron donation to the ETC and thus enables ATP synthesis by 
OXPHOS. Glycolysis in an oxygen-independent process that occurs in the cytosol, 
during which 1 molecule of glucose is converted (in a series of 10 enzyme 
reactions) into 2 molecules of pyruvate, with a net production of 2 X ATP and 2 X 
NADH molecules (Rich and Marechal, 2010). The NADH, an electron carrier, is 
shuttled into the mitochondria by the malate-aspartate shuttle where it is oxidised 
by complex I and contributes electrons to the ETC. In addition, some NADH in the 
cytosol is passed to the Q pool by the action of glycerophosphate dehydrogenase. 
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The pyruvate (X 2) is transported into the mitochondrial matrix where it is 
decarboxylated by pyruvate dehydrogenase, forming 1 molecule of acetyl-coA and 
releasing 1 molecule of NADH (per pyruvate) to be oxidised by complex I. The 
acetyl-coA sourced from glycolysis contributes to a larger pool of acetyl-coA (from 
the oxidation of amino acids and fatty acids) and enters the CAC, an 8-enzyme 
series of reactions that results in amino acid precursors, co-factors (CoA-SH), 
electron carriers (NADH, FADH2 and QH2) and energy equivalents (GTP or ATP) 
as well as CO2 and H2O by-products (Akram, 2014). Each molecule of acetyl-coA 
is oxidised to 3 X NADH, 1 X FADH2, 1 X GTP (or ATP) and 2 X CO2. NADH and 
FADH2 products from the CAC cycle (and also directly from fatty acid oxidation) 
donate electrons to the ETC via complex I and II, respectively. The succinate 
intermediate of the CAC cycle also contributes electrons to the ETC via complex II. 
While glycolysis produces 2 X ATP (net) directly from 1 molecule of glucose, 
aerobic respiration theoretically produces a further ~ 36 X ATP from 1 molecule of 
glucose: 2 X ATP from the CAC and ~ 34 X ATP from OXPHOS (with electron 
donations from 10 X NADH2 and 4 X FADH2 (including 2 X FADH2 from 2 X 
succinate oxidation). Thus, aerobic respiration of glucose is more energy efficient 
than glycolysis alone (Rich and Marechal, 2010). Fatty acids (FAs) are energy-rich 
compounds and their oxidation produces about twice the energy compared with 
carbohydrates (39 KJ g–1 for palmitate compared with 15 KJ g–1 for glucose. 
During fatty acid oxidation, every 2-carbon unit released from acyl-CoA generates 
1 X FADH2 and 1 X NADH. Every acetyl-CoA molecule then yields 3 X NADH, 1 X 
FADH2 and  1 X GTP in the CAC cycle, resulting in a total yield of ~ 130 X ATP for 
the degradation of the 16-carbon FA palmitate (Rohrig and Schulze, 2016). Thus, 
fatty acid oxidation is more energy efficient than glucose oxidation. Below I outline 
in greater detail the individual contributions of the respiratory complexes and FOF1-
ATP synthase to the OXPHOS process.  
NADH is oxidised at the flavin mononucleotide (FMN) site of complex I (NADH:Q 
oxidoreductase), releasing 2 electrons, which are transferred along a series of Fe-
S clusters (with increasing reduction potential (Eh)) in complex I, and then onto Q to 
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form QH2 (Sazanov, 2015, Hirst and Roessler, 2016) Electron transfer is coupled to 
H+ pumping by complex I across the IMM, contributing to the ΔP. Electrons also 
enter the ETC via complex II (succinate:Q oxidoreductase). Succinate is oxidised 
to fumarate by the succinate dehydrogenase activity of complex II. This results in 
reduction of the complex II co-factor FAD to FADH2. FADH2 is then re-oxidised to 
FAD as electrons are transferred from FADH2 along a series of Fe-S clusters to Q, 
which becomes reduced (QH2). FADH2 is also produced as a by-product of acetyl-
coA oxidation in the CAC cycle and also during fatty acid oxidation, and can 
directly contribute electrons to Q via complex II. No protons are pumped during this 
electron transfer through complex II. Electrons from QH2 are then donated to 
complex III (cytochrome bc1 complex) at the Q0 site. In a reaction known as the Q 
cycle, 1 electron from QH2 is transferred onto an Fe-S cluster on complex III and 
the second electron to a b-haem group. 2 X H+s are transferred into the IMS. The 
Fe-S domain then rotates and the electron is transferred to Cyt c in the IMS. The 
other electron is transferred to a second b-haem group of a higher Eh on complex 
III. Q then binds at a second Q-binding site, Qi and becomes re-reduced to QH2 (by 
the haem electrons) in a 2-step process that requires 2 cycles of QH2 oxidation at 
Q0. Thus, 1 X QH2 molecule is oxidised and 2 X Cyt c molecules are reduced 
coupled to the pumping of 4 X H+ and 2 X charges across the IMM. Cyt c then 
transfers electrons to complex IV (cytochrome c oxidase). O2 is reduced to 2 X H2O 
molecules using 4 X e- from Cyt c and 4 X H+ from the matrix. During this process, 
a further 4 X charges and 2 X H+ are transported from the matrix to the IMS. In 
summary, during respiration, charges and protons are transferred from the 
mitochondrial matrix to the IMS, generating the ΔP: 10 from NADH, 6 from 
succinate (Figure 1.2). 
 
FOF1-ATP synthase then uses the H+ gradient established across the IMM by the 
ETC to synthesise ATP from ADP and Pi (Figure 1.2). ADP and Pi bind the β 
subunit of FOF1-ATP synthase, which can cycle between different conformational 
states that either favour the binding of ADP and Pi, or the phosphorylation of ADP 
and release of ATP (Watt et al., 2010). As H+s re-enter the matrix through FOF1-
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ATP synthase, the 8-subunit c-ring rotates. The c-ring is attached to an asymmetric 
stalk that also rotates and causes conformational change in the β subunit that 
favours phosphorylation of ADP to form ATP. ATP is then released and exported to 
the cytosol to for energy requiring processes. The Pi for phosphorylation is 
imported into the matrix via the phosphate carrier and ATP is exported from the 
matrix in exchange for ADP by the adenine nucleotide translocase (ANT).  
 
 
Figure 1.2:  The electron transport chain and process of oxidative phosphorylation in 
mammalian mitochondria. Electrons are donated to complex I or complex II of the ETC from 
electron carriers NADH or FADH2, respectively. Electrons are passed along the respiratory 
complexes, aided by ubiquinone (Q) in the IMM and cytochrome c (Cyt C) in the IMS, each with 
increasing reduction potential (Eh) (i.e. more oxidising). Finally, electrons are passed to the terminal 
electron acceptor, O2, which is reduced to H2O at complex IV. The electron transport is an 
exergonic process and provides energy to complexes I, III and IV to pump protons and charges 
from the matrix to the IMS against the electrochemical proton gradient, establishing the ΔP. The ΔP 
then drives H+ back down the gradient into the matrix via FOF1-ATP synthase, which uses the 
energy to phosphorylate ADP to form ATP. 2.7 protons are required by the F-ATPase to make each 
ATP molecule (Watt et al., 2010). 	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1.2.3 Other functions of mitochondria 
Mitochondria are involved in many processes other than carbohydrate, fatty acid 
and amino acid metabolism and ATP synthesis (Duchen and Szabadkai, 2010, 
Murphy, 2009, Wallace et al., 2010, Smith et al., 2011, Smith et al., 2012). Below I 
outline other functions of mitochondria that are closely integrated into the workings 
of the cell. 
 
Mitochondria are involved in many other biosynthetic processes, such as the 
assembly of iron-sulfur (Fe–S) clusters and haem biosynthesis (Paul and Lill, 2015, 
Ye and Rouault, 2010). Fe–S clusters are small, highly conserved, inorganic 
protein co-factors present in the mitochondria, cytosol and nucleus. They enable a 
range of functions in proteins, including electron transfer in redox reactions (e.g. in 
respiratory complexes) and catalytic activity in chemical reactions (e.g. aconitase 
and SDH in the CAC cycle). Fe–S proteins play a role in ATP synthesis, amino acid 
and co-factor biosynthesis, tRNA modification, and are necessary for genome 
stability.	   All Fe–S protein biogenesis is initiated by the mitochondrial iron-sulfur 
cluster (ISC) assembly machinery (Paul and Lill, 2015). Iron-containing heme 
groups are also synthesised in (and exported from) mitochondria and are found in 
cytochromes, haemoglobin and myoglobin. Thus, heme groups play a vital role in 
ATP production, oxygen transport and muscle function (Ye and Rouault, 2010).  
 
Mitochondria play a role in calcium storage and signalling. Mitochondria are 
intimately associated with the endoplasmic reticulum (Murley and Nunnari, 2016) 
which assists in determining the fission of the organelle, and also the movement of 
calcium from the endoplasmic reticulum to the cytosol and from there into the 
mitochondrial matrix as a way of modulating mitochondrial ATP production 
(Mammucari et al., 2011, Brand and Murphy, 1987). 
 
Mitochondria exert control over cell death and survival. Mitochondria play a central 
role in programmed cell death by apoptosis. The mitochondrial pathway of 
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apoptosis involves the release of factors such as Cyt c from the IMS as a critical 
step in committing the cell to activating the apoptotic cell death programme (Tait 
and Green, 2010). As well as programmed cell death, the central role of 
mitochondria in ATP production means that damage to the organelle, such as loss 
of ΔP (depolarization), will lead to necrotic cell death, due to the lack of ATP 
preventing the cell from sustaining ion gradients.  During necrotic cell death the 
induction of the mitochondrial permeability transition pore (MPTP) is a major 
player, committing the cell to a rapid death (Halestrap, 2005, Rasola and Bernardi, 
2011). Mitochondria have quality control mechanisms in place to maintain a 
polarized ΔP and thus sufficient cell ATP/ADP ratios to avoid necrotic cell death. 
As previously described, mitochondria have a dynamic morphology brought about 
by continuous processes of fission and fusion of the mitochondria (Lee and Yoon, 
2016). Polarized mitochondria can undergo fusion, creating continuous, reticulated 
networks. This is thought to maximize OXPHOS potential and potentiation of 
functional mtDNA to a greater network of mitochondria.  Fusion processes are ΔP-
dependent and in depolarized mitochondria (insufficient ΔP to make ATP or enable 
active transport), fusion is inhibited. With fusion inhibited, increased mitochondrial 
fission occurs, which isolates dysfunctional mitochondria from the greater network. 
Fission results in the division of a mitochondrion into daughter organelles. There is 
often great heterogeneity in the daughter organelles, due to differential segregation 
of multiple copies of mtDNA during fission, some which may have developed 
mutations in genes that contribute to mitochondrial dysfunction. Those daughter 
organelles with depolarized ΔP can be targeted for destruction by mitophagy, 
whereas daughter organelles with polarized mitochondria can recommence normal 
fusion and fission cycling and re-join the population of functional mitochondria in 
the cell.  
 
1.3 Mitochondrial ROS production  
Our understanding of how mitochondria impact on the rest of the cell has expanded 
considerably over the past few years. In addition to their metabolic roles, 
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mitochondria are now emerging as hubs for a range of signalling processes. One 
way in which this may occur is through the generation of ROS that emanates from 
the organelle as a redox signal. Mitochondria are a major source of ROS within the 
cell (Murphy, 2009, Arnoult et al., 2011, Tormos et al., 2011). These ROS come 
from the respiratory chain, primarily in the form of superoxide that then goes on to 
form hydrogen peroxide (H2O2) (Murphy, 2009). These ROS can overwhelm the 
multitude of antioxidant defences within the mitochondrial matrix and thereby cause 
extensive oxidative damage to mitochondria that contributes to a wide range of 
pathologies (Smith et al., 2012). More interesting is the growing view that the 
production of ROS from mitochondria can act as a redox signal to the rest of the 
cell, suggesting that the production of ROS by mitochondria may be a way in which 
the mitochondria "talks" to the rest of the cell, coordinating the function of the 
mitochondria with that of the cell (Murphy, 2009, Arnoult et al., 2011, Tormos and 
Chandel, 2010, Holmstrom and Finkel, 2014). Below I outline the main sources of 
ROS production in mitochondria, the mechanisms of production and also 
degradation. Later, I outline the involvement of mitochondrial ROS in cellular redox 
signalling.  
1.3.1 Sources of mitochondrial ROS production 
The superoxide anion (O2.-) (produced from the one electron reduction of O2) is the 
proximal ROS liberated by the respiratory chain, mainly from the reduced FMN of 
complex I (Pryde and Hirst, 2011, Murphy, 2009, Chouchani et al., 2016) (releasing 
superoxide towards the matrix) and from the Q cycle of complex III (releasing 
superoxide into both the matrix and the IMS). The production of superoxide by 
complex III occurs in response to inhibition at the internal Q-binding site by 
inhibitors such as antimycin A, which is unlikely to be physiological (Murphy, 2009). 
However, there are a number of reports that complex III may be a source of 
superoxide as a signal during hypoxia (Bell and Chandel, 2007, Chandel et al., 
1998), but the mechanistic details of how this occurs are obscure. Other enzymes 
can also interact with the Q pool and lead to superoxide production by complex I, 
e.g. electron transfer flavoprotein (ETC), which is reduced during fatty acid 
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oxidation and transfers electrons to the Q pool (Murphy, 2009).  
Superoxide can be also generated within the matrix from other sources, e.g. 
dehydrogenases and the adrenodoxin reductase/adrenodoxin/cytochrome P450 
system that receives electrons from the NADPH pool (Murphy, 2009). However, in 
many situations ROS production from these complexes is in response to damage 
leading to a back up of electrons that spill out as superoxide (Murphy, 2009). As a 
potential redox signal, it is likely that the ROS generation would be more regulated 
(Holmstrom and Finkel, 2014). Superoxide generation from complex I can be 
regulated (Murphy, 2009), particularly through the process of RET and may be the 
best understood potential source of redox signalling from mitochondria (Chouchani 
et al., 2016).  
There are other locations within mitochondria, such as the IMS that can also 
produce superoxide, which may be important in redox signalling, e.g. α-
glycerophosphate dehydrogenase at the outer surface of the IMM can produce 
superoxide (Murphy, 2009). However, redox signals generated from the matrix may 
most directly enable the organelle to feed back to the rest of the cell about its 
metabolic status (Chouchani et al., 2016).  
1.3.2 Superoxide production by complex I  
Complex I is one of the main sites of superoxide production in mitochondria, which 
can be produced during either forward or reverse electron transfer (Murphy, 2009) 
(Figure 1.3). Superoxide production during forward electron transfer can occur 
when there is a highly reduced matrix NADH/NAD+ ratio. NADH donates electrons 
to the ETC via complex I. An FMN co-factor on complex I accepts the electrons 
and passes them through a chain of seven Fe-S centres to the Q-binding site. 
When the FMN is fully reduced (dependent on a reduced NADH/NAD+ pool), 
superoxide is generated from the reaction between O2 and reduced FMN. Inhibition 
of complex I with rotenone increases superoxide production by this mechanism, as 
rotenone binds the Q-binding site on complex I and leads to a back up of electrons 
onto FMN, causing it to become hyper-reduced. Physiologically, superoxide could 
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be produced by this mechanism due to damage to or mutation of the respiratory 
chain, ischaemia, loss of Cyt c or low ATP demand, which would increase the 
matrix NADH/NAD+ ratio.  
 
Superoxide can also be generated from complex I by reverse electron transfer 
(RET) (Murphy, 2009, Chouchani et al., 2016). RET requires a highly reduced Q 
pool and a high ΔP, which forces electrons back from the Q pool onto complex I, 
reducing the FMN. The reduced FMN can then either donate electrons to NAD+ to 
form NADH or to O2 to form superoxide.  The Q pool can be reduced by electron 
donation by succinate, α-glycerophosphate, fatty acid oxidation or by co-
expressing the alternative respiratory enzyme, NDI1 (a single subunit NADH 
dehydrogenase) (Murphy, 2009, Chouchani et al., 2016, Mills et al., 2016, Scialo et 
al., 2016). A high ΔP can be achieved if the Q pool is reduced enough to donate 
electrons to complex III and IV as well as to the FMN of complex I, and is 
enhanced by low rates of ATP synthesis. Superoxide production by RET is 
inhibited by rotenone, indicating that electrons enter into complex I through the Q-
binding site(s) (Murphy, 2009, Chouchani et al., 2016).  
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A 
 
B 
 
Figure 1.3. Forward and reverse electron transport by complex I. (A) In forward electron 
transfer, NADH donates two electrons to complex I, which transfer along a series of Fe-S clusters to 
reduce Q to QH2. When the NADH/NAD+ ratio is high, or electron transfer to the rest of the ETC is 
inhibited, electrons can back up and hyper-reduce the FMN, leading to superoxide generation by 
reduction of O2. The redox energy difference from the transfer of electrons between NADH/NAD+ 
and Q/QH2 (ΔEh) drives the pumping of four protons across the IMM to maintain the protonmotive 
force (ΔP) that drives ATP synthesis. For forward electron transfer, the ΔEh needs to be greater 
than the energy required to pump the protons against the ΔP: 2ΔEh > 4ΔP. (B) The direction of 
electron transport can be reversed if the ΔP is high and/or the Q pool is very reduced so that 4ΔP > 
2ΔEh. Then, electrons can flow backward through complex I and onto the FMN from where they can 
reduce NAD+ to NADH or O2 to superoxide. The red arrow in complex I indicates the direction of 
electron transfer. Cyt c, cytochrome c; SDH, succinate dehydrogenase. (Chouchani et al., 2016). 
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1.3.3 Mitochondrial superoxide and hydrogen peroxide 
metabolism 
Superoxide produced in the matrix is itself not highly reactive and cannot permeate 
membranes. However, nitric oxide (NO•) can diffuse into mitochondria and react 
with superoxide to generate peroxynitrite (ONOO−), which is highly reactive and 
damaging. Superoxide can also directly inactivate some Fe-S centers in proteins, 
such as aconitase (Murphy, 2012). Superoxide is generally dismutated rapidly to 
H2O2, spontaneously or enzymatically by the high concentration of MnSOD 
(Murphy, 2009). H2O2 in the presence of ferrous or cuprous ions can generate the 
very reactive hydroxyl radical (OH•) (Murphy, 2012). The hydroxyl radical and 
peroxynitrite can cause oxidative damage to mitochondrial proteins, DNA and 
lipids. The IMM contains a high proportion of unsaturated fatty acids, which are 
susceptible to lipid peroxidation. This can make the IMM more permeable to 
protons, which can uncouple OXPHOS and disrupt the activity of membrane 
proteins. Lipid peroxidation can also generate reactive species, such as 4-
hydroxynonenal, which can also damage mitochondrial proteins and DNA. To 
prevent oxidative damage to DNA, lipids and protein, H2O2 can be scavenged by a 
number of matrix non-protein and protein thiols with specialised functions, including 
the peroxiredoxin/thioredoxin and mitochondrial glutathione systems (Figure 1.4) 
(Murphy, 2012, Cox et al., 2009), explained in greater detail below.  
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Figure 1.4 A simplified schematic of mitochondrial superoxide and H2O2 metabolism. 
Superoxide produced to the matrix is dismutated to H2O2 by manganese superoxide dismutase 
(MnSOD). H2O2 is metabolised to H2O by the action of peroxidases, including peroxiredoxin (Prx) 
and glutathione peroxidase (Gpx). Prx is recharged by thioredoxin (Trx). Levels of reduced Trx are 
controlled by thioredoxin reductase (TrxR), which in turn is regulated by the NADPH/NADP+ pool 
and its determinants. Gpx uses glutathione (GSH) to reduce oxidised Prx, which is recycled by 
glutathione reductase (GR). H2O2 is also membrane permeable (Vissers et al., 2018). 
 
1.3.3.1 The peroxiredoxin/thioredoxin system 
Peroxiredoxins (Prx) are a family of thiol peroxidases that help to maintain the 
redox balance of the cell by reducing H2O2 to H2O and are re-charged by 
thioredoxin (Trx) (Chae et al., 1994, Cox et al., 2009, Murphy, 2012). Different Prx 
isoforms are located in different subcellular compartments: Prx 1, 2, and 6 in the 
cytosol; Prx 3 and 5 in the mitochondrial matrix (Prx 5 is also present in 
peroxisomes); Prx 4 is secreted. Active Prx monomers form reversible, inter-protein 
disulfide bridges when oxidised, which results in Prx homodimerisation and 
temporary inactivation. Typically, two cysteine Prxs contain an active thiol that 
reacts rapidly with H2O2 to generate a sulfenic acid (-SOH). This sulfenic acid then 
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reacts with an adjacent thiol on another Prx to form a dimer with an inter-protein 
disulfide. The modification is readily reversible by interaction with Trx, which 
reduces the disulfide to a dithiol form (-SH). Extended oxidation can cause thiol 
modifications that do not lead to Prx dimerisation: sulfinic acid (–SO2H), which is 
slowly reversible by sulfiredoxin, and sulfonic acid (–SO3H)), which is not 
reversible. Trxs (Trx 2 in the mitochondrial matrix, Trx 1 in the cytosol) reduce 
disulfide bonds on proteins, including those in Prxs. An active thiol in Trx acts as a 
nucleophile, attacking the target disulfide bond and forming an intermediate 
disulfide bridge with the substrate protein. This is then reduced by the attack of the 
second Trx thiol, resulting in a dithiol on the substrate protein. Trx is then recycled 
from a disulfide form to a dithiol form by thioredoxin reductase (TR), which uses 
NADPH as a reducing modality (Murphy, 2012) (Figure 1.5).   
 
1.3.3.2 The mitochondrial glutathione system 
Glutathione (GSH) is synthesized in the cytosol and then transported into 
mitochondria. Inside mitochondria, the GSH pool is primarily (95%–99%) reduced, 
with a small amount of oxidised glutathione disulfide (GSSG). The GSH pool is 
maintained and reduced by glutathione reductase (GR), which uses NADPH as a 
reducing power (Figure 1.6). GSH degrades peroxides using glutathione 
peroxidase (Gpx), of which two forms exist in the matrix: soluble Gpx 1 mainly 
degrades H2O2 and Gpx 4 is adsorbed to the matrix surface of the IMM, where it 
degrades phospholipid hydroperoxides to alcohols, protecting against lipid 
peroxidation. Glutathione-S-transferases (GSTs) use GSH to detoxify electrophiles 
including xenobiotics and products of oxidative damage, such as epoxides and 
alkyl hydroperoxides. Glutaredoxins (Grx) catalyze the deglutathionylation of 
proteins, which can occur when protein thiols are oxidised and react with GSH.  
Grx 2 exists in mitochondria and Grx 1 in the cytosol (Murphy, 2012).  
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Figure 1.5 The peroxiredoxin/thioredoxin system. Peroxiredoxins (Prxs) reduce H2O2 to H2O, 
forming sulfenic acids (-SOH), which lead to the formation of inter-molecular homodimers linked by 
disulfide bridges. Hyperoxidation can lead to sulfinic acid (-SO2H) or sulfonic acid (-SO3H) 
modifications, which are slowly reversible (by sulfiredoxin (SRX)), or irreversible, respectively.  
Hyperoxidised Prxs are inactive and indicative of oxidative damage.  Prx dimers are recycled by 
thioredoxins (Trx), which in turn are regulated by thioredoxin reductase (TR) and NADPH.  
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Figure 1.6 The mitochondrial glutathione system. (A) Glutathione peroxidase (Gpx) metabolises 
H2O2 to H2O, using reduced glutathione (GSH). Oxidised glutathione (GSSG) is recycled back to 
GSH by glutathione reductase (GR). (B) GSH exchanges with protein (Pr) thiols, catalysed by 
glutaredoxin (Grx). (C) GSH reacts with electrophiles (RX), catalyzed by glutathione-S-transferase 
(GST).  
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1.4 Mitochondrial Redox Signalling 
Mitochondrial redox signalling may be an essential facet of the health and fate of 
the cell. Situations in which mitochondrial ROS signalling seems to be particularly 
important are in the activation of cells such as macrophages during inflammation 
(Mills et al., 2016, Green et al., 2011) and also when mitochondria act as signalling 
hubs in the response to viral infections (Buskiewicz et al., 2016). However, there 
are considerable uncertainties about the mechanisms and significance of 
mitochondrial redox signalling, some key points of which I discuss below.  
1.4.1 How mitochondrial ROS can behave as a redox signal 
For mitochondrial H2O2 to be a redox signal it is important that it be responsive to 
mitochondrial status (Holmstrom and Finkel, 2014, Finkel, 2012, Janssen-
Heininger et al., 2008). One way in which this can occur is in the alteration to the 
generation of superoxide at complex I in response to changes in the ΔP and the 
redox state of the Q pool (Murphy, 2009, Chouchani et al., 2016). RET is 
exquisitely sensitive to these factors, both of which are central components of 
mitochondrial function and which vary in direct response to mitochondrial activity 
and do not require artificial intervention. For example, ROS production by RET 
might be enhanced when mitochondria are inactive and over-supplied with 
electrons and minimised when mitochondria are active (Murphy, 2009, Chouchani 
et al., 2016). Therefore, the current view of our and other labs is that RET at 
complex I may be a major physiological source of superoxide within the 
mitochondrial matrix.  
In addition to modulation by the factors that affect ΔP and Q redox state, RET 
could be affected by other changes to complex I, for example by post translational 
modifications (PTMs) such as phosphorylation (Covian and Balaban, 2012). This is 
only a theoretical possibility at this stage. The rate of RET by complex I is also 
affected by the proportion of complex I that is in the active or the deactive state. 
For example, during ischaemia, complex I adopts the deactive state (Gorenkova et 
al., 2013, Drose et al., 2016) but whether such transitions are used to regulate RET 
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is not known. Finally, complex I can exist as an isolated complex, or as a 
supercomplex with other respiratory chain complexes (Moreno-Loshuertos and 
Enriquez, 2016). The physiological role, if any, of supercomplex formation is not 
clear at present (Blaza et al., 2014). However, as changes in the extent of complex 
I incorporation into supercomplexes correlates with changes in mitochondrial ROS 
formation it may be that these processes are interrelated (Lopez-Fabuel et al., 
2016, Moreno-Loshuertos and Enriquez, 2016). Therefore, RET at complex I is 
determined by factors that alter the ΔP and the Q redox state, with the possibility 
that PTMs, conformation changes or incorporation into supercomplexes may also 
affect RET. 
 
The process of RET has been found to be biologically relevant in several 
scenarios. Pathologically, after blood flow is restored to ischaemic tissue (e.g. after 
heart attacks and strokes) superoxide production by RET has been found to 
contribute to tissue damage known as ischaemia reperfusion injury. The rapid 
oxidation of the succinate that accumulates during ischaemia favours reduction of 
the Q pool. The reduced Q pool favours proton pumping by complexes III and IV, 
helping maintain a large ΔP upon reperfusion and the degradation of adenine 
nucleotides during ischaemia limits ADP availability upon reperfusion that would 
otherwise diminish ΔP by stimulating mitochondrial ATP synthesis (Chouchani et 
al., 2016). The result is a burst of superoxide by RET through complex I when 
oxygenated blood flow is restored. RET has also been reported to contribute to the 
metabolic adaptation of immune cells during inflammation (Mills et al., 2016), the 
immune response to viral infection (Buskiewicz et al., 2016) and lifespan extension 
in fruit flies (Scialo et al., 2016).  
1.4.2 Regulation of mitochondrial ROS 
Once formed within the mitochondrial matrix, the H2O2 level can then be regulated 
by its degradation or rate of release. Superoxide produced in the matrix is 
dismutated to membrane-permeable H2O2 by the high concentration of MnSOD 
(Murphy, 2009). Although superoxide is a negatively charged molecule that will not 
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readily diffuse through membranes, it is possible that some superoxide that 
escapes MnSOD may also act independently as a signalling molecule within the 
matrix, by acting on the Fe-S centre in aconitase, for example (Gardner, 2002, 
Hurd et al., 2012). There are effects of MnSOD level of expression on cell fate that 
are poorly understood (Hart et al., 2015), perhaps suggesting that the balance 
between superoxide and H2O2 level may modulate signalling pathways.  
Most studies indicate that the Prx 3 is the major peroxidase in mitochondria (Cox et 
al., 2009, Winterbourn and Hampton, 2008). Thus, regulating the activity of Prx 3 
may be a key way of modulating H2O2 levels within mitochondria. The activity of 
Prx is modulated by the ratio of its active to reversibly inactive form, due to disulfide 
bond formation (Cox et al., 2009, Cox et al., 2008). Extended oxidation can also 
cause less readily reversible thiol modifications that do not lead to dimerisation. Prx 
can be oxidised to a sulfinic acid form that can be slowly reactivated by sulfiredoxin 
(Noh et al., 2009) or a sulfonic acid form that is not reversed. These alterations 
may alter the flux of H2O2 from the mitochondria. There is also the possibility that 
Prx activity may be altered by PTMs, or by the formation of higher order structures 
of Prx (Barranco-Medina et al., 2009), but the details of these are not clear yet. 
Finally, the activity of Prx and other peroxidases in mitochondria is determined by 
the redox state of the mitochondrial nicotinamide adenine dinucleotide phosphate 
(NADPH) pool. The NADPH pool itself can respond to a number of factors: the 
activity of ΔP-dependent transhydrogenase (TH), isocitrate dehydrogenase (ICDH) 
and malic enzyme which maintain NADPH, and the redox state of the GSH and Trx 
systems which are reduced by NAPDH (Murphy, 2012, Murphy, 2015, Nickel et al., 
2015).  Thus, several factors potentially regulate the steady state level of H2O2 in 
mitochondria. 
1.4.3 Transfer of mitochondrial redox signals from mitochondria 
to the cytosol 
The concept of mitochondrial redox signalling as a mode of communication to other 
cell compartments is based on the assumption that H2O2 produced in the 
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mitochondria can also diffuse to the cytosol. In the cytosol, H2O2 could alter 
enzyme activity either directly through reversible oxidation of cysteine thiols, or 
indirectly by facilitating redox-relay interactions with other redox-sensitive proteins 
(Prxs, Trxs etc.) (Herrmann and Riemer, 2012, Sobotta et al., 2015). For H2O2 itself 
to act as a redox signal it has to leave the mitochondria and enter the cytosol. It is 
known that isolated mitochondria can produce a flux of H2O2 from both the IMS and 
the matrix (Murphy, 2009) and this indicates that H2O2 itself can leave the 
mitochondrion and pass to the cytosol. However, the evidence for this occurring in 
whole cells is less clear. The passage of H2O2 through the plasma membrane, for 
example in response to its generation outside the cell by NADPH oxidases, is 
mediated by aquaporins (Bienert et al., 2007, Miller et al., 2010). There have been 
reports of aquaporin 8 in the IMM (Calamita et al., 2005, Marchissio et al., 2012), 
however these have been disputed (Yang et al., 2006) and no aquaporins are 
found in data bases of mitochondrial proteins, such as MitoCarta2. The very large 
ratio of the surface area of the IMM to the matrix volume may enable the rapid 
diffusion of H2O2 through the IMM phospholipid bilayer in the absence of 
aquaporins (Yang et al., 2006). In the IMS the H2O2 should then be able to diffuse 
out of that compartment by movement through porins in the OMM. However, due to 
the multitude of antioxidant defence systems in the matrix, the level of ROS 
production required to overwhelm these systems and pass to the cytosol may be 
high.  
 
The above scenario indicates how H2O2 itself could move from the matrix to the 
rest of the cell. It is also possible that the H2O2 in the mitochondrial matrix can alter 
mitochondrial metabolism, perhaps by altering the activity of metal-centre proteins 
(Winterbourn, 2013), and thus lead to the generation of another signal that can 
pass on to the rest of the cell, for example by generating an electrophile.  
1.4.4 The role of cysteine thiols in redox signalling 
The way in which H2O2 acts as a signal requires that it affect the activity or location 
of a protein in some way (Collins et al., 2012, Gough and Cotter, 2011, Holmstrom 
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and Finkel, 2014). This is usually thought to happen by the redox modification of a 
target cysteine residue. Cysteine residues in proteins contain reactive thiol groups, 
whose redox state is a critical mediator of protein function. Under normal 
physiological conditions, the majority of exposed thiol groups are maintained in a 
reduced state (Leichert and Jakob, 2004, Menger et al., 2015). However, 
fluctuations in cellular redox state can lead to a range of oxidative thiol 
modifications, including the formation of disulfide bonds, S-sulfenylation, S-
nitrosation, S-acetylation or S-glutathionylation (Paulsen and Carroll, 2013). These 
oxidative modifications can affect the activity, binding interactions, lifetime or 
localisation of a protein (Holmstrom and Finkel, 2014). Importantly, the majority of 
these post-translational redox modifications are reversible, therefore they are 
capable of functioning as a signalling mechanism, as well as in the response of the 
cell to oxidative stress (Collins et al., 2012). Thiol groups can become irreversibly 
oxidised under conditions of oxidative stress, often leading to degradation of the 
affected proteins. Compared to other amino acids, cysteines are under-represented 
in proteins due to their high reactivity and either tend to be extremely highly, or very 
poorly, conserved (Marino and Gladyshev, 2010). However, not all cysteines are 
equally susceptible to oxidative modification. For instance, solvent-exposed 
cysteines are more likely to be redox-sensitive than cysteines buried within the 
protein structure (Murphy, 2012). Since multiple redox-reactive cysteine residues 
with different susceptibilities to oxidation can be present within a protein, many 
redox states are possible for a single protein. Thus, it is important to be able to 
identify and quantify the changes in these protein thiols under various biological 
conditions. 
 
Cysteine thiol oxidation can be caused by the direct reaction of H2O2 with the 
target, and can be reversible, (e.g. reversible inactivation of tyrosine phosphatases 
through oxidation of an active site cysteine thiol (Meng et al., 2002)) or irreversible 
(e.g. thiol akylation of Kelch-like ECH-associated protein 1 (KEAP 1), inducing 
nuclear translocation of nuclear factor erythroid 2-related factor 2 (NRF 2) 
(Kobayashi and Yamamoto, 2006)). However, an alternative mechanism has also 
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been described in some cases such that it is not H2O2 itself that acts as a direct 
signal but that it is picked up by a disulfide relay such that this then passes on the 
redox signal to the target protein (Sobotta et al., 2015, Azevedo et al., 2003, 
Herrmann and Riemer, 2012) (Figure 1.7).  
 
 
Figure 1.7 Protein thiol oxidation by (A) direct interaction with H2O2 or (B) a possible 
disulfide relay mechanism.  H2O2 can modify proteins (A) directly, e.g. disulphide formation, or (B) 
indirectly, via disulfide formation with ROS scavaging proteins. Both mechanisms can temporarily 
alter protein function. Pr, protein. 
1.4.5 Redox regulated proteins 
Whether a redox signal emanates from mitochondria as H2O2, a redox relay or 
another signalling molecule, this will ultimately have to act on a target protein and 
lead to a biological effect. Interesting examples of this include cytosolic stabilisation 
of hypoxia-inducible factor-1α (HIF-1α) in response to mitochondrial ROS during 
hypoxia and inflammation (leading to transcriptional adaptation) (Sanjuan-Pla et al., 
2005, Mills et al., 2016) and mitochondrial ROS-induced oligomerisation of 
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mitochondrial antiviral signalling (MAVS) protein in immune cells in response to 
viral infection, enhancing production of pro-inflammatory cytokines (Buskiewicz et 
al., 2016). Many proteins have been claimed to be targets for mitochondrial redox 
signals but often the evidence is circumstantial or indirect. The development of 
redox proteomic methods should enable theses targets to be picked up more 
definitively (Rinalducci et al., 2008, Kumar et al., 2013, Menger et al., 2015). 
However, it may be a recurring problem that these changes are a series of 
reversible redox changes that have multiple small effects that may be challenging 
to detect definitively. Going forward, our lab is particularly interested in 
investigating the down stream effects of mitochondrial ROS production by RET, 
particularly the response of signalling enzymes that have the ability to modify 
mitochondrial function and cellular metabolism, including AMP-activated protein 
kinase (AMPK). 
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1.5 AMP-activated protein kinase: a metabolic sensor and 
regulator  
1.5.1 Mitochondrial respiratory control 
The evolution of mitochondria as efficient generators of ATP has enabled the 
development of complex life. Mitochondria can acutely respond to short-term 
energy demand by increasing or decreasing ATP synthesis by OXPHOS, a 
phenomenon known as respiratory control (Brown, 1992, Murphy and Brand, 1987, 
Chance and Williams, 1956). Mechanistically, respiration can be controlled at 
several steps in the OXPHOS process, including: 1) ATP synthesis by the FOF1-
ATP synthase is limited by the availability of ADP and Pi, which are imported into 
the mitochondria from the cytosol (ADP in exchange for ATP). If ATP usage 
(hydrolysis) in the cytosol is increased, the breakdown products ADP and Pi will 
thus increase and favour increased ATP synthesis in the mitochondria. If ATP use 
in the cytosol is decreased, the supply of ADP and Pi for further ATP synthesis will 
also decrease (Chance and Williams, 1956); 2) Increased ATP synthesis will 
decrease the ∆P across the IMM (due to the H+ influx into the matrix from the IMS) 
and this will also stimulate respiration in the short-term (Brown et al., 1990); 3) 
Respiration can be controlled by the supply of electrons to respiratory complexes, 
mainly from NADH, therefore an increased mitochondrial NADH/NAD+ ratio 
(perhaps from increased flux through the CAC or fatty acid oxidation) will enhance 
OXPHOS by raising the ∆P (Brown et al., 1990); 4) increased calcium levels can 
increase respiration by stimulating calcium-sensitive matrix dehydrogenases which 
increase NADH supply (McCormack et al., 1990); 5) FOF1-ATP synthase can be 
inhibited by proteins, such as IF1, although the physiological role of these inhibitory 
proteins are unclear (Nakamura et al., 2013); 6) ATP production can also be 
inhibited by the degree of proton leak, such as occurs in brown adipose tissue 
when potential energy is dissipated as heat (Brown, 1992).  
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1.5.2 Signaling between mitochondria and the rest of the cell 
While mitochondrial respiratory control ensures that ATP synthesis can rapidly 
adapt to meet demand, this adaptation is limited in the short-term by substrate 
availability and in the long-term by the number and mass of mitochondria in the 
cell. To increase flux through catabolic pathways or to increase mitochondrial 
biogenesis under conditions of chronic ATP demand, mitochondria signal to 
several regulatory systems in the cell. AMP-activated protein kinase (AMPK) plays 
a key role in energy sensing and is considered to be one of the cell’s master 
regulators of energy metabolism (Carling et al., 2011, Hardie et al., 2012, Garcia 
and Shaw, 2017, Hardie et al., 2016). AMPK senses energy demand as an 
increase in cellular AMP and ADP relative to ATP and then adapts a broad range 
of cellular processes to promote ATP production and inhibit ATP expenditure. 
AMPK exerts control over several signalling pathways that affect mitochondrial 
function.  	  
In quiescent cells performing mainly catabolic processes the main source of ATP is 
the efficient OXPHOS process (O'Neill and Hardie, 2013). Fatty acid oxidation is a 
major contributor of electrons to the ETC (via NADH and FADH2) and so promotes 
OXPHOS. Fatty acids are transported from the cytosol into the mitochondria for 
oxidation as acyl-coA, via the Carnitine/Palmitoyl-Transferase 1 (CPT1) (Schreurs 
et al., 2010). Proliferating cells on the other hand, such as some activated immune 
cells, require increased anabolic processes such as fatty acid and protein 
synthesis, required for cell growth and division. Switching from OXPHOS to 
glycolysis favours NADPH production necessary for these anabolic processes 
(Hamanaka and Chandel, 2012, O'Neill and Hardie, 2013). Increased fatty acid 
synthesis has the effect of simultaneously inhibiting fatty acid oxidation. Both 
processes are largely controlled by acetyl CoA carboxylase (ACC) isoforms 1 and 
2, respectively, whose activity is sustained by citrate emanating from the 
mitochondrial CAC cycle for biosynthetic purposes at the expense of electron 
donation to the ETC (Schreurs et al., 2010). ACC1 (cytosolic) converts cytosolic 
acetyl CoA (from citrate) to malonyl CoA, a requirement for fatty acid biosynthesis. 
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ACC2 (associated with the cytosolic face of the OMM) also converts acetyl CoA to 
malonyl CoA, which inhibits CPT1 transport of acyl-coA into the mitochondria for 
oxidation. Thus, when both isoforms are activated, fatty acid biosynthesis is 
promoted and fatty acid oxidation is inhibited. Under conditions of ATP demand, 
however, fatty acid metabolism is switched back to favour oxidation, and AMPK 
plays a key role in this metabolic switch (Hardie, 2011, O'Neill and Hardie, 2013, 
Schreurs et al., 2010). AMPK, when activated under conditions of ATP demand, 
phosphorylates and inhibits both ACC isoforms. This adaptation inhibits fatty acid 
synthesis (as malonyl CoA production is now inhibited) and promotes fatty acid 
oxidation (with increased mitochondrial acyl-coA import via uninhibited CPT1). 
Thus, AMPK, by exerting control over the activity of ACC1 and 2 (amongst other 
pathways), can acutely control electron donation to the ETC for OXPHOS to meet 
the ATP demand of the cell.   
 
The volume of mitochondria and the area of the IMM in a cell varies greatly 
depending on cell type and energy demand (Jornayvaz and Shulman, 2010). 
Continuously working muscles, such as the heart, have greater mitochondrial 
content and activity than sporadically contracting muscle, e.g. back muscles (Paul 
and Sperling, 1952). Chronic exercise, cold exposure, dietary restriction, cell 
division and differentiation are all associated with increased mitochondrial 
biogenesis in cells (Puigserver et al., 1998, Civitarese et al., 2007, Holloszy, 1967, 
Jornayvaz and Shulman, 2010), i.e. the growth and division of pre-existing 
mitochondria. Mitochondrial biogenesis requires the cytosolic synthesis and 
mitochondrial import of ~ 1000 – 1500 proteins encoded by the nuclear genome, as 
well as the mitochondrial synthesis of proteins encoded by mtDNA. Peroxisome-
proliferator-activated receptor γ co-activator-1α (PGC-1α) is a transcriptional 
coactivator that facilitates mitochondrial biogenesis by activating different 
transcription factors: nuclear respiratory factor (NRF) 1 and 2, which activate 
nuclear transcription of mitochondrial genes and also activate mitochondrial 
transcription factor A (Tfam), which drives transcription and replication of 
mitochondrial DNA. PGC-1α also regulates mitochondrial antioxidant defence 
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systems. PGC-1α expression and activity is regulated by several signalling 
pathways in the cell, including AMPK which, when activated by energy chronic 
demand, upregulates PGC-1α activity through phosphorylation (Jornayvaz and 
Shulman, 2010, Hardie, 2011, Jager et al., 2007). Thus, AMPK can bring about 
long-term adaptation of cells to a higher ATP demand by increasing the mass of 
mitochondria in the cell.  	  
1.5.3 Sensitivity to ATP/AMP and ATP/ADP ratios as an energy 
sensing strategy in the cell  
Cells require a high ratio of ATP/ADP (i.e. 10 - 20) in order to perform energy-
requiring processes typically involving ATP hydrolysis (usually to ADP and Pi) 
(Hardie and Hawley, 2001).  Adenylate kinase in cells (which catalyses the 
interconversion of ATP, ADP and AMP) maintains the reaction 2ADP ↔ ATP + 
AMP close to equilibrium. In healthy cells, the high ATP/ADP ratio ensures the 
adenylate kinase reaction is shifted towards ADP production, with AMP levels 
maintained low. During acute or chronic energy demand, when ATP synthesis is 
inhibited or ATP consumption increases, this decrease in ATP (measured as 
lowered ATP/ADP ratio) is countered by the adenylate kinase reaction shifting 
towards ATP production to promote maintenance of a high ATP/ADP ratio. This 
shift will also cause AMP levels to increase.  As the ATP/AMP ratio varies as the 
square of the ATP/ADP ratio (Hardie and Hawley, 2001) (Figure 1.8), small 
decreases in the ATP/ADP ratio translate to much larger relative decreases in the 
ATP/AMP ratio. Thus, enzyme regulation by the ATP/AMP ratio has evolved as a 
highly sensitive, energy sensing strategy in the cell. A number of metabolic 
enzymes are regulated by AMP, including glycogen phosphorylase, and fructose-
1,6-bisphosphatase, which switch on catabolic or switch off anabolic pathways, 
respectively (Hardie, 2011).  AMPK is also activated by decreased ATP/AMP and 
ATP/ADP ratios and this results in downregulation of anabolic (ATP-consuming) 
pathways in the cell and upregulation of catabolic (ATP-generating) pathways. 
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Thus, activated AMPK works with adenylate kinase to maintain the high ATP/ADP 
ratios in cells needed for survival.  
 
 
Figure 1.8 The cell ATP/AMP ratio varies as the square of the ATP/ADP ratio. Adapted from 
(Hardie and Hawley, 2001).  
 
1.5.4 Discovery of AMPK 
AMPK is a highly conserved serine/threonine kinase with orthologs found in all 
eukaryotes except Encephalitozoon cuniculi, an obligate intracellular parasite that 
has also lost its mitochondria during evolution (Miranda-Saavedra et al., 2007). Its 
ubiquity highlights the importance of AMPK in integrating mitochondrial function 
with the rest of the cell. AMPK is not found in prokaryotes, but the β subunit 
carbohydrate-binding module (CBM), which binds glycogen and can facilitate 
allosteric inhibition of AMPK (McBride et al., 2009), is similar to that found in 
prokaryotic enzymes that metabolise starch and glycogen (Machovic and Janecek, 
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2006, Hardie, 2011), suggesting that the function of AMPK may have origins in 
glucose sensing. The key experiments that led to the discovery of AMPK were 
performed in Saccharomyces cerevisiae. Inactivating mutations in (or knockouts of) 
genes of the SNF1 complex (later labelled as orthologs of mammalian AMPK 
subunits) resulted in failure of the yeast to grow on substrates other than glucose 
(Hardie, 2011). SNF1 is insensitive to activation by AMP (Zhang et al., 2017). 
Thus, AMPK orthologs are essential to survival and proliferation of complex life, but 
mainly conferred protection from glucose starvation in lower order eukaryotes. The 
discovery of AMPK in mammalian cells came about as phosphorylation-induced 
inactivation of enzymes involved in fatty acid biosynthesis (ACC and HMG-CoA 
reductase) were found to be caused by one enzyme that was activated by AMP, 
leading to the renaming of the enzyme as AMP-activated protein kinase (Hardie et 
al., 2011). Importantly, knockout of the AMPK catalytic α subunit (both isoforms 
simultaneously) causes embryonic lethality in mice (Ross et al., 2016), highlighting 
the essential role of AMPK in complex life.  Recent studies have re-emphasised the 
role of AMPK as a glucose sensor as well as an energy sensor, with the discovery 
of an AMP/ADP-independent mechanism for AMPK activation during glucose 
starvation before the onset of energy stress (Zhang et al., 2017, Zhang et al., 
2014). For the remainder of this chapter I will focus on how AMPK functions as a 
metabolic sensor in mammalian cells, and the potential role of ROS in AMPK 
regulation. 
1.5.5. Structure of AMPK 
AMPK is a heterotrimeric serine/threonine kinase (Figure 1.9). The complex is 
composed of a catalytic α subunit and regulatory β and γ subunits, with seven 
mammalian genes encoding different subunit isoforms: α1 and α2, β1 and β2, and 
γ1, γ2 and γ3 (Ross et al., 2016). The α subunit contains an N-terminal kinase 
domain (α-KD), containing an activation loop that is phosphorylated (at T172) by 
upstream kinases, including LKB1 and CaMKKβ, which is required for activation. 
The α subunit contains C-terminal regulatory domains: auto-inhibitory domain (α-
AID), which associates either with the α-KD (inactive conformation) or the γ subunit 
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(active conformation); α‐linker, which connects the α-AID to the C‐terminal domain 
(α‐CTD), essential for allosteric regulation by adenine nucelotides; 
serine/threonine-rich loop (ST-loop), which mediates inhibitory phosphorylation and 
signalling by PI3K/Akt and glycogen synthase kinase 3 (at S487). The β subunit 
contains a regulatory carbohydrate-binding module (CBM), which is 
phosphorylated (at S108) and makes up the allosteric drug and metabolite (ADaM) 
binding pocket along with the α-KD N-lobe. The β subunit also contains and an N-
terminal myristoylation site, which is also regulatory and required for activation 
during glucose starvation. The γ subunit contains four nucleotide-binding 
cystathionine-β-synthase (CBS) domains, which allow the enzyme to sense and 
respond to changing levels of adenine nucleotides (ATP, ADP and AMP) as a 
readout of the energy status of the cell (Xiao et al., 2007). In structural studies, only 
three of these sites have been found occupied: one molecule of AMP binds 
irreversibly at CBS4 and molecules of AMP, ADP or ATP can bind reversibly at 
CBS1 and CBS3 (Xiao et al., 2007, Xiao et al., 2011).  It is considered that each of 
the different subunit isoforms can recombine with any of the partner subunit 
isoforms to form functional enzymes (12 combinations in total), but some isoform 
combinations are more favoured in different cell and tissue types, e.g. predominant 
α2/β2/γ3 activation in skeletal muscle (Ross et al., 2016, Birk and Wojtaszewski, 
2006). However, isoform specificity is not fully understood and variation in isoform 
combination is not fully characterised.  
 
  
Chapter 1 – Introduction  
	   37	  
 
A 
 
B 
 
 
Figure 1.9 Domain map and structure of human AMPK α1/ β2/ γ1. (A) Domain map of AMPK 
α1/β2/γ1.  α-KD, kinase domain; α-AID, auto-inhibitory domain; CTD, C-terminal domain; ST loop, 
serine/threonine rich loop; NES, nuclear export sequence; CBM, carbohydrate binding module; 
CBS, cystathionine-β-synthase domain. (B) Structure of human AMPK α1β2γ1 complex. The CBM 
and catalytic sites are occupied by cyclodextrin and staurosporine, respectively. The ADaM site is 
empty. The ‘module boundary’ shows the approximate boundary between the ‘catalytic module’ 
(containing the α-KD and the β-CBM) and the ‘nucleotide-binding module’ (containing the γ subunit 
and the α and β CTD). Extracted from (Hardie et al., 2016). 	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1.5.6. Downstream targets of AMPK 
In response to activating phosphorylation, AMPK in turn phosphorylates and 
modifies the activity of a wide range of downstream proteins (over 50 proteins cited 
in the literature), with the general effect of increasing and conserving ATP levels in 
the cell. Situations that induce AMPK activation in cells and tissues include skeletal 
muscle contraction during exercise (Winder and Hardie, 1996, O'Neill et al., 2011, 
Jager et al., 2007), glucose deprivation (Zhang et al., 2017), hypoxia and 
ischaemia (Marsin et al., 2000, Hardie, 2011). Table 1.1 lists a selection of 
enzymes, transcription factors/activators and transporters under the control of 
AMPK (Garcia and Shaw, 2017, Carling et al., 2011, Hardie, 2017, O'Neill and 
Hardie, 2013, Hardie et al., 2012).  
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Target Target function Effect of AMPK activation on 
target function 
Anabolic pathways 
ACC1 Fatty acid synthesis Inhibition 
SREBP1c Transcription of lipogenic 
genes ChREBP 
HMGR Sterol synthesis 
mTORC1 Protein synthesis 
GS Glycogen synthesis 
Catabolic pathways 
ACC2 Fatty acid oxidation Activation/induction 
PGC1α Mitochondrial biogenesis, 
OXPHOS, antioxidant defence 
GLUT1/4 Glucose uptake 
ULK1 Autophagy 
CD36 Fatty acid uptake 
FOXO Antioxidant defence 
PFK1/2 Glycolysis 
 
Table 1.1 Selection of enzymes, transcription factors/activators and transporters under the 
control of AMPK. ACC, acetyl CoA carboxylase; SREBP1c, sterol regulatory element-binding 
protein 1c; ChREBP, carbohydrate-responsive element-binding protein; HMGR, 3-hydroxy-3-
methylglutaryl coenzyme A reductase; mTORC1, mammalian target of rapamycin complex 1; GS, 
glycogen synthase; PGC1α, peroxisome proliferator-activated receptor gamma coactivator 1- α; 
GLUT1/4, glucose transporter 1/4; ULK1, unc-51-like autophagy-activating kinase 1; CD36, cluster 
of differentiation 36 (fatty acid translocase); FOXO, forkhead box O; PFK1/2, phosphofructokinase 
1/2.  
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1.5.7. Regulation of AMPK by adenine nucleotides 
In general terms, AMPK senses energy stress as increased cellular AMP and ADP 
relative to ATP. This leads to allosteric activation of AMPK by AMP, which binds to 
the CBS domains of the γ subunit and induces a conformational change that 
promotes phosphorylation of AMPK by upstream kinases (which induces high 
levels of kinase activity), leads to allosteric activation and also protects AMPK from 
inactivating dephosphorylation (Xiao et al., 2007). Activated AMPK phosphorylates 
and turns on or off a broad range of enzymes, generally shifting metabolic 
pathways toward ATP production and conservation (Carling et al., 2011, Hardie et 
al., 2012). As cellular ATP levels rise again, increased binding of ATP to the γ 
subunit removes the positive allosteric effect of AMP and AMPK activity is 
decreased in an elegant feedback mechanism (Oakhill et al., 2011, Hardie et al., 
2011).  
 
In greater detail, when in a basal state (assuming a high cellular ATP/ADP ratio) 
AMPK is bound by one molecule of AMP at γ subunit CBS4 and most likely two 
molecules of magnesium-bound ATP (MgATP) (at CBS1 and CBS3) (Xiao et al., 
2011). Binding of MgATP maintains interaction between the AID and α-KD, 
inhibiting kinase activity. During moderate energy stress (with rising AMP and ADP 
concentrations relative to ATP), AMP replaces MgATP bound at CBS3, 
disengaging the AID from the α-KD, putting AMPK in an ‘active’ conformation 
(Cheung et al., 2000). This promotes phosphorylation of threonine 172 (Thr172) 
within the α-KD activation loop by upstream kinases, which stabilises enzyme in 
the active conformation and results in up to several hundred-fold increase in AMPK 
activity (Oakhill et al., 2010). Binding of AMP (or ADP at CBS3) also protects 
AMPK from inactivating dephosphorylation by protein phosphatases (e.g. PP2A, 
PP2C) (Oakhill et al., 2011, Xiao et al., 2011, Davies et al., 1995). During more 
severe energy stress, binding of AMP to CBS1 results in additional allosteric 
activation of phosphorylated AMPK (Xiao et al., 2011, Gowans et al., 2013, Xiao et 
al., 2007).  
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In healthy cells, concentrations of free adenine nucleotides are reported to be in 
the following ranges: 3 – 8 mM ATP, 50 – 200 μM ADP and 0.5 – 5 μM AMP (Xiao 
et al., 2011). ATP is greatly in excess, but as most ATP in cells is bound to Mg 
(and AMP and ADP are not) AMPK binds AMP and ADP significantly more strongly 
than ATP in cells. As ADP is typically in excess of AMP, ADP is more effective than 
AMP at displacing CBS-bound MgATP and protecting AMPK from 
dephosphorylation, suggesting that this may be the main physiological mechanism 
of AMPK activation (Hardie et al., 2011, Xiao et al., 2011). But only AMP induces 
allosteric activation of AMPK and promotes phosphorylation-dependent high levels 
of activity (Xiao et al., 2011). Thus, AMPK can sensitively sense and respond to 
varying levels of energy demand, ranging from mild to severe. In a feedback 
mechanism, when cell ATP/ADP and ATP/AMP ratios are high, increased binding 
of MgATP to CBS1 and CBS3 inhibits allosteric activation of the complex or 
protection from dephosphorylation (Carling et al., 2011, Xiao et al., 2011).  
 
 
 
 
Figure 1.10 AMPK is regulated by adenine nucleotides in a tripartite mechanism. Binding of 
AMP or ADP induces conformational change, which promotes phosphorylation and activation of 
AMPK by upstream kinases and protects against dephosphorylation by phosphatases. Further 
binding of AMP to phosphorylated AMPK allosterically activates the enzyme. Adapted from (Hardie 
and Alessi, 2013).  
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A      B 
 
Figure 1.11 Structure of human AMPK α1 in (A) ‘inactive’ and (B) ‘active’ conformations. (A) 
Binding of MgATP to the γ subunit CBS domains maintains the interaction between the AID and α-
KD, inhibiting kinase activity. (B) When AMP replaces MgATP, the AID disengages from the α-KD, 
putting AMPK in an ‘active’ conformation. Side chains of the regulatory spine: Leu81, white; Leu70, 
red; Phe160, magenta; His139, blue. Extracted from (Hardie et al., 2016).  
 
1.5.8. Regulation of AMPK by co- and post-translational 
modifications 
For AMPK to phosphorylate and regulate other enzymes, AMPK itself needs to be 
phosphorylated at the conserved Thr172 residue of the α catalytic subunit, which 
locks the enzyme in an active conformation. (Hawley et al., 1996). This 
phosphorylation is promoted and protected by the effects of AMP (Davies et al., 
1995) and also protected by AMP and ADP (Xiao et al., 2011). The tumour 
suppressor Liver Kinase B1 (LKB1) is the main upstream AMPK kinase (Hawley et 
al., 2003, Hong et al., 2003, Shaw et al., 2004). Furthermore, C-terminal 
farnesylation of LKB1 is required for maximal AMPK activation in response to 
energy stress (Houde et al., 2014). Binding of ADP or AMP to AMPK protects 
AMPK from dephosphorylation by protein phosphatases (e.g. PP2A, PP2C) 
(Oakhill et al., 2011, Xiao et al., 2011, Davies et al., 1995). Increases in cytosolic 
calcium levels can also induce AMPK phosphorylation and activation via 
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Ca2+/calmodulin-activated protein kinase kinase β (CAMKKB) (Hawley et al., 2005, 
Woods et al., 2005). AMPK activity can be inhibited by phosphorylation of the α 
subunit at Ser487 by Akt during insulin signalling (Ross et al., 2016). The AMPK β 
subunit also contains a co-translational N-myristoylation site, which is required for 
AMPK phosphorylation and perinuclear AMPK accumulation during glucose 
starvation (Oakhill et al., 2010). β subunit N‐myristoylation may also play a role in 
mitophagy (i.e. the destruction of damaged mitochondria by autophagy), possibly 
by enabling association between AMPK and mitochondrial membranes (Liang et 
al., 2015). The AMPK β subunit is also phosphorylated, which is important for 
AMPK activation by compounds that bind the allosteric drug and metabolite 
(ADaM) binding site (Hardie, 2016).  
1.5.9 AMPK as a clinical target 
As AMPK can inhibit anabolic pathways required for cell proliferation, AMPK has 
become an attractive target in the study of cancer metabolism. Whereas some 
AMPK subunit isoforms tend to be mutated in certain cancers (i.e. α2 and β1) 
perhaps conferring a loss of function, other AMPK subunit isoforms tend to be 
amplified in certain cancers (α1 and β2), suggesting they confer a pro-survival 
advantage (Ross et al., 2016). This discrepancy points towards different subunit 
isoforms having different substrate or cell type specificities that are not fully 
understood, and this complicates the interpretation of the role of AMPK in cancer 
development and progression. Further complicating matters is the characterization 
of the main AMPK kinase, LKB1, as a tumour suppressor, suggesting that at least 
some of its tumour suppressing function is mediated by AMPK signalling (Hardie 
and Alessi, 2013). Similarly, AMPK is inhibited via α subunit phosphorylation by Akt 
in cancers in which the tumour suppressor PTEN is non-functional and whole‐body 
AMPK α1 knock-out mice have accelerated B cell lymphoma development driven 
by Myc over‐expression (Ross et al., 2016). Thus, the role of AMPK in cancer 
metabolism is highly complicated and factors such as the cell type, cancer stage 
(early or invasive) and tumour microenvironment (i.e. sufficient or deficient oxygen 
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and/or nutrient availability) likely play a role in characterizing AMPK as an 
oncogene or a tumour suppressor (Ross et al., 2016).  
 
AMPK has become an attractive target in protection against inflammation. 
Activated immune cells that promote inflammation are highly proliferative and thus 
have a glycolytic phenotype (O'Neill and Hardie, 2013). Non-proliferating, anti-
inflammatory immune cells instead preferentially make ATP by OXPHOS. As 
AMPK promotes oxidative metabolism, AMPK has emerged as drug target for 
inflammatory diseases. Furthermore, the long-used anti-inflammatory drug 
salicylate (which also arises from aspirin metabolism) is now known to directly bind 
and activate AMPK via the ADaM binding site (Hawley et al., 2012). AMPK 
activation has also been protective in models of cardiac ischaemia reperfusion 
injury (IRI), possibly mediating some of the effects of the phenomenon of ischaemic 
preconditioning by upregulating antioxidant defence systems and pro-survival 
pathways in the heart (Greer et al., 2007, Zaha et al., 2016, Qi and Young, 2015, 
Kim et al., 2011, Shao et al., 2014). 
 
AMPK is also a potential drug target in treatment of type-2 diabetes (T2D) (Hardie, 
2016). Metformin is a widely-prescribed drug treatment for T2D that helps to 
normalise blood glucose levels without causing hypoglycaemia or lactic acidosis in 
otherwise healthy patients. Metformin (and the more hydrophobic biguanide, 
phenformin) non-specifically inhibit complex I in isolated mitochondria and in cells 
in vitro at mM concentrations (Owen et al., 2000, Bridges et al., 2014). The 
concurrent activation of AMPK at these concentrations has been considered to be 
largely due to decreased ATP/ADP ratios resulting from inhibition of respiration 
(Zhou et al., 2001). Although the exact mechanism(s) of metformin action are not 
completely understood, there is evidence that AMPK activation contributes to some 
of the beneficial effects of metformin (Fullerton et al., 2013, Hardie, 2016). AMPK 
α2 knockout mice are insulin‐resistant and glucose‐intolerant, and exercise, which 
activates AMPK, also helps to maintain and normalise blood glucose levels.  Thus, 
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selective AMPK activators are being investigated as therapeutic agents for T2D 
(Hardie, 2017).  
 
1.5.10 AMP/ADP-independent regulation of AMPK 
The small molecule AMPK activators A-769662 and 991, and salicylate (a 
metabolite of aspirin), bind at one site at the interface of the phosphorylated β 
subunit CBM and the N-lobe the α subunit kinase domain, which is known as the 
allosteric drug and metabolite (ADaM) binding site (Langendorf and Kemp, 2015, 
Xiao et al., 2013). Binding of compounds at this site increases AMPK activity 
independently of adenine nucleotide-binding to the y subunit by inducing a 
conformational change that puts AMPK into the ‘active’ conformation (i.e. the 
kinase domain is unblocked by the AID). This conformational change does not 
require Thr172 phosphorylation but the phosphorylation appears to enhance AMPK 
activity (Willows et al., 2017). This AMP/ADP-independent allosteric activation can 
also act in synergy with AMP, as combined A-769662 and AMP binding have an 
additive effect on AMPK activity (Xiao et al., 2013). There are currently no known 
naturally occurring metabolites that bind the ADaM site. Binding of glycogen and 
cyclodextran to the β subunit CBM may have an inhibitory effect on AMPK 
(McBride et al., 2009). However, an alternative hypothesis is that the binding of 
glycogen enables co‐localization of AMPK with glycogen synthase, which is 
inactivated by AMPK phosphorylation (Ross et al., 2016). It is possible that 
glycogen binding may also regulate AMPK activation by an as yet unknown natural 
ADaM-site activator. All the known allosteric activators that bind this site have a 
much higher affinity for complexes containing β1 rather than β2 (Ross et al., 2016). 
Furthermore, it is reported that the β2 subunit binds glycogen more strongly than 
the β1 subunit (Koay et al., 2010). Ultimately, the importance of glycogen binding 
remains somewhat unclear and remains an interesting area of investigation. AMPK 
activity can also be inhibited by Compound C (also known as dorsomorphin), 
however, the mechanism by which Compound C inhibits AMPK is unclear and the 
compound has been reported to inhibit several other kinases (Liu et al., 2014).  
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AMPK is also activated in an ADP/AMP-independent manner by glucose 
deprivation. Previously, AMPK activation during glucose deprivation has been 
considered an adenine nucleotide-dependent event. As glucose is a key source of 
ATP in the cell, generated via either glycolysis or OXPHOS, historically it was 
thought that glucose deprivation would be an energy stress on the cell, causing 
decreased ATP/ADP and/or AMP/ATP ratios (Salt et al., 1998). However, glucose 
deprivation has not always been accompanied by measurable decreases in 
ATP/ADP or ATP/AMP ratios. Recently, it has been found that glucose deprivation 
activates AMPK by an alternative mechanism (Zhang et al., 2017). Briefly, as 
extracellular glucose deceases, so too do intracellular levels of fructose-1,6-
bisphosphate (FBP), an intermediate in the glycolysis pathway. Aldolase, a 
glycolytic enzyme that catalyses the reversible conversion of FBP to 
glyceraldehyde 3-phosphate and dihydroxyacetone phosphate, senses the fall in 
levels of FBP. When unbound by FBP, aldolase promotes formation of a multi-
enzyme lysosomal complex that has previously been shown to be necessary for 
AMPK activation. The complex contains at least: v-ATPase, ragulator, axin, LKB1 
and AMPK (Zhang et al., 2014, Zhang et al., 2013). Binding of aldolase by FBP 
promotes dissociation of LKB1 and AMPK from the multi-enzyme scaffold, which 
inhibits AMPK phosphorylation by LKB1. Thus, high glucose has an inhibitory 
effect on AMPK activation and low glucose promotes AMPK activation by an 
AMP/ADP and ADaM-binding site – independent mechanism.  
1.5.11 Evidence for and against redox-regulation of AMPK 
ROS have also been investigated as an atypical regulator of AMPK as a further 
way of relaying information about the metabolic state or demands of the cell and 
thus promoting pro-survival adaptation (Shao et al., 2014, Emerling et al., 2009, 
Hart et al., 2015, Zmijewski et al., 2010, Mungai et al., 2011, Hawley et al., 2010, 
Auciello et al., 2014). It is conceivable that redox-regulation of AMPK may enable 
feedback about the redox state of the cell and promote upregulation of antioxidant 
defense systems (Greer et al., 2007, Zaha et al., 2016, Qi and Young, 2015, Kim et 
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al., 2011). Below I will discuss the key findings from the published articles that 
have most influenced the experimental goals of this thesis.  
 
One of the first papers to examine the role of ROS in AMPK regulation in detail was 
presented by (Zmijewski et al., 2010) in which the authors described an AMP/ADP-
independent redox mechanism for AMPK activation in HEK 293 cells. The authors 
detected redox changes to cysteine residues in the AMPK α catalytic subunit 
(specifically glutathionylation of C299 and C304) in response to exogenous H2O2 
delivered as a bolus (250 μM) and also in response to H2O2 generated by glucose 
oxidase (10 milliunits/ml). The authors observed concurrent activation of AMPK in 
these experiments, measured as increased AMPK(T172) and ACC(S79) 
phosphorylation (a downstream target). Although the authors described observing 
decreased cell ATP/ADP ratios in cells treated with 250 μM H2O2, they did not 
observe decreases in cell ATP/ADP ratios in cells treated with glucose oxidase, 
which generates H2O2 in cell culture media gradually. The authors also observed 
increased AMPK activity in extracellular experiments when recombinant AMPK 
was incubated with H2O2 or H2O2 + GSH, with effects negated when C299 and 
C304 were mutated. Thus, the authors concluded that H2O2 was activating AMPK 
by a redox-dependent mechanism.  
 
Building upon this and other previous studies, Auciello et al. (2014) also utilised the 
glucose oxidase method of extracellular H2O2 generation, testing the effects of 
H2O2 on HEK 293 cells expressing the AMP/ADP-insensitive AMPK γ subunit 
R531G (RG) mutant, which renders AMPK unable to be allosterically activated by 
AMP or allosterically protected from dephosphorylation by AMP or ADP. In this 
study, the authors observed decreases in cell ATP/ADP ratios after treatment with 
glucose oxidase. The high level of AMPK activity observed in wild-type (WT) cells 
was abrogated in RG cells, indicating that the H2O2 was primarily acting by an 
AMP/ADP-dependent mechanism. The authors did observe low-grade but 
statistically significant increases in AMPK activity with time, suggesting that H2O2 
may play a minor role in AMPK regulation by inhibiting AMPK dephosphorylation, 
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potentially by H2O2-induced inhibition of upstream phosphatases.  
 
The authors of (Shao et al., 2014) described a different mechanism of AMPK redox 
regulation, in which AMPK activity was inhibited by cysteine thiol oxidation. AMPK 
α was identified as a target of Trx 1, which prevented oxidation of AMPK α cysteine 
thiols (C130 and C174 in the α-KD) and so prevented AMPK inhibition during 
glucose deprivation and cardiac ishaemia, both associated with increased cellular 
ROS. It is plausible that immortalised cell lines have upregulated antioxidant 
defence systems compared to primary cells and tissues (e.g. high expression of 
Trxs and a highly reduced NADPH/NADP pool, a key reducing modality in the cell 
(Murphy, 2015)), which may explain why this remains the only report of redox-
dependent AMPK inhibition that I have observed to date.  
 
The role of mitochondrial ROS in AMPK activity is less studied and interpretation of 
results is more complicated. It has been reported that ROS produced during 
hypoxia (Emerling et al., 2009, Mungai et al., 2011) can increase AMPK activity in 
different AMP/ADP-independent ways, e.g. involving LKB1, or via ROS-induced 
increases in cytosolic calcium (which activates the alternative AMPK kinase, 
CAMKKB). It is reported that during hypoxia, mitochondrial superoxide is 
generated from complex III, and can be liberated directly to the mitochondrial 
matrix or to the IMS (Murphy, 2009). Superoxide generated to the IMS would 
bypass the protein-dense barrier of the IMM and theoretically provide an easier 
pathway to transfer to the cytosol than mitochondrial superoxide generated to the 
matrix only. Mitochondrial ROS has also been reported to play a role in AMPK 
activation via MnSOD upregulation in cancer cells, however the exact mechanism 
of the pathway, reported to involve CAMKKB, remains unclear (Hart et al., 2015).  
 
The highly varied reports of AMP/ADP-dependent or AMP/ADP-independent AMPK 
regulation by ROS indicate that there is still much that is not known about the 
factors that affect AMPK activity in cells. There are a number of possible technical 
and biological reasons for the above and other diverse reports of AMPK regulation. 
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it is possible that varying sensitivities in methods of measuring adenine nucleotides 
can affect the interpretation of AMP/ADP-dependent or AMP/ADP-independent 
mechanisms. Different levels of ROS scavenging proteins in different cell types 
(and other factors that affect the redox state of the cell) may affect AMPK redox 
state and thus activity. Different expression levels of AMPK subunit isoforms and 
enzymes which co- or post-translationally modify AMPK may affect how AMPK 
responds to different ROS. Different cellular nutrient availability (e.g. high or low 
[glucose]) may also differentially affect AMPK responses to ROS. With regard to 
mitochondrial ROS, the site of ROS production may determine how the ROS 
affects cellular signaling pathways, including AMPK (e.g. ROS production from 
complex I versus that from complex III, or ROS production produced by forward or 
reverse electron transfer). Due to the vital role played by AMPK in metabolic 
regulation and cell survival, it is vital that the diverse mechanisms governing AMPK 
regulation are elucidated.  
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1.6 Summary and aims 
Above, I have introduced the key steps in mitochondrial energy metabolism and 
highlighted the importance of mitochondria to complex life as we know it. As a by-
product of energy metabolism, mitochondria can also produce ROS from several 
sources within mitochondria, including from respiratory complexes of the electron 
transport chain, in our view mainly from complex I (Murphy, 2009). These ROS can 
overwhelm the multitude of antioxidant defence systems within the mitochondrial 
matrix and cause oxidative damage, which can contribute to cell death (Smith et 
al., 2012). ROS may also behave as signalling molecules, by reversibly oxidising 
proteins at cysteine residues that are important for protein function (Collins et al., 
2012, Gough and Cotter, 2011, Holmstrom and Finkel, 2014). Historically, 
mitochondrial ROS production was considered to be an unregulated process, 
produced by dysfunctional mitochondria. More interesting is the recent view that for 
mitochondrial ROS to behave as a signal to the rest of the cell it should be 
regulated and responsive to mitochondrial status (Holmstrom and Finkel, 2014, 
Finkel, 2012, Janssen-Heininger et al., 2008). Thus, mitochondrial ROS produced 
by RET has emerged as a potentially biologically relevant signal, as it is a tightly-
regulated process dependent on a highly-reduced mitochondrial Q pool and high 
mitochondrial ΔP (Chouchani et al., 2016). Mitochondrial ROS production by RET 
is reported to play a role in metabolic adaptation of immune cells during 
inflammation (Mills et al., 2016), the immune response to viral infection (Buskiewicz 
et al., 2016) and lifespan extension (Scialo et al., 2016), as well as being a key 
source of ROS during ischaemia-reperfusion (IR) injury, highlighted in a study that 
enabled greater understanding of the metabolic requirements necessary for RET to 
occur in biology (Chouchani et al., 2014). One way in which mitochondrial ROS 
may behave as a signal is by altering the activity of AMPK, a key metabolic sensor 
and regulator of cell metabolism (Carling et al., 2011, Hardie et al., 2012, Garcia 
and Shaw, 2017, Hardie et al., 2016). AMPK is primarily regulated by adenine 
nucleotides, mainly AMP, which, when levels rise relative to ATP during energy 
stress, binds to and activates the enzyme. When activated, AMPK generally 
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enhances ATP generating pathways and inhibits ATP consuming pathways to 
promote cell survival. As mitochondria are key generators of ATP, they can signal 
to AMPK via the magnitude of the cellular ATP/AMP and ATP/ADP ratios. 
Mitochondria may also signal to AMPK via ROS. AMPK exerts control over several 
transcriptional responses in the cell, including PGC1α and NRF 1 and 2, and 
FOXO3, which upregulate the expression of genes required for mitochondrial 
biogenesis and antioxidant defence, respectively (Jager et al., 2007, Greer et al., 
2007). Thus, the role of ROS in AMPK activity has been investigated in recent 
years. Several important papers have helped to clarify the role of exogenously-
generated or cytosolic ROS in AMPK regulation.  However, the role of 
mitochondrial ROS, including that produced by RET, remains unclear. Thus, the 
main focus of this thesis has been to build upon previous work in the field and work 
towards characterising the effects of ROS, specifically mitochondrial ROS, on 
AMPK activity in cells. This goal was divided into three individual but interrelated 
sub-projects, which I discuss in detail in the following three chapters, and introduce 
briefly below.  
 
Aim 1. An important step in determining if a protein is potentially redox regulated is 
monitoring the redox state of the protein itself in response to ROS (Requejo et al., 
2010). Proteins can be oxidatively modified at cysteine residues (specifically at the 
thiol group), which can affect the functioning of that protein. There are several 
mass spectrometry techniques that can enable a screen of the redox state of the 
proteome (Held et al., 2010, Leichert et al., 2008, Menger et al., 2015), but the 
readouts are often biased towards abundant proteins that can be easily detected. 
Complementary methods utilise targeted approaches that enable the redox state of 
candidate proteins to be determined. In Chapter 3, I describe a method of 
candidate protein redox state analysis, which I developed in collaboration with co-
first author Lucie A.G. van Leeuwen and corresponding author Helena M Cochemé 
(both of MRC London Institute of Medical Sciences, Du Cane Road, London W12 
0NN, UK; Institute of Clinical Sciences, Imperial College London, Hammersmith 
Hospital Campus, Du Cane Road, London W12 0NN, UK), and others.  The 
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chapter describes the steps involved in optimising the new method (which offers 
more flexibility than previous methods), for which we used a known redox-
regulated protein, GAPDH, as a model. I then discuss adapting the method to 
analyse purified AMPK, with the ultimate aim of analysing the redox state of AMPK 
in cell lysates. Progress was made in this regard, suggesting future optimisations 
will enable AMPK redox state in cells to be analysed. Results emerging from 
experiments discussed in Chapter 4 then shifted the focus away from redox state 
analysis and towards analysis of AMPK regulation. 
 
Aim 2. The second aim of this thesis was to characterise the effects of exogenous 
or selective, mitochondrially-derived ROS on AMPK activity, cell ATP/ADP ratios 
and subcellular redox state to determine if the effects of different sources of ROS 
on AMPK activity can be explained as AMP/ADP-dependent regulation or 
AMP/ADP-independent (redox) regulation. These results are presented in Chapter 
4. It remains unclear to what extent mitochondrial ROS can transfer to the cytosol 
and affect signalling processes there. While mitochondrial ROS is often implicated 
in cytosolic or nuclear signalling pathways, there is often limited data showing a 
biological effect of mitochondrially-derived ROS in other cellular compartments. 
Thus, an aim was to use peroxiredoxin dimerisation as a biologically relevant 
measure of the oxidation state of multiple subcellular compartments in response to 
different sources of ROS (Sobotta et al., 2013). As AMPK is a predominantly 
cytosolic protein, a reversible change in the redox state of a cytosolic protein 
involved in antioxidant defence and redox signalling would likely be required for 
there to be any potential biologically relevant redox regulation of AMPK. An 
irreversible change in redox state would be indicative of oxidative damage. By 
combining cellular sub-compartment redox state analysis with measures of AMPK 
activity and cell ATP/ADP ratios, I aimed to clarify the effects of ROS on 
endogenous AMPK activity, using screening methodology that can be readily 
adapted to any cell type.  
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Aim 3. The third aim of this thesis was to create a cell system for further 
investigating the downstream effects of mitochondrial ROS produced by RET, 
hypothesised to be a natural way in which mitochondria signal to the rest of the 
cell. To do this I aimed to stably express the alternative respiratory enzymes, NDI1 
and the alternative oxidase, AOX (introduced in detail in Chapter 5) in mammalian 
cell lines, as there is evidence that these enzymes (when co-expressed alongside 
mammalian respiratory complexes) increase or decrease, respectively, ROS 
production by RET (Scialo et al., 2016, El-Khoury et al., 2013). This is reported to 
occur because the enzymes hyper-reduce or oxidise the Q pool, respectively, and 
Q pool redox state is a key determinant of RET. I aimed to express the genes in a 
tetracycline-inducible cell system so that a gradient of protein expression could be 
consistently achieved. As RET is also dependent on the magnitude of the ΔP, high 
expression levels of IMM-associated proteins could potentially negatively affect the 
ΔP or inhibit ATP production in different ways, complicating the interpretation of 
results. Thus, a gradient of protein expression would be desirable in using these 
enzymes to modulate ROS production by RET. The preliminary results of this 
project are discussed in Chapter 5. Future aims involve investigating the 
downstream targets of ROS production by RET in cells, including the response of 
AMPK. 	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2.1 General materials and methods 
2.1.1 Chemicals and consumables 
All chemicals and consumables were obtained from Sigma-Aldrich, UK or Merck 
unless otherwise stated. 
2.1.2 Quantitative and qualitative protein assays and reagents 
2.1.2.1 Antibodies  
All antibodies used were purchased from Sigma-Aldrich, UK unless otherwise 
stated, and were polyclonal antibodies unless otherwise stated as being 
monoclonal.  
2.1.2.1.1	  Primary antibodies and Western blot working dilution   
§ rabbit-acetyl coA carboxylase (ACC) isoform 1/2: (Cell Signalling 
Technology (CST): 3662), 1:1,000 (dilution); 
§ rabbit-ACC1/2-phosphoS79:	  (CST: 3661), 1:1,000; 
§ rabbit-AMP-activated protein kinase (AMPK) subunit α isoform 1/2: 
(CST: 2532), 1:1,000; 
§ rabbit-AMPKα1/2-phosphoT172 monoclonal (mAb) 40H9: (CST: 2535), 
1:1,000; 
§ rabbit-AMPKβ1/2 mAb 57C12: (CST: 4150), 1:1,000; 
§ rabbit-AMPKγ1: (CST: 4187), 1:1,000; 
§ rabbit-AOX: from Professor Howy Jacobs, Institute of Biotechnology, 
University of Helsinki (originally supplied by 21st Century Biochemicals 
(Marlboro, MA))(Fernandez-Ayala et al., 2009), 1:50,000;  
§ mouse-FLAG® M2 mAb: (F1804), 1:1,000; 
§ rabbit-glyceraldehyde 3-phosphate dehydrogenase (GAPDH): (G9545), 
1:10,000; 
§ rabbit-manganese superoxide dismutase (MnSOD):	   (Abcam: ab13534), 
1:5,000; 
§ mouse-Myc mAb 4A6: (Merck Millipore: 05-724), 1:1,000; 
§ rabbit-myogenin mAb [EPR4789]: (Abcam: (ab124800), 1:1,000; 
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§ rabbit-NDI1: from Professor Takao Yagi, The Scripps Research Institute, 
Department of Molecular and Experimental Medicine, San Diego, California, 
USA (Seo et al., 1998), 1:1,000; 
§ mouse-peroxiredoxin 2 (Prx 2): (Abcam: ab50862), 1:4,000; 
§ rabbit-Prx 3: (Abcam: ab73349), 1:500; 
§ rabbit-Prx-SO3: (Abcam: ab16830), 1:2,000; 
§ rabbit-Sip2 (yeast ortholog of mammalian AMPKβ) mAb: from Professor 
David Carling, MRC Clinical Sciences Centre, Hammersmith Hospital 
Campus, London, UK (Woods et al., 1996), used for immunoprecipitation 
(0.3 μl serum/100-200 μg whole cell protein); 
§ mouse-α-tubulin mAb B-5-1-2:	  (T5168), 1:8,000; 
§ rabbit-voltage-dependent anion channel (VDAC): (Abcam: ab15895), 
1:1,000; 
§ mouse-VDAC mAb 20B12AF2:	  (Abcam: ab14734), 1:5,000. 
2.1.2.1.2 Secondary antibodies and Western blot working dilution 
§ IRDye® 800 goat-anti-rabbit IgG (H&L):	  (Rockland Antibodies and Assays: 
611-132-003), 1:20,000; 
§ IRDye® 680RD goat anti-mouse IgG (H+L):	   (LI-COR Biosciences: 926-
68070); 1:40,000.  
2.1.2.2 Bicinchoninic acid assay 
Concentrations of purified protein or cell lysate were determined using a 
Bicinchoninic acid (BCA) assay kit (Pierce TM), for use with 96-well microplates 
(Costar®) and a microplate reader (SpectraMax® Plus 384 Microplate Reader), 
recording absorbance at 562 nm. Samples were diluted in 1% (v/v) Triton X-100 
(Tx100) and measured against a 7-part standard curve of Bovine Serum Albumin 
(BSA) (diluted 0 – 1 mg/ml in 1% (v/v) Tx100). Diluted protein samples were 
normalised against a 1% (v/v) Tx100 blank reaction spiked with protein 
reconstitution buffer or cell lysis buffer. All samples, standards and blanks were 
loaded in triplicate wells.  
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2.1.2.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Purified protein or cell lysate (mass of protein as indicated in the individual 
experiment) was heated in an appropriate volume of 4X Laemmli sample buffer 
(125 mM Tris (pH 6.8), 4% (w/v) sodium dodecyl sulphate (SDS), 40% (v/v) 
glycerol, 25 mg bromophenol blue and freshly added reducing agent (50 mM DTT 
or 10 mM TCEP)) for 5 min at 95˚C. For non-reducing SDS-PAGE, reducing agents 
were omitted from the sample buffer. Samples were loaded on Mini-PROTEAN® 
TGXTM Precast 7.5%, 10%, 12% or 4-20% gradient gels (BIO-RAD), depending on 
the molecular weight of the target protein(s). Proteins were electrophoresed at 100 
V (until the loading dye had just run off the gel) using a running buffer containing 25 
mM Tris (pH 8.3), 192 mM glycine, 0.1% (w/v) SDS. Protein standards (5 μl) were 
loaded and electrophoresed alongside samples so that sample protein sizes could 
be estimated from the gel. Precision Plus Protein Dual Color standards (BIO-RAD) 
were loaded on all gels: all bands are visible and stained blue except two reference 
bands (25 kDa and 75 kDa), which are stained pink. For gels with which Western 
blots would later be performed, MagicMark™ XP Western Protein Standard 
(ThermoFisher) was also loaded on gels, which can be visualized by colorimetric 
detection (e.g. Coomassie protein stain) or fluorescent detection (e.g. Odyssey® 
CLx Infrared Imaging System).  
2.1.2.4 Western blotting  
Electrophoresed proteins were transferred to Immobilon®-FL Polyvinylidene 
difluoride (PVDF) membranes (Merck Millipore: IPFL00010) by wet transfer 
performed at 100 V for 1 h at 4˚C.  PVDF membranes were activated in methanol 
for 15 s prior to pre-equilibration of the membranes, gels, filter paper and fiber pads 
in pre-chilled transfer buffer (25 mM Tris, 192 mM glycine, 20% (v/v) methanol, pH 
8.4 (unadjusted) at 4˚C). Post-transfer, the membranes were blocked with 
Odyssey® Blocking Buffer (PBS) (LI-COR Biosciences: 927-40003) for 1 h at RT 
with gentle shaking (Bibby Stuart Platform Rocker STR6 at 30 revolutions/min 
(rpm)). Membranes were incubated in primary antibodies in 4% (v/v) blocking 
buffer in PBST (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 
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0.05% (v/v) Tween-20) or TBST (20 mM Tris, 150 mM NaCl, 0.1% (v/v) Tween-20) 
(both pH 7.4 at RT (adjusted with HCl)) overnight at 4˚C. Membranes were 
incubated in secondary antibodies in 4% (v/v) blocking buffer/PBST or TBST (1 h 
at RT, protected from light). Both the primary and secondary antibody dilutions 
used were specific for the antibody, see 2.1.2.1 Antibodies. All primary antibodies 
were raised in rabbit or mouse. All secondary antibodies were raised in goat and 
specific for either rabbit or mouse IgG. Membranes were washed before and after 
secondary antibody incubations in PBST or TBST at RT (4 – 5 buffer changes in 1 
h). Incubations and washings were performed with gentle shaking (30 rpm). Final 
washings were performed in PBS or TBS (without Tween-20). The signal 
intensities of target bands were measured as fluorescence emission at 680 nm or 
800 nm (depending on the secondary antibody used) with the Odyssey® CLx 
Infrared Imaging System. The signal intensities of target bands were quantified with 
LI-COR Biosciences Image Studio™ Lite software and were normalised against 
those of a suitable protein loading control, such as a protein located in same cell 
subcompartment as the target protein, whose levels in cells tend to remain stable 
and for which there is a sensitive and specific primary antibody. For normalisation, 
the signal intensity of target band was divided by the signal intensity of the control 
band of the same lane so that small differences in total protein loaded between 
samples did not affect the quantification of the target band. Transfer buffer was re-
used up to five times and stored at 4˚C. Blocking buffers and antibody buffers were 
reused up to five times and up to three times, respectively, and stored at -20˚C.  
2.1.2.5 Coomassie Protein Stain 
Coomassie Brilliant Blue R-250 (BIO-RAD: 161-0436) or QC Colloidal Coomassie 
protein stain (BIO-RAD: 161-0803) was used to visualise protein separation on 
SDS-PAGE gels, according to the manufacturer’s guidelines (http://www.bio-
rad.com/en-uk/sku/1610436-coomassie-brilliant-blue-r-250-staining-solution) or 
(http://www.biorad.com/webroot/web/pdf/lsr/literature/10032602.pdf), respectively.  
Gels were scanned using an Epson perfection V750 Pro scanner. 
Chatper 2 – Materials and Methods 
	   61	  
2.1.2.6 Ponceau S reversible protein stain  
To visualise protein transfer to PVDF membranes (and any transfer inefficiencies 
due to air bubbles etc.), PVDF membranes (prior to blocking) were incubated in 
Ponceau S reversible protein stain for 10 min at RT with gentle shaking. The stain 
was decanted and the membranes washed 3 – 5 times in Milli-Q (MQ) H2O to 
remove background stain and allow visualisation of protein bands. Protein bands 
were destained with further washings in MQ H2O before incubating the membranes 
in blocking buffer and continuing with Western blotting.  
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2.2 Mammalian cell culture 
2.2.1 Cell culture media, buffers, reagents and cell lines 
§ Standard medium: Dulbecco's Modified Eagle’s Medium (DMEM) 
(Gibco™): high glucose (4.5 g/l) or low glucose (1.0 g/l), GlutaMAX™ (2 
mM), sodium pyruvate (110 mg/ml); supplemented with 10 % (v/v) fetal 
bovine serum (FBS) (E.U.-approved, South American origin, Gibco™), 100 
U/ml penicillin and 100 μg/ml streptomycin (Gibco™); 
§ C2C12 differentiation medium: DMEM: high glucose (4.5 g/l), GlutaMAX™ 
(2 mM), sodium pyruvate (110 mg/ml); supplemented with 1 % (v/v) FBS, 
100 U/ml penicillin and 100 μg/ml streptomycin; 
§ Tetracycline (Tet) - free medium: DMEM: high glucose (4.5 g/l) or low 
glucose (1.0 g/l), GlutaMAX™ (2 mM), sodium pyruvate (110 mg/ml); 
supplemented with 10 % (v/v) tetracycline-free FBS (Clontech), 100 U/ml 
penicillin and 100 μg/ml streptomycin; 
§ Cell freezing medium: 90% (v/v) FBS, 10% (v/v) dimethyl sulfoxide 
(DMSO) (Fisher BioReagents); 
§ Phosphate-buffered saline (PBS): Dulbecco's phosphate-buffered saline 
(Gibco™) without calcium, magnesium or phenol red; 
§ Trypsin: Trypsin-EDTA (0.25%), phenol red (Gibco™); 
§ Cell lines: C2C12 mouse myoblast cell line (American Type Culture 
Collection (ATCC)); Human Embryonic Kidney (HEK 293) cell line (ATCC); 
Flp-In™ T-REx™ 293 cell line (Thermo Fisher Scientific);  
Flp-In™ T-REx™ 293-NDI1 stable cell line & Flp-In™ T-REx™ 293-AOX 
stable cell lines (both generated in this body of work); C2C12-mito-roGFP-
ORP1 & C2C12-cyto-roGFP-ORP1 stable cell lines (laboratory stocks 
generated by Andrew R. Hall, (MRC Mitochondrial Biology Unit, University of 
Cambridge, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, 
Hills Road, Cambridge CB2 0XY, UK)). See Appendix A for expression 
vectors used in generation of stable cell lines.   
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2.2.2 Growth and maintenance of cell lines 
Cell lines were typically cultured in T75 or T125 (Thermo Scientific™, Nunclon™ 
Delta treated, vented) flasks in standard DMEM medium (high glucose), unless 
otherwise stated. Cells were incubated in a humidified atmosphere (5% CO2/95% 
air) at 37 °C and routinely subcultured (at ~ 70% confluency). For subculturing, 
standard medium and PBS were pre-warmed from 4°C to 37°C in a water bath and 
trypsin was pre-warmed from 4°C to RT. In the cell culture hood, medium was 
aspirated and cells were washed in 5 ml PBS. PBS was aspirated and 5 ml trypsin 
was added to cells. For adherent cells (e.g. C2C12 cells), excess trypsin was 
aspirated, leaving ~ 1 ml trypsin and cells were incubated at 37°C for 3 - 5 min. 
Cells were then resuspended by gentle pipetting up and down after addition of 9 ml 
standard medium. For semi-adherent cells (e.g. HEK 293 cells), cells were 
incubated in 5 ml trypsin at 37°C for 3 - 5 min before resuspension by gentle 
pipetting up and down after addition of 5 ml standard medium. The cell suspension 
was centrifuged in a 15 ml Falcon tube (1,000 X g for 3 min at RT) to pellet the 
cells. The supernatant was aspirated and cells were gently resuspended in 10 ml 
standard medium by pipetting. Fresh T75 or T125 flasks (containing 10 ml or 25 ml 
standard medium, respectively) were seeded with a 1/10 – 1/50 dilution of cell 
suspension. Media in subconfluent flasks was replaced every 2 - 3 days. 
2.2.3 Freezing, storing and re-thawing cell lines 
Cells in T75 or T125 flasks were trypsinised, resuspended and counted by a 
Trypan Blue Exclusion assay. Cell suspension (10 μl) was mixed with the same 
vol. of Trypan Blue stain 0.4% (Invitrogen™) and the mix was loaded on a 
Countess™ cell counting chamber slide (10 μl per chamber). The concentration of 
live cells (capable of excluding the stain) per ml and the concentration of dead cells 
(where the stain had permeated the plasma membrane) per ml were counted using 
a Countess™ II FL hemocytometer (Invitrogen™). After live cell quantification, the 
cells were pelleted by centrifugation (described above). The supernatant was 
aspirated and cells were gently resuspended in cell freezing medium (described 
above) at a density of 1 - 5 x 106 cells/ml. 1 ml cell suspensions were transferred to 
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cryovials and placed in a Nalgene® Mr. Frosty freezing container (pre-warmed at 
37°C), containing isopropyl alcohol to facilitate a slow (~1°C/min) cooling rate 
required for cell cryopreservation. The container was stored at - 80°C for a 
minimum of 24 h, after which cryovials were transferred to liquid N2 for long-term 
storage. To re-thaw and culture cells, frozen cell stocks were thawed rapidly in a 
37°C water bath before transferring the cell suspension to a fresh T75 flask 
containing 20 ml standard medium (pre-warmed at 37°C). After cell adherence had 
occurred (time depending on the cell line, e.g. ~ 4 h for C2C12s, ~ 24 h for HEK 
293 cells), cell medium was replaced with 10 ml fresh standard medium.  
2.2.4 Differentiation and treatment of C2C12 cells  
C2C12 mouse myoblast cells were terminally differentiated to myotubes by serum 
depletion with C2C12 differentiation medium for seven days (Yoshiko et al., 2002, 
Leary et al., 1998), with media changes every 2 days. Cells were seeded at a 
density of 20,000 cells/cm2 on 6 cm plates or 6-well plates (Nunclon Delta Surface, 
Thermo Scientific) in 3 ml or 2 ml standard medium (respectively) and cultured to ~ 
90 % confluency prior to serum depletion. Experiments were performed 7 or 8 days 
after serum depletion and for these experiments fresh differentiation medium or 
serum-free medium (for H2O2 experiments) was added. Differentiation was 
confirmed by cell shape changes detected by microscopy (single, rounded cells 
changing to elongated, fused cells (Andres and Walsh, 1996, Elkalaf et al., 2013)) 
and Western blotting for a marker of differentiation, myogenin, which is expressed 
from initiation of differentiation (Yoshiko et al., 2002, Andres and Walsh, 1996). 
Although in the initial days of serum depletion protein expression levels of 
myogenin varied between batches, expression levels became stable from day 5 of 
serum depletion (Figure 2.1).  
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A      B 
	  
C      D 
 
E      F 
 
Figure 2.1 C2C12 myoblast to myotube differentiation is accompanied by cell shape and 
protein profile changes. (A & B, E & F) C2C12 myoblasts were plated on 6 cm plates at 20,000 
cells/cm2 in high glucose standard medium. When cells reached ~ 90% confluency (day 0), 
myoblast to myotube differentiation was induced by serum depletion (replacing standard medium 
with differentiation medium). Cells were cultured for a further 8 days with differentiation medium 
changes every 2 days. (A & B) C2C12 myoblasts photographed (A) prior to differentiation (day 0) or 
(B) after differentiation (day 8 of differentiation media). Cells were visualised in bright-field using a 
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Nikon Eclipse TS100 inverted routine microscope (10X lens X 4X objective) and photographed 
using a QImaging QIClick™ digital CCD camera attachment. Photographs show whole field of view;  
(C & D) Cells were plated and treated as described in 2.7 Live cell confocal microscopy and 
imaging. Undifferentiated (C) and differentiated (D) C2C12-cyto-roGFP-ORP1 cells imaged using a 
Zeiss LSM 880 confocal microscope (63X objective, oil lens), excitation: 488 nm, emission: 500 – 
550 nm (E) Cells were lysed in Hepes lysis buffer supplemented with DTT and protease inhibitors 
(see 2.4.1 Buffers/reagents for AMPK assays). SDS-PAGE (~ 25 μg protein per well) and 
Western blots were performed as previously described. Post blocking, PVDF membranes were cut 
horizontally with a razor blade (as indicated by the grey dotted line) and each section was 
individually incubated with the appropriate primary antibody for the Mw range of that section, 
indicated by band descriptions (see 2.1.2.1.1 Primary antibodies). Rabbit and mouse primary 
antibodies were differentially labeled with fluorescent secondary antibodies (see 2.1.2.1.2 
Secondary antibodies).	   Western blots were imaged using the Odyssey® CLx Infrared Imaging 
System (fluorescence emission at 800 nm for myogenin or 680 nm for α-tubulin); (F) The Western 
blot signal intensity of myogenin (quantified with LI-COR Biosciences Image Studio™ Lite software) 
was normalised to that of α-tubulin as a loading control and expressed as % day 0. Graphed data 
represents mean ± range of n = 2 biological replicates, except day 7 (n = 1).  
2.2.5 Maintenance of the Flp-In™ T-REx™ 293 host cell line 
Flp-In™ T-REx™ 293 host cells were cultured in T75 flasks in 10 ml standard 
medium. 24 h after seeding, cell medium was replaced with fresh standard medium 
supplemented with 100 μg/mL zeocin (Invitrogen) to select for cells that contain a 
Flp Recombination Target (FRT) recombination site in the genome, linked to the 
lacZ-Zeocin™ fusion gene which confers zeocin resistance. The medium was also 
supplemented with 15 μg/ml blasticidin (Invitrogen) to select for cells that stably 
express the tetracycline (Tet) repressor gene. The Tet repressor gene in the host 
cell genome is under the same transcriptional control as a gene conferring 
blasticidin resistance. Therefore, cells resistant to both zeocin and blasticidin have 
the genetic properties that allow Flp-recombinase dependent gene integration and 
tetracycline-dependent gene expression. Cell medium was replaced every 2 – 3 
days with standard medium supplemented with freshly added blasticidin and 
zeocin. 
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2.2.6 Exogenous gene expression in cells 
2.2.6.1 Standard transfection procedure 
For transfection, cDNA vectors were diluted to the desired concentration in Opti-
MEM I Reduced Serum Media (Gibco™), (see for further details: 2.2.6.2 Transient 
gene expression, and 2.2.6.3 Transfection, selection and maintenance of 
stable, inducible Flp-In™ T-REx™ 293 cell lines). The final vol. of DNA/ Opti-
MEM I mix = 150 μl per 6 cm cell plate to be transfected. In parallel, 
Lipofectamine® 2000 (Thermo Fisher Scientific) was diluted in Opti-MEM I 
(Lipofectamine® 2000 (15 μl) + Opti-MEM I (135 μl) per 6 cm cell plate). The DNA/ 
Opti-MEM I mix (150 μl) was added to the Lipofectamine® 2000/Opti-MEM I mix 
(150 μl). The final 300 μl mix was mixed gently and allowed to rest at RT for 5 min. 
The final mix was then pipetted drop-wise (using a Gilson P1,000 Pipetman) over 5 
– 10 s onto plated cells in 3 ml standard medium (~ 70 % confluent at time of 
transfection) and the plates were swirled gently before replacing in the incubator.  
2.2.6.2 Transient gene expression  
HEK 293 cells were plated at a density of 20,000 cells/cm2 on 6 cm plates in 3 ml 
standard media. At 60 - 70% confluency, cells were transfected with 1 μg DNA of 
each cDNA vector. 24 h after transfection, cells were lysed and assayed by 
Western blot to confirm translation of the novel or over-expressed protein of 
interest. 
2.2.6.3 Transfection, selection and maintenance of stable, inducible Flp-In™ 
T-REx™ 293 cell lines 
Flp-In™ T-REx™ 293 host cells were plated on 6 cm plates at a seeding density of 
20,000 cells/cm2 in 3 ml Tet-free medium. When ~ 60 - 70% confluent, cells were 
transfected with a total of 3 μg DNA per plate (2.7 μg pOG44 Flp recombinase 
expression plasmid + 0.3 μg pcDNA5/FRT/TO expression vector (containing the 
gene of interest)), see Appendix A for sequences. 24 h later, cells were 
trypsinised and transferred to a T75 flask in 10 ml Tet-free medium. 24 – 48 h later, 
cell medium was replaced with 10 ml Tet-free medium supplemented with 15 μg/ml 
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blasticidin and 100 μg/ml hygromycin (Invitrogen) to select for cells in which 
integration of pcDNA5/FRT/TO expression vector had occurred (at a Flp-
recombinase dependent site), conferring hygromycin resistance and zeocin 
sensitivity to the cells. Due to low levels of integration, typically > 90% of the cells 
die 2 - 3 days after the initial hygromycin treatment. 3 days post-selection, the cell 
medium was replaced with fresh Tet-free medium supplemented with blasticidin 
and hygromycin, removing the dead cells and allowing the resistant cells to 
repopulate. Medium was replaced every 2 days until 2 – 3 stable cell colonies were 
apparent. Cells were trypsinised and transferred to a T25 flask in 5 ml Tet-free 
medium supplemented with blasticidin and hygromycin to allow the polyclonal cell 
repopulation to proceed. When 70% confluency was reached, cells were 
subcultured and maintained as standard in Tet-free medium supplemented with 
blasticidin and hygromycin. Cells were frozen in 90% (v/v) Tet-free FBS, 10% (v/v) 
DMSO.  
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2.3 Click-PEGylation 
2.3.1 Buffers and reagents  
§ HEND buffer: 25 mM HEPES, 1 mM EGTA, 10 μM neocuproine, 100 μM 
DPTA, 2% (w/v) SDS, pH 7.4 with NaOH; 
§ Purified glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (from 
rabbit muscle): Sigma: G2267, 1 mg protein/ml stock in HEND buffer 
(freshly made before use);  
§ Purified AMP-activated protein kinase (AMPK) (α1/β1/γ1), active, His 
tagged human: Sigma: A1233 
§ Tris (2-carboxyethyl)phosphine hydrochloride (TCEP): (Thermo Fisher 
Scientific: 20490), 500 mM stock in HEND buffer, adjusted to pH 7.4 with 
NaOH, aliquoted and stored at -20°C; 
§ Diamide: (Sigma: D3648), 25 mM stock in HEND buffer, aliquoted and 
stored at -20°C; 
§ Spin columns: Micro Bio-Spin 6, 6,000 MW limit, Tris-buffered (BIO-RAD: 
732–6222); pre-equilibrated in HEND buffer prior to use according to the 
manufacturer’s guidelines; 
§ Propargyl-malemide: (Jena Bioscience: CLK-TA113 or Click Chemistry 
Tools: TA113), 100 mM stock in HEND buffer (freshly made before use);  
§ N-ethylmaleimide (NEM): (Sigma: E1271), 200 mM stock in HEND buffer 
(freshly made before use); 
§ Tris buffer: 50 mM Tris-HCl (pH 7.4), 0.5% (w/v) SDS; 
§ Methoxypolyethylene glycol azide (azide-PEG): azide-PEG5,000 (5 kDa) 
(Sigma: 689475 or Creative PEGworks: PLS-2024), 50 mM in Tris buffer 
(freshly made before use); 
§ L-Ascorbic acid: (Sigma: A5960), 125 mM in Tris buffer (freshly made 
before use), then just before use this was diluted (to minimize pipetting 
error) to 23 mM in Tris buffer containing 10 mM azide-PEG5,000; 
§ Tris[(1-benzyl-1H-1,2,3,-triazol-4-yl)methyl]amine (TBTA): (Sigma: 
678937); 1.7 mM in 80% (v/v) t-butanol:20% (v/v) DMSO, then just before 
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use this was diluted (to minimize pipetting error) to 0.94 mM in Tris buffer 
containing 10 mM azide-PEG5,000; 
§ CuSO4·5H2O: (Sigma: C7631), 50 mM in Tris buffer (freshly made before 
use), then just before use this was diluted (to minimize pipetting error) to 9.3 
mM in Tris buffer containing 10 mM azide-PEG5,000. 
2.3.2 Sample preparation 
Purified protein was reconstituted in HEND buffer at a protein concentration of 
0.1 mg/mL (for GAPDH) or 20 or 10 μg/ml (for AMPK to be detected by Coomassie 
protein staining or by Western blot, respectively), based on the protein 
concentration stated on product information sheets/lot numbers. Protein 
concentration of GAPDH HEND stock was confirmed by BCA assay, as previously 
described. Protein concentration of AMPK HEND stock was not confirmed by BCA 
assay, due to limited availability of stock. To obtain maximally reduced and 
oxidised controls, samples (100 μl starting vol.) were pre-treated with either TCEP 
(10 mM) or diamide (1 mM), respectively, and incubated at 37°C for 30 min with 
gentle shaking (500 rpm, Eppendorf ThermoMixer). Reduced controls were 
bubbled through with N2 gas for 30 s and sealed with Parafilm prior to incubation. 
Afterwards, excess TCEP and diamide was removed by applying samples to a spin 
column.  
2.3.3 Labelling of reduced cysteine residues by Click-PEGred 
The Click-PEGred protocol facilitates labelling of reduced cysteine residues. 
Samples were incubated with 5 mM propargyl-maleimide at 37°C for 30 min with 
agitation (1,000 rpm). Excess propargyl-maleimide was then removed by passing 
samples through a spin column. Optionally, oxidised thiols can then be reduced 
with TCEP (10 mM), and alkylated by reaction with NEM (100 mM), followed by a 
spin column step to remove excess NEM. 
2.3.4 Labelling of oxidised cysteine residues by Click-PEGox 
The Click-PEGox protocol facilitates labelling of reversibly oxidised cysteine 
residues. Samples were first incubated with NEM (100 mM) at 37°C for 30 min with 
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agitation (1,000 rpm) to alkylate reduced thiols. Excess NEM was removed by 
passing the samples through a spin column. The flow-through was treated with 
TCEP (10 mM) to reduce reversibly oxidised thiols, and N2 gas was bubbled 
through the samples for 30 s prior to incubation at 37°C for 30 min with gentle 
shaking (500 rpm). Excess TCEP was removed from the samples by passing 
through a spin column. Samples were then reacted with propargyl-maleimide (5 
mM) at 37°C for 30 min with agitation (1,000 rpm), after which excess propargyl-
maleimide was removed by passing samples through a spin column. 
2.3.5 Click reaction 
It is important to remove chelating agents from the above Click-PEGred and Click-
PEGox samples as they would impede the copper-catalysed Click reaction between 
propargyl-maleimide and azide-PEG. To do this, the protein was precipitated by 
adding ice-cold acetone (4 – 6 vol.) and storing the protein samples at –20°C for a 
minimum of 2 h. Precipitated protein was pelleted by centrifugation (30 min at 
17,000 X g at 4°C) and then the pellet was washed once with ice-cold acetone. The 
resulting pellet was air-dried at 37°C, then resuspended in Tris buffer (28 μl), 
containing azide-PEG5,000 (10 mM). A range of other azide-PEG moieties of 
different sizes are available including: azide-PEG10,000 (10 kDa), azide-PEG2,000 (2 
kDa) and azide-PEG1,000 (1 kDa). The optimal PEG size depends on the molecular 
weight of the protein target and the number of redox-sensitive cysteine residues. 
The sample was then divided into 2 X 12.5 μl aliquots; upon one of which the Click 
reaction would be performed (+ catalyst) with the other serving as a negative 
control (- catalyst).  
To initiate the Click reaction, the copper catalyst is added to the solution to a final 
concentration of 10% (v/v) (or Tris-HCl buffer for the ‘– catalyst’ control). The 
catalyst is composed of 3 reagents, typically added in the following order and 
proportions (Kolb et al., 2001): 125 mM L-ascorbic acid (1 vol.): final concentration 
= 2.5 mM, 1.7 mM TBTA (3 vol.): final concentration = 0.1 mM, and 50 mM copper 
sulphate (1 vol.): final concentration = 1 mM. For a starting sample vol. of 12.5 μl, 
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the vol. of each catalyst reagent to be added would be 0.28 μl, 0.84 μl and 0.28 μl, 
respectively. To avoid pipetteing small volumes that may have high error, catalyst 
components were first diluted into Tris buffer containing 10 mM azide-PEG5,000 (to 
minimise further diluting the azide-PEG5,000 concentration), such that 2 μl of each 
catalyst component (6 μl in total, containing 6.7 mM azide-PEG5,000) were added 
without altering the final concentrations of each catalyst component. Tris-HCl buffer 
containing 6.7 mM azide-PEG5,000 (6 μl) was added for the ‘– catalyst’ control. 
Samples were incubated at 37°C for 1 h at 1,000 rpm. The reaction was stopped 
by adding the appropriate vol. of reducing gel loading buffer to the samples (4X 
Laemmli buffer, supplemented with DTT (50 mM) or TCEP (10 mM)) and heating 
for 5 min at 95 °C, followed by brief centrifugation. Samples were assayed 
immediately or stored at –20°C until required for mass shift analysis by SDS-PAGE 
and coomassie staining/Western blot. 
2.3.6 Preparation of cell lysate samples for Click-PEGylation 
C2C12 mouse myoblast cells were lysed in ice-cold HEND buffer containing 5 mM 
propargyl-maleimide (ClickPEGred protocol) or 100 mM NEM (ClickPEGox protocol), 
incubated at 37 °C for 30 min with agitation (1,000 rpm), sonicated (10 X 1 s pulse; 
Q700 sonicator, Qsonica), centrifuged (13,000 X g for 20 min at 4°C), and the 
protein concentration of the resulting supernatant adjusted to 0.5 mg protein /mL. 
The protein concentration was estimated by lysing a plate of cells from the same 
batch in HEND buffer without propargyl-maleimide or NEM and performing a BCA 
assay on this lysate (propargyl-maleimide and NEM can interfere with the BCA 
assay). For maximal denaturation of complex biological samples, 6 M urea was 
added to the HEND buffer. The Click-PEGred and Click-PEGox protocols were then 
performed as described above for the purified protein samples (100 μl starting 
vol.). 
2.3.7 SDS PAGE and Western blotting for Click-PEGylation 
SDS-PAGE and Western blotting were performed as standard. Samples (~ 2 – 
5 μg for purified GAPDH, ~ 0.5 - 1μg for purified AMPK; ~ 25 μg whole cell protein 
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for complex biological samples) in reducing loading buffer were separated by SDS-
PAGE (typically on a 10% PAGE gel for GAPDH or 7.5% PAGE gel for AMPK), the 
% PAGE gel depending on the size of the target protein and the number of redox-
reactive cysteine residues. Protein bands were either stained directly (with 
Coomassie Brilliant Blue R-250 or QC Coomassie stain for purified protein 
samples) or detected by Western blotting. To quantify redox-dependent mobility 
shifts, Coomassie stained gels or Western blot images were analysed for profile 
plots of lanes or relative band signal intensities, measured using FIJI or Li-Cor 
Image Studio Lite software, respectively. 
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2.4 AMPK assays 
2.4.1 Buffers and reagents  
§ Hepes buffer: 50 mM Hepes, 50 mM sodium fluoride, 5 mM sodium 
pyrophosphate, 1 mM EDTA, 10 % (v/v) glycerol, pH 7.4 at 4°C. To this was 
added just before use: 1 mM dithiothreitol (DTT) (from a 1 M stock made in 
MQ H2O) and protease inhibitors: 4 μg/ml soybean trypsin-chymotrypsin 
inhibitor (from a 4 mg/ml stock made in Hepes buffer), 1 mM benzamidine 
(from a 1 M stock made in Hepes buffer) and 0.1 mM 
phenylmethanesulfonyl fluoride (PMSF) (from a 0.1 M stock made in EtOH); 
§ Hepes lysis buffer (HLB): Hepes buffer, 1 % (v/v) Tx-100. To this was 
added just before use: DTT and protease inhibitors (as above); 
§ SAMStide (peptide): (Signal Chem: S07-58) 1 mM stock made in Hepes 
buffer containing DTT and protease inhibitors as above, aliquoted, snap 
frozen and stored at -80°C.  
§ Kinase assay mix (15 μl per reaction): 333.3 μM AMP (5 μl 1 mM stock 
made in Hepes buffer), 333.3 μM SAMStide (5 μl 1 mM stock made in 
Hepes buffer), HLB (5 μl). Hepes buffer and HLB contained DTT and 
protease inhibitors as above; 
§ SAMStide blank assay mix (15 μl per reaction): 333.3 μM AMP (5 μl of 1 
mM stock made in Hepes buffer), Hepes buffer (5 μl), HLB (5 μl). Hepes 
buffer and HLB contained DTT and protease inhibitors as above; 
§ radiolabelled ATP mix (5 μl per reaction): 100 μCi/ml [γ-32P]ATP (Perkin 
Elmer), 1 mM ATP (from 100 mM stock made in Hepes buffer), 25 mM 
MgCl2 (from 100 mM stock made in Hepes buffer), made up to 5 μl with 
Hepes buffer. Hepes buffer contained DTT and protease inhibitors as above. 	  
2.4.2 Cell lysis  
Immediately after media aspiration, cells for AMPK assays were washed rapidly 
(within seconds) in ice-cold PBS (using a plastic 2 ml Pasteur pipette) on an ice-
cold aluminium block. The PBS was then aspirated and cells were lysed rapidly 
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(within seconds) in ice-cold HLB (250 μl from a Gilson p1000 Pipetman per 6 cm 
plate). Cells were scraped from the plate surface using plastic cell scrapers 
(Sarstedt, 25 cm). Scraped lysate was transferred to ice-cold Eppendorf tubes and 
centrifuged (17,000 X g for 10 min at 4°C). Supernatants were stored on ice for 
immediate use or aliquoted, snap-frozen on dry ice and stored at - 80°C. 
2.4.3 AMPK SAMS kinase assay on whole cell lysates 
The specific kinase activity of AMPK can be determined by the radiometric SAMS 
peptide assay, which measures the incorporation of radiolabelled phosphate from 
[γ-32P]ATP into the SAMS peptide (SAMStide) as it undergoes phosphorylation by 
active AMPK (Hardie et al., 2000). The SAMStide is a synthetic peptide substrate 
of AMPK, derived from the amino sequence of ACC1 (mouse) 
(https://www.signalchem.com/shared_product_sheets/R339-3.pdf), a natural 
phosphorylation target of AMPK.  The SAMStide (HMRSAMSGLHLVKRR) consists 
of residues corresponding to those at positions 73 – 85 of the full-length mouse 
ACC1 protein, with the following modifications: a serine residue at position 77 is 
replaced with alanine (to prevent phosphorylation by cAMP-dependent protein 
kinase) and two arginine residues (which have positively charged side-chains) are 
incorporated at the C-terminal end of the peptide to facilitate binding to negatively 
charged P81 phosphocellulose paper, enabling the removal of unincorporated 
MgATP in washing steps. The SAMStide is phosphorylated by AMPK at the serine 
residue that corresponds to position 79 in the full length mouse ACC1 protein. 
 
Kinase assays were performed on AMPK immunoprecipitated from 100 - 200 μg 
whole cell lysate protein using 0.3 μl Sip2 serum (yeast AMPKβ ortholog antibody) 
and 30 μl protein A (from Staphylococcus aureus) - Sepharose® beads (Sigma: 
P9424) (50 % (v/v) slurry in Hepes buffer). The beads were pipetted with cut-off 
pipette tips (∼ 3 mm was cut off the narrow end of the pipette tips with a clean razor 
blade) to avoid trapping beads in the pipette tips. Immunoprecipitation was 
performed in a total vol. of 250 μl (made up with HLB) in 1.5 mL Eppendorf tubes at 
4˚C for 2 h with overhead rotation. Washings were performed by addition of 1 X 1 
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ml HLB (followed by centrifugation (1,000 x g for 1 min at 4˚C) and supernatant 
aspiration (using gel loading tips to avoid pipetting the beads)), and then 2 x 500 μl 
Hepes buffer washings (as above). The beads were then resuspended in 40 μl 
Hepes buffer (with cut-off pipette tips) and divided into 4 x 10 μl aliquots in 1.5 ml 
Eppendorf tubes, each equivalent to ¼ of the whole cell protein from which AMPK 
was immunopreciptated. 
 
Kinase assays were performed on duplicate aliquots alongside one blank assay 
(without SAMStide). Kinase assays were performed with the addition of 15 μl 
kinase assay mix (or blank assay mix without SAMStide) and initiated with 5 μl 
radiolabelled ATP mix. Reactions were incubated at 37˚C for 30 min before 
spotting 25 μl onto P81 phosphocellulose paper (Whatman). The papers were 
washed to quench the reaction and wash off any unbound γ-32P, first with 1% (v/v) 
phosphoric acid (3 x 500 ml) with vigorous stirring (decanted in the sink), then MQ 
H2O (2 x 500 ml). The papers were then added to 3 ml organic scintillant (Ultima 
Gold™ AB) and phosphorylation of the SAMS peptide by active AMPK was 
measured by scintillation counting, measured as counts per minute. 
 
The specific radioactivity of the radiolabelled ATP mix was measured by spotting 5 
μl radiolabelled ATP mix (5 nmol ATP) onto P81 paper (in duplicate) followed by 
immediate scintillation counting (no washings). The mean specific kinase activity of 
AMPK (nmol γ-32P/μg cell protein/min) was measured as follows, where counts per 
minute = CPM; specific radioactivity = SR (CPM.nmol-1); incubation time = T (min); 
kinase reaction vol. = V (μl): 
 
CPM (mean kinase – blank) X total V (30 μl) 
SR (CPM.nmol-1) X pipetted V (25 μl) X T (30 min) X cell protein (25 - 50 μg)	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2.4.4 AMPK and ACC phosphorylation assays 
The kinase activity of AMPK can also be assayed by Western blot, where 
phosphorylation at T172 of the AMPKα1/2 catalytic subunit and phosphorylation of 
the downstream target ACC1/2 at S79 can be detected with antibodies to the 
phospho-specific epitopes (Hardie et al., 2000). Total AMPK and ACC levels can 
be monitored with antibodies to the AMPKβ1/2 subunits and to the ACC1/2 protein, 
respectively. For same-gel signal intensity normalization, the signal intensity of the 
phospho-specific epitopes of AMPK and ACC can both be normalised to the signal 
intensity of the AMPKβ1/2 subunit to control for changes in total expression of 
AMPK. Whole cell lysate (25 μg protein) was electrophoresed in reducing, 
denaturing conditions on 4 – 20 % gradient SDS-PAGE gels as described in 
2.1.2.4 SDS-PAGE. Following wet transfer to PVDF membranes and blocking as 
described in 2.1.2.5 Western blotting, membranes were sectioned (with a clean 
razor blade) at the 50 kDa molecular weight marker and at the 100 kDa molecular 
weight marker (Precision Plus Protein™ Dual Color Standards (BIO-RAD)).  The ‘0 
– 50 kDa’ membrane section was incubated with rabbit-AMPKβ1/2 primary 
antibodies (AMPKβ1 ∼ 38 kDa, AMPKβ2 ∼ 30 kDa), the ‘50 – 100 kDa’ membrane 
section was incubated with rabbit-AMPKα1/2-phosphoT172 primary antibodies (∼ 
62 kDa) and the ‘> 100 kDa’ membrane section was incubated with rabbit-ACC1/2-
phosphoS79 (ACC1 ∼ 265 kDa, ACC2 ∼ 280 kDa) primary antibodies. Antibody 
catalogue numbers and Western blot dilutions are listed in 2.1.2.1.1 Primary 
antibodies. Following overnight incubation and washings, the membrane sections 
were incubated with the same goat-α-rabbit fluorescent secondary antibodies (see 
2.1.2.1.2 Secondary antibodies) and washed as previously described. TBS was 
used instead of PBS for all buffers and washings. Membrane sections were 
visualized simultaneously using the Odyssey® CLx Infrared Imaging System 
(fluorescence emission at 800 nm) and target bands quantified using the LI-COR 
Biosciences Image Studio™ Lite software. The signal intensity of AMPKα1/2-
phosphoT172 and ACC1/2-phosphoS79 bands were normalised to the signal 
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intensity of AMPKβ2 bands to control for changes in AMPK protein expression 
after a given treatment.  	    
Chatper 2 – Materials and Methods 
	   79	  
2.5 Measuring cell and tissue ATP/ADP ratios by 
bioluminescence 
2.5.1 Background 
The luciferase/luciferin bioluminescence reaction can be utilised in a sensitive 
assay to measure adenosine triphosphate (ATP) and adenosine diphosphate 
(ADP) in extracts from cells and tissues (Strehler, 1974). The concentrations of 
luciferin and luciferase are fixed, allowing the ATP concentrations in unknowns to 
be determined against ATP standards by measuring light production in a 
luminometer. Furthermore, ADP in cells and tissues can be measured by first 
degrading the endogenous ATP with ATP sulfurylase and then enzymatically 
converting endogenous ADP to ATP using a pyruvate kinase/phosphoenolpyruvate 
mix (Figure 2.2). 
 
 
Figure 2.2 Reactions involved in measurement of ATP and ADP by luciferase/luciferin 
bioluminescence. (A) Photons are produced in proportion to ATP, D-luciferin and luciferase 
concentrations; (B) ATP sulfurylase catalyses the adenylation of sulfate using ATP, producing APS 
and PPi; (C) Pyruvate kinase catalyses the phosphorylation of ADP, forming ATP and pyruvate.  
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Nucleotides are extracted from cells or snap-frozen tissue samples using perchloric 
acid to rapidly denature any endogenous proteins that may alter the relative levels 
of ATP, ADP and adenosine monophosphate (AMP) in vitro, primarily adenylate 
kinase, and to stabilise pH-labile adenine nucleotides. The acidified, deproteinised 
extract is then neutralised with potassium hydroxide (in the presence of the pH 
buffer MOPS), forming a KClO4 precipitate. Enzymatic reactions are then performed 
on the neutralised supernatant. 
2.5.2 Stock Solutions  
§ ADP and ATP stock solutions: 20 mM stocks (sodium salts) in HCl-acidfied 
H2O (pH 1 – 2), snap frozen in 100 μl aliquots, stored at -80°C;  
§ Perchloric acid (HClO4) extractant (PCA): 3% (v/v) HClO4, 2 mM 
Na2EDTA, 0.5% (v/v) Triton X-100, stored at 4°C; 
§ Potassium hydroxide solution (KOH): 2 M KOH, 2 mM Na2EDTA, 50 mM 
MOPS, stored at 4°C; 
§ Tris-acetate (TA) buffer: 100 mM Tris, 2 mM Na2EDTA, 50 mM MgCl2 (pH 
7.75 with glacial acetic acid), stored at 4°C;  
§ D-Luciferin sodium salt: 2 mM in TA buffer, snap frozen in 200 μl aliquots 
in opaque Eppendorf tubes and stored at -80°C;  
§ Luciferase from Photinus pyralis (firefly): 1 mg lyophilised preparation 
(~150 μg luciferase protein) in 1.86 ml TA buffer (25% (v/v) glycerol) (~ 80 μg 
protein/ml), snap frozen in 100 μl aliquots in opaque Eppendorf tubes and 
stored at -80°C;  
§ Phosphoenoylpyruvate cyclohexylammonium salt (PEP): 114 mM in TA 
buffer, snap frozen in 150 μl aliquots and stored at -80°C;  
§ Tris-HCl buffer: 100 mM Tris-HCl, 10 mM MgCl2 (pH 8.0) stored at 4°C; 
§ Guanosine 5′-monophosphate disodium salt hydrate (GMP): 100 mM in 
Tris-HCl buffer, stored at 4°C; 
§ Sodium molybdate (Na2MoO4): 1 M in MQ H2O, stored at 4°C; 
§ Bovine serum albumin (BSA) fatty acid free (Sigma): 100 mg/ml in TA 
buffer snap frozen and stored at -80°C; 
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2.5.3 Working solutions (prepared just before use) 
§ 2X ATP sulfurylase assay buffer (250 μl per reaction): 20 mM Na2MoO4, 
5 mM GMP, 0.2 U ATP sulfurylase (New England Biolabs), Tris-HCl buffer to 
250 μl, stored on ice until use; 
§ Pyruvate kinase / PEP mix (10 μl per reaction):  100 mM PEP, 6 U 
pyruvate kinase suspension (type II, from rabbit muscle: P1506), stored on 
ice until use; 
§ Luciferase/Luciferin mix (100 μl per reaction): 7.5 mM DTT (from 1 M 
stock made in MQ H2O), 0.4 mg/ml BSA, 1.92 μg luciferase/ml, 120 μM 
luciferin, TA buffer (25% (v/v) glycerol) to 100 μl, stored at RT (protected 
from light).  
2.5.4 Preparation of ATP and ADP standard curves 
ATP and ADP (20 mM stocks) were thawed quickly at 37°C and then serially diluted 
in ice-cold PCA to make 10-part standard curves, typically ranging between 0 (100 
% v/v PCA) and 20 μM in 1 ml aliquots. Standards were stored on ice and 400 μl of 
each standard was carried forward to the neutralization step.  
2.5.5 Nucleotide extraction from cells 
C2C12 cells were plated at a density of 20,000 cells/cm2 on 6 cm plates and 
differentiated as previously described. Cells were washed rapidly in ice-cold PBS 
on an ice-cold aluminium block (as for AMPK assays) and rapidly lysed in ice-cold 
PCA (500 μl per 6 cm plate). Lysed cells were scraped from the plate surface with 
a plastic cell scraper and lysate was transferred to 1.5 ml Eppendorf tubes stored 
on ice. Tubes were vortexed and centrifuged (17,000 X g for 10 min at 4°C) to 
pellet the insoluble material. Supernatants were diluted 1:5 in 1 ml PCA and 
maintained on ice for immediate use or snap frozen (along with undiluted PCA 
extracts) and stored at -80°C. 400 μl of the diluted PCA extracts were carried 
forward to the neutralization step.  
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2.5.6 Nucleotide extraction from tissues 
2.5.6.1 Porcine heart tissue biopsy freezing, storage and homogenization: 
Core needle biospies (Celero vacuum assisted biopsy device) (diameter: ~ 1 mm, 
length: 5 – 10 mm, weight: ∼ 5 mg) were excised immediately (within ∼ 5 s), snap 
frozen in liquid nitrogen (suspended from a clean forceps) for ∼ 15 s and 
transferred to pre-chilled cryotubes (Nunc®, 1.8 ml) on dry ice. Biopsies were 
transferred and stored at – 80°C until further preparation. Prior to nucleotide 
extraction, biopsies were mechanically homogenised using a pestle and mortar 
(Haldenwanger™ 5500, unglazed, 20 ml). A pestle, mortar, forceps and spatula 
were pre-chilled on dry ice for 30 min. Wearing cryogloves and safety glasses, 
liquid nitrogen was poured into the mortar (maintained on dry ice in a Styrofoam 
container) and the frozen biopsy was transferred into the liquid nitrogen in the 
mortar. The frozen biopsy was rapidly homogenised (5 – 10 s) in the mortar with 
the pestle, under liquid nitrogen. After the liquid nitrogen had evaporated, the 
resulting frozen powder was scraped into a pre-chilled cryovial (on dry ice) with a 
spatula and maintained on dry ice. The pestle, mortar and spatula were washed 
thoroughly in ethanol and MQ H2O between biopsy homogenizations. On a fine 
balance (Sartorius®, CP124S), samples of frozen homogenate (1 - 5 mg) were 
rapidly weighed into pre-chilled (on dry ice) Eppendorf tubes, using a pre-chilled 
spatula and forceps to transfer and handle the homogenate and cold tubes, 
respectively. The weighed homogenate was rapidly returned to dry ice until 
nucleotide extraction.  
 
2.5.6.2 Nucleotide extraction from tissue homogenate:	  Ice-cold PCA (1 ml) was 
added to weighed homogenate (on dry ice) and the solution was vortexed 
immediately for ∼10 s until the sample was fully dissolved. Tubes were centrifuged 
(17,000 X g for 20 min at 4°C). Acidified supernatants were stored on ice and 
diluted to 1 mg frozen homogenate extract /ml PCA in 500 μl aliquots.  Diluted PCA 
extracts were used immediately or snap frozen (along with the remaining undiluted 
PCA extracts) and stored at -80°C. 
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2.5.7 Neutralisation of PCA extracts and standards 
Ice-cold PCA extracts, ATP and ADP standards (400 μl) had their pH adjusted to 
pH 7 – 7.5 by addition of ice-cold KOH solution (containing MOPS as a pH 
buffering agent) of about 110 – 118 μl (vol. optimised on test samples). Each tube 
was vortexed immediately after KOH addition for 5 s until formation of a white 
precipitate (KClO4). Samples were replaced on ice to allow the precipitate to settle. 
The pH of the neutralised supernatant was tested by pipetting 2 μl of each sample 
onto pH indicator strips (Sigma, pH 4.5 – 10.0). If a sample remained too acidic, a 
further 4 μl of KOH was added, the sample vortexed and the pH re-checked. This 
step was repeated until the optimum pH was achieved. Samples with a pH > 8 
were discarded in favour of fresh acidified extracts/standards, as nucleotides are 
unstable in basic solutions. After neutralization was confirmed, the white KClO4 
precipitate in all samples was pelleted by centrifugation (1,000 X g for 1 min at 
4°C) and supernatants were stored on ice. The vol. KOH added to the standards 
(initially 400 μl) was noted so as to later calculate nucleotide concentrations. As 
cell and tissue ATP and ADP content is expressed as a ratio, the differences in vol. 
of the KOH additions between samples do not affect the ratio.  
2.5.8 ATP/ADP measurements 
Light emission from the luciferase/luciferin reaction in the presence of ATP (from 
standards and extracts) was recorded using a luminometer (Berthold Technologies 
AutoLumat LB 953 Multi-Tube luminometer; software: Eg&g Berthold Tubemaster 
Version 1.0 (1997-99)) fitted with an autoinjector to deliver the luciferase/luciferin 
solution to individual tubes. Samples were loaded in luminometer tubes (Sarstedt 
Rohren tubes (5 ml, 75 X 12 mm, PS)). TA buffer (400 μl) was added to all 
luminometer tubes (and maintained at RT) before sample additions, as follows: 
§ ATP measurement in ATP standards: neutralised ATP standard 
supernatant (100 μl) was added to TA buffer (400 μl) in luminometer tubes 
(in duplicate or triplicate); 
§ ATP measurement in samples: neutralised sample supernatant (100 μl) 
was added to TA buffer (400 μl) in luminometer tubes; 
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§ ADP à  ATP measurement in ADP standards: neutralised ADP standard 
supernatant (100 μl) was added to TA buffer (400 μl) in luminometer tubes 
(in duplicate). PK/PEP cocktail (10 μl) to be added later to convert the ADP 
to ATP; 
§ ADP àATP measurements in samples: neutralised sample supernatant 
(250 μl) was added to 2X ATP sulfurylase assay buffer (250 μl), vortexed 
briefly and incubated at 30°C for 20 min with gentle shaking. Samples were 
centrifuged (17,000 X g for 1 min at RT), boiled at 100°C for 5 min and 
cooled on ice. ATP sulfurylase-treated sample (the ATP should now be 
degraded) (200 μl) was added to TA buffer (400 μl) in luminometer tubes (in 
duplicate). PK/PEP cocktail (10 μl) to be added later to one of the duplicate 
tubes to convert the ADP to ATP. The other duplicate tube (without addition 
of PK/PEP cocktail) serves as an ATP ‘blank’ value.  
Luminometer preparation: The autoinjector was washed (6 x 100 μl injections) 
with 0.5 M HCl, then washed with 0.5 M NaOH and finally washed three times with 
MQ H2O. The washings (collected in luminometer tubes) were discarded. Just 
before running the samples, the autoinjector was primed (6 x 100 μl injections) with 
freshly made Luciferase/Luciferin mix. The mix was collected in a clean 
luminometer tube and recycled back into the working stock Falcon tube for use in 
the assay.   	  
Sample running: Prepared luminometer tubes containing samples and standards 
were placed in the luminometer. PK/PEP cocktail (10 μl) was added to all tubes 
requiring an ADP à ATP conversion. The tubes were mixed gently and replaced in 
the luminometer in the correct order. All tubes were incubated in the luminometer 
for 30 min at 30°C to allow the ADP à ATP conversion to proceed. The assay was 
commenced with the following settings: read time: 30 s, background read time: 5 s, 
cycle time: 40 s, post-injection delay: 5 s, total time: 80 s, temp.: 30°C, injection 
vol.: 100 μl.  	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Signal quantification and analysis:	   	   Emitted light, recorded as Relative Light 
Units (RLU) was analysed using Microsoft Excel and GraphPad Prism 5.0. Vol.- 
corrected ATP standard curve values (pmol ATP per tube) were plotted against 
corresponding RLU values (expressed as mean and range/SEM of 
duplicates/triplicates). A linear regression was performed to assess the linearity of 
the standard curve (see Figure 2.3 for typical standard curves). Then the RLU 
values of the samples (for ATP and ATP ‘blank’ measurements) were plotted 
against the standard curve and unknown values (pmol ATP) were interpolated from 
a linear regression analysis. The unknown pmol ATP values of the vol.- corrected 
ADP standards were similarly interpolated from this standard curve.  The linearity 
of the ADP à ATP conversion standard curve was assessed by plotting these 
interpolated pmol ATP values against their corresponding mean RLU values and 
performing a linear regression. The RLU values corresponding to ADP à ATP 
conversion measurements from samples were then plotted against this linear ADP 
à ATP conversion standard curve and unknown pmol ATP values were 
interpolated from this data set by performing a linear regression analysis.  Finally, 
the ratio of ATP/ADP in the samples was calculated as follows:  
 
Sample ATP values (pmol ATP) 
Sample ADP values (pmol ATP) – sample ATP ‘blank’ values (pmol ATP). 
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A      B 
 
 
 
C 
 
 
Figure 2.3 Example of an ATP/ADP ratio measurement experiment: comparing cardiac left 
ventricle ATP/ADP ratios before and after alternate methods of organ reperfusion in a 
preclinical model of deceased circulatory donation (DCD) heart transplantation. (A & B) 
Typical ATP and ADP standard curves. Data points are mean ± range of n = 2 technical replicates. 
(C) In a side project with collaborator Simon J. Messer (Department of Cardiovascular Surgery, 
Papworth Hospital NHS Foundation Trust, Cambridge, UK)	   et al.: Functional and biochemical 
comparisons of alternate methods of DCD heart transplantation in a pig model (research article in 
submission), I measured ATP/ADP ratios in left ventricle core needle biopsies. Data is expressed as 
mean ± SEM of n = 6 biological replicates. Statistical analysis was performed using two-way ANOVA 
with a Bonferroni multiple comparisons post test comparing ATP/ADP ratio recovery during reperfusion 
by DPP or NRP (method) over different time-points (OCS + 15 to 150 min). There was no statistically 
significant difference between the two methods of reperfusion. Method: P = 0.2470, Time: P = 0.8955. 
DPP: direct procurement and perfusion; NRP: normothermic regional perfusion; ECMO: Extracorporeal 
membrane oxygenation; OCS: Organ Care System (TransMedics™).   
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2.6 Peroxiredoxin dimerisation assays  
2.6.1 Buffers and reagents  
§ Radioimmunoprecipitation (RIPA) buffer: 150 mM sodium chloride, 1.0 % 
(v/v) Triton X-100, 0.5 % (w/v) sodium deoxycholate, 0.1 % (w/v) SDS, 50 
mM Tris, pH 8.0 at 4°C; 
§ methyl methanethiosulfonate (MMTS): 500 mM in PBS (freshly made in 
fume hood before use); 
§ Prx lysis buffer (working stock):	  RIPA buffer containing 80 mM freshly 
made MMTS. To this was added protease inhibitors, as previously 
described. 
2.6.2 Cell treatment and lysis  
After desired cell treatments, MMTS was added directly to cell medium to a final 
concentration of 80 mM (from 500 mM stock) to alkylate thiols and prevent artificial 
oxidation occurring during lysis (Sobotta et al., 2013). Cells were incubated for 10 
min in an externally vented hood. Then, transferred onto an ice-cold aluminium 
block, medium was aspirated and cells were washed rapidly in ice-cold PBS (as for 
2.4 AMPK assays). Ice-cold Prx lysis buffer (250 μl per 6 cm plate) was rapidly 
added to cells. Cells were scraped from the surface with a plastic scraper, 
transferred to pre-chilled Eppendorf tubes and stored on ice. Tubes were 
centrifuged (17,000 X g for 10 min at 4°C) to pellet undissolved material.  
2.6.3 Non-reducing SDS-PAGE and Western blotting 
The protein concentration in the supernatants was estimated by performing a BCA 
assay on a control cell plate without MMTS treatment, because the high 
concentration of MMTS in the sample lysates can interfere in protein quantification. 
Test sample supernatant (~ 25 μg protein) was then added to 4X Laemmli sample 
buffer without reductant. Samples were heated at 95°C for 5 min. Samples were 
electrophoresed on 4-20% SDS-PAGE gels. Western blot was performed with 
primary antibodies to Prx 2 (mouse) and Prx 3 (rabbit) on the same membrane or 
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individually on duplicate membranes, and then differential labeling using goat-α-
mouse and goat-α-rabbit secondary antibodies, respectively (see 2.1.2.1 
Antibodies for catalogue numbers and Western blot dilutions). The Western blot 
signal intensities (SI) of Prx 2 and Prx 3 dimers were quantified using LI-COR 
Biosciences Image Studio™ Lite software, normalised against those of their 
respective monomer bands and expressed as % dimer (% dimer = (SI dimer / (SI 
dimer + SI monomer)) x 100). Absolute SI for both monomer and dimer (total of 
one or multiple bands where present) were used for quantification (i.e. dimer signal 
intensity was not halved). 	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2.7 Live cell confocal microscopy and imaging  
2.7.1 Background 
C2C12-mito-roGFP-ORP1 and C2C12-cyto-roGFP-ORP1 stable cell lines were 
generated by Andrew R. Hall (MRC Mitochondrial Biology Unit, University of 
Cambridge, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, Hills 
Road, Cambridge CB2 0XY, UK). The cells stably express redox-sensitive Green 
Fluorescent Protein (roGFP) coupled to Orp1 (glutathione peroxidase, S. 
cerevisiae) to improve sensitivity to H2O2. The mito-roGFP-ORP1 probe is targeted 
to the mitochondria by a mitochondria targeting sequence (MTS) so detects 
mitochondrial H2O2 and cyto-roGFP-ORP1 detects cytosolic H2O2 (Gutscher et al., 
2009). The presence of a dithiol/disulphide switch alters the excitation spectra of 
GFP (488 nm (green label) and 405 nm (blue label), respectively) enabling a 
ratiometric fluorescent read-out of thiol oxidation by H2O2.  
2.7.2 Cell preparation and imaging  
C2C12-mito-roGFP-ORP1 cells or C2C12-cyto-roGFP-ORP1 cells were plated on 
glass coverslips in 6-well plates (20,000 cells per cm2) in 2 ml standard media. 
Cells were terminally differentiated to myotubes as previously described and 
imaged on day 8 of serum depletion. Undifferentiated cells (myoblasts) were plated 
at the same density and imaged 24 h later. Prior to imaging, coverslips were placed 
in Attofluor cell chambers (Thermo Fisher) and 1 ml standard media was added. 
Cells were imaged using a Zeiss LSM 880 confocal microscope (63X objective, oil 
lens) with imaging intervals every 30 s for 1 h. Emitted light was collected between 
500 – 550 nm for both excitation wavelengths. Videos were exported as 
uncompressed avi files and processed in FIJI. Single time-point images were 
exported as tiff files.   	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2.8 Seahorse XF96 Respirometry  
2.8.1 Background 
The Seahorse XF96 Analyser measures respiration in live cells in real time in a 
multi-well plate. The respiration calculations are automated, as are plate 
calibrations, compound injections and mixing. Cell respiration (measured as 
oxygen consumption rate (OCR)) is measured following sequential injections of 
selective inhibitors of respiratory chain complexes or FOF1ATP synthase, and can 
thus be used to measure key parameters of respiration (Figure 2.4). Respiration 
can be measured with and without test conditions or additions of test compounds to 
interrogate the effects of the variables on cellular respiration.  
 	  
	  	  
Figure 2.4 Model of mitochondrial respiration as measured by the Seahorse XF96 Analyser. 
Measurable parameters of mitochondrial function: basal respiration, ATP production, proton leak, 
maximal respiration and spare respiratory capacity. 	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2.8.2 Buffers and reagents  
§ Seahorse assay medium: DMEM base (Sigma) (4.15 g/l), glucose (1 g/l), 
GlutaMAX™ supplement (2 mM), sodium pyruvate (110 mg/l), phenol red 
(15 mg/l), HEPES (20 mM), pH 7.4 at 37°C with NaOH. Assay medium was 
supplemented with Tet-free FBS (0.4% (v/v), 100 U/ml penicillin and 100 
μg/ml streptomycin. 
§ Seahorse XF96 well culture plates (Agilent) 
§ Seahorse XF96 sensor cartridges (Agilent) 
§ Calibrant solution (Agilent) 
§ Stock solutions: oligomycin (126 mM), rotenone (10 mM), FCCP (10 mM), 
antimycin A (90 mM) (all made in EtOH). 
2.8.3 Cell preparation  
Flp-In™ T-REx™ 293 - NDI1 (Doxycycline inducible) cells were plated at a density 
of 50,000 cells/ well of a Seahorse XF96 well culture plate in low glucose (1 g/l) 
Tet-free medium (see 2.2.1 Cell culture media, buffers, reagents and cell 
lines), supplemented with blasticidin (15 μg/ml) and hygromycin (100 μg/ml) (200 
μl/well). Cells were plated ± Doxycycline (1 μg/ml). 24 h later, cell medium was 
replaced with Seahorse assay medium (180 μl/well), following a cell wash in the 
same medium. The cell plate was incubated in a CO2-free incubator for 1 h at 37ºC 
prior to assay.   
2.8.4 Seahorse XF96 Analyser preparation and running 
Sensor cartridges were incubated in calibrant solution overnight in 
a CO2-free incubator at 37ºC (200 μl/well). On day of assay, injector ports were 
loaded with compounds (diluted in Seahorse assay medium), and incubated at 
37ºC, see Table 2.1. Assays were performed at 37°C according to the 
manufacturer’s guidelines: http://www.agilent.com/en-us/products/cell-analysis-
%28seahorse%29/seahorse-analyzers/seahorse-xfe96-analyzer/basic-procedures-
to-run-an-xf96-assay.  
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Table 2.1 Seahorse XF96 port injections.  	    
Port Compound Conc. (10 X) Injection vol. (μl) 
(10% of well vol.) 
A oligomycin 10 μM 20 
B FCCP 10 μM 22 
C rotenone 2 μM 24 
D antimycin A 50 μM 27 
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2.9 Molecular cloning 
2.9.1 Escherichia coli growth media  
All media was prepared and autoclaved in the Media Kitchen, MRC/Wellcome 
Trust Building, Cambridge Biomedical Campus, Hills Road, Cambridge, UK. 
§ LB broth + Ampicillin (AMP): 0.5% (w/v) yeast extract, 1% (w/v) tryptone, 
0.1 mM NaCl, pH 7.0, 100 μg/ml ampicillin; 
§ LB agar + AMP: 0.5% (w/v) yeast extract, 1% (w/v) tryptone, 0.14 mM 
NaCl, 1.5% (w/v) agar, pH 7.4, 100 μg/ml ampicillin; 
§ SOC transformation media: 0.5% (w/v) yeast extract, 2% (w/v) tryptone, 
10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2.6H2O, 20 mM glucose, pH 7.0 
2.9.2 cDNA vectors 
pWPI-NDI1 and pWPI-AOX vectors were a gift from Dr. Alberto Sanz (Institute for 
Cell and Molecular Biosciences & Newcastle University Institute for Ageing, 
Newcastle University, Newcastle, UK)(Scialo et al., 2016). AMPK subunit 
expression vectors pcDNA3-AMPKα2-CT-FLAG, pcDNA3-AMPKβ1 and pcDNA3-
AMPKγ1-NT-Myc were a gift from Professor David Carling (MRC Clinical Sciences 
Centre, Hammersmith Hospital Campus, London, UK). See Appendix A for 
sequences.  
2.9.3 Molecular subcloning strategy 
Mammalian cell expression vectors containing different genes of interest were 
created by molecular subcloning, strategy outlined in (Figure 2.5). Methods 
described below are accompanied by examples from a project that involved 
subcloning a cDNA sequence for a single subunit NADH dehydrogenase, NDI1 or 
an alternative oxidase, AOX (both alternative respiratory enzymes) from a pWPI 
donor plasmid into a pcDNA5/FRT/TO recipient expression vector. All scale 
plasmid maps and annotations were created using SerialCloner 2-6-1 and 
restriction sites were confirmed using NEBCutter V2.0. Molecular cloning of AOX 
was perfomed by Aonghus McCarthy (MRC Mitochondrial Biology Unit, University 
of Cambridge, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, 
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Hills Road, Cambridge CB2 0XY, UK) in the course of a summer studenship 
sponsored by the Amgen Scholars programme, Cambridge 2016. 
 
 
 
Figure 2.5: A mammalian cell expression vector containing a novel gene of interest (GOI) 
created by molecular subcloning. This was performed using enzymatic restriction digest to cut a 
double-stranded (ds) recipient expression vector (plasmid) of choice at two different sites in the 
Multiple Cloning Site (MCS) and then inserting a ds cDNA gene of interest (flanked by compatible 
restriction sites) into the MCS of the expression vector in the correct orientation and reading frame, 
creating a novel expression vector. The ds cDNA gene of interest was initially amplified from a 
donor plasmid by PCR and modified to include flanking restriction sites.   
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2.9.4 Agarose Gel Electrophoresis 
Linear dsDNA (plasmid fragments) were separated according to size (bp) by 
agarose gel electrophoresis. Agarose gels (0.8 % (w/v) or 1.0 % (w/v)) were made 
by heating (in a microwave) agarose in a conical flask in 100 ml (per gel) TAE 
buffer (40 mM Tris (pH 7.6), 20 mM acetic acid, 1 mM EDTA) until fully dissolved. 
GelRed™ (Biotium) was added to the agarose (cooled enough so that the flask 
could be held comfortably) to allow visualisation of DNA under UV light. The 
agarose was poured into horizontal gel chambers (Engineering & Design Plastics 
Ltd - Laboratory Equipment and Electrophoresis Division: EM100 - Mini Gel Unit) 
and a 10-well comb was inserted. After the gel had set, TAE buffer was poured 
over the gel in the chamber until both gel and electrodes were fully submerged and 
the well combs were then removed. Samples were loaded in Purple Loading Dye 
without SDS (NEB) and electrophoresed at 100 V for ~ 30 min to separate DNA 
fragments of different sizes. A 1 kbp DNA ladder (Invitrogen: 15615-016) was 
loaded along with the samples to estimate fragment size. According to the 
manufacturer’s guidelines (tool.thermofisher.com/content/manuals/15615016.pdf), 
the ladder has an upper range composed of 1 – 12 repeats of a 1018 bp DNA 
fragment, combined with a lower range of plasmid DNA fragments ranging between 
75 and 1636 bp, and is suitable for sizing DNA fragments between 500 bp and 12 
kbp.  DNA was visualised using a UV Transilluminator (ChemiDoc™ XRS+ System 
(BIO-RAD) with Image Lab™ Software).  
2.9.5 DNA quantification 
2.9.5.1 Circular DNA quantification 
Plasmid DNA was quantified with a NanoDrop™ 8,000 Spectrophotometer. The 
instrument was initially zeroed with DNAase-free H2O (Qiagen) and then blanked 
with DNA elution buffer (10 mM Tris-HCl, pH 8.5) or TE buffer (10 mM Tris-HCl, 1 
mM disodium EDTA, pH 8.0).  A ratio of absorbance at 260 nm to that at 280 nm of 
~1.8 was considered pure for DNA. The 260/230 ratio is a secondary measure of 
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purity, with 2.0-2.2 considered pure for DNA, whereas a lower ratio indicates 
contaminants. 
2.9.5.2 Linear DNA quantification (approximation) 
Linear dsDNA was approximately quantified by densitometry using Image Lab™ 
software (Figure 2.6). A serial dilution of DNA sample of unknown mass was 
electrophoresed on an agarose gel alongside a serial dilution of 1 kbp DNA ladder 
(Invitrogen) of known concentration (1 μg DNA/μl). The ~1.6 kbp band contains ~ 
10% of the mass applied to the gel, according to the manufacturer’s guidelines 
(https://tools.thermofisher.com/content/sfs/manuals/15615016.pdf). Therefore, a 
serial dilution of 1 kbp ladder can be used to assess the approximate mass of DNA 
present in samples of unknown concentration.  
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Figure 2.6.  Linear dsDNA quantification (approximation) by densitometry. (A) A serial dilution 
of 1 kbp ladder of known concentration (1 μg/μl) was applied to the gel, (following dilution in 
DNAase-free H2O and addition of an appropriate vol. of 6X loading buffer). The ~1.6 kbp band 
(highlighted in red) contains ~ 10% of the mass loaded on the gel (e.g. 2 μl equivalent of 1 kbp 
ladder = 2 μg DNA in total; ~1.6 kb band ~ 200 ng DNA). Known vol. of linear PCR product 
(unknown concentration) were also loaded on the gel. After electrophoresis, the DNA in the gel was 
visualized using a UV transilluminator (at 300 nm, appropriate for GelRed™ nucleic acid stain) and 
the image scanned and exported. The image was imported into Image LabTm and signal intensities 
(SI) of the 1.6 kbp bands of the DNA ladder of known mass (standard curve) were recorded. (B) 
These values were exported to GraphPad Prism 5.0 and a linear regression was performed: SI 
versus DNA mass (ng). (C) The SI of the PCR product bands were then recorded (in Image Lab™) 
and plotted (in GraphPad Prism 5.0) alongside vol. to assess SI-vol. linearity (in red). The mass of 
the PCR product bands were then interpolated from the standard curve (expressed as SI) by linear 
regression. The calculated masses were then plotted alongside their equivalent volumes (linear 
regression through zero), with the slope of the line estimating the PCR product DNA concentration 
(ng/μl ± standard error). All data points are n = 1.  
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2.9.6 Enzymatic restriction digest 
All restriction enzymes (RE) and buffers were purchased from New England 
Biolabs (NEB).  Cohesive-end RE digest of plasmid or PCR-amplified DNA was 
performed in a total vol. of 20 or 50 μl in the presence of DNAase-free H2O, 
compatible buffer (CutSmart® where appropriate, containing 50 mM potassium-
acetate, 20 mM Tris-acetate, 10 mM magnesium-acetate, 100 μg/ml BSA, pH 7.9 
at 25°C) and 10 U of each RE per 1 μg DNA. Reactions were performed at 37°C 
for 1 h at 500 rpm (unless otherwise indicated). When restriction sites were 
selected (Figure 2.7), the online resource, NEBCloner™ 
(http://nebcloner.neb.com/#!/redigest) was referred to for buffer compatibility and 
reaction time guidelines. Typically, RE digests were performed on small amounts of 
plasmid DNA (diagnostic tests) (Figure 2.8) before digesting larger amounts for 
ligation reactions, to assess the ability of selected REs to cut the DNA at expected 
sites. Plasmid DNA (250 ng) was digested by 1 or 2 REs (for single and double-
digests, respectively) for diagnostic tests and plasmid DNA or PCR product (1 μg) 
was double-digested for ligation preparation. Post digest, reactions were heated at 
65 or 80°C for 20 min (where indicated) to heat inactivate the REs prior to ligation.  
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Figure 2.7. Scale map of pcDNA5/FRT/TO expression vector highlighting restriction sites. 
Restriction sites KpnI and NotI are present in the Multiple Cloning Site (MCS) and XbaI is present in 
the MCS and at one other site in the vector. RE digest with enzymes KpnI-HF or NotI-HF would 
linearise the vector (cutting one time each), resulting in dsDNA fragments of 5.137 kbp. A double 
digest with KpnI-HF and NotI-HF would create orientation specific ligation sites for a compatible 
insert (5’KpnI, 3’NotI). The restriction site XbaI can be used to aid identification of the vector, as RE 
digest with enzyme XbaI would result in two linear dsDNA fragments, one of 0.572 kbp and one of 
4.57 kbp, and thus the electrophoretic migration pattern of these fragments would act as a 
signature. The scale map was created using SerialCloner 2-6-1, with the pcDNA5/FRT/TO DNA 
sequence imported from the manufacturer’s online resource 
(https://tools.thermofisher.com/content/sfs/vectors/pcdna5frtto_seq.txt). See also Appendix A for 
sequence.  
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Figure 2.8. Diagnostic 1% (w/v) agarose gel of pcDNA5/FRT/TO vector (250 ng per lane) 
digested with REs KpnI-HF, NotI-HF, XbaI or undigested. KpnI-HF and NotI-HF REs efficiently 
digested the vector (presenting as different DNA band migration compared to undigested vector), 
cutting once each as expected (no other DNA bands were visible) and creating bands of the same 
size, although suggesting a higher than expected plasmid size. However, this was likely artifactual 
due to gel heat warping at the top of the middle lanes (not visible). XbaI digested the plasmid DNA 
at two sites as expected, generating two bands that electrophoresed approximately according to 
expected sizes (0.572 kbp and 4.57 kbp). Undigested vector, which can exist in varying circular or 
pseudo-linear conformations (e.g. supercoiled) each affecting gel migration differently, 
electrophoresed further than linear vector.  	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2.9.7 Polymerase Chain Reaction (PCR) 
Target cDNA sequences in plasmids were amplified by PCR (Figure 2.9 - 2.11) in 
a TProfessional Basic Gradient Thermocycler (Biometra). PCR was performed in a 
total vol. of 20 μl (in DNAase-free H2O) with 10 ng template (plasmid) DNA, 
Phusion™ High Fidelity DNA Polymerase (final concentration 0.02 U/ml), GC buffer 
and dNTPs (final concentration 200 μM per dNTP) (Thermo Scientific). Custom 
extension/amplification primers were synthesised by Sigma Genosys 
Biotechnologies and used at a final concentration of 0.5 μM (see Appendix B for 
sequences). Routine PCR was performed as described below (Table 2.2). 
Samples from post-PCR reactions were electrophoresed on agarose gels to 
confirm DNA amplification of product of the desired size (Figure 2.11).   
 
Step Sub-step Temperature (°C) Time (s) 
Initial denaturation  98 30 
Thermocycling Denaturation 98 10 
 Primer annealing varied 30 
 Extension 72 30 (per kbp) 
Final extension  72 600 
Hold  4 Indefinitely 	  
Table 2.2 Routine PCR settings. Primer annealing temperature varied depending on the size of 
the primers. Primer melting temperatures (Tm) were calculated from only the nucleotides 
complementary to the target sequence (NDI1) by referring to the online resource, NEB Tm 
Calculator (http://tmcalculator.neb.com/#!/) which takes into account optimum temperatures for the 
specific polymerase and buffer in the PCR reaction (simplified equation: Tm (°C) = 2° X (A + T) + 4° 
X (G + C)); Primers greater than 20 nucleotides in length were annealed at 3°C above the Tm of the 
lower Tm primer; primers less than 20 nucleotides in length were annealed at the Tm of the lower Tm 
primer. All other PCR settings remained constant.  
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Figure 2.9.  Scale map of pWPI plasmid containing the NDI1 template sequence to be PCR-
amplified. The NDI1 sequence (1541 nt) did not contain internal KpnI or NotI restriction sites (to be 
incorpated onto the 5’ and 3’ ends, respectively, of the NDI1 sequence during PCR to allow 
orientation specific ligation with the pcDNA5/FRT/TO recipient vector). The NDI1 sequence did 
contain an internal XbaI restriction site which was used to help confirm the identity of the eventual 
PCR product. RE digest of the PCR product with enzyme XbaI would result in two linear ds DNA 
fragments (917 bp and 651 bp) whose electrophoretic mobility pattern would aid identification of the 
PCR product. The scale map was created using SerialCloner 2-6-1, using the pWPI-NDI1 DNA 
template imported from Dr. Alberto Sanz (Institute for Cell and Molecular Biosciences & Newcastle 
University Institute for Ageing, Newcastle University, Newcastle, UK) (see Appendix A), who gifted 
me the vector.  
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Figure 2.10 Description of NDI1 PCR primers and the expected PCR product. (A) The forward 
primer was designed to introduce a 5’ KpnI restriction site and a modified Kozak consensus 
sequence (to aid initiation of translation) before the start codon (ATG) of NDI1; the reverse primer 
was designed to introduce a NotI restriction site after the NDI1 stop codon; (B) the expected PCR 
product size was 1568 bp. The scale map was created using SerialCloner 2-6-1, using the NDI1 
DNA template from the previously described source. 
NDI1 PCR primers:        Description/legend:   Tm:
Forward: TTA ATC GGT ACC GCC ACC ATG CTA TCG AAG AAT TTG TAT 5’ -KpnI-Kozak-Start-NDI1-3’  54°C
Reverse: CG GGT AGC GGC CGC CTA TAA TCC TTT AAA AAA GTC TCT T 5'-NDI1-Stop-NotI-3'   55°C
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Figure 2.11 Diagnostic agarose gels of the NDI1 PCR product. (A) Diagnostic 1% (w/v) agarose 
gel of 1 μl of NDI1 post-PCR mix which confirmed amplification of a single product which 
electrophoresed to the ~ 1.6 kbp DNA marker. (B) Diagnostic 1% (w/v) agarose gel of 1 μl of NDI1 
post-PCR mix restriction digested with XbaI which cut the PCR product into two fragments 
(expected: 917 bp and 651 bp) due to the XbaI site in the middle of the NDI1 sequence, the 
electrophoretic mobility pattern offering evidence of the identity of the PCR product.    
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2.9.8 Dephosphorylation of recipient vector 
RE digest introduces 5’ phosphate groups, which are required for ligation to occur. 
In order to inhibit recipient vector self-ligation (in cases where double-digestion was 
incomplete) and promote ligation between the recipient vector and a 5’ 
phosphorylated insert, the double-digested recipient vector was dephosphorylated 
with Antarctic Phosphatase (NEB). Typically, 1 μg DNA was desphosphorylated 
with 5 U Antarctic Phosphatase in the presence of Antarctic Phosphatase Reaction 
Buffer (50 mM Bis-Tris-Propane HCl, 1 mM MgCl2, 0.1 mM ZnCl2, pH 6.0 @ 25°C). 
Samples were incubated at 37°C for 1 h and then heat inactivated at 65°C for 5 
min or at the temperature and time required to heat inactivate any active REs still 
present (according to the manufacturer’s guidelines).  
2.9.9 Gel purification 
PCR amplified cDNA sequences or linear RE-digested vectors were gel purified 
prior to further processing (RE-digestion or ligation). This was done to isolate and 
purify linear cDNA of a specific size from a PCR reaction or vector backbone and 
also to remove primers and other contaminants which may inhibit further enzymatic 
reactions. Samples were loaded onto 0.8 % (w/v) agarose gels, as previously 
described, and visualised using UV light. DNA bands were cut from the gel using a 
clean razor blade and placed in a pre-weighed, sterile 1.5 ml Eppendorf tube. The 
Eppendorf tube was weighed again to calculate the gel mass and DNA was purified 
from the gel using a QIAquick Gel Extraction Kit (Qiagen), according to the 
manufacturer’s instructions. Briefly, the gel slice (containing DNA) was melted 
(65°C, 10 min) in a high salt, acidic buffer (3 vol. buffer QG : 1 vol. gel) to provide 
the optimum pH (pH ≤ 7.5) for DNA binding to the silica spin column provided in the 
same kit. DNA was then washed on the column, first with QG buffer (to remove 
agarose), then with an ethanol-containing buffer that removes salts and other 
contaminants that do not bind to the column. DNA was eluted from the column in a 
low salt, basic elution buffer (10 mM Tris·Cl, pH 8.5).  
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2.9.10 DNA ligation 
Double digested, dephosphorylated recipient vector and double digested, 5’ 
phosphorylated PCR product were ligated in a 3 : 1 (insert : vector) molar ratio 
calculated as follows:  	  
Required mass insert (ng) = desired insert : vector molar ratio (3)  x mass of vector 
(50 ng) x ratio of insert : vector lengths (variable). 	  
Ligation was performed in a total vol. of 20 μl, containing vector DNA (50 ng) and 
insert DNA (variable), T4 DNA Ligase Buffer (50 mM Tris-HCl, 10 mM MgCl2, 1 mM 
ATP, 10 mM DTT, pH 7.5 @ 25°C (NEB)), DNAase-free H2O and 5 U T4 DNA 
ligase (NEB). The reaction was mixed gently, centrifuged (1,000 X g for 1 min) and 
incubated at RT overnight. The ligation mix was heat inactivated at 65°C for 10 min 
prior to transformation.  
2.9.11 Bacterial transformation  
In order to isolate and amplify the novel ligated vector, 40 μl XLI-Blue 
electrocompetant E. coli (Aligent Technologies) were transformed with 1 μl ligation 
mix by electroporation in an electroporation cuvette (2 mm gap, Flowgen 
Bioscience). Warm SOC media (960 μl) was then added to the bacteria in the 
electroporation cuvette and incubated at 37°C for 1 h. The E.coli/SOC broth was 
then plated (20 μl) on LB-agar plates containing 100 µg/ml ampicillin and incubated 
at 37°C overnight in order to select for bacterial colonies resistant to ampicillin 
(conferred by the intact vector). The transformation efficiency of the ligation mix 
was compared to that of 1 μl circular, undigested vector as a positive control 
(Table 2.3). E. coli were also transformed with 1 μl ‘ – insert’ ligation mix (double-
digested dephosphorylated vector (50 ng), T4 DNA Ligase Buffer, DNAase-free 
H2O and 5 U T4 DNA ligase (NEB), total vol. 20 μl, incubated for the same time as 
the ‘ + insert’ ligation mix) as a negative control to assess the background 
presence of undigested vector or self-ligated vector, as only circular plasmids and 
not linear DNA fragments are taken up by E.coli during transformation. 
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Plate Plasmid Insert (NDI1 PCR 
product, double-
digested) 
Colonies per plate 
1 Undigested pcDNA5/FRT/TO - > 1,000 
2 Double-digested, dephosphorylated 
pcDNA5/FRT/TO 
- 19 
3 Double-digested, dephosphorylated 
pcDNA5/FRT/TO 
+ ~ 70 
 
Table 2.3. Example of analysis of transformation efficiency. XLI-Blue electrocompetant E. coli 
were transformed with 1 μl of undigested pcDNA5/FRT/TO vector as a positive control (plate 1), 
plated on an LB-agar plate containing 100 μg/ml ampicillin and incubated overnight at 37°C as 
described above. Colony growth (> 1,000 colonies) was evidence of viability of the E.coli and the 
effectiveness of the transformation protocol.  As a negative control (plate 2), E. coli were 
transformed with 1 μl of ‘- NDI1 insert’ ligation mix to assess the relative amount of undigested 
vector or self-ligated vector. The presence of 19 colonies was evidence of some intact vector 
present in mix, suggesting that there might be some false positives on the test plate; E. coli were 
transformed with 1 μl of the ‘+ NDI1 insert’ ligation mix (plate 3). The presence of ~ 70 colonies 
suggested that there would be ~ 3.5 times more positive colonies (containing NDI1-ligated vector) 
on the test plate than false-positive colonies (containing undigested or self-ligated vector).  
 
2.9.12 Isolating plasmid DNA from bacterial colonies for 
diagnostic tests	  	  
Plasmid DNA was purified from bacterial colonies by the QIAprep Spin Miniprep Kit 
(Qiagen), according to manufacturer’s instructions.  Briefly, 3 ml aliquots of LB 
broth + AMP (in 15 ml Falcon tubes) were inoculated with individual bacterial 
colonies from LB agar + AMP plates (typically 20 colonies per batch). Cultures 
were grown overnight at 37°C with agitation. Cultures were pelleted by 
centrifugation (5,000 X g for 5 min at RT). Supernatant was decanted and pellets 
were resuspended in a buffer containing RNAase A, which degrades single-
stranded RNA. 1 vol. of alkaline lysis buffer was added to the resuspension and 
mixed thoroughly. After 3 - 5 min, the solution was pH neutralised by addition of 
neutralisation buffer, which has a high salt content to promote DNA binding to the 
silica column. The neutralised solution was centrifuged (17,000 X g for 10 min at 
RT) to separate DNA-containing supernatant from the precipitate. The supernatant 
was passed through a silica spin column. Salts were removed from the silica-bound 
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DNA with an ethanol-containing buffer.  Finally, DNA was eluted in a low salt 
elution buffer (10 mM Tris·Cl, pH 8.5). 
2.9.13 Identification of plasmid DNA in transformed E.coli by RE- 
digest  
Samples of mini-prep plasmid stocks from transformed E.coli were RE double-
digested with the same REs used to ligate the insert to the vector backbone (KpnI-
HF and NotI-HF). Samples were electrophoresed alongside a DNA ladder. 
Samples that linearized into 2 fragments (one having the approximate size of the 
vector backbone and the other having the approximate size of the desired insert 
(Figure 2.12 & 2.13)) were marked as potential positive samples. Potential positive 
samples were sent for DNA sequence analysis to confirm the identity of the 
plasmid and to rule out any de novo mutations (see Appendix A). 
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Figure 2.12  Scale map of the expected pcDNA5/FRT/TO plasmid containing the NDI1 gene. 
The pcDNA5/FRT/TO recipient vector was double digested at the KpnI and NotI RE sites and 
dephosphorylated (with Antarctic phosphatase) prior to ligation (with T4 DNA ligase) to a PCR-
amplified NDI1 insert double digested at flanking 5’KpnI and 3’NotI RE sites (introduced by PCR). 
Ligation was performed overnight at RT. To isolate ligated vector, XL1 Blue electrocompetant E.coli 
were transformed with 1 ul of ligation mix. Transformed E.coli were selected on LB plates + AMP 
(overnight at 37°C) and propogated in LB broth + AMP (overnight at 37°). Plasmid DNA was 
isolated by Qiagen Miniprep. Positive clones were identified first by RE digest and then confirmed 
by DNA sequence analysis. The scale map was created using SerialCloner 2-6-1, using the 
pcDNA5/FRT/TO template (digested in silico at the KpnI and NotI RE sites) and the expected NDI1 
PCR product (digested in silico at the KpnI and NotI RE sites).  
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Figure 2.13 Isolated plasmid DNA extracted from transformed E.coli diagnosed by RE double 
digest followed by agarose gel electrophoresis. Unidentified plasmid DNA from transformed 
E.coli (250 ng) was double digested by RE enzymes KpnI-HF and NotI-HF and electrophoresed on 
a 1% (w/v) agarose gel. Plasmid DNA that digested into two fragments, one of ~1.6 kbp, was 
marked as a potential positive clone (pcDNA5/FRT/TO-NDI1) and sent for Sanger DNA sequencing 
for confirmation.   
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2.9.14 DNA sequence analysis 
Plasmid DNA was sequenced by Sanger sequencing (Source Bioscience), using 
stock primers or custom primers (see Appendix B for sequences) where 
necessary. Samples were diluted to 100 ng DNA /μl in TE buffer before sample 
submission.  
2.9.15 Isolating endotoxin-free vector for mammalian cell 
transfection  
In order to prepare a large quantity of endotoxin-free vector for mammalian cell 
transfection, bacteria were retransformed with the plasmid of interest and isolated 
as described above. New colonies that formed after plating on LB-agar + AMP 
plates were picked and grown in LB broth + AMP and DNA was isolated according 
to the Qiagen Midi-prep protocol (below), quantified by Nano-drop and sent for 
Sanger sequencing analysis. (qiagen.com/cn/resources/resourcedetail?id=c164 
c4ce-3d6a-4d18-91c4-f5763b6d4283&lang=en).  
2.9.16 Creation of bacterial glycerol stocks for long-term storage  
An overnight culture of transformed bacteria in LB broth + AMP (500 μl) was mixed 
with 500 μl of 50 % (v/v) glycerol (in MQ H2O) in a cryovial. Glycerol stocks were 
snap frozen on dry ice and stored at -80°C.  	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2.10 Statistical analysis   
Data analysis was performed with GraphPad Prism 5.0. Results (n = 2) were 
expressed as mean ± range. Results (n ≥ 3) were analysed by unpaired, one-tailed 
t-tests (2 groups) or one-way analysis of variance (ANOVA) (> 2 groups), typically 
with Dunnet’s post-tests (comparing all columns to control) (unless otherwise 
stated) and expressed as mean ± standard error of the mean (SEM). P-values < 
0.05 were considered statistically significant.  	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3.1 Introduction 
The redox state of cysteine thiols is critical for protein function. Whereas cysteines 
play an important role in the maintenance of protein structure through the formation 
of internal disulfides, their nucleophilic thiol groups can become oxidatively 
modified in response to diverse redox challenges and thereby function in signalling 
and antioxidant defences. These oxidative modifications occur in response to a 
range of agents and stimuli, and can lead to the existence of multiple redox states 
for a given protein. To assess the role(s) of a protein in redox signalling and 
antioxidant defence, it is thus vital to be able to assess which of the multiple thiol 
redox states are present and to investigate how these alter under different 
conditions.  
As discussed in Chapter 1, AMPK, a master regulator of cell metabolism and 
mitochondrial biogenesis, has been a focus of interest in the redox biology field. 
ROS have been investigated as an atypical regulator of AMPK by several potential 
redox mechanisms, including by direct cysteine oxidation of the catalytic subunit. 
However, direct redox-regulation of AMPK in cells is not uniformly observed 
(Emerling et al., 2009, Auciello et al., 2014, Hawley et al., 2010). Also, the effects 
on AMPK redox-state and activity by different sources of ROS (i.e. cytosolic versus 
mitochondrially-derived ROS) have not yet been compared. As previously 
discussed, mitochondrially-derived ROS is of particular interest as a redox signal, 
with several labs including our own having described how ROS production by RET 
could be a potential way in which mitochondria relay information about the 
metabolic state and demands of the cell. Thus, it remains necessary to be able to 
readily measure the redox state of AMPK in cells and tissues (as well as 
measuring AMPK activity and cell adenine nucleotide ratios) in order to determine if 
different sources of ROS directly alter AMPK activity (e.g. through cysteine thiol 
oxidation) or if ROS only alters AMPK activity indirectly (e.g. by decreasing ATP 
levels or by inhibiting upstream phosphatases). 
A number of methods are available to assess the redox state of protein thiols, the 
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most quantitative of which are redox proteomic approaches utilising mass 
spectrometry, such as OxICAT (Held et al., 2010, Leichert et al., 2008). These 
untargeted approaches can both identify the cysteine residues affected and 
quantify the extent of oxidation. However, these screens are time-consuming and 
coverage is often biased towards abundant proteins. In addition, detection of 
cysteine residues by mass spectrometry can be complicated by their location within 
regions that are challenging to access using currently available proteases 
(Verrastro et al., 2015). Therefore, candidate protein approaches based on 
antibody binding are often used in parallel to enable low abundance proteins to be 
interrogated (e.g. specific kinases), or to obtain a more complete redox profile of 
the protein of interest. Typically, the redox-altered protein thiols are selectively 
tagged to a large group, such as a polyethylene glycol (PEG) moiety connected to 
a maleimide compound (Burgoyne et al., 2013). Maleimide compounds react 
relatively selectively and irreversibly with thiol groups through the formation of a 
thioether bond. Samples can then be separated by electrophoresis, and probed 
with an antibody against the protein of interest, avoiding the need to purify proteins 
prior to analysis. PEGylated cysteines will cause a mobility shift, and the result will 
typically show a series of bands corresponding to different redox forms of the 
protein interrogated. Providing an appropriate antibody is available for the protein 
itself or for an epitope tag on the protein (if existing), the extent of the redox 
modification for even low abundance proteins can be quantified quickly and 
cheaply. However, a limitation of this approach is that the reaction of a cysteine 
residue with a large (typically ~2 – 5 kDa) reactive PEG moiety can be slow, 
leading to incomplete reaction with protein thiols. 
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3.2 Aims and strategy 
To investigate redox modifications of AMPK in cells, my aim was to develop a more 
robust and flexible method for redox-selective PEGylation. Here I have utilised a 
Click chemistry approach, where free thiol groups are first labelled with a small and 
reactive reagent modified to contain an alkyne moiety, which is subsequently Click-
reacted with a PEG molecule containing a complementary azide function (Figure 
3.1). This strategy can be adapted to study reduced or reversibly oxidised 
cysteines. Separation of the thiol labelling step from the PEG conjugation 
enhances the fidelity and flexibility of this candidate protein approach. The method 
was initially optimised using purified glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) as an exemplar protein, then adapted to analyze GAPDH in cell lysates, 
and finally AMPK became the focus of continued Click-PEGylation experiments.  
 
 
 
 
Figure 3.1. Click-PEGyation concept. Reduced thiols are first labeled with an alykating agent 
containing an alkyne group. Then using Click chemistry, a large PEG molecule containing an azide 
group is conjugated to the alkyne. Oxidised thiols are reduced and remain unlabeled by PEG. The 
net effect is electrophoretic mobility shift dependent on the number of PEG-bound thiols groups.  
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3.3 Collaborations and publications 
This work led to a publication: Click-PEGylation – A mobility shift approach to 
assess the redox state of cysteines in candidate proteins (2017) (Free Radic Bio 
Med, 108, 374 – 382) in collaboration with the co-first author Lucie A.G. van 
Leeuwen (LvL hereafter), corresponding author Helena M. Cochemé (both of MRC 
London Institute of Medical Sciences, Du Cane Road, London W12 0NN, UK; 
Institute of Clinical Sciences, Imperial College London, Hammersmith Hospital 
Campus, Du Cane Road, London W12 0NN, UK) and Ellen L. Robb and Michael P. 
Murphy (MRC Mitochondrial Biology Unit, University of Cambridge, Wellcome 
Trust/MRC Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 
0XY, UK)(van Leeuwen et al., 2017) (see Appendix C).  
 
The experimental work discussed below (excluding 3.5 Method Application) was 
divided between LvL and me (the division is described in each figure legend) with 
preliminary experiments performed by Ellen L. Robb (data not shown). All 
experiment design, troubleshooting and optimisation decisions discussed below 
were made by both LvL and me. Prior to publication, I presented a poster of this 
work at the Gordon Research Conference: Thiol-Based Redox Regulation & 
Signalling, 2016 (Stoweflake Conference Center, Stowe, VT, USA) and gave a 
short talk at the associated Gordon Research Seminar for PhD students and post-
doctoral researchers.  
3.4 Method development and results  
3.4.1 Choosing a model protein 
We set out to optimise and assess the potential utility of the Click-PEG protocols 
using GAPDH as an exemplar protein. GAPDH is one of the most well-
characterised redox sensitive proteins. It is the most abundant S-thiolated protein 
during conditions of oxidative stress in yeast, with the thiol oxidation reversibly 
decreasing the enzyme’s activity and therefore acting as a redox switch in 
regulating glycolysis (Grant et al., 1999, Shenton et al., 2002). Initially, we utilised 
purified GAPDH protein from rabbit, which contains 4 cysteine residues, enabling 
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the effectiveness of the Click-PEG reactions to be directly assessed by SDS-PAGE 
and Coomassie protein staining. To test if the Click-PEGylation method is 
applicable to a broad range of proteins of differing sizes, we also tested another 
candidate protein, catalase, which has a higher molecular weight (~ 60 kDa) and 4 
cysteine residues. Having validated the Click-PEGylation technique with purified 
GAPDH and catalase as a proof-of-principle, we next wanted to demonstrate that 
the Click-PEGylation approach can be applied to detect redox state changes of 
target proteins within complex biological samples, such as cell lysates and tissue 
extracts. I looked at GAPDH from lysates of C2C12 mouse myoblast cells, noting 
that mouse GAPDH contains 5 cysteine residues, and not 4 as in rabbit.  
3.4.2 Basic Click-PEGylation protocol 
The basic Click-PEGylation reaction scheme is shown in Figure 3.2. The essence 
of the assay is to differentially label cysteine residues that are unmodified (i.e. 
reduced) and those that are reversibly oxidised, with either a low molecular weight 
thiol alkylating agent, or with one that can be further conjugated to a high molecular 
weight PEG polymer, containing an azide group. In Click chemistry, azide and 
alkyne groups are selectively reacted with each other in the presence of a Cu1+ 
catalyst (Rostovtsev et al., 2002, Tornoe et al., 2002). This assay can be designed 
to PEGylate either the reduced or reversibly oxidised thiols, described as Click-
PEGred and Click-PEGox, respectively.  
 
To label reduced cysteine residues by Click-PEGylation (Click-PEGred Figure 3.2 
(B)), reduced thiols are initially reacted with a maleimide compound containing a 
Click-reactive alkyne moiety (propargyl-maleimide), then subsequently conjugated 
to a large PEG molecule containing a complementary Click-reactive azide moiety 
(azide-PEG), to selectively PEGylate the Click-tagged thiols. The sample can then 
be separated by electrophoresis, and analysed by protein staining or by Western 
blotting. Thus, in Click-PEGred, proteins with reduced cysteine residues undergo a 
mobility shift and appear as higher molecular weight bands, enabling the redox 
state of the protein to be inferred. This basic protocol can also be altered to Click-
Chapter 3 – Click-PEGylation  
	   120	  
PEGylate reversibly oxidised cysteine residues (Click-PEGox, Figure 3.2 (C)), 
providing complementary information. In this case, reduced thiol groups are first 
blocked with N-ethylmaleimide (NEM), before reducing any reversibly oxidised 
thiols with TCEP or DTT and subjecting these to Click-PEGylation. There are 
potential advantages to both approaches depending on the protein of interest and 
its inherent redox status (e.g. if a protein’s thiols exist in a mostly reduced state, 
more obvious redox shifts may be observed by performing Click-PEGox  than Click-
PEGred and vice versa). Most importantly, analysing a sample in parallel by Click-
PEGred and Click-PEGox should generate complementary information that 
enhances confidence in the redox state determined.  
Other advantages of this Click-PEGylation approach are: 1) it can be applied 
simply to the experimental sample, avoiding the slow and difficult direct reaction of 
a bulky maleimide-PEG polymer with cysteine residues; 2) the method could be 
adapted to detect a specific cysteine residue modification selectively, by exploiting 
a particular biochemical reactivity at the labelling stage - e.g. treatment with 
Cu/ascorbate to identify S-nitrosation, dimedone for S-sulfenylation, or 
hydroxylamine for S-acetylation (Jaffrey et al., 2001, Benitez and Allison, 1974, 
Drisdel and Green, 2004); 3) this Click chemistry approach to label cysteine thiol 
groups can be extended by substituting the azide-PEG moiety for any desired 
azide-containing tag to allow other modes of detection, e.g. fluorescence. 
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Figure 3.2. Click-PEGylation schemes. (A) Principle of the Click-PEGylation reaction. A reduced 
thiol is alkylated with propargyl-maleimide, then conjugated with an azide-PEG of high molecular 
weight (e.g. 5 kDa) using copper-catalysed Click chemistry. (B) Click-PEGred reaction to label 
reduced thiols. A protein with two potentially reversibly oxidisable cysteine residues is shown. For 
Click-PEGred, the sample is reacted with propargyl-maleimide to label reduced cysteines, which are 
subsequently derivatised with azide-PEG via Click chemistry. Optionally, oxidised cysteines can 
then be reduced and blocked with NEM before separation by electrophoresis. (C) Click-PEGox 
reaction to label oxidised thiols. Conversely, for ClickPEGox, the sample is first reacted with NEM to 
block any reduced cysteine residues. Next, previously oxidised thiols are reduced, allowing their 
reaction with propargyl-maleimide and derivatisation with azide-PEG. Finally, samples are 
separated by electrophoresis to determine the resulting redox mobility shifts. 	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3.4.3 Assessing the Click-PEGylation protocols using purified 
GAPDH 
The Click-PEGred protocol, designed to facilitate the selective labelling and gel 
shifts of reduced protein thiols, was tested on purified GAPDH. The GAPDH was 
reacted with propargyl-maleimide and derivatised with azide-PEG5,000  (~5 kDa) in a 
Click reaction step, then visualised by Coomassie staining after SDS-PAGE 
(Figure 3.3). For the Click reaction step, samples were split and treated in parallel 
with and without Click catalyst, to visualise the redox-dependent mobility shift (‘+ 
catalyst’). The unshifted lane (‘– catalyst’) serves as a loading control, indicating 
total levels of a particular target protein, which is important for quantification 
purposes.  
 
We compared untreated GAPDH (i.e. reflecting the endogenous redox state), with 
GAPDH that was either treated with reductant or oxidant to highlight the redox 
range extremes. For all conditions, GAPDH samples in the absence of Click 
catalyst were present only as a single band, confirming that PEGylation is fully 
catalyst-dependent. In samples treated with the reductant TCEP, Click-PEGylation 
resulted in a redox-dependent mobility shift of GAPDH relative to the untreated 
condition, visible as the appearance of higher molecular weight bands. Conversely, 
in response to pre-treatment with the thiol oxidant diamide, loss of PEGylation was 
observed relative to the untreated condition. This experiment confirmed that 
GAPDH was present in a range of redox forms with 0–4 reduced thiols groups that 
were responsive to the redox environment. The redox-dependent PEGylation-
induced mobility shifts can easily be visualised by plotting the densitometry profiles 
for each ‘+ catalyst’ lane (profile plot).  Individual PEGylated bands can also be 
quantified by densitometry, to show the relative distribution of GAPDH thiol redox 
states in response to the various treatments.  
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A       B 
  
 
Figure 3.3. Assessment of Click-PEGylation by Coomassie staining using purified GAPDH. 
(A) Click-PEGred of purified rabbit GAPDH, which contains 4 cysteine residues, and can therefore 
exist as 5 possible bands on a gel: 0 to 4 labelled cysteine thiols. Coomassie-stained mobility shift 
gel of GAPDH under untreated (i.e. endogenous), reduced (10 mM TCEP), and oxidised (1 mM 
diamide) conditions, showing redox-dependent band shifting. Profile plots of the ‘+ catalyst’ lanes 
were performed in FIJI. (B) Quantification of GAPDH cysteine redox state distribution from (A). 
Band densitometry was performed in FIJI and expressed as a % of total band intensity per lane. 
Data are means ± SEM of n = 4 independent experiments. The gel and densitometry was provided 
by LvL.  
 
  
# labelled thiols
250
150
100
75
50
37
25
- +
reduced oxidiseduntreated
catalyst
4
3
2
1
0
Mw
(kDa) - + - +
Mw
(kDa)
Mw
(kDa)
35
55
70
100
130
250
2 kDa 5 kDa1 kDa
catalyst
azide-PEG
1 kDa 2 kDa 5 kDa
4
3
2
1
0
4
3
2
1
0
4
3
2
1
0
30
60
80
100
120
220
50
40
- +- + - + - +
- +- + - +
reduced
Click-
PEGox
Click-
PEGred
oxidised
Click-
PEGox
Click-
PEGred
4
3
2
1
0
# labelled thiols
# labelled thiols
# labelled thiols
Click-PEGred
4
3
2
1
0
catalyst
0   1   2   3   4 0 1 2 3 4 0 1 2 3 4
catalyst
0  1  2  3  4 0  1  2  3  4 0  1  2  3  4 0  1  2  3  4
reduced oxidiseduntreated
D
is
tri
bu
tio
n 
(%
)
0
20
40
60
80
100
0   1   2   3   4 0   1   2   3   4 0   1   2   3   40
10
20
30
40 azide-PEG
profile
plot
profile
plot
profile
plot
profile
plot
m
obility
shift
S
S
S
S
S
S
S
S
_
-G
A
P
D
H
0
20
40
60
80
100
D
is
tri
bu
tio
n 
(%
)
D
is
tri
bu
tio
n 
(%
)
oxidisedreduced
Click-PEGred Click-PEGox
oxidisedreduced
# labelled thiols
# labelled thiols
M
w
 la
dd
er
M
w
 la
dd
er
M
w
 la
dd
er
Click-PEGred
Chapter 3 – Click-PEGylation  
	   124	  
In addition, we confirmed that purified GAPDH in its different redox states could 
similarly be assessed by Western blotting (Figure 3.4), obtaining similar results to 
the direct protein staining. We also tested the efficacy of the Click-PEGred and 
Click-PEGox protocols performed in parallel using purified GAPDH, comparing 
reduced and oxidised samples. These approaches provided complementary 
information on redox state. Reduced GAPDH displayed strong band shifting when 
detected by Click-PEGred but not by Click-PEGox, and vice versa for oxidised 
GAPDH.  
 
 
A       B 
 
 
Figure 3.4. Assessment of Click-PEGylation by Western blotting using purified GAPDH. (A) 
Parallel Click-PEGred and Click-PEGox of purified GAPDH under reduced (10 mM TCEP), and 
oxidised (1 mM diamide) conditions, detected by Western blotting, showing redox-dependent band 
shifting. The Western blot sections shown are from 1 PVDF membrane. After the Western blot was 
imaged, the image was cropped vertically and sections were separated or rearranged (as indicated 
by the black dotted lines) for clarity. After imaging, the profile plots of the ‘+ catalyst’ lanes were 
performed in FIJI. (B) Quantification of GAPDH cysteine redox state distribution from (A). Band 
densitometry was performed in FIJI and expressed as a % of total band intensity per lane (n=1). I 
provided the Western blot and the densitometry was provided by LvL. 
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3.4.4 Effect of azide-PEG size on redox-dependent band shifts 
To test the effect of azide-PEG polymer size, we compared the Click-PEGylation 
response of purified GAPDH reacted with propargyl-maleimide and then 
conjugated to a range of PEG moieties including 1, 2, and 5 kDa (Figure 3.5). 
Using samples of reduced GAPDH to focus on maximal shifting, the densitometry 
profile plots illustrate how varying the PEG size results in a corresponding shifting 
of the bands, with 5 kDa (azide-PEG5,000) providing the best band separation and 
resolution for the Click-PEGylation of GAPDH. However, regardless of the azide-
PEG size selected, the resulting distribution pattern of GAPDH thiol redox state 
was not affected.  Therefore, depending on the overall molecular weight of the 
candidate protein, as well as the total number of cysteine residues present, the 
optimal PEG size can be established. Other azide-PEG sizes, e.g. 10 kDa, are also 
commercially available.  
 
A      B 
 
Figure 3.5. Effect of azide-PEG size on redox-dependent band shifts using purified GAPDH. 
(A) Effect of different azide-PEG sizes on the Click-PEGred band shifting. Coomassie-stained 
mobility shift gel of purified GAPDH under reduced conditions (10 mM TCEP) derivatised with either 
1, 2 or 5 kDa azide-PEG. The gel sections shown are from 1 gel. After the gel was imaged, the 
image was cropped vertically and sections were separated or rearranged (as indicated by the black 
dotted line) for clarity. Profile plots of the ‘+ catalyst’ lanes were performed in FIJI. (B) Quantification 
of band shifting distribution from (A). Band densitometry was performed in FIJI and expressed as a 
% of total band intensity per lane (n = 1). The gel and densitometry was provided by LvL. 
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We found no loss of sample upon PEGylation comparing total protein content 
between the ‘– and + catalyst’ lanes both in the case of direct protein detection by 
Coomassie staining and Western blotting (although Western blotting was more 
variable) (Figure 3.6).  
 
 
A      B 
  
Figure 3.6. Assessment of sample recovery following the Click-PEG reaction. (A) 
Quantification of total band intensity for the ‘+ catalyst’ lane of the Coomassie-stained gel in Figure 
3.3 (A), assessed using FIJI and normalised to the ‘– catalyst’ lane as a loading control. Data are 
means ± SEM of n = 3 independent experiments (data provided by LvL). (B) Quantification of total 
band intensity for the ‘+ catalyst’ lane of the Western blot in Figure 3.4 (A), assessed using LiCor 
Image Studio software and normalised to the ‘– catalyst’ lane as a loading control. Data are means 
± SEM of n = 3 independent experiments (data provided by me).  
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3.4.5 Optimisation of the Click-PEGylation protocols 
To optimise labelling conditions during the Click-PEGylation protocols, we 
performed a number of control experiments. First, we considered sample protein 
concentration, and found that PEGylation efficiency was significantly improved by 
decreasing the starting protein concentration from 1 to 0.1 mg/mL (Figure 3.7).  
This is consistent with previous findings for redox proteomic sample preparation 
(Menger et al., 2015), and indicates the need to optimise the ratio of protein thiol 
content to tag compound in order to ensure complete labelling and therefore an 
accurate representation of protein redox status.  
 
 
Figure 3.7 Effect of protein concentration on labelling efficiency during the Click-PEG 
reaction. Coomassie-stained mobility shift gels of purified GAPDH under untreated conditions 
reacted by Click-PEGred, comparing starting concentrations of 1 and 0.1 mg protein/mL. Profile plots 
of the ‘+ catalyst’ lanes were performed in FIJI. Data was provided by LvL.  
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Next, we optimised the duration of the propargyl-maleimide reaction step to ensure 
complete labelling, comparing 10, 30 and 120 min incubation times (Figure 3.8). 
We confirmed by both direct protein staining and Western blotting that propargyl-
maleimide labelling was complete by 10 min incubation, with no further changes at 
subsequent time points. This was true for both Click-PEGred  and Click-PEGox 
labeling.  
 
In examining the effects of the propargyl-maleimide timecourse on purified GAPDH 
labeling, 2 different stocks of GAPDH were used: a new stock in (A – D) and an 
older stock in (E – F). We determined that the older stock had likely become 
hyperoxidised as we observed incomplete labeling of GAPDH (for equivalent 
starting protein concentrations) indicating the increased presence of irreversibly 
oxidised thiols in the older stock that would not become labeled. Thus, we 
determined that the experiments should be performed on fresh protein stocks if 
possible.    
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A      B
   
C      D 
 
E      F 
 
Figure 3.8. Effect of propargyl-maleimide incubation time on Click-PEG labelling. (A) 
Coomassie-stained gel of purified GAPDH under reduced conditions (10 mM TCEP) reacted by 
Click-PEGred, comparing propargyl-maleimide (50 mM) incubation times of 10, 30 and 120 min. 
Profile plots of the ‘–/+ catalyst’ lanes were performed in FIJI. (B) Quantification of GAPDH thiol 
redox state distribution from (A). Band densitometry was performed in FIJI and expressed as a %  
of total band intensity per lane. Data are means ± range of n = 2 independent experiments. Gel and 
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densitometry provided by LvL. (C) Western Blot of purified GAPDH under reduced conditions 
(10 mM TCEP) reacted by Click-PEGred, comparing incubation times of 10, 30 and 120 min. Profile 
plots of the ‘–/+ catalyst’ lanes were performed in FIJI. (D) Quantification of GAPDH thiol redox 
state distribution from (C). Band densitometry was performed in FIJI and expressed as a % of total 
band intensity per lane. Data are means ± range of n = 2 independent experiments. Gel and 
densitometry provided by LvL. (E) Western Blot of purified GAPDH (older stock) under oxidised 
conditions (1 mM diamide) reacted by Click-PEGox or Click-PEGred, comparing incubation times of 
10, 30 and 120 min. The Western blot sections shown are from 1 PVDF. After the Western blot was 
imaged, the image was cropped vertically (as indicated by the black dotted lines) and sections were 
rearranged for clarity. Profile plots of the ‘–/+ catalyst’ lanes were performed in FIJI. (F) 
Quantification of GAPDH thiol redox state distribution from (E). Band densitometry was performed 
in Image Studio and expressed as a % of total band intensity per lane (n = 1). I provided the 
Western blot and densitometry. 
 
Furthermore, we optimised the concentration of propargyl-maleimide during the 
initial labelling of redox-reactive free thiols (Figure 3.9). While an excess of 
propargyl-maleimide at this step is desirable to ensure complete labelling, previous 
studies have shown that excessive maleimide to thiol ratio leads to non-specific 
protein labeling of residues other than cysteines (Tyagarajan et al., 2003, Pretzer 
and Wiktorowicz, 2008). Previously, it has been difficult to observe any off-target 
labeling of purified GAPDH by 50 mM propargyl-maleimide because purified 
GAPDH doesn’t exist in 100% reduced or 100% reversibly oxidised states, instead 
existing in a range of redox states.  This is perhaps due to some irreversible 
oxidation that occurred during preparation of the purified protein, which increased 
with duration of storage, as previously suggested. Thus, any redox-insensitive (off-
target) band shifting, if existing, was difficult to identify. However, to minimize the 
risk of off-target labeling we reduced the concentration of propargyl-maleimide (50 
mM to 5 mM) and found comparable target band labeling (30 min incubation). 
Therefore, in following experiments 5 mM propargyl-maleimide was used for 
labelling to minimize the risk of off-target labeling by higher concentrations. With 
this lower concentration of propargyl-maleimide I observed that 10 min was now 
insufficient for complete labeling, however, complete labeling could be achieved 
with longer incubations (≥ 30 min). Therefore, the majority of experiments 
presented in this study were performed with a 30 min propargyl-maleimide 
incubation.  
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A 
 
B 
 
C       D 
 
Figure 3.9 Effect of propargyl-maleimide concentration on Click-PEG labelling. (A) 
Coomassie-stained mobility shift gel of purified GAPDH reacted by Click-PEGred comparing 5 or 
50 mM propargyl-maleimide under untreated, reduced (10 mM TCEP) and oxidised (1 mM diamide) 
conditions. (B) Quantification of GAPDH thiol redox state distribution from (A). Band densitometry 
was performed in FIJI and expressed as a % of total band intensity per lane. Data are means ± 
range of n = 2 independent experiments. Gel and densitometry was provided by LvL. (C) Western 
Blot of purified GAPDH under oxidised conditions (1 mM diamide) reacted by Click-PEGox or Click-
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PEGred, comparing the labeling of 5 mM propargyl-maleimide after incubation times of 10, 30 and 
120 min. After the Western blot was imaged, the image was cropped vertically (as indicated by the 
black dotted lines) and sections were rearranged for clarity. Profile plots of the ‘–/+ catalyst’ lanes 
(Click-PEGox) were performed in FIJI. (D) Quantification of GAPDH thiol redox state distribution 
reacted by Click-PEGox from (C). Band densitometry was performed in Image Studio and expressed 
as a % of total band intensity per lane (n = 1). I provided the Western blot and densitometry.  
 
3.4.6 Assessing the redox state of higher molecular weight 
proteins by Click-PEGylation: catalase 
So far the Click-PEGylation assay has been used effectively with purified GAPDH, 
which has a molecular weight of ~36 kDa. To confirm that the Click-PEGylation 
method is widely applicable to a broad range of proteins with differing sizes, we 
also tested another candidate, catalase (Figure 3.10), with a higher molecular 
weight (~60 kDa predicted) and 4 cysteine residues (Sevinc et al., 1995). 
Comparable to experiments with GAPDH, we found that purified catalase was 
increasingly Click-PEGylated upon reduction and that this was decreased upon 
oxidation. Again we compared the effect of different sized azide-PEGs (1 kDa, 
2 kDa, and 5 kDa) on the band shifting resolution of fully reduced catalase by Click-
PEGred. Unlike with GAPDH, we found that only azide-PEG5,000 was able to resolve 
the different redox-shifted bands sufficiently whereas the 1 and 2 kDa sizes were 
ineffective, as evident from the unresolved profile plots. This highlights the 
importance of optimising the size of the azide-PEG moiety for a given protein of 
interest. 
 
A      B 
 
Figure 3.10. Application of Click-PEGylation to purified catalase. (A) Click-PEGred of purified 
catalase under untreated, reduced (10 mM TCEP) and oxidised (1 mM diamide) conditions, 
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detected by Western blotting. Profile plots of the ‘+ catalyst’ lanes were performed in FIJI. (B) Effect 
of different azide-PEG sizes on the Click-PEGred band shifting. Western blot of purified catalase 
under reduced conditions (10 mM TCEP) derivatised with either 1, 2 or 5 kDa azide-PEG. Profile 
plots of the ‘+ catalyst’ lanes were performed in FIJI. Western blots were provided by LvL. 	  
3.4.7 Assessing the redox state of GAPDH in complex biological 
samples by Click-PEGylation  
To assess endogenous redox state for a given target, the Click-PEGylation 
reaction is performed on the complex protein sample, and then specific detection of 
the redox mobility shifting for the protein of interest is achieved by Western blotting. 
Therefore, the redox state of multiple proteins can be assessed from the sample by 
parallel/successive Western blotting using appropriate antibodies. Tagged proteins 
(e.g. Flag, HA) could also be assessed, using antibodies against the relevant tag. 
 
Here, we consider the response of endogenous GAPDH in cell culture. We applied 
the Click-PEGylation technique to label GAPDH in mouse C2C12 myoblast lysates 
(Figure 3.11). I performed parallel Click-PEGred and Click-PEGox protocols on 
TCEP- and diamide-treated cell lysates, and observed complementary redox-
dependent band shifting for these reduced and oxidised conditions. I also 
considered untreated cell lysates, and found that endogenous GAPDH in cell 
culture is present in a range of redox states, which is consistent with reports in the 
literature for GAPDH in vivo (Menger et al., 2015, Brandes et al., 2009). Therefore, 
the Click-PEGred and Click-PEGox protocols are useful techniques when used 
individually or in parallel to determine protein redox state by mobility shift 
electrophoresis in complex biological samples. 
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A       B 
 
Figure 3.11. Analysis of endogenous GAPDH from cell lysates (C2C12 mouse myoblast) by 
Click-PEGox and Click-PEGred detected by Western blotting. (A) Cell lysates were Click-
PEGylated after reduction (10 mM TCEP) or oxidation (1 mM diamide). In situ analysis of GAPDH 
redox status (untreated) was also performed by lysing the cells in the presence of 5 mM propargyl-
maleimide. The Western blot sections shown are from 1 PVDF membrane. After the Western blot 
was imaged, the image was cropped vertically and separated for clarity. (B) Quantification of band 
shifting in (A). Band densitometry was performed in FIJI and expressed as a % of total band 
intensity per lane (n=1). I performed the cell experiment and Western blot, densitometry was 
performed by LvL.  
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3.5 Method application 
3.5.1 Towards assessing AMPK redox shifts using the Click-
PEGylation protocols  
In working towards elucidating any possible direct redox-regulation of AMPK, a 
series of experiments were performed on purified AMPK and AMPK in cell lysates 
to test if the Click-PEG protocols could resolve redox shifts in the enzyme. Although 
promising advancements were made in optimising the Click-PEG protocols to suit 
AMPK analysis, activity experiments conducted in parallel (discussed in Chapter 
4) indicated that AMPK activity changes in response to ROS in C2C12 myotubes 
correlated with changes to cell ATP/ADP ratios, suggesting indirect effects. Thus, 
optimisation of the AMPK redox-state analysis was halted in favor of further 
characterizing AMPK regulation and cellular redox state by different sources of 
ROS cells. However, it remains of critical importance to be able to analyze the 
redox state of AMPK to further confirm indirect regulation by ROS in the C2C12 cell 
model. Also, as AMPK redox-regulation could potentially be cell type specific (or 
dependent on other variables), further optimisation of AMPK redox-state analysis 
by Click-PEGylation will advance the experimental techniques available to our and 
other labs in determining the nature of AMPK regulation in response to ROS in 
different cell types. Discussed below are the steps I took towards optimising AMPK 
redox-state analysis by Click-PEGylation, initially using purified AMPK and then 
continued with AMPK in cell lysates.  
Initially, prior to any Click-PEGylation reactions, a serial dilution of purified AMPK 
was performed and then separated by SDS-PAGE to identify the limit of detection 
by Coomassie protein staining (Figure 3.12). The 3 subunits of AMPK: α1-His tag 
(~62 kDa), β1-His tag (~38 kDa), γ1-His tag (~ 40 kDa) (Sigma: A1233 (human), 
data sheet size estimations) were visible upon SDS-PAGE and Coomassie Brilliant 
Blue R-250 staining of ≥ 0.5 μg protein. Considering that for Click-PEGylation the 
initial starting protein would be halved before the Click catalyst reaction and 
assuming some loss of protein would occur during the different Click-PEGylation 
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reaction steps, I decided to use a starting protein concentration of 2 μg/100 μl for 
Click-PEGylation of purified AMPK to be detected by Coomassie protein staining. I 
also decided to switch to QC Colloidal Coomassie protein stain for future gels in 
order to maximise the sensitivity of detection.  
 
 
Figure 3.12. Serial dilution of purified AMPK α1/ β1/ γ1 (-His tagged) followed by SDS-PAGE 
and Coomassie protein staining to determine the limit of detection. Purified human AMPK was 
serially diluted, loaded on a 12% SDS-PAGE gel electrophoresed in reducing conditions. The gel 
was stained with Coomassie Brilliant Blue R-250 and destained according to the manufacturer’s 
instructions. The gel was scanned using an Epson perfection V750 Pro scanner. 
 
Next, purified AMPK was reacted by Click-PEGred and derivatised with azide-
PEG5,000 followed by SDS-PAGE and QC Colloidal Coomassie protein staining to 
see if redox-dependent shifts could be observed (Figure 3.13). The gel and profile 
plot showed that catalyst-dependent labelling was occurring and there were 
obvious differences in the labelling pattern between pre-reduced (10 mM TCEP) 
and pre-oxidised (1 mM diamide) protein.  A complication of detecting Click-PEGred 
– labelled purified AMPK by SDS-PAGE and Coomassie protein staining is that all 
3 subunits are detected, so it is impossible to identify individual subunit mobility 
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shifts with any clarity. Also, the α1 subunit is cysteine-rich (11 cysteine residues in 
human) and combined with the β1 and γ1 subunits (3 cysteines each in human) 
(Figure 3.14), a total of potentially 20 bands could potentially be observed 
(unlabelled α1, β1 and γ1 + 17 cysteine residues that could potentially be labeled). 
In spite of the technical limitations, this experiment did confirm that catalyst-
dependent labelling had occurred and that broad redox-dependent shifts had also 
occurred.  
 
 
 
Figure 3.13. Purified AMPK α1/ β1/ γ1 reacted by Click-PEGred followed by SDS-PAGE and 
Coomassie protein staining. QC Colloidal Coomassie stained gel (12%) of purified human his-
tagged AMPK (starting concentration:  2 μg protein /100 μl) reacted by Click-PEGred under reduced 
(10 mM TCEP) or oxidised (1 mM diamide) conditions. In ‘- catalyst ‘ lanes, all subunits of AMPK 
were detected: α1, β1 and γ1. The gel was scanned and the image was cropped vertically (as 
indicated by the black dotted lines) and sections were rearranged for clarity. Profile plots of the ‘–/+ 
catalyst’ lanes were performed in FIJI. 
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A 
5'-AMP-activated protein kinase catalytic subunit alpha-1 isoform 1 [Homo 
sapiens] 
11 cysteines in α1 subunit 
001 MRRLSSWRKM ATAEKQKHDG RVKIGHYILG DTLGVGTFGK VKVGKHELTG HKVAVKILNR        
061 QKIRSLDVVG KIRREIQNLK LFRHPHIIKL YQVISTPSDI FMVMEYVSGG ELFDYICKNG        
121 RLDEKESRRL FQQILSGVDY CHRHMVVHRD LKPENVLLDA HMNAKIADFG LSNMMSDGEF        
181 LRTSCGSPNY AAPEVISGRL YAGPEVDIWS SGVILYALLC GTLPFDDDHV PTLFKKICDG        
241 IFYTPQYLNP SVISLLKHML QVDPMKRATI KDIREHEWFK QDLPKYLFPE DPSYSSTMID        
301 DEALKEVCEK FECSEEEVLS CLYNRNHQDP LAVAYHLIID NRRIMNEAKD FYLATSPPDS        
361 FLDDHHLTRP HPERVPFLVA ETPRARHTLD ELNPQKSKHQ GVRKAKWHLG IRSQSRPNDI        
421 MAEVCRAIKQ LDYEWKVVNP YYLRVRRKNP VTSTYSKMSL QLYQVDSRTY LLDFRSIDDE        
481 ITEAKSGTAT PQRSGSVSNY RSCQRSDSDA EAQGKSSEVS LTSSVTSLDS SPVDLTPRPG        
541 SHTIEFFEMC ANLIKILAQ 
 
B 
5'-AMP-activated protein kinase subunit beta-1 [Homo sapiens] 
3 cysteines in β1 subunit 
001 MGNTSSERAA LERHGGHKTP RRDSSGGTKD GDRPKILMDS PEDADLFHSE EIKAPEKEEF        
061LAWQHDLEVN DKAPAQARPT VFRWTGGGKE VYLSGSFNNW SKLPLTRSHN NFVAILDLPE        
121 GEHQYKFFVD GQWTHDPSEP IVTSQLGTVN NIIQVKKTDF EVFDALMVDS QKCSDVSELS        
181 SSPPGPYHQE PYVCKPEERF RAPPILPPHL LQVILNKDTG ISCDPALLPE PNHVMLNHLY        
241 ALSIKDGVMV LSATHRYKKK YVTTLLYKPI 
 
C 
5'-AMP-activated protein kinase subunit gamma-1 isoform 1 [Homo sapiens] 
3 cysteines in γ1 subunit 
001 METVISSDSS PAVENEHPQE TPESNNSVYT SFMKSHRCYD LIPTSSKLVV FDTSLQVKKA         
061 FFALVTNGVR AAPLWDSKKQ SFVGMLTITD FINILHRYYK SALVQIYELE EHKIETWREV        
121 YLQDSFKPLV CISPNASLFD AVSSLIRNKI HRLPVIDPES GNTLYILTHK RILKFLKLFI        
181 TEFPKPEFMS KSLEELQIGT YANIAMVRTT TPVYVALGIF VQHRVSALPV VDEKGRVVDI        
241 YSKFDVINLA AEKTYNNLDV SVTKALQHRS HYFEGVLKCY LHETLETIIN RLVEAEVHRL        
301 VVVDENDVVK GIVSLSDILQ ALVLTGGEKK P 
Figure 3.14. Amino acid sequences of AMPK α1, β1 and γ1 subunit isoforms (human) from 
the National Center for Biotechnology Information (NCBI). Cysteine residues are highlighted in 
red. (A) Amino acid sequence of AMPK α1 (human) containing 11 cysteine residues. NCBI 
Reference Sequence: NP_006242.5; (B) amino acid sequence of AMPK β1 (human) containing 3  
cysteine residues. NCBI Reference Sequence: NP_006244.2; (C) amino acid sequence of AMPK 
γ1 (human) containing 3 cysteine residues. NCBI Reference Sequence: NP_002724.1. 
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In order to detect redox shifts in only the AMPKα catalytic subunit, purified AMPK 
α1/ β1/ γ1 was reacted by Click-PEGox and then analysed by SDS-PAGE and 
Western blotting with a primary antibody to the α subunit (Figure 3.15). A lower % 
SDS-PAGE gel (7.5%) was selected in order to maximize the area of the gel to 
where AMPKα bands were expected to migrate. The Click-PEGox reaction showed 
that catalyst and redox-dependent mobility shifting had occurred. Band resolution 
was improved from Coomassie detection, but remained imperfect. The large 
number of cysteine residues (which would present as up to 12 potential bands) 
combined with the relatively large molecular weight of the subunit (similar to 
catalase) are likely the reasons for the resolution difficulties. However, broad redox 
shifts could be identified with the purified protein suggesting similar shifts could 
also be detected in biological samples.  
 
Figure 3.15. Purified AMPK α1/ β1/ γ1 reacted by Click-PEGred or Click-PEGox followed by 
SDS-PAGE and Western blotting with a primary antibody to the α subunit. Purified human his-
tagged AMPK (starting concentration: 1 μg protein /100 μl) reacted by Click-PEGox under reduced  
(10 mM TCEP) or oxidised (1 mM diamide) conditions. Samples were loaded on a 7.5 % gel and 
SDS-PAGE was performed in reducing conditions. In the ‘- catalyst’ lanes, only AMPKα was 
detected. The gel was scanned and the image was cropped vertically (as indicated by the black 
dotted line) and sections were rearranged for clarity. Profile plots of the ‘–/+ catalyst’ lanes were 
performed in FIJI. 
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3.5.2 Optimising Click-PEGylation on endogenous AMPK in cells 
Optimisation of Click-PEGylation for detecting redox shifts in purified AMPK was 
limited by the need for relatively large quantities of expensive purified stock in each 
reaction. Thus, I decided to continue the optimisation using cell lysates, as the goal 
of the experiment is to detect redox shifts in AMPK in complex biological samples, 
not in purified protein. The cell lysates I used were from a C2C12 mouse myoblast 
cell line in the proliferating, undifferentiated state. The primary antibody to AMPKα 
detects isoforms 1 and 2. Mouse AMPKα1 has high homology to human AMPKα1 
and all the cysteine residues are conserved (Figure 3.16), meaning that potentially 
12 bands could be observed following a Click-PEGylation reaction (unlabeled 
AMPKα1 + 11 cysteine residues that could be labeled). Mouse AMPKα2 has 11 
cysteine residues (compared to 10 in human). However, there is evidence that the 
protein expression of AMPK subunits changes during myogenesis with only 
AMPKα2 being detected in proliferating, undifferentiated C2C12 myoblast cells and 
protein expression of AMPKα1 occurring during differentiation (Niesler et al., 2007).  
 
A 
AMPKα1 amino acid sequence alignment: Human v Mouse 
Human  1    MRRLSSWRKMATAEKQKHDGRVKIGHYILGDTLGVGTFGKVKVGKHELTGHKVAVKILNR  60 
Mouse  1    MRRLSSWRKMATAEKQKHDGRVKIGHYILGDTLGVGTFGKVKVGKHELTGHKVAVKILNR  60 
	  
	   	   	   	   	   	   	  Human  61   QKIRSLDVVGKIRREIQNLKLFRHPHIIKLYQVISTPSDIFMVMEYVSGGELFDYICKNG  120 
Mouse  61   QKIRSLDVVGKIRREIQNLKLFRHPHIIKLYQVISTPSDIFMVMEYVSGGELFDYICKNG  120 
	  
	   	   	   	   	   	   	  Human  121  RLDEKESRRLFQQILSGVDYCHRHMVVHRDLKPENVLLDAHMNAKIADFGLSNMMSDGEF  180 
Mouse  121  RLDEKESRRLFQQILSGVDYCHRHMVVHRDLKPENVLLDAHMNAKIADFGLSNMMSDGEF  180 
	  
	   	   	   	   	   	   	  Human  181  LRTSCGSPNYAAPEVISGRLYAGPEVDIWSSGVILYALLCGTLPFDDDHVPTLFKKICDG  240 
Mouse  181  LRTSCGSPNYAAPEVISGRLYAGPEVDIWSSGVILYALLCGTLPFDDDHVPTLFKKICDG  240 
	  
	   	   	   	   	   	   	  Human  241  IFYTPQYLNPSVISLLKHMLQVDPMKRATIKDIREHEWFKQDLPKYLFPEDPSYSSTMID  300 
Mouse  241  IFYTPQYLNPSVISLLKHMLQVDPMKRAAIKDIREHEWFKQDLPKYLFPEDPSYSSTMID  300 
	  
	   	   	   	   	   	   	  Human  301  DEALKEVCEKFECSEEEVLSCLYNRNHQDPLAVAYHLIIDNRRIMNEAKDFYLATSPPDS  360 
Mouse  301  DEALKEVCEKFECSEEEVLSCLYNRNHQDPLAVAYHLIIDNRRIMNEAKDFYLATSPPDS  360 
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Human  361  FLDDHHLTRPHPERVPFLVAETPRARHTLDELNPQKSKHQGVRKAKWHLGIRSQSRPNDI  420 
Mouse  361  FLDDHHLTRPHPERVPFLVAETPRARHTLDELNPQKSKHQGVRKAKWHLGIRSQSRPNDI  420 
	  
	   	   	   	   	   	   	  Human  421  MAEVCRAIKQLDYEWKVVNPYYLRVRRKNPVTSTYSKMSLQLYQVDSRTYLLDFRSIDDE  480 
Mouse  421  MAEVCRAIKQLDYEWKVVNPYYLRVRRKNPVTSTFSKMSLQLYQVDSRTYLLDFRSIDDE  480 
	  
	   	   	   	   	   	   	  Human  481  ITEAKSGTATPQRSGSVSNYRSCQRSDSDAEAQGKSSEVSLTSSVTSLDSSPVDLTPRPG  540 
Mouse  481  ITEAKSGTATPQRSGSISNYRSCQRSDSDAEAQGKPSDVSLTSSVTSLDSSPVDVAPRPG  540 
	  
	   	   	   	   	   	   	  Human  541  SHTIEFFEMCANLIKILAQ  559 
	   	   	   	  Mouse  541  SHTIEFFEMCANLIKILAQ  559 
	   	   	   	  
 
B 
AMPKα2 amino acid sequence alignment: Human v Mouse 
Human  1    MAEKQKHDGRVKIGHYVLGDTLGVGTFGKVKIGEHQLTGHKVAVKILNRQKIRSLDVVGK  60 	  
Mouse  1    MAEKQKHDGRVKIGHYVLGDTLGVGTFGKVKIGEHQLTGHKVAVKILNRQKIRSLDVVGK  60 
       	  
Human  61   IKREIQNLKLFRHPHIIKLYQVISTPTDFFMVMEYVSGGELFDYICKHGRVEEMEARRLF  120 
Mouse  61   IKREIQNLKLFRHPHIIKLYQVISTPTDFFMVMEYVSGGELFDYICKHGRVEEVEARRLF  120 	  
       	  
Human  121  QQILSAVDYCHRHMVVHRDLKPENVLLDAHMNAKIADFGLSNMMSDGEFLRTSCGSPNYA  180 
Mouse  121  QQILSAVDYCHRHMVVHRDLKPENVLLDAQMNAKIADFGLSNMMSDGEFLRTSCGSPNYA  180 
       	  
Human  181  APEVISGRLYAGPEVDIWSCGVILYALLCGTLPFDDEHVPTLFKKIRGGVFYIPEYLNRS  240 	  
Mouse  181  APEVISGRLYAGPEVDIWSCGVILYALLCGTLPFDDEHVPTLFKKIRGGVFYIPDYLNRS  240 	  
       	  
Human  241  VATLLMHMLQVDPLKRATIKDIREHEWFKQDLPSYLFPEDPSYDANVIDDEAVKEVCEKF  300 
Mouse  241  VATLLMHMLQVDPLKRATIKDIREHEWFKQDLPSYLFPEDPSYDANVIDDEAVKEVCEKF  300 
       	  
Human  301  ECTESEVMNSLYSGDPQDQLAVAYHLIIDNRRIMNQASEFYLASSPPSGSFMDDSAMHIP  360 
Mouse  301  ECTESEVMNSLYSGDPQDQLAVAYHLIIDNRRIMNQASEFYLASSPPSGSFMDDSAMHIP  360 
       	  
Human  361  PGLKPHPERMPPLIADSPKARCPLDALNTTKPKSLAVKKAKWHLGIRSQSKPYDIMAEVY  420 
Mouse  361  PGLKPHPERMPPLIADSPKARCPLDALNTTKPKSLAVKKAKWHLGIRSQSKACDIMAEVY  420 
       	  
Human  421  RAMKQLDFEWKVVNAYHLRVRRKNPVTGNYVKMSLQLYLVDNRSYLLDFKSIDDEVVEQR  480 
Mouse  421  RAMKQLGFEWKVVNAYHLRVRRKNPVTGNYVKMSLQLYLVDSRSYLLDFKSIDDEVVEQR  480 
       	  
Human  481  SGSSTPQRSCSAAGLHRPRSSFDSTTAESHSLSGSLTGSLTGSTLSSVSPRLGSHTMDFF  540 
Mouse  481  SGSSTPQRSCSAAGLHRARSSFDSSTAENHSLSGSLTGSLTGSTLSSASPRLGSHTMDFF  540 
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Human  541  EMCASLITTLAR  552     	  
Mouse  541  EMCASLITALAR  552     	  
 
Figure 3.16. Amino acid sequence alignments of AMPK α1 and α2 subunit isoforms, comparing 
the human and mouse homologues. (A) Amino acid sequence alignment of AMPK α1 comparing 
human (NP_006242.5) and mouse (NP_001013385.3) α1. Alignments were performed by NCBI protein 
BLAST® (NCBI protein sequence ID numbers in parentheses). Sequence differences are highlighted in 
yellow. Cysteine residues are highlighted in red. Both human and mouse AMPKα1 contains 11 cysteine 
residues; (B) amino acid sequence alignment of AMPKα2 comparing human (NP_006243.2) and mouse 
(NP_835279.2) α2. Alignments were performed by NCBI protein BLAST® (NCBI protein sequence ID 
numbers in parentheses). Sequence differences are highlighted in yellow. Cysteine residues are 
highlighted in red. Human AMPKα1 contains 10 cysteine residues and mouse AMPKα1 contains 11 
cysteine residues.  
 
 
Prior to Click-PEGylation experiments, I first tested if the thiol-alkylating agents 
used in Click-PEGylation would affect antibody-epitope (AMPKα1/2) recognition in 
cell lysates (Figure 3.17). Although AMPKα1 Western blot signal was easily 
detected with purified protein, reduced antibody-epitope recognition due to 
alkylating agents could be more detrimental to an experiment on cell lysate due to 
smaller amounts of target protein likely to be detected on a Western blot. C2C12 
cells were lysed in the presence of DTT and then reacted with NEM or propargyl-
maleimide before sample analysis by SDS-PAGE and Western blotting with a 
primary antibody to AMPKα1/2. Firstly, AMPKα1/2 bands of the appropriate size 
were observed after all treatments, confirming that the antibody was compatible 
with these thiol modifications. It was also observed that the higher concentration of 
propargyl-maleimide (50 mM) did result in the appearance of a non-specific band, a 
risk discussed previously. The non-specific band was not visible in lysate treated 
with a lower concentration of propargyl maleimide (5 mM), confirming that this 
concentration would be preferable. A non-specific band was also visible in lysate 
treated with NEM (100 mM) so a lower concentration of NEM should also be 
considered in future optimisation steps.  
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Figure 3.17. Endogenous AMPKα1/2 from C2C12 cell lysate detected by Western blotting 
following cell lysate incubations with Click-PEGylation thiol-alkylating agents. C2C12 cells 
were plated at 20,000 cells per cm2 on 6 cm plates and cultured to ~ 80% confluency. Cells were 
lysed in the presence of DTT (50 mM), and then diluted to a concentration of 500 μg protein/ml 
(determined by BCA assay) to maximize labeling potential. Lysates were then reacted with NEM 
(100 mM) or propargyl-maleimide (50 mM or 5 mM) or remained untreated (DTT only) and 
incubated for 30 min at 37°C with shaking (1,000 rpm). Samples (~ 25 μg protein) were analysed by 
SDS-PAGE (7.5% gel) in reducing conditions followed by Western blotting using the AMPKα1/2 
primary antibody. 
 
Click-PEGylation was then performed in C2C12 cell lysates (Figure 3.18). Cells 
were lysed in the presence of NEM (for Click-PEGox) or propargyl-maleimide (for 
Click-PEGred). Thus, the in situ or ‘untreated’ endogenous AMPKα was being 
tested to see if Western blot signal would be observed after PEGylation. Compared 
to Figure 3.17, the AMPKα1/2 Western blot signal in the ‘- catalyst’ lanes for both 
Click-PEG protocols was greatly reduced. The Click-PEGylation reactions were 
performed on a starting amount of 50 μg whole cell protein (100 μl of 500 μg 
protein/ml), a previously optimised amount and concentration of whole cell protein 
for Click-PEGylation of endogenous GAPDH from cell lysates. The total protein, 
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when halved at the catalyst addition stage, would result in theoretically 25 μg whole 
cell protein to be analysed by SDS-PAGE (equivalent to the amount of protein 
loaded on the gel per lane in Figure 3.17, from which AMPKα1/2 was readily 
detectable by Western Blot). However, this calculation did not take into account the 
possibility for protein loss during the Click-PEGylation steps and it does appear that 
the final amount of AMPKα1/2 in the ‘- catalyst’ lanes (Figure 3.18) was much less 
than in Figure 3.17. Furthermore, there was no AMPKα1/2 signal in the ‘+ catalyst’ 
lanes, suggesting that there was further protein degradation during the catalyst 
reaction or else perhaps the azide-PEG labeling was affecting the antibody-epitope 
recognition.  
 
Ultimately, further optimisation steps are needed to use this technique to assess 
AMPK redox state in cell lysates, including increasing the starting amount of whole 
cell lysate protein, investigating the use of protease inhibitors in the catalyst 
incubation that may inhibit protein degradation and investigating the use of AMPK 
expression vectors to overexpress epitope-tagged AMPK in cells.  
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Figure 3.18. Endogenous AMPKα1/2 from C2C12 cell lysate reacted by Click-PEGox  or Click-
PEGred and detected by Western blotting. C2C12 myoblast cells were plated at 20,000 cells per 
cm2 on 6 cm plates and cultured to ~ 80% confluency. Cells were lysed in the presence of 100 mM 
NEM (Click-PEGox) or 5 or 50 mM propargyl-maleimide (Click-PEGred). Lysate was diluted to a 
concentration of ~500 μg whole cell protein/ml and Click-PEGylation was performed on 100 μl 
aliquots. Samples were analysed by SDS-PAGE (7.5% gel) in reducing conditions followed by 
Western blotting using the AMPKα1/2 primary antibody. The Western blot sections shown are from 
1 PVDF membrane, analysed using Image Studio. After the Western blot was imaged, the image 
was cropped vertically (indicated by the black dotted lines) and separated for clarity.  
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3.5.3 Overexpressing epitope-tagged AMPK in cells as an 
alternative approach for optimising Click-PEGylation of AMPK in 
cells 
An alternative approach to optimising Click-PEGylation of AMPK in cell lysates was 
to overexpress AMPK in cells. Overexpressed AMPK would be more readily 
detected on a Western blot of whole cell lysate. A further benefit would be the 
option to perform Western blots with primary antibodies to N- or C- terminal epitope 
tags if engineered onto the AMPK subunits. This would avoid any possible 
inhibitory effect of the bulky azide-PEG on AMPK antibody-epitope recognition, 
provided the new epitope tags did not contain any cysteine residues.  
 
Expression vectors containing cDNA sequences of the AMPK subunits were a gift 
from Professor David Carling, MRC Clinical Sciences Centre, Hammersmith 
Hospital Campus, London, UK (see Appendix A for sequences). The sequence for 
AMPKα2 contained a C-terminal (CT) FLAG tag and the sequence for AMPKγ1 
contained an N-terminal Myc tag. The sequence for AMPKβ1 was untagged. The 
subunit sequences were independently encoded in individual expression vectors 
and were transiently transfected into cells simultaneously. As a proof of concept, a 
number of Western blots were performed to assess the protein expression of the 
AMPK subunits in untransfected and transfected cells and also to test the detection 
of the epitope tags, where present (Figure 3.19 & 3.20). I chose to test the 
transfection and detection on HEK293 cells initially, as they are readily compatible 
with transient transfection.  
 
The protein expression of AMPKα2-CT-FLAG (~	   62 kDa) in HEK293 cells was 
analysed first. Western blot (A) was performed with a primary antibody to the FLAG 
tag. I also simultaneously probed for AMPKβ1/2 (38/30 kDa) to confirm increases 
in AMPK protein expression and for ACC1/2 (265/280 kDa) as a loading control. 
The FLAG-BAP™ protein was detected by the FLAG antibody, confirming the 
compatibility of the antibody with the FLAG tag. AMPKβ1 was overexpressed in 
Chapter 3 – Click-PEGylation  
	   147	  
transfected cells (relative to ACC1/2), confirming that this transfection was 
effective. However, AMPKα2-CT-FLAG signal was poor. Western blot (B) was 
performed with a primary antibody to AMPKα1/2, and also simultaneously probed 
for ACC1/2 and AMPKβ1/2 as before. Again, AMPKβ1 was overexpressed in 
transfected cells (relative to ACC1/2). AMPKα1/2 signal was also increased 
(relative to ACC1/2) confirming that both AMPKα1/2 and AMPKβ1 were 
successfully overexpressed. The reason for the poor detection of AMPKα2-CT-
FLAG by the FLAG antibody is unclear, but it is possible that some cleavage of the 
FLAG-tag occurred in the cells, possibly if the serum in the cell culture media 
contained excessive enteropeptidase, which cleaves the FLAG tag (Zhao et al., 
2013). It was also clear from the Western blots and quantification that transfection 
of cells with 1 μg expression vector DNA (per vector) offered more α and β subunit 
overexpression than cells transfected with 10 μg DNA. As an aside, it can be 
observed from both Western blots that AMPKβ1 (~	   38 kDa) is the dominantly 
expressed β subunit in HEK293 cells, with the Western blot signal of β1 in 
untransfected cells being much stronger than β2 (~	  30 kDa).  
 
Next, I tested the protein expression of AMPKγ1-NT-Myc (~	  38 kDa). Western blot 
(C) was performed with a primary antibody to the Myc tag and simultaneously 
probed for AMPKα1/2 to confirm increases in AMPK protein expression and for 
ACC1/2 as a loading control. AMPKγ1-NT-Myc Western blot signal was easily 
visible in transfected cells and not in untransfected cells, confirming that the 
overexpression was successful and that the Myc-antibody was compatible with the 
tag. In parallel, the Western blot in (D) was performed with a primary antibody to 
AMPKγ1/2, and also simultaneously probed for ACC1/2 and AMPKα1/2 as before. 
The Western blot showed that the AMPKγ1/2 antibody was poor and so for 
detecting overexpressed AMPKγ1-NT-Myc, the Myc antibody is preferable. To 
summarize, the AMPK subunit expression vectors can be used to increase AMPK 
protein expression in cells. The AMPKα1/2 antibody was more effective than the 
FLAG antibody at detecting AMPKα2-CT-FLAG and the Myc antibody was more 
effective than the AMPKγ1/2 antibody at detecting AMPKγ1-NT-Myc. The AMPKβ1 
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vector did not encode an epitope tag but the AMPKβ1/2 antibody is effective at 
detecting endogenous and overexpressed protein. Cells transfected with 1 μg 
expression vector DNA (per vector) offered more protein overexpression than cells 
transfected with 10 μg DNA (per vector).  
 
Above, I have assessed the functionality of the expression vectors and confirmed 
the appropriate antibodies to use for detection of each of the overexpressed AMPK 
subunits. In future experiments, Click-PEGylation could be performed on these 
lysates containing overexpressed and tagged AMPK subunits. However, extensive 
work conducted in Chapter 4 indicated that all AMPK activity changes in response 
to different sources of ROS in C2C12 myotubes correlated with changes to cell 
ATP/ADP ratios, suggesting indirect effects. Thus, optimisation of the AMPK redox-
state analysis was temporarily halted in this body of work.  
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A       B	  
	  
C       D 
 
 
Figure 3.19. Epitope-tagged and untagged AMPK subunits overexpressed in HEK293 cells, 
detected by Western blotting. (A - D) HEK 293 cells were plated at a density of 20,000 cells/cm2 
on 6 cm plates in 3 ml standard media. At 50 – 70 % confluency, cells were transfected with 1 μg or 
10 μg of each cDNA vector. 24 h after transfection, cells were lysed in Hepes lysis buffer (see 2.4 
AMPK assays) and assayed by Western blot (25 μg protein per well) to confirm translation of 
overexpressed proteins of interest. For method details, see 2.2.6.1 Standard transfection 
procedure. Samples from untransfected and transfected cells were loaded on quadruplicate 4 – 
20% SDS-PAGE gels, (A) alongside a sample of purified FLAG-BAP™ protein (Sigma) (~ 49 kDa): 
a positive control for the FLAG antibody. Post blocking, membranes were sectioned (grey dotted 
lines) and each section was incubated with the appropriate primary antibody for the Mw range of 
that section (indicated by descriptions). Western blots were performed as standard (2.1.2.5 
Western blotting).  
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A 
 
B       C 
 
D       E 
 
Figure 3.20. Quantification of epitope-tagged and untagged AMPK subunits overexpressed 
in HEK293 cells, detected by Western blotting. (A – E) Signal intensities of target bands (from 
Figure 3.19) were normalized to those of ACC1/2 as a loading control. (A & B) Graphed data 
represents mean ± SEM n = 3 or 4 technical replicates. (C – E) Graphed data is n = 1.  
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3.6 Discussion and future work 
The above experiments describe an approach to differentially label cysteine 
residues according to thiol redox state, which is assessed by mobility shift 
electrophoresis. In Click-PEGylation, the thiol labelling step by maleimide 
derivatisation is separated from the PEG labelling, via a Click chemistry 
conjugation reaction, which gives improved flexibility over existing single-step 
strategies (e.g. the PEG-switch assay from which Click-PEGylation drew 
inspiration) (Burgoyne et al., 2013, van Leeuwen et al., 2017). Thiol labelling, 
particularly of proteins in their native state, can be impaired by the bulkiness of the 
PEG polymers, which can limit them from reaching their target sites. For this 
reason, the Click-PEGylation approach - utilising a Click chemistry intermediate 
linking step between the labelling and the tagging – is a useful alternative method.  
 
Click-PEGylation can also be adapted to incorporate different tags. One could for 
example react samples with propargyl-maleimide and, as well as PEGylating some 
of them, react the remaining samples with other tags (e.g. a fluorescent label or 
biotin) for further enrichment, mass spectrometry or other downstream applications. 
Compared to other electrophoretic gel-based redox assays, thiol PEGylation has 
the advantage of providing the user with details about the contribution of different 
redox states of a protein whereas other assays, such as fluorescent labelling, 
generally result in a measure of overall protein oxidation. 
 
The Click-PEGylation approach complements redox proteomics-based techniques 
as it is quicker and can, depending on the antibody, also facilitate a targeted 
assessment of candidate proteins, including proteins that are low in abundance or 
proteomically challenging. In 3.4 Method development and results, as a proof-of-
principle and to optimise the Click-PEGylation protocol, we used purified GAPDH. 
However, we also showed that the protocol can be applied to complex samples 
(cell lysates) and to thiol-containing proteins of a higher molecular weight, like 
catalase. Click-PEGylation would be useful to assess the effects of a range of 
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different conditions on the redox state of candidate proteins, with interesting 
findings followed up by using complementary mass spectrometry-based redox 
methods to identify the specific cysteine residues involved. Click-PEGylation also 
allows the redox state of multiple targets to be interrogated from a single sample by 
detection with different antibodies. 
 
Above we focused on differentially labelling reduced and reversibly oxidised thiols. 
To distinguish between the various possible oxidised modifications more 
selectively, additional steps can be incorporated into the standard Click-PEGylation 
protocol at the initial thiol labelling stage. For instance, S-nitrosated thiols could be 
selectively reduced using Cu/ascorbic acid, or S-sulfenylation specifically studied 
by labelling with a dimedone-containing alkyne group (e.g. DYn-2 (Yang et al., 
2015)). With the increasing use of Click chemistry as a selective and efficient 
conjugation strategy, the range of available azide-tagged probes is constantly 
expanding, which will allow further enhancement of the Click-PEGylation approach. 
 
In establishing and optimising this method, we discovered a number of important 
points that need to be considered before adapting the method to a new protein of 
interest. In some cases, depending on the proximity of cysteine residues, 
conjugation of the target protein with PEG polymers may obstruct the epitope 
recognition site of some antibodies, leading to loss of Western blot signal upon 
Click-PEGylation, but not in the ‘– catalyst’ control. If this occurs, alternative 
antibodies (particularly polyclonal) can be explored, where PEGylation will not 
interfere with antibody recognition of the protein.  
 
The molecular weight shifts obtained upon Click-PEGylation are not directly 
additive to the combined size of the PEG moieties. This is due to drag and steric 
hindrance for the migration of branched Click-PEGylated proteins through a gel 
compared to unlabelled linear proteins during electrophoresis. The PEG labeling 
also affects the SDS-coating of the protein, which also alters how the proteins 
migrate on an SDS-PAGE gel.  
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We showed that the Click-PEGylation protocols can be used to detect redox shifts 
in complex biological samples by lysing the cells in the presence of NEM or 
propargyl-maleimide to alkylate the reduced thiols during lysis. As thiol oxidation 
can occur rapidly during cell lysis, cell protein can potentially be acid-precipitated 
prior to Click-PEGylation to prevent any artefactual oxidation (Held and Gibson, 
2012). Future work with the Click-PEGylation protocols can include testing the 
benefits of this step.  
 
From my work on AMPK, and also further work by others in the lab to which this 
method has been applied, I observed that it is more difficult to resolve individual 
bands of proteins with a large number of cysteine residues. In this instance, it is 
worth considering the structure of the protein and whether or not some cysteine 
residues may be involved in internal structures (e.g. Fe-S clusters) that may render 
them unlikely to be reversibly modified physiologically in the context of redox-
signalling. If this is the case, native labeling of only the easily accessible cysteines 
(labeling without initial denaturation of the protein by SDS, urea or heat) can be 
attempted which will decrease the number of thiols PEGylated and importantly 
focus on the thiols which are most likely to be biologically relevant in redox 
signaling. Similarly, in other applications of this method in the lab it has been found 
that with some proteins, maleimides can react with groups other than thiols or 
cross-react with certain antibodies (although I did not observe any evidence of this 
with the model protein GAPDH or with AMPK after the propargyl maleimide 
concentration had been optimised). In this instance, the thiol alkylating agent 
iodoacetamide can be used instead of maleimide to good effect (Hill et al., 2009), 
and propargyl-iodoacetamide compounds exist commercially to use with this Click-
PEGylation method.  
 
Investigating AMPK redox states by Click-PEGylation would require further 
experiments. For testing endogenous AMPK, the starting protein amount needs to 
first be increased and protease inhibitors and antioxidants in the catalyst addition 
stage can also be investigated to prevent protein degradation. In parallel, 
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overexpressing AMPK subunits in cells, some with epitope tags, may also prove to 
be useful in optimising the Click-PEGylation reactions. However, as discussed in 
greater detail in Chapter 4, it does remain to be seen just how relevant AMPK 
redox states are in the context of AMPK regulation by ROS in cells.  
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Chapter 4   
AMPK activation in C2C12 myotubes by H2O2 and 
mitochondrially-derived ROS 
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4.1 Introduction and aims 
AMPK is a key sensor and regulator of cellular and whole-body energy metabolism 
which promotes cell survival by adapting metabolic pathways to energy demand 
(Carling et al., 2011, Hardie et al., 2012). The enzyme has been identified as a 
potential therapeutic target in T2 diabetes (Cool et al., 2006, Coughlan et al., 2014, 
Hardie, 2017), inflammation (O'Neill and Hardie, 2013) and cardiac ischaemia 
reperfusion injury (Kim et al., 2011, Zaha et al., 2016, Shao et al., 2014, Qi and 
Young, 2015). The enzyme’s activity is directly regulated by adenine nucleotides 
(Oakhill et al., 2011, Hardie et al., 2011), primarily by AMP, which, when levels 
increase relative to ATP (measured as a decreased ATP/AMP or ATP/ADP ratio), 
binds the γ subunit and allosterically activates the enzyme. However, reactive 
oxygen species (ROS) have also been investigated as an atypical regulator of 
AMPK by several potential redox mechanisms. The role of mitochondrial ROS in 
AMPK activity is of particular interest. Mitochondria are key regulators of the 
adenine nucleotide pool and so play an important role in ADP and/or AMP-
dependent AMPK regulation (hereafter, AMP/ADP-dependent regulation). 
Mitochondria are also important producers of ROS and their generation, particularly 
by RET, is now suggested by us and other labs to be a potential way in which 
mitochondria may signal to the rest of the cell during periods of metabolic 
adaptation (Chouchani et al., 2014, Mills et al., 2016, Scialo et al., 2016, 
Chouchani et al., 2016).  
The prospect that ROS may alter AMPK activity as a further way of relaying 
information about the metabolic state or demands of the cell and thus promoting 
pro-survival adaptation has been investigated in a number of ways (Shao et al., 
2014, Zmijewski et al., 2010, Emerling et al., 2009, Hart et al., 2015, Mungai et al., 
2011, Hawley et al., 2010, Auciello et al., 2014). However, as discussed in 1.5.11 
Evidence for and against redox-regulation of AMPK, while AMPK can be 
allosterically activated in an AMP/ADP-independent mechanism (Xiao et al., 2013, 
Hawley et al., 2012, Zhang et al., 2017, Garcia and Shaw, 2017) (Figure 4.1), 
AMP/ADP-independent AMPK activation by ROS is not uniformly observed 
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(Auciello et al., 2014, Hawley et al., 2010). It is possible that varying sensitivities in 
methods of measuring adenine nucleotides, different expression levels of ROS 
scavenging proteins in different cell types and possibly different cellular glucose 
availability (Auciello et al., 2014, Shao et al., 2014, Zhang et al., 2017) are causes 
for the lack of consensus. Although AMPK redox state in response to exogenous 
oxidants has been investigated by different methods and found to be altered 
(Zmijewski et al., 2010, Shao et al., 2014), it has not been determined to what 
extent the ROS tested alter the redox state of the cells. As AMPK is localised in the 
cytosol, a reversible change in the redox state of the cytosol (particularly to known 
ROS scavenging and ROS signaling proteins) would likely be required for any 
potential redox-regulation of AMPK to occur physiologically as a signalling 
mechanism. An irreversible change in redox state would be indicative of oxidative 
damage. Furthermore, the effects on AMPK activity by different sources of ROS 
(i.e. cytosolic versus mitochondrially-derived ROS) have not been compared in 
detail, nor what effect compartmentalisation of ROS has on the redox state of the 
cytosol and on AMPK activity.  
 
To address these uncertainties, my aim was to characterise the effects of 
exogenous and selective, mitochondrially-derived ROS on AMPK activity and cell 
ATP/ADP ratios to determine if the effects of different sources of ROS on AMPK 
activity could be explained as AMP/ADP-dependent regulation or AMP/ADP-
independent regulation. If confirmed, I aimed to determine the nature of AMP/ADP-
independent regulation, which could be evidence of 1) direct redox effects on 
AMPK activity in cells (e.g. due to redox changes to key cysteine thiols on AMPK) 
or 2) indirect redox effects on AMPK activity in cells (e.g. ROS-induced inhibition of 
upstream phosphatases or ROS-induced increases in cytosolic calcium, etc.). As 
well as measures of AMPK activity and cellular ATP/ADP ratios, I aimed to use 
peroxiredoxin dimerisation as a biologically relevant measure of the oxidation state 
of multiple subcellular compartments. I used differentiated C2C12 myotubes as the 
cell model (for reasons discussed below), treated on day 7 or 8 post initiation of 
differentiation. In greater detail, I first measured the dynamic range of AMP/ADP-
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dependent and AMP/ADP-independent AMPK activation caused by several control 
compounds that alter AMPK activity by known mechanisms. This enabled the 
creation of a set of calibration graphs with which to determine the mode of action of 
other AMPK activating treatments whose mechanism is unclear. I then measured 
the effects on AMPK activity and ATP/ADP ratios of cellular oxidation by 
exogenous H2O2, which I confirmed was sufficient to oxidise the cytosol (where 
AMPK is localized) and also the mitochondria. Then to investigate the effects of 
selective, mitochondria-generated ROS on AMPK and ATP/ADP ratios, I utilised 
the mitochondria-targeted redox-cycler, MitoParaquat (MPQ) (Robb et al., 2015), 
confirming that ROS was generated and contained within mitochondria only and 
not transferred to the cytosol. Using the calibration graphs and other supporting 
data, I aimed to infer the mechanisms of action of both the exogenous and 
mitochondria-generated ROS on endogenous AMPK activity using a screening 
methodology that can be readily adapted to any cell type.  
 
 
 
Figure 4.1 Known and potential regulators of AMPK activity by AMP/ADP dependent or 
AMP/ADP independent mechanisms.  ADaM-site, allosteric drug and metabolite binding site; α-
ST-loop, α subunit C-terminal domain serine/threonine-rich loop; β-CBM, β subunit carbohydrate 
binding module.   
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4.2 Methods and results 
4.2.1 Cell model background and characterization 
C2C12 cells are a mouse skeletal muscle (myoblast) cell line, which I chose as the 
cell model for this project for several reasons: 1) C2C12s have sufficient levels of 
mitochondria to be able to study mitochondrial function (Leary et al., 1998, Elkalaf 
et al., 2013); 2) C2C12 myoblasts can be terminally differentiated to myotubes to 
provide an alternative set of biological parameters (discussed in greater detail 
below); 3) C2C12s are a useful model to study AMPK activity as AMPK plays an 
important role in skeletal muscle function, regulating glucose uptake, fatty acid 
oxidation and mitochondrial biogenesis (O'Neill et al., 2011, Jager et al., 2007).  
 
C2C12 myoblasts are typically cultured in a high glucose (4.5g/l or 25 mM) DMEM 
GlutaMAX media, supplemented with 10% fetal bovine serum (FBS) that provides 
mitogens that maintain the cells in an undifferentiated, myoblast state (Yoshiko et 
al., 2002). As a highly proliferative cell line, C2C12 myoblasts are typically 
glycolytic (Leary et al., 1998). For investigating mitochondria - AMPK cross-talk, I 
chose to differentiate the myoblasts to myotubes as there is evidence that 
myotubes are more dependent on mitochondrial ATP production (OXPHOS) than 
myoblasts (Leary et al., 1998, Sin et al., 2016). Myotubes are thus a more 
physiologically relevant model than myoblasts because being terminally 
differentiated, they are more similar in morphology and bioenergetics to skeletal 
muscle fibers than are myoblasts. Differentiation also provides a useful quality 
control system, as there is evidence that cells with dysfunctional mitochondria do 
not differentiate (Wagatsuma and Sakuma, 2013). Finally, differentiation allows 
easier and more direct comparisons of short and long (i.e. 24 h) treatment time-
points without the cell density changing (as myotubes are non-proliferating, 
compared to highly proliferative myoblasts).  
 
C2C12 myoblasts can be differentiated to myotubes by two main methods: 1) 
changing the serum in the media from 10% (v/v) FBS to 2% (v/v) adult horse serum 
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(Andres and Walsh, 1996) or 2) decreasing the FBS in the media from 10% (v/v) to 
1% (v/v) (Yoshiko et al., 2002). Both methods decrease the amount of mitogens 
present in the culture media. This induces endogenous expression of insulin-like 
growth factors (IGFs), which halts proliferation and promotes differentiation 
(Yoshiko et al., 2002). As reasons for and against both methods of differentiation 
are not well characterized and preference is likely due to individual lab traditions, I 
chose FBS serum-depletion as the method of C2C12 differentiation as it negates 
the need for an additional reagent (horse serum) whose components (like FBS) are 
unclear and variable from batch to batch. 
 
C2C12 differentiation is accompanied by cell shape and protein expression 
changes (Andres and Walsh, 1996, Elkalaf et al., 2013, Yoshiko et al., 2002, Leary 
et al., 1998) which I confirmed by microscopy and Western blotting for myogenin, a 
marker of differentiation which is expressed from initiation of differentiation (see 
2.2.4 Differentiation and treatment of C2C12 cells). I also observed apparent 
increases in protein expression of a mitochondrial membrane protein, VDAC, in 
differentiated cells compared to undifferentiated cells, an indicator of increased 
mitochondrial content (Figure 4.2). This is consistent with literature indicating 
mitochondrial biogenesis is upregulated during C2C12 differentiation (Leary et al., 
1998, Sin et al., 2016, Elkalaf et al., 2013). I observed a change in protein 
expression of the AMPKβ subunit isoforms (Figure 4.2). In undifferentiated cells, 
AMPKβ1 was the dominant AMPKβ isoform expressed, but there was increased 
protein expression of AMPKβ2 from day 5 of differentiation. This is consistent with 
literature indicating that AMPKβ2 is mainly expressed in muscle (Birk and 
Wojtaszewski, 2006). It has been found that AMPKβ2 can bind glycogen (a 
potential negative regulator of AMPK activity) tighter than AMPKβ1 (Koay et al., 
2010) and so targeting AMPKβ2 for activation may be a way of selectively 
increasing AMPK activity in muscle for blood glucose-lowering benefit to diabetic 
patients (Koay et al., 2010, Hardie, 2017).   
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A      B 
 
 
C      D   
 
Figure 4.2. Differential protein expression profiles during C2C12 differentiation. (A - D) 
C2C12 myoblasts were plated at 20,000 cells/cm2 in high glucose standard medium. When cells 
reached ~ 90% confluency (day 0), myoblast to myotube differentiation was induced by serum 
depletion (see 2.2.4 Differentiation and treatment of C2C12 cells). Cells were rapidly lysed in 
Hepes lysis buffer supplemented with DTT and protease inhibitors (see 2.4 AMPK assays). SDS-
PAGE (~ 25 μg protein per well) and Western blot were performed as described in 2.1.2.4 Western 
blotting or 2.4 AMPK assays. Post blocking, PVDF membranes were cut horizontally with a razor 
blade (as indicated by the grey dotted lines) and each section was individually or dual incubated 
with the appropriate primary antibody(s) for the Mw range of that section, indicated by band 
descriptions (see 2.1.2.1.1 Primary antibodies). Rabbit and mouse primary antibodies were 
differentially labelled with fluorescent secondary antibodies (see 2.1.2.1.2 Secondary antibodies). 
Western blots were imaged using the Odyssey® CLx Infrared Imaging System ((A) fluorescence 
emission at 800 nm for myogenin or 680 nm for VDAC and α-tubulin and (B) fluorescence emission 
at 800 nm for all proteins). (C) The Western blot signal intensities of myogenin and VDAC 
(quantified with LI-COR Biosciences Image Studio™ Lite software) were normalised to that of α-
tubulin as a loading control. Results were expressed as % day 0. (D). The Western blot signal 
intensities AMPKβ1 or AMPKβ2 were calculated as % total AMPKβ1+2 and then expressed as % 
day 0. All data points represent mean ± range of n = 2 biological replicates, except day 7 (n = 1).  
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4.2.2 Characterizing AMP/ADP-dependent and AMP/ADP-
independent AMPK activity in C2C12 myotubes  
The cellular adenine nucleotide pool (consisting of ATP, ADP and AMP) is the 
primary regulator of AMPK (Oakhill et al., 2011, Hardie et al., 2011). Increases in 
cellular AMP and ADP relative to ATP (measured as decreased ATP/AMP or 
ATP/ADP ratios) (Carling et al., 2011) occur during acute and chronic energy 
demand and promote AMPK activation by an allosteric mechanism. To 
characterize the cell line-specific dynamic range of this regulation of AMPK in 
response to energy stress (AMP/ADP-dependent activation), C2C12 myotubes 
were treated with mitochondrial respiratory chain inhibitors or an uncoupler that 
inhibit mitochondrial ATP production in different ways, thereby increasing AMP and 
ADP levels. Initially, phosphorylation of the AMPK catalytic α subunit at T172 and 
of a downstream target, Acetyl Co-A carboxylase (ACC) at S79, were assayed by 
Western blotting (Figure 4.3). Rotenone and phenformin (specific and non-specific 
inhibitors, respectively, of mitochondrial complex I), FCCP (mitochondrial 
uncoupler) and oligomycin (inhibitor of ATP synthase) all significantly increased 
AMPK and ACC phosphorylation after 30 min treatment.  
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B      C 
 
D      E 
 
 
Figure 4.3. AMPK activity markers (phospho-AMPKα(T172) and phospho-ACC(S79)) in C2C12 
myotubes in response to inhibitors of mitochondrial ATP production, assessed by Western 
blotting. (A) C2C12 myotubes were treated with mitochondrial respiratory chain inhibitors or an 
uncoupler (FCCP) for 30 min to inhibit ATP production and activate AMPK. Cells were treated in 
fresh medium (1% (v/v) FBS) with rotenone (2 μg/ml), phenformin (5 mM), FCCP (1 μM) or 
oligomycin (100 ng/ml). Cells were rapidly lysed in ice-cold Hepes lysis buffer: 250 μl lysis buffer 
per 6 cm plate (see 2.4 AMPK assays). Western blotting (25 μg protein) was performed as 
previously described. (B & C) The Western blot signal intensities of AMPKα1/2-phosphoT172 and 
ACC1/2-phosphoS79 target bands were normalised to those of AMPKβ2 as a loading control. 
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Graphed data is mean ± SEM of n = 3 biological replicates; (D & E) Graphed data is mean ± SEM 
of n = 3 biological replicates (from (B & C)), expressed as % untreated (UT) control. Statistical 
analysis was performed by one-way analysis of variance (ANOVA) with Dunnett’s Multiple 
Comparison post-test comparing all treatments to UT control. Means were considered significantly 
different when P < 0.05. **P < 0.01, *** P < 0.001. 
 
AMPK specific activity in response to these inhibitors of mitochondrial ATP 
production was then measured by the radiometric SAMS kinase assay (Figure 
4.4). In agreement with the phosphorylation assays, AMPK specific activity was 
increased in response to treatment with the different compounds that inhibit 
mitochondrial ATP production. 
 
A      B 
 
Figure 4.4 AMPK specific activity in C2C12 myotubes in response to inhibitors of 
mitochondrial ATP production, assessed by the AMPK SAMS kinase assay. (A) AMPK was 
immunoprecipitated from 200 μg protein from freshly thawed whole cell lysate aliquots (described in 
Figure 4.3), and then divided into 4 X 10 μl aliquots. SAMS kinase assays were performed as 
described in 2.4 AMPK assays on duplicate aliquots (equivalent to 50 μg whole cell protein) in 
Hepes buffer with AMP (167 μM) and SAMS peptide (167 μM) (final concentrations). A ‘blank’ 
reaction was performed on a third aliquot (without SAMS peptide). All kinase reactions were 
initiated with radiolabelled ATP mix: [γ-32P]ATP (16.7 μCi/ml), ATP (167 μM) and MgCl2 (4.2 mM) 
(final concentrations). SAMS peptide phosphorylation (radiolabelled) by AMPK was measured by 
scintillation counting and quantified by measuring the specific radioactivity (SR) of a known amount 
of radiolabelled ATP (5 nmol). The mean specific activity of AMPK was calculated as follows: (mean 
kinase – blank counts per min (CPM)) X total V (30 μl))/(SR (CPM.nmol-1) X pipetted V (25 μl) X T 
(30 min) X cell protein (50 μg)). Graphed data is mean ± SEM of n = 3 biological replicates 
presented as pmol [γ-32P]ATP /μg cell protein/min; (B) Graphed data is mean ± SEM of n = 3 
biological replicates from (A) expressed as % untreated (UT) control. Statistical analysis was 
performed by one-way ANOVA with Dunnett’s Multiple Comparison post-test comparing all 
treatments to UT control. Means were considered significantly different when P < 0.05. *P < 0.05, 
**P < 0.01, *** P < 0.001. 
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In parallel, the ATP/ADP ratio of C2C12 myotubes was measured in response to 
the respiratory chain inhibitors (Figure 4.5). The cell ATP/ADP ratio is readily 
measurable using a luciferase/luciferin-based bioluminescence assay (Strehler, 
1974), see 2.5 Measuring cell and tissue ATP/ADP ratios by bioluminescence. 
The ATP/ADP ratio was measured instead of the ATP/AMP ratio because the 
concentration of AMP in cells tends to be one or two orders of magnitude lower 
than those of ADP and ATP (Hardie, 2011) so it can be difficult to measure AMP 
reliably. As the cell ATP/AMP ratio varies as the square of the ATP/ADP ratio 
(Hardie and Hawley, 2001), small decreases in the ATP/ADP ratio translate to 
larger relative decreases in the ATP/AMP ratio. Thus, even small decreases in the 
ATP/ADP ratio can enable allosteric activation of AMPK by AMP. Furthermore, 
increased cell ADP levels relative to ATP also activate AMPK by protecting AMPK 
from dephosphorylation (and thus inactivation) by upstream phosphatases. The 
ATP/ADP ratiometric measurement avoids discrepancies in absolute quantification 
of ATP or ADP that can occur due to slight changes in cell numbers. Absolute 
ATP/ADP ratios in untreated (UT) cells averaged at 16.1 ± 2.1 (mean ± SEM of n = 
3 biological replicates). As it is thought that healthy cells require a ratio of ATP/ADP 
of ~ 10 - 20 in order to perform energy-requiring processes (Hardie and Hawley, 
2001), the average ratio I measured in untreated cells suggests that the cells were 
healthy and also that the method of nucleotide measurement was sensitive and 
offered results comparable with literature. ATP/ADP ratios in treated cells ranged 
between 7.4 ± 0.7 (rotenone) and 11.4 ± 1.8 (FCCP), ~ 46 and ~ 71% of UT cells, 
respectively, confirming that ATP production was inhibited. Decreased cell 
ATP/ADP ratios combined with the increased AMPK activity shown above is 
characteristic of AMP/ADP-dependent regulation of AMPK activity by these control 
compounds.  
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A       B 
 
Figure 4.5 ATP/ADP ratios in C2C12 myotubes in response to inhibitors of mitochondrial 
ATP production, measured by a luciferase/luciferin bioluminescence assay. (A) C2C12 
myotubes were treated with compounds as described in Figure 5.3. Cells were rapidly lysed in ice-
cold perchloric acid extractant (PCA). For ATP measurements, pH neutralised sample (100 μl) was 
added to 400 μl Tris-Acetate buffer in luminometer tubes. ATP was measured by light emission in a 
luminometer (Berthold AutoLumat LB 953 Multi-Tube) following addition of luciferase/luciferin 
solution (100 μl per tube, delivered by autoinjector, protected from light). For ADP measurements, 
endogenous ATP was first degraded by ATP sulfurylase and then endogenous ADP was converted 
to ATP using a pyruvate kinase/ phosphoenoylpyruvate solution. Newly converted ATP was then 
measured by luciferase/luciferin solution as previously described. ATP and ADP values were 
quantified from standard curves. Sample ATP and ADP values were expressed as ratios, calculated 
as follows: ATP (pmol ATP)/(ADP (as pmol ATP) – ‘blank’ (pmol ATP)). Graphed data is mean ± 
SEM of n = 3 biological replicates. For detailed methods and buffers see 2.5 Measuring ATP/ADP 
ratios by bioluminescence. (B) Graphed data is mean ± SEM of n = 3 biological replicates (from 
(A)) expressed as % untreated (UT) control. Statistical analysis was performed by one-way ANOVA 
with Dunnett’s Multiple Comparison post-test comparing all treatments to UT control. Means were 
considered significantly different when P < 0.05. **** P < 0.0001. 
 
AMPK can also be directly activated in an AMP/ADP-independent manner by a 
number of small molecules: the synthetic AMPK activators A-769662 and 991 and 
the naturally occurring plant compound, salicylate (a metabolite of aspirin) (Xiao et 
al., 2013, Hawley et al., 2012). These compounds bind at one site at the interface 
of the α subunit kinase domain and the β subunit carbohydrate-binding module 
(CBM), known as the allosteric drug and metabolite (ADaM)-binding pocket 
(Langendorf and Kemp, 2015), and increase AMPK activity independently of 
adenine nucleotide-binding. This AMP/ADP-independent allosteric activation can 
also act in synergy with AMP, with combined A-769662 and AMP binding having 
an additive effect on AMPK activity (Xiao et al., 2013). Treatment of C2C12 
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myotubes with 991 increased AMPKα(T172) phosphorylation and ACC(S79) 
phosphorylation dose-dependently (Figure 4.6). Compound C, a non-specific 
inhibitor of AMPK by an unclear mechanism (Liu et al., 2014) was also tested on 
cells (Figure 4.6). The inhibitor had no effect on phosphorylation markers 
compared to untreated cells, suggesting that the untreated cells already had low 
levels of AMPK activation. Although not tested, Compound C may have an 
inhibitory effect on above-basal AMPK activation in cells, caused either due to 
energy stress (AMP/ADP-dependent activation) or following pre-treatment with 991 
(AMP/ADP-independent activation).  
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A  
 
B      C 
 
D      E 
 
 
Figure 4.6 AMPK activity markers (phospho-AMPKα(T172) and phospho-ACC(S79)) in C2C12 
myotubes in response to a selective AMPK activator or inhibitor, assayed by Western 
blotting. (A) C2C12 myotubes were treated with the selective AMPK activator, 991 or the AMPK 
inhibitor, Compound C (CC) to activate or inhibit AMPK by an AMP/ADP-independent mechanism. 
Cells were treated in fresh medium (1% (v/v) FBS) with 991 (1 or 10 μM) or CC (10 μM) and 
incubated for 30 min. Cells were rapidly lysed in ice-cold Hepes lysis buffer and Western blots were 
performed on freshly thawed aliquots as previously described. After the representative Western blot 
was imaged, the image was cropped vertically and merged (as indicated by the black dotted line) to 
exclude middle lanes that were not relevant for this experiment; (B & C) The Western blot signal 
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intensities of AMPKα1/2-phosphoT172 and ACC1/2-phosphoS79 target bands were normalised 
against those of AMPKβ2 as a loading control. Graphed data is mean ± SEM of n = 3 or 4 biological 
replicates; (D & E) Graphed data is mean ± SEM of n = 3 or 4 biological replicates (from (B & C)), 
expressed as % untreated (UT) control. Statistical analysis was performed by one-way ANOVA with 
Dunnett’s Multiple Comparison post-test comparing all treatments to UT control. Means were 
considered significantly different when P < 0.05. *P < 0.05, **P < 0.01, *** P < 0.001.  
 
AMPK specific activity in response to 991 and Compound C was measured by the 
radiometric SAMS kinase assay (Figure 4.7).  991 induced dose-dependent AMPK 
activation and Compound C had no effect (compared to untreated cells), all in 
agreement with the previous Western blot analyses.   
 
A       B 
  
Figure 4.7 AMPK specific activity in C2C12 myotubes in response to a selective AMPK 
activator or inhibitor, assessed by the AMPK SAMS kinase assay. (A) SAMS kinase assays 
were performed as previously described on AMPK immunoprecipitated from 200 μg protein from 
freshly thawed lysate aliquots, described in Figure 4.6. (A) Graphed data is mean ± SEM of n = 3 
biological replicates presented as pmol [γ-32P]ATP/μg cell protein/min; (B) Graphed data is mean ± 
SEM of n = 3 biological replicates from (A) expressed as % untreated (UT) control. Statistical 
analysis was performed by one-way ANOVA with Dunnett’s Multiple Comparison post-test 
comparing all treatments to UT control. Means were considered significantly different when P < 
0.05. **P < 0.01, *** P < 0.001. 
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The ATP/ADP ratio of C2C12 myotubes was then measured in response to the 
activator, 991 or inhibitor, Compound C (Figure 4.8). 991 did not decrease cell 
ATP/ADP ratios, consistent with this mode of AMPK activation being independent 
of AMP or ADP levels. Instead, a low dose of 991 increased ATP/ADP ratios above 
untreated cells, possibly evidence of metabolic changes induced by low-grade 
AMPK activation in the absence of energy stress (promotion of ATP generating 
pathways and inhibition of ATP consuming pathways). The higher dose of 991 did 
not significantly affect ATP/ADP ratios, perhaps due to off-target effects or effects 
caused by very high levels of AMPK activity. The inhibitor, Compound C, also had 
no significant effect on ATP/ADP ratios. 
 
 
A      B 
 
Figure 4.8 ATP/ADP ratios in C2C12 myotubes in response to a selective AMPK activator or 
inhibitor, measured by a luciferase/luciferin bioluminescence assay. (A) C2C12 myotubes 
were treated with compounds as described in Figure 4.6. Cells were rapidly lysed in ice-cold PCA 
and ATP/ADP assays were performed as previously described. Graphed data is mean ± SEM of n = 
3 biological replicates; (B) Graphed data is mean ± SEM of n = 3 biological replicates (from (A)) 
expressed as % untreated (UT) control. Statistical analysis was performed by one-way ANOVA with 
Dunnett’s Multiple Comparison post-test comparing all treatments to UT control. Means were 
considered significantly different when P < 0.05. *P < 0.05. 
 
 
I next combined all the data derived from testing AMP/ADP-dependent and 
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creating calibration graphs. Using these graphs I aimed to determine the 
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AMP/ADP-independent. The relationship between the three AMPK activity markers 
(AMPK phosphorylation, ACC phosphorylation and AMPK specific activity) and 
ATP/ADP ratios after cell treatments were compared (with all data presented as % 
untreated (UT) control, so that UT control for all variables = 100 %) (Figure 4.9). 
Plotting all the data together in this way allowed me to clearly visualize the dynamic 
range of the variables in response to control compounds for both AMP/ADP-
dependent and AMP/ADP-independent activation. It was apparent that these 
differing forms of AMPK activation have distinct signatures: AMP/ADP-dependent 
activators induce AMPK activation while decreasing ATP/ADP ratios (red 
background); the AMP/ADP-independent activator induces AMPK activation 
without decreasing ATP/ADP ratios (green background).  
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A 
 
B 
 
C 
 
Figure 4.9 Calibration graphs showing the relationship between AMPK activation markers 
and ATP/ADP ratios in C2C12 myotubes. (A - C) Graphed data shows AMPK activation markers: 
(A) AMPKα(T172) phosphorylation (B) ACC(S79) phosphorylation and (C) AMPK specific activity 
plotted against their respective cell ATP/ADP ratios. Data points are mean ± SEM of n ≥ 3 biological 
replicates. All values are expressed as % UT control.  
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4.2.3 Effects of H2O2 on cellular redox state, AMPK activity and 
ATP/ADP ratios 
Having established the calibration graphs with control compounds that affect 
AMPK activity by AMP/ADP-dependent or AMP/ADP-independent mechanisms, I 
tested the effects of exogenous H2O2 on AMPK activity and ATP/ADP ratios, to 
determine whether: 1) exogenous H2O2 has AMP/ADP-independent effects on 
AMPK activity in cells (e.g. via a redox dependent mechanism) or 2) the effects 
on AMPK are indirect, by altering ATP/ADP ratios (AMP/ADP-dependent 
activation). C2C12 myotubes were treated with serially diluted boluses of H2O2 
for 10 or 30 min, ranging from 7.5 μM to 750 μM, which spans the reported limit 
of physiological concentrations in cells and in vivo (300 nM - 10 μM) (Mueller and 
Arnhold, 1995, Sobotta et al., 2013) to supra-physiological concentrations (> 10 
μM). Boluses were delivered in serum-free media to minimize extracellular 
catalase (in serum), which catalyzes the rapid decomposition of H2O2 to H2O. I 
first tested if the bolus concentrations were sufficient to alter the redox state of 
the cells, with particular interest in changes in the cytosol as that is where AMPK 
is localized. Consequently, a requirement of potential AMPK redox-regulation in 
cells would be a reversible change in the redox state of this subcompartment. I 
was also interested in the redox state of the mitochondria as increased oxidation 
here could potentially impact ATP production, affecting AMPK indirectly (by an 
AMP/ADP-dependent mechanism). 
 
Biological effects of oxidation can be monitored by measuring peroxiredoxin (Prx) 
dimerisation (see 1.3.3.1 The peroxiredoxin/thioredoxin system, 1.4.2 
Regulation of mitochondrial ROS and 2.6 Peroxiredoxin dimerisation assays). 
Prx are a family of thiol peroxidases that help to maintain the redox balance of the 
cell by reducing H2O2 to H2O. When oxidised, Prx can form intermolecular 
reversible disulfide bridges (-S-S-), resulting in Prx homodimerisation and 
inactivation. These inactive dimers (measurable by Western blotting with an 
antibody to Prx, which recognises both the monomer and the dimer) are relevant in 
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redox signalling as they are readily reversible. Thus, the activity of Prx is 
modulated by the ratio of its active to reversibly inactive form, due to disulfide bond 
formation in response to oxidation (Cox et al., 2009, Cox et al., 2008), and 
increased formation of dimer relative to monomer can be used as a measure of 
extracellular, submicromolar concentrations of H2O2 (Sobotta et al., 2013). 
Extended oxidation can cause thiol modifications that do not lead to Prx 
dimerisation (sulfinic acid (–SO2H), sulfonic acid (–SO3H)), more likely associated 
with oxidative damage than redox signalling as they are not readily reversible. This 
hyper-oxidation presents on a Western blot as loss of peak dimerisation, but can 
be visualised using an antibody to the sulfonic acid modification: Prx-SO3 (Riquier 
et al., 2014). To summarise, Prx dimerisation tends to follow an inverted U-shaped 
curve in response to H2O2: dimerisation increases as H2O2 level increase reaching 
a peak (typically measurable as 80 – 90 % dimer), then as H2O2 levels further 
increase, dimerisation decreases due to hyper-oxidation (Sobotta et al., 2013). A 
second benefit of Prx-dimerisation as a measure of cellular oxidation/ extracellular 
H2O2 level is that the redox state of different subcellular compartments can be 
analysed simultaneously. As previously discussed, different Prx isoforms are 
located in different subcellular compartments. Using antibodies specific to Prx 2 
and Prx 3, I was able to monitor the effects of H2O2 boluses on both the cytosol 
and the mitochondrial matrix, respectively, at the same time (Figure 4.10 and 
4.11). Cells were treated with diamide (thiol-specific oxidant (Kosower and 
Kosower, 1995) as a positive control for both Prx 2 and Prx 3 dimerisation, 
showing the dynamic range of dimerisation that is possible to measure in both 
subcompartments simultaneously.  
 
I found that both Prx 2 and Prx 3 dimerisation started to increase in response to 
H2O2 boluses between 7.5 and 75 μM, measured at 10 min post bolus addition.  
Prx 2 dimerisation (cytosol) peaked after treatment with the 75 μM bolus, reaching 
44.3 ± 9.3% dimer (mean ± SEM of n = 3), compared to 19.4 ± 4.1% dimer in the 
UT control. Then % dimer decreased with higher bolus concentrations of H2O2. 
This suggests hyper-oxidation to sulfinic or sulfonic acid was occurring at or higher 
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than this 75 μM bolus. It is possible that hyper-oxidation would have occurred 
between the 7.5 and 75 μM boluses, as other literature has shown peak Prx 2 
dimerisation of ~ 80% dimer after treatment with a 25 μM H2O2 bolus measured at 
5 min post bolus addition (Sobotta et al., 2013). However, this bolus concentration 
was not tested in this experiment. Peak Prx 3 (mitochondrial matrix) dimerisation 
occurred after treatment with the 375 μM H2O2 bolus (80.7 ± 8.5% dimer, 
compared to 46.1 ± 6.0% dimer in the UT control), measured 10 min post-bolus 
addition. % dimer started to decrease after treatment with the 750 μM bolus (72.9 ± 
10.8% dimer) suggesting that hyper-oxidation was occurring between the 375 and 
750 μM boluses. That peak Prx 3 dimerisation occurred after a higher bolus of 
H2O2 than peak Prx 2 dimerisation suggests several possibilities: 1) Prx-H2O2 
oxidation is slower in the mitochondrial matrix compared to the cytosol for 
equivalent [H2O2]; 2) it takes longer for the H2O2 to transfer into the mitochondrial 
matrix than the cytosol, making the local [H2O2] in the matrix lower than in the 
cytosol; 3) some H2O2 metabolism occurred in the cytosol before reaching the 
matrix. A loss of both Prx 2 and Prx 3 dimer signal was observed at 30 min post 
bolus addition. There are several possible reasons for this: 1) the H2O2 was being 
rapidly metabolised to H2O by peroxidases; 2) Prx dimerisation was being rapidly 
enzymatically reversed (by Trx); 3) hyper-oxidation to sulfinic and/or sulfonic acid 
was occurring across the range, presenting as loss of dimerisation. Prx 3 dimers 
were visible as double bands, due to the different electrophoretic mobility of dimers 
linked by one or two disulfide bridges (Dietz et al., 2002, Hall et al., 2009). 
 
Although a number of interpretations can be made from this data set, I have come 
to the following conclusions: 1) the H2O2 boluses tested had a sufficient range to 
reversibly oxidise monomer Prx to dimers (biologically relevant in redox signaling) 
and at higher boluses to hyper-oxidise Prx with loss of dimerisation (consistent with 
oxidative damage); 2) both Prx 2 and Prx 3 formed dimers, confirming that the 
cytosol was oxidised, and so was the mitochondrial matrix; 3) the dimerisation 
subsided at 30 min, possibly as the H2O2 was metabolised from the cell. Although 
Prx-SO3 Western blots to test for formation of hyper-oxidised Prxs (with a pan-Prx 
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antibody specific to the sulfonic acid modification, see 2.1.2.1.1 Primary 
antibodies) were attempted at both time-points, but the antibodies were poor and 
so this will require further analysis in future work.  
 
A 
 
B 
 
C  
 
Figure 4.10. Prx 2 (cytosol) and Prx 3 (matrix) dimerisation in C2C12 myotubes in response 
to boluses of H2O2, assayed by Western blot. (A) Diamide oxidises protein thiols forming 
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disulfide bonds (adapted from (Tortorella et al., 1998). (B & C) C2C12 myotubes were treated with 
serially diluted boluses of H2O2 (7.5, 75, 375 or 750 μM) or diamide (500 μM) in serum-free media 
for 10 or 30 min to oxidise cells. Prior to treatment, cells were washed once in 3 ml serum free 
media. After treatment, cells were incubated in methyl methanethiosulfonate (MMTS) (80 mM) for 
10 min at RT to alkylate thiols. Cells were rapidly lysed in ice-cold RIPA buffer supplemented with 
80 mM MMTS (250 μl lysis buffer per 6 cm plate). Non-reducing SDS-PAGE (~ 25 μg protein) and 
Western blotting was performed, see 2.6 Peroxiredoxin dimerisation assays.  Representative 
Western blots of Prx 2 and Prx 3 were imaged using the Odyssey® CLx Infrared Imaging System 
(fluorescence emission at 680 nm (Prx 2) or 800 nm (Prx 3)). After imaging, the middle sections 
outlined above by vertical black dotted lines were reflected so that lanes containing H2O2 treated 
lysates were arranged low (7.5 μM) to high (750 μM), from left to right for clarity.  
 
 
A       B 
 
C       D 
 
Figure 4.11 Prx 2 (cytosol) and Prx 3 (matrix) dimerisation in C2C12 myotubes in response to 
boluses of H2O2: Western blot quantification. (A - D) The Western blot signal intensities (SI) of 
Prx 2 and Prx 3 dimers (quantified from Figure 4.10) were normalised to those of their respective 
monomer bands and expressed as % dimer (% dimer = (SI dimer / (SI dimer + SI monomer)) x 
100). Graphed data is mean ± SEM of n = 3 or mean ± range of n = 2 biological replicates. 
Statistical analysis was performed by one-way ANOVA (where n ≥ 3) with Dunnett’s Multiple 
Comparison post-test comparing H2O2 treatments to UT control, at 10 or 30 min. Means were 
considered significantly different when P < 0.05. * P < 0.05, ***P < 0.001.  (C & D) Graphed data 
highlights the peak Prx2 and Prx3 dimerisation measured after treatment with 75 μM or 375 μM 
H2O2 boluses, respectively. Data is presented as mean ± SEM of n = 3 biological replicates, 
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expressed as % dimer and analysed by unpaired, one-tailed t tests. Means were considered 
significantly different when P < 0.05. * P < 0.05.  
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AMPK activity markers (AMPKα(T172) and ACC(S79) phosphorylation) were 
measured in response to cell treatments with serially diluted boluses of H2O2 in 
serum-free media for 10 or 30 min (Figure 4.12). H2O2 induced dose-dependent 
increases in both AMPK and ACC phosphorylation at both time-points, with the 750 
μM dose effect being statistically significant and peaking at 30 min.   
 
A 
 
 
B      C  
 
Figure 4.12 AMPK activity markers (phospho-AMPKα(T172) and phospho-ACC(S79)) in 
C2C12 myotubes in response to boluses of H2O2, assayed by Western blot. (A) C2C12 
myotubes were treated with serially diluted boluses of H2O2 in serum-free media for 10 or 30 min 
as described in Figure 4.10. Cells were lysed in ice-cold Hepes lysis buffer and Western blots 
were performed as previously described. (B & C) The Western blot signal intensities of 
AMPKα1/2-phosphoT172 and ACC1/2-phosphoS79 target bands (from (A)) were normalised to 
those of AMPKβ2 as a loading control. Graphed data is mean ± SEM of n = 3 biological replicates 
expressed as % untreated (UT) control. Statistical analysis was performed by one-way ANOVA 
with Dunnett’s Multiple Comparison post-test comparing H2O2 treatments to UT control, at 10 or 
30 min. The difference in AMPK phosphorylation at 10 and 30 min was analysed by unpaired, 
one-tailed t test. Means were considered significantly different when P < 0.05. * P < 0.05;  *** P < 
0.001.   
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In parallel, AMPK specific activity was measured in response to H2O2 treatment 
(Figure 4.13). H2O2 induced dose-dependent increases in specific activity at both 
time-points (with the 750 μM dose effect reaching statistical significance), but the 
effect was diminished at 30 min. These overall results largely agree with the 
phosphorylation assays, but differ in that specific activity peaked at 10 min but 
AMPK phosphorylation peaked at 30 min. It was also apparent that increasing 
AMPK specific activity at 10 min coincided with loss of Prx 2 dimerisation (a proxy 
of cytosolic hyper-oxidation) at high [H2O2] (> 75 μM). AMPK specific activity also 
somewhat correlated with increased Prx 3 dimerisation (mitochondrial matrix 
oxidation). Across the markers of AMPK activation tested, statistically significant 
AMPK activation only occurred at supra-physiological concentrations of H2O2.  
 
A 
 
B      C 
  
Figure 4.13 AMPK specific activity in C2C12 myotubes in response to boluses of H2O2, 
assessed by the AMPK SAMS kinase assay. (A) SAMS kinase assays were performed on AMPK 
immunoprecipitated from 100 μg protein from freshly thawed cell lysate aliquots, described in 
Figure 4.12. Graphed data is mean ± SEM of n = 3 or mean ± range of n = 2 biological replicates, 
measured as pmol [γ-32P]ATP/μg cell protein/min and expressed as % untreated (UT) control. 
AMPK specific activity 
10 30
0
100
200
300
400
500
600
700
750
375
75
7.5**
UT
**
Time (min)
Sp
ec
ifi
c 
ac
tiv
ity
 
(%
 U
T 
co
nt
ro
l)
[H
2 O
2 ] (µM
)
*
Prx 2 dimerisation vs AMPK specific activity
0 100 200 300 400 500 600 700
0
10
20
30
40
50
60
70
80
AMPK specific activity (% UT)
%
 d
im
er
(d
im
er
/(d
im
er
 +
 m
on
om
er
) x
 1
00
 
[H
2 O
2 ]
UT
Prx 3 dimerisation vs AMPK specific activity
0 100 200 300 400 500 600 700
0
10
20
30
40
50
60
70
80
90
100
110
AMPK specific activity (% UT)
%
 d
im
er
(d
im
er
/(d
im
er
 +
 m
on
om
er
) x
 1
00
 
[H
2 O
2 ]
UT
Chapter 4 – AMPK activation by ROS  
	   182	  
Statistical analysis performed by one-way ANOVA (where n ≥ 3) with Dunnett’s Multiple 
Comparison post-test comparing H2O2 treatments to UT control, at 10 or 30 min. The difference in 
AMPK specific activity at 10 and 30 min was analysed by unpaired, one-tailed t test. Means were 
considered significantly different when P < 0.05. * P < 0.05; ** P < 0.01. (B) Graphed data shows 
that loss of Prx 2 dimerisation (hyper-oxidation) in response to high [H2O2] (>75 μM) (from Figure 
4.11 (10 min)), coincides with increasing AMPK specific activity. (C) Graphed data shows that 
increasing Prx 3 dimerisation (from Figure 4.11 (10 min)) coincides with increasing AMPK specific 
activity. Data is presented as mean ± SEM of n = 3 or mean ± range of n = 2 biological replicates.  
 
Next, ATP/ADP ratios were measured in cells treated with the H2O2 boluses 
(Figure 4.14). H2O2 appeared to have a dose-dependent effect on ATP/ADP ratios: 
the 750 μM bolus decreased the cell ATP/ADP ratios at 10 min to 73.1 ± 8.2 % UT 
control (mean ± SEM of n = 3 biological replicates) but the ATP/ADP ratios 
appeared to recover at 30 min (94.2 ± 6.5 % UT control). It also became apparent 
that the decreasing ATP/ADP ratios at 10 min coincided with loss of Prx 2 
dimerisation and increasing Prx 3 dimerisation, as did AMPK specific activity 
(Figure 4.13).  Although cytosolic oxidation (Prx 2 dimerisation) occurred in 
response to H2O2 boluses lower than 750 μM without appearing to decrease the 
cell ATP/ADP ratios, AMPK activity did not significantly change, suggesting that 
AMPK activity only responds to the cell ATP/ADP ratio and not directly to the H2O2. 
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A       
 
 
B      C 
   
Figure 4.14 ATP/ADP ratios in C2C12 myotubes in response to boluses of H2O2, measured by 
a luciferase/luciferin bioluminescence assay. (A) C2C12 myotubes were treated with serially 
diluted boluses of H2O2 in serum-free media for 10 or 30 min as described in Figure 4.10.  Cells 
were rapidly lysed in ice-cold PCA and ATP/ADP assays were performed as previously described. 
Graphed data is mean ± SEM of n = 3 biological replicates, expressed as % untreated (UT) control. 
Statistical analysis was performed by one-way ANOVA with Dunnett’s Multiple Comparison post-
test comparing H2O2 treatments to UT control, at 10 or 30 min. Means were considered significantly 
different when P < 0.05. [H2O2] at 10 min (750 μM): P = 0.0589. (B & C) Graphed data shows loss 
of Prx 2 dimerisation (hyper-oxidation) at 10 min in response to high [H2O2] (>75 μM) or increasing 
Prx 3 dimerisation coincides with decreasing ATP/ADP ratios in cells. Data is presented as mean ± 
SEM of n = 3 or mean ± range of 2 biological replicates.  
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Further comparison of AMPK activity and ATP/ADP ratios from H2O2-treated cells 
to those treated with control compounds using the calibration graphs (Figure 4.15) 
confirmed that the increase in AMPK activity markers correlated with decreasing 
ATP/ADP ratios. The specific activity spike and high phosphorylation at 10 min 
might thus be considered AMP/ADP-dependent events due to a ~ 27% decrease in 
the cell ATP/ADP ratio at this time-point, which approached recovery at 30 min. At 
this later time-point the specific activity of AMPK was also partially ablated. The 
maintained high phosphorylation of AMPK at 30 min might be evidence of ROS-
induced inhibition of dephosphorylation, previously shown to play a minor role in 
AMPK activation in response to H2O2 (Auciello et al., 2014). Under this assumption, 
it could be possible that hyper-oxidation from the 750 μM H2O2 bolus maintained 
and increased AMPK phosphorylation, even as the allosteric activation decreased 
when cell ATP/ADP ratios recovered. The spike in AMPK specific activity at 10 min 
might also be evidence of a small effect of the cysteine thiol oxidation mechanism 
proposed by (Zmijewski et al., 2010). These possibilities are currently speculative 
and are further detailed in 4.3 Discussion and future work.  From the combined 
results, however, I concluded that the cell ATP/ADP ratio is the key determinant of 
AMPK activity in H2O2-treated C2C12 myotubes, impacted on by cellular hyper-
oxidation in response to supra-physiological concentrations of H2O2.  There is no 
evidence of AMPK activation by biologically relevant concentrations of H2O2 in the 
absence of energy stress.  
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A  
 
B     
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Figure 4.15 Calibration graphs showing the relationship between AMPK activation markers 
and ATP/ADP ratios in C2C12 myotubes in response to H2O2, compared to AMP/ADP-
dependent and AMP/ADP-independent AMPK activators. (A - D) Graphed data shows AMPK 
activation markers (A) AMPKα(T172) phosphorylation (B) ACC(S79) phosphorylation and (C) 
AMPK specific activity, plotted against their respective cell ATP/ADP ratios. Plotted along side the 
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control compounds (respiratory chain inhibitors, selective AMPK activator (991) and inhibitor (CC)) 
is the H2O2 titration (10 and 30 min). Data is graphed as mean ± SEM of n ≥ 3 or mean ± range of n 
= 2 biological replicates. All values are expressed as % UT control. The graph shows AMP/ADP-
dependent (red background) and AMP/ADP-independent (green background) distinct signatures of 
AMPK activation, as previously described.  
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4.2.4 Effects of mitochondrial ROS on cellular redox state, AMPK 
activity and ATP/ADP ratios 
To test the effects of mitochondrial ROS on AMPK activity, C2C12 myotubes were 
treated with the mitochondria-targeted redox cycler, MitoParaquat (MPQ), which 
generates superoxide rapidly and selectively within mitochondria (Robb et al., 
2015) (Figure 4.16). 
 
Figure 4.16. Uptake of MitoParaquat (MPQ) by the mitochondria and generation of 
superoxide from complex I. MPQ is comprised of a triphenylphosphonium lipophilic cation 
conjugated to the redox cycler, paraquat by a carbon linker. MPQ accumulates selectively in the 
mitochondrial matrix, driven by the membrane potential, where MPQ produces superoxide by redox 
cycling at the flavin mononucleotide (FMN) site of complex I, selectively increasing superoxide 
production within mitochondria (Robb et al., 2015). 
 
To confirm that ROS was being generated in the mitochondrial matrix and not in 
the cytosol, I tested the effects of increasing concentrations of MPQ on Prx 3 
(matrix) and Prx 2 (cytosol) dimerisation (Figure 4.17 & 4.18). Again, diamide was 
used as a positive control for maximal Prx 2 and Prx 3 dimerisation. MPQ caused 
dose-dependent and cumulative increases in mitochondrial Prx 3 dimerisation from 
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6 h to 24 h, but had no effect on cytosolic Prx 2 dimerisation, suggesting that the 
ROS generated in the mitochondrial matrix was not transmitted to the cytosol.  
 
Prx 3 dimerisation was maintained at 24 h at close to maximal levels, presumably 
as a result of continuous low-grade ROS production by MPQ in the matrix and not 
a single high-dose bolus of H2O2 that has rapid effects. Similarly, Prx 2 dimerisation 
caused by diamide was only observed at 30 min and not at later time-points, 
suggesting the diamide was either being metabolized and Prx 2 dimerisation 
reversed or Prx 2 was becoming hyper-oxidised with formation of sulfinic or 
sulfonic acid modifications that present as loss of dimerisation. Prx 3 dimerisation 
in response to diamide was only slightly diminished at 6 and 24 h, possibly for the 
same reasons that H2O2 had more observable effects on Prx 3 dimerisation than 
on Prx 2 dimerisation: 1) diamide-Prx oxidation may be slower in the mitochondrial 
matrix compared to the cytosol for equivalent [diamide]; 2) it may take longer for 
the diamide to transfer into the mitochondrial matrix than the cytosol, making the 
local [diamide] in the matrix lower than in the cytosol; 3) some diamide metabolism 
may have occurred in the cytosol before reaching the matrix. 
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A 
 
B 
 
C 
 
Figure 4.17 Prx 2 (cytosol) and Prx 3 (matrix) dimerisation in C2C12 myotubes in response 
to MPQ, assayed by Western blot. C2C12 myotubes were treated with MPQ (500 nM, 1 μM, 5 
μM or 10 μM), or EtOH as a vehicle control or diamide (500 μM) as a positive control for thiol 
oxidation in fresh media for (A) 0.5 h, (B) 6 h or (C) 24 h to selectively increase mitochondrial 
ROS production. Cells were rapidly lysed in ice-cold RIPA buffer and Prx dimerisation assays 
were performed as described in Figure 4.9. Representative Western blots (A - C) were imaged 
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using the Odyssey® CLx Infrared Imaging System (fluorescence emission at 680 nm (for Prx 2) 
or 800 nm (for Prx 3)). After imaging, the middle sections outlined above were reflected so that 
lanes containing MPQ treated lysates were arranged low (500 nM) to high (10 μM), from left to 
right for clarity. 
 
A    
 
 
B 
 
C 
 
Figure 4.18 Prx 2 (cytosol) and Prx 3 (matrix) dimerisation in C2C12 myotubes in response to 
MPQ: Western blot quantification. (A - C) The Western blot signal intensities (SI) of Prx 2 (A) and 
Prx 3 (B) dimers (quantified from Figure 4.17) were normalised to those of their respective 
monomer bands and expressed as % dimer (% dimer = (SI dimer / (SI dimer + SI monomer)) x 
Prx 2 dimerisation (% total Prx 2)
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100). (A & B) Graphed data (0.5 h) is mean ± SEM of n ≥ 3 or mean ± range of n = 2 (EtOH) 
biological replicates; graphed data (6 h) is mean ± SEM of n ≥ 3 biological replicates; graphed data 
(24 h) is mean ± range of n = 2 biological replicates. Statistical analysis was performed by one-way 
ANOVA (where n ≥ 3) with Dunnett’s Multiple Comparison post-test comparing MPQ treatments or 
EtOH to UT control, at 0.5 or 6 h time-points. Means were considered significantly different when P 
< 0.05. ** P < 0.01, *** P < 0.001. (C) Graphed data highlights the cumulative increase in Prx 3 
dimerisation by MPQ. Data is presented as mean ± SEM of n ≥ 3 or mean ± range of n = 2 (24 h) 
biological replicates, analysed by unpaired, one-tailed t tests compared to individual UT controls. 
Means were considered significantly different when P < 0.05. ** P < 0.01.  
 
 
AMPK activity markers in cells were then tested in response to increasing [MPQ] 
(Figure 4.19). MPQ had low-grade effects on ACC phosphorylation at 6 h (237 ± 
46 % UT control after 5 μM MPQ (mean ± SEM of n = 4)), however this was not 
statistically significant compared to the vehicle (EtOH) control. Prx 3 (matrix) 
dimerisation was first observed at this time-point. Low-grade ACC phosphorylation 
appeared to be sustained at 24 h, as was Prx 3 dimerisation, without any evidence 
of oxidation of the cytosol. The results suggest that the low-grade AMPK activation 
(measured as ACC phosphorylation) occurred independently of a change in the 
redox state of the cytosol but coinciding with a redox change in the matrix. 
Supporting data is currently limited: MPQ effects on AMPK phosphorylation were 
only observed at 24 h and were highly variable at 233 ± 144% of UT control (mean 
± range of n = 2) and AMPK specific activity has not yet been measured, so future 
experiments will be required to expand the results.  
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A 
 
B       C 
 
D       E 
 
 
Figure 4.19 AMPK activity markers (phosphorylation) in C2C12 myotubes in response MPQ, 
assayed by Western blot. (A) C2C12 myotubes were treated with MPQ (500 nM, 1 μM, 5 μM or 
10 μM) or EtOH as a vehicle control, as described in Figure 4.17. Cells were rapidly lysed in ice-
cold Hepes lysis buffer and Western blots were performed as previously described. (B & C) The 
Western blot signal intensities of (B) AMPKα1/2-phosphoT172 and (C) ACC1/2-phosphoS79 target 
bands (from (A)) were normalised to those of AMPKβ2 as a loading control. Graphed data is mean 
± SEM of n ≥ 3 biological replicates expressed as % untreated (UT) control, except for 10 μM MPQ 
at 30 min (n = 1), and the 24 h treatments (mean ± range of n = 2) (D & E) Graphed data shows the 
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relationship between Prx dimerisation and ACC phosphorylation in MPQ-treated cells at 6 h. Data is 
presented as mean ± SEM of n ≥ 3 biological replicates.  
 
MPQ had no statistically significant effect on cell ATP/ADP ratios at 30 min (Figure 
5.20), however, a low dose of MPQ appeared to increase ATP/ADP ratios by an as 
yet unclear mechanism. At 6 h, ATP/ADP ratios appeared to slightly decrease with 
increasing [MPQ], with an ATP/ADP ratio of 86.5 ± 2.8 % UT control (mean ± SEM 
of n = 4 biological experiments) in cells treated with 10 μM MPQ, however this did 
not reach statistical significance. The ATP/ADP ratio trend appeared to correlate 
with increasing Prx 3 (matrix) dimerisation and occurred in the absence of Prx 2 
(cytosolic) dimerisation. These results suggest that a change in the redox state of 
the mitochondrial matrix by ROS produced by MPQ may cause slight decreases in 
cell ATP/ADP ratios.   
 
A 
 
B      C 
 
Figure 4.20 ATP/ADP ratios in C2C12 myotubes in response to MPQ, measured by a 
luciferase/luciferin bioluminescence assay. (A) C2C12 myotubes were treated with MPQ (500 
nM – 10 μM, or EtOH as a vehicle control) as described in Figure 4.17. Cells were rapidly lysed in 
ice-cold PCA and ATP/ADP assays were performed as previously described. Graphed data is mean 
± SEM of n ≥ 3 biological replicates, expressed as % untreated (UT) control. (B & C) Graphed data 
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shows the relationship between Prx dimerisation and ATP/ADP ratios in MPQ-treated cells at 6 h. 
Data is presented as mean ± SEM of n ≥ 3 biological replicates. 
 
 
When compared to control compounds of AMP/ADP-dependent (red background) 
and AMP/ADP-independent (green background) AMPK activation (Figure 4.21), it 
was apparent that both H2O2- and MPQ-induced activation of AMPK (low-grade 
with respect to MPQ) appear to follow an AMP/ADP-dependent mechanism, only 
occurring when the cell ATP/ADP ratios are decreased.  
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A 
 
B 
 
Figure 4.21 Relationship between AMPK activity markers and ATP/ADP ratios in C2C12 
myotubes in response to MPQ, compared to AMP/ADP-dependent and AMP/ADP-
independent AMPK activators. (A & B) Graphed data shows AMPK activation markers (A) 
AMPKα1/2-T172 phosphorylation and (B) ACC1/2-S79 phosphorylation plotted against their 
respective cell ATP/ADP ratios. Plotted along side the control compounds (respiratory chain 
inhibitors, selective AMPK activator (991) and inhibitor (CC)) is the H2O2 titration (10 and 30 min) 
and the MPQ titration (0.5 & 6 h). All data points are graphed as mean ± SEM of n ≥ 3 or mean ± 
range of n = 2 biological replicates. All values are expressed as % UT control.  
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4.3 Discussion and future work 
In summary, the results from this chapter have indicated that in differentiated 
C2C12 mouse skeletal myotubes, exogenous H2O2 and selective mitochondria-
generated ROS both activate AMPK in a primarily AMP/ADP-dependent way. H2O2 
boluses greater than 7.5 μM oxidised Prx 2 in the cytosol, an important redox-
regulated protein that protects against oxidative stress and can also participate in 
redox-relays that facilitate H2O2 signalling (Sobotta et al., 2015). AMPK was not 
significantly activated by exogenous H2O2 until treatment with the 750 μM bolus, at 
which point there was evidence of oxidative stress: loss of Prx 2 dimerisation and 
cell ATP/ADP ratios appeared to decrease. In response to this oxidative stress, a 
high level of AMPK activity was observed at 10 min post bolus addition and at a 
lower level at 30 min as ATP/ADP ratios appeared to recover. On the other hand, 
selective mitochondria-generated ROS by the redox-cycler, MPQ, increased matrix 
Prx 3 oxidation over time. There was no detectable Prx 2 dimerisation over time, 
indicating that the ROS was contained within the mitochondria and was not 
transmitted to the cytosol where AMPK is located. At 6 h, there appeared to be 
slight decreases in the cell ATP/ADP ratio and slight increases in ACC 
phosphorylation, a marker of AMPK activity. The effects were not statistically 
significant and raised important questions relating to the compartmentalization of 
ROS in cells, discussed further below. 
 
The results discussed in this chapter compliment and expand previous studies into 
the role of ROS in AMPK activity (Auciello et al., 2014, Hawley et al., 2010, 
Zmijewski et al., 2010). An AMP/ADP-independent redox mechanism for AMPK 
activation was proposed in (Zmijewski et al., 2010), in which the authors detected 
redox changes to conserved cysteine residues in the AMPK catalytic subunit in 
response to continuous, extracellular H2O2 generation by glucose oxidase. Here, 
the H2O2 stimulus was sustained and not metabolized rapidly as are individual 
boluses of H2O2. The authors observed increases in AMPK activity in extracellular 
experiments and in HEK 293 cells without detectable decreases in cell ATP/ADP 
Chapter 4 – AMPK activation by ROS  
	   197	  
ratios and thus credited the activation to cysteine-oxidation induced allosteric 
activation. Building upon this and other previous studies, (Auciello et al., 2014) also 
utilised the glucose oxidase method of extracellular H2O2 generation, using HEK 
293 cells expressing the AMP/ADP-insensitive AMPK γ subunit R531G (RG) 
mutant, which renders AMPK unable to be allosterically activated by AMP or 
allosterically protected from dephosphorylation by AMP or ADP. In this study, the 
authors no longer observed high levels of AMPK activity even as ATP/ADP ratios 
were significantly decreased, however, they did observe a low-grade but 
statistically significant increase in AMPK activity with time. The authors also tested 
the effects of single high-dose H2O2 boluses on the RG mutant expressing cells. 
Again, high levels of AMPK activity were no longer observed in these cells even as 
ATP/ADP levels decreased. But again, small increases in AMPK activity were 
observed at 10 min, decreasing with time, as the H2O2 was metabolized from the 
cell. The authors excluded the action of Ca2+-activated CaMKKβ as an alternative 
AMPK kinase in response to H2O2. Thus, the authors concluded that activation of 
AMPK by exogenous H2O2 is primarily an AMP/ADP-dependent event, and that 
different sensitivities in measuring cell ATP/ADP ratios may have played a role in 
the discrepancies between their study and that of (Zmijewski et al., 2010). 
However, (Auciello et al., 2014) did show evidence that H2O2 may play a minor role 
in AMPK regulation by inhibiting AMPK dephosphorylation, potentially by H2O2- 
induced inhibition of upstream phosphatases.  
 
My work largely agrees with (Auciello et al., 2014), in that I only observed 
significant increases in AMPK activity markers in response to boluses of H2O2 
when cell ATP/ADP ratios appeared to be decreased (Figure 4.12 – 4.14). The 
benefit of treating cells with boluses of H2O2 and not glucose oxidase, which 
maintains steady or increasing levels of extracellular H2O2 with time, is that time-
dependent effects of H2O2 and its degradation can be observed. In a change from 
(Auciello et al., 2014), I administered the H2O2 boluses in serum-free media, to 
eliminate catalase and other proteins in serum that may speed up the degradation 
of extracellular H2O2. I also simultaneously monitored the redox state of the H2O2 
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scavenger, Prx, in different cellular subcompartments, as a read-out of the 
intracellular effects of extracellular H2O2 boluses. I observed that 
immunoprecipitated AMPK kinase activity was increased at 10 min (which 
appeared to coincide with decreased ATP/ADP ratios). The specific activity later 
decreased at 30 min (as cell ATP/ADP ratios recovered) but remained significantly 
increased from baseline (Figure 4.13). I also observed the possibility that H2O2 
may inhibit AMPK and ACC dephosphorylation, as AMPK and ACC 
phosphorylation were maintained and increased at 30 min post bolus addition 
(Figure 4.12), even as cell ATP/ADP ratios appeared to recover (Figure 4.14). 
Protein phosphatases are reported to be sensitive to oxidative stress, although by 
an unclear mechanism (Jin Jung et al., 2013). Thus, one explanation for this result 
is that while dephosphorylation of AMPK and ACC may have been independently 
inhibited in cells due to H2O2 inhibition of phosphatases, allosteric activation of 
AMPK may have been decreased at 30 min due to a removal of the allosteric 
effects of AMP. Another possibility is that the redox-dependent mechanism 
reported in (Zmijewski et al., 2010) may have contributed to increased AMPK 
specific activity at 10 min, and decreased at 30 min as H2O2 was further 
metabolized and degraded. Although I performed the extracellular kinase assays in 
reducing conditions, cysteine thiol glutathionylation, reported to promote kinase 
activity (Zmijewski et al., 2010), may have been preserved. The authors of (Auciello 
et al., 2014) also did not exclude the possibility of the cysteine oxidation 
mechanism playing a minor role in this model of AMPK activation. 
 
Regarding my experiments using exogenous H2O2 boluses, a number of 
experiments can be performed in future work in order to expand and clarify the 
results. In analyzing the Prx dimerisation data set, it is currently unclear if the 
H2O2 boluses were degraded between the 10 min and 30 min time-points or if the 
H2O2 continued to hyper-oxidise the Prx pools, presenting as loss of dimerisation 
(here I refer to a detailed study which investigated the metabolism of H2O2 
boluses and Prx dynamics (Sobotta et al., 2013)).  However, this study was 
performed in a different cell model and I note that in C2C12 myotubes, the cell 
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ATP/ADP ratios recovered at 30 min from an apparent decrease at 10 min, which 
suggests the H2O2 was being degraded. Although Prx-SO3 Western blots to test 
for formation of hyper-oxidised Prxs were attempted, the Western blots were poor 
and will require optimisation in future work. Similarly, some intracellular H2O2-
measurement experiments on live cells were attempted using cytosol or 
mitochondrial matrix targeted fluorescent H2O2 probes, visualized by confocal 
microscopy: cyto-roGFP-Orp1 or mito-roGFP-Orp1 (Albrecht et al., 2011), 
discussed in 2.7 Live cell confocal microscopy and imaging. High sensitivity 
to H2O2 boluses (50 μM) was observed in transiently transfected undifferentiated 
C2C12 myoblasts in preliminary experiments (data not shown). However, as 
previously discussed, protein expression profiles are different in undifferentiated 
C2C12 myoblasts compared to differentiated C2C12 myotubes so H2O2 
metabolism may also be different. Thus, the experiment was repeated using 
stable C2C12 cell lines expressing the genes so that H2O2 levels in differentiated 
C2C12 myotubes could also be analysed. As differentiated C2C12 myotubes are 
non-proliferating, transient transfection with the current retroviral host vector 
posed technical difficulties so the cells were transfected and selected in the 
undifferentiated, myoblast state before initiating differentiation of the stable, 
transgene-expressing cells. In preliminary experiments, it was observed that 
H2O2 –sensitivity was greatly decreased in stable C2C12 cell lines expressing the 
cyto-roGFP-Orp1 or mito-roGFP-Orp1 gene (in both the undifferentiated 
(myoblast) or the differentiated (myotube) state), compared to transiently 
transfected C2C12 myoblasts. The reasons for the decreased sensitivity are 
currently unclear, but it may be possible that some post-translational 
modifications of the probes occurred in the cells which affected the sensitivity, 
particularly as the stable cell lines were expressing the genes constitutively. 
Thus, in future work I aim to optimise this experiment because real-time data 
showing relative levels of intracellular H2O2 and its degradation will be valuable in 
elucidating a clear picture of how AMPK activity responds to H2O2.   
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I expanded the work of (Auciello et al., 2014, Zmijewski et al., 2010) by 
investigating the effects of selective mitochondrially-derived ROS on AMPK activity, 
as we and other labs hypothesize that mitochondria may be a key source of 
physiologically relevant ROS in the cell. I hope to use the roGFP-Orp1 or other 
probes to further analyze ROS production by MPQ and characterize the spatio-
temporal characteristics of mitochondrially-derived ROS: i.e. does ROS generated 
in the mitochondrial matrix transfer to the cytosol at a detectable level and thus 
affect signalling processes there, or is mitochondrially-derived ROS 
compartmentalized within healthy mitochondria, only being released upon damage 
to the mitochondria? Although extracellular boluses of H2O2 were capable of 
oxidising the mitochondrial matrix, suggesting that H2O2 can transfer across the 
mitochondrial membranes, matrix Prx 3 dimerisation only increased at supra-
physiological concentrations of H2O2 (≥ 75 uM bolus). As previously discussed, it is 
possible that cytosolic Prx 2 hyper-oxidation may have started to occur at this 
bolus concentration. If confirmed, this would indicate oxidative damage, not 
physiologically relevant redox-signalling. On the other hand, MPQ generated 
superoxide selectively and cumulatively within the mitochondrial matrix, inducing ~ 
87% Prx 3 dimerisation at 24 h, compared to ~ 44% dimerisation in untreated cells. 
Even with this high level of mitochondrial ROS production, there was no detectable 
increase in cytosolic Prx 2 dimerisation, suggesting that the ROS was contained 
within the matrix. Furthermore, at 6 h, the ATP/ADP ratio was only slightly 
decreased, measuring at ~	   87% UT control and was not statistically significant. 
Combined with the supporting data showing undetectable changes in AMPK 
phosphorylation and only slight increases in ACC phosphorylation, the experiment 
suggested that the cells were not undergoing a high level of stress. It is possible 
that mitochondrial compartmentalization of matrix-generated ROS is dependent on 
the expression levels of ROS scavenging proteins, and this may be cell type 
specific (Shao et al., 2014, Auciello et al., 2014). Thus, in this model it would be 
interesting to modulate the protein expression level of Trx 2 in the mitochondrial 
matrix, which catalyses the reversal of inactive Prx dimers back to functional 
monomers, preventing oxidative damage. Furthermore, it has been reported that 
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the action of Trx 1 in the cytosol prevents oxidation and inactivation of AMPK in the 
heart (Shao et al., 2014). As this remains the only report of reversible redox-
dependent AMPK inhibition, it is possible that in different cells types with different 
ROS scavenging protein profiles, the same levels of ROS can either part-take in 
reversible redox signalling, or irreversible oxidative damage.  
 
A further point of interest that has arisen from the comparison of whole cellular 
oxidation versus selective mitochondrial oxidation are the relative effects on cell 
ATP/ADP ratios. Combined cytosolic and mitochondrial matrix oxidation had a 
more severe effect on ATP/ADP ratios (Figure 4.14) (and thus AMPK activity) than 
mitochondrial matrix oxidation alone (Figure 4.20). Although, as previously 
discussed, differentiated C2C12 myotubes have relatively high mitochondrial 
content, glycolysis remains a key source of ATP production in this cell model, as in 
all commonly used cell lines. Evidence of this can be observed in Figure 4.5, as 
inhibition of mitochondrial ATP production by oligomycin, which inhibits FOF1ATP 
synthase, decreased cell ATP/ADP ratios by ~ 53%, suggesting that glycolysis was 
also an important source of ATP. One possible reason for the more severe effects 
of whole cellular oxidation on ATP/ADP ratios is ROS-induced inhibition of 
glycolysis, also discussed by (Auciello et al., 2014). For example, GAPDH 
catalyses the 6 th step in glycolysis, thereby regulating ATP production by this 
pathway. GAPDH is a highly redox-responsive protein and its activity is inhibited by 
H2O2 (Grant et al., 1999). Thus, it is possible that exogenous H2O2 effected both 
glycolytic and mitochondrial ATP production by several possible mechanisms, 
whereas MPQ may have only affected mitochondrial ATP production in a minor 
way. 
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5.1 Introduction and aims 
Mitochondrial ROS production has previously been considered a nonspecific by-
product of respiratory chain dysfunction during or following oxidative damage or 
energy stress. However, recently it has been shown that ROS production by RET 
(known to be a tightly regulated process dependent on high mitochondrial 
membrane potential and/or a highly reduced Q pool) is a physiologically relevant 
signalling mechanism that drives inflammation (Mills et al., 2016), promotes 
lifespan (Scialo et al., 2016) and in pathology, is a key source of ROS contributing 
to ischaemia reperfusion injury (Chouchani et al., 2016). In order to study the 
downstream effects of RET in pathology or in redox signalling, it is necessary to be 
able to modulate the levels of ROS generated from mitochondria without the use of 
inhibitors (e.g. antimycin A, rotenone, oligomycin), as these will inhibit ATP 
production and alter the ΔP as well as increasing ROS production and so will 
greatly complicate the interpretation of results. One way of modulating 
mitochondrial ROS production without inhibiting respiratory chain function is by co-
expressing alternative respiratory enzymes (from lower order organisms) alongside 
native respiratory complexes in a higher order model of interest (e.g. mammalian 
cell line, fruit fly, mouse etc.). There is now evidence that expressing these 
alternative respiratory enzymes alongside their native counterparts can alter the 
redox state of the Q pool in the IMM, which in turn can change the level of 
superoxide production by RET from complex I (Scialo et al., 2016, El-Khoury et al., 
2013, Mills et al., 2016, Rustin and Jacobs, 2009). Co-expressing alternative 
respiratory enzymes with native complexes does not halt OXPHOS and in fact can 
bypass respiratory chain deficiencies and so is being explored as a potential 
therapy (Rustin and Jacobs, 2009, El-Khoury et al., 2013, Fernandez-Ayala et al., 
2009, Seo et al., 1999, Kemppainen et al., 2014, El-Khoury et al., 2014, Yagi et al., 
2006). 
The immediate aim of this project was to create a stable mammalian cell line 
allowing inducible, titratable expression of the single subunit NADH 
dehydrogenase, NDI1, hypothesized to increase ROS production by RET (Scialo et 
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al., 2016). In parallel, a second stable cell line was created, expressing the single-
subunit alterative oxidase, AOX (hypothesized to inhibit ROS production by RET). 
A second aim was to characterize the effects of each alternative respiratory 
enzyme on mitochondrial ROS production and on cellular bioenergetics (OXPHOS, 
cell ATP/ADP ratios etc.). Ultimately, we hope to create a model system for 
investigating down-stream effects of increased or decreased mitochondrial ROS 
production by RET without requiring respiratory chain inhibitors which may cause 
non-specific effects. The model system would also allow further investigation into 
the possibility of AMPK redox regulation and other potential redox crosstalk 
mechanisms between mitochondria and other cell compartments. Unlike the 
models of ROS tested in Chapter 4, mitochondrial ROS production by RET is 
hypothesized to be a natural mitochondrial redox signal that may occur under 
different physiological or pathophysiological stresses (Chouchani et al., 2016, Mills 
et al., 2016, Scialo et al., 2016, Buskiewicz et al., 2016). Thus, creating a cell 
system that allows us to sensitively modulate ROS production by RET will prove 
useful in further understanding the biological relevance of this phenomenon.  
 
5.2 Alternative respiratory enzymes: background and 
hypotheses  
Mitochondrial respiratory chain dysfunction plays a role in a number of human 
diseases. Dysfunction can be caused by inherited or somatic DNA mutations 
(Viscomi and Zeviani, 2017, Gorman et al., 2016), or following exposure to toxins 
or other environmental stresses (Exner et al., 2012). Respiratory chain dysfunction 
often presents as degenerative neuromuscular syndromes with often 
heterogeneous symptoms in multiple organs or organ systems, e.g. 
cardiomyopathy, deafness, diabetes and epilepsy (Viscomi and Zeviani, 2017, 
Gorman et al., 2016). Although progress has been made in the elucidation of the 
molecular mechanisms and pathogenesis of such disorders (e.g. development of 
metabolic acidosis, metabolic blockade, loss of ion homeostasis, increased ROS 
production) they remain untreatable in many cases (Viscomi and Zeviani, 2017, 
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Rustin and Jacobs, 2009). One treatment strategy that is being investigated by 
several research groups is respiratory chain bypass by expression of alternative 
respiratory enzymes (Rustin and Jacobs, 2009, Fernandez-Ayala et al., 2009, 
Barber-Singh et al., 2009, Yagi et al., 2006, Kemppainen et al., 2014). Alternative 
respiratory enzymes are not found naturally in mammals or other higher order 
animals but confer respiratory chain flexibility to lower order organisms (e.g. plants, 
yeast and invertebrates), including insensitivity to certain environmental toxins (e.g. 
rotenone and cyanide). For example, in plants, alternative respiratory enzymes 
play a role in maintaining mitochondrial redox balance and metabolite cycles in 
daylight when OXPHOS is inhibited by high rates of ATP production from 
photosynthesis (Rustin and Jacobs, 2009, Affourtit et al., 2001). Below, I outline in 
greater detail the contributions of the alternative respiratory enzymes NDI1 and 
AOX to respiratory chain bypass experiments and the effects of these enzymes on 
mitochondrial ROS production.  
5.2.1 Single subunit NADH dehydrogenase - NDI1 
In most eukaryotes, complex I catalyses mitochondrial NADH oxidation and 
electron donation to the ETC, and proton pumping from the matrix to the IMS 
contributing to the ΔP required for ATP production by OXPHOS. However, S. 
cerevisiae has lost complex I in evolution, instead using two simpler, single-
subunit, non-proton translocating enzymes, Nde1p and Ndi1p, which oxidise 
cytosolic and mitochondrial NADH, respectively, and pass electrons to the Q pool 
in the IMM (Yagi et al., 2006). Unlike complex I, the single subunit NADH 
dehydrogenase (NDI1) is rotenone-insensitive, allowing growth in the presence of 
this environmental toxin. In mammalian cell line, fruit fly and mouse experiments, 
transgenic NDI1 expression has been found to successfully bypass complex I 
deficiencies (Seo et al., 1999, Sanz et al., 2010, Barber-Singh et al., 2009), 
permitting ongoing research into NDI1 delivery as a therapeutic strategy for human 
complex I deficiency disorders (Rustin and Jacobs, 2009). Furthermore, when co-
expressed alongside complex I in D. melanogaster, it has been found that NDI1 
increases mitochondrial ROS production (Scialo et al., 2016). As more electrons 
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pass into the Q pool following the enzymatic action of NDI1, without being opposed 
by proton pumping, the Q pool becomes hyper-reduced.  This very reduced Q pool 
can subsequently drive the production of superoxide from complex I by RET 
(Figure 5.1). As discussed in 1.4.1 How mitochondrial ROS can behave as a 
redox signal, superoxide production by RET is emerging as a physiologically 
relevant redox signal in the cell.  
 
A 
 
B 
 
Figure 5.1. Effects of NDI1 expression on Q pool redox state and mitochondrial ROS 
production. (A) NDI1 catalyses the oxidation of NADH and donates electrons to the Q pool. (B) 
When NDI1 is co-expressed with functional complex I, the Q pool becomes hyper-reduced. 
Combined with a high ΔP generated by the rest of the respiratory chain, this hyper-reduced Q pool 
can cause electrons to be driven backward from the Q pool onto the flavin mononucleotide (FMN) of 
complex I, reducing the FMN, which can pass one electron to oxygen to generate superoxide. The 
red arrow in complex I indicates RET.  
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5.2.2 Alternative oxidase - AOX 
Alternative oxidases (AOX) are found in many species of fungi, plants, protists and 
metazoans, but not in vertebrates or arthropods (Rustin and Jacobs, 2009). The 
AOX gene from the urochordate Ciona intestinalis is most commonly used in AOX-
transgene experiments, including those in cell lines, fruit fly and mouse. A terminal 
oxidase, the cyanide-insensitive, non-proton-pumping AOX can bypass complexes 
III and IV of the respiratory chain by receiving electrons from reduced Q and 
transferring them directly to oxygen to form water. In this way, AOX can maintain 
electron transfer in case of a blockade of the cytochrome pathway and bypass 
experiments have been successfully performed in mammalian cell lines, fruit fly 
and mouse. It has also been observed that AOX does not negatively affect 
respiration when co-expressed with functional complex III and IV (Rustin and 
Jacobs, 2009, El-Khoury et al., 2013, Fernandez-Ayala et al., 2009, Dassa et al., 
2009). As AOX uses electrons from the Q pool to reduce oxygen, AOX expression 
thereby prevents the hyper reduction of the Q pool and thus prevents RET. 
Therefore, as well as a therapeutic strategy for combatting complex III or IV 
deficiency in humans, AOX expression can be used to modulate mitochondrial 
ROS production by RET.  In a mouse model, mitochondrial ROS production caused 
by antimycin A is inhibited by AOX expression (El-Khoury et al., 2013). Similarly, 
by preventing hyper-reduction of the Q pool, it has been found that when AOX is 
co-expressed alongside NDI1 and complex I in D. melanogaster, the previously 
observed increased superoxide production from complex I by RET is negated 
(Scialo et al., 2016) (Figure 5.2). 
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Figure 5.2. Effects of AOX expression on Q pool redox state and mitochondrial ROS 
production. (A) AOX uses electrons from reduced Q to reduce oxygen to water. (B) AOX negates 
the effect of NDI1 and complex I co-expression on Q pool hyper-reduction, inhibiting ROS 
production by RET.  
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5.2.2 Mammalian cell lines expressing NDI1 and AOX 
In early studies investigating the potential therapeutic benefit of alternative 
respiratory enzymes in bypassing human respiratory chain deficiencies, NDI1 and 
AOX were expressed in human and other cell lines by various methods (Hakkaart 
et al., 2006, Seo et al., 1999, Seo et al., 2000, Birsoy et al., 2014). A Flp-In™T-
REx™293-AOX cell line has previously been created (Hakkaart et al., 2006), which 
allows Doxycycline (Dox) -induced expression of the gene. This method of stable 
cell line creation offers control of the genome integration site and control of protein 
expression, preventing basal protein expression, which may lead to adaptive 
responses over time. NDI1 cell lines have been created in a number of ways, 
including:  the Invitrogen pHook™ system (allows transfection of dividing cells 
without genome integration and allows separation of transfected and untransfected 
cells) (Seo et al., 1999); recombinant Adeno-Associated Virus (rAAV) transfection 
(achieves high frequency transfection of dividing and non-dividing cells without 
genome integration) (Seo et al., 2000); retroviral transfection (transfection of 
dividing cells only, with genome integration) (Birsoy et al., 2014). Although these 
methods of transfection offer several useful characteristics (e.g. the ability to 
transfect non-dividing or difficult to transfect cells), the level of protein expression 
achieved is difficult to control, can be variable between experiments, and in some 
cases can result in non-specific genome integration, which may cause off-target 
effects in the cell. While these issues may not be problematic in preliminary tests of 
respiratory chain bypass experiments, where enzymatic activity is easily 
detectable, a more controlled cell expression system is preferable for investigating 
the effects of NDI1 on mitochondrial ROS production by RET. Thus, the main aim 
of this project was to create a Flp-In™T-REx™293-NDI1 stable cell line, allowing 
controlled, Dox-inducible protein expression and site-specific genome integration. 
A Flp-In™T-REx™293-AOX cell line was also created at the same time using host 
cells from the same stock to minimize variation.  By being able to modulate the 
redox state of the Q pool and mitochondrial ROS production, human cell models 
expressing alternative respiratory enzymes can be useful tools in elucidating 
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mitochondrial redox-signalling pathways and particularly the biological role of RET 
in cells. Below is a summary of preliminary data in the development of NDI1 and 
AOX cell lines. 	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5.3 Methods and Results 
5.3.1 Flp-In™ T-REx™ cell expression system 
Flp-In™ T-REx™ host cell lines allow exogenous gene insertion into a specific site 
in the host cell genome and also inducible expression of this gene of interest by the 
addition of a tetracycline (Dox) to the culture medium (Figure 5.3). The cDNA of a 
gene of interest can be cloned into the pcDNA5/FRT/TO inducible expression 
vector designed for use with the Flp-In™ T-REx™ System. When cotransfected 
with the pOG44 Flp recombinase expression plasmid into a Flp-In™ T-REx™ host 
cell line, the pcDNA5/FRT/TO vector containing the gene of interest is integrated in 
a Flp recombinase-dependent manner into a specific site in the host cell genome, 
creating a stable, tetracycline-inducible cell line. 
A   
 
B 
 
 
Figure 5.3. Transfection and selection of a stable Flp-In™ T-REx™cell line and induction of 
gene expression. (A)	   The Flp-InTM T-REx™ Host Cell Line is co-transfected with the 
pcDNA5/FRT/TO expression vector (containing the gene of interest (GOI)) and the pOG44 Flp 
Recombinase expression vector; (B) Flp recombinase-mediated homologous recombination at FRT 
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sites integrates the pcDNA5/FRT/TO expression vector into the host cell genome, bringing the 
SV40 promoter and start codon into proximity and frame with the hygromycin resistance gene and 
the GOI transcription machinery, and simultaneously inhibiting transcription of the Zeocin resistance 
gene. Treatment of cells with a tetracycline (Dox) then inhibits the TET repressor binding to the TET 
operator, allowing GOI trancription. 	  
5.3.2 NDI1 expression vector preparation, amplification and 
purification 
The cDNA insert coding for NDI1 (approx. 1.5 kb) was PCR amplified from the 
pWPI donor plasmid and subcloned into the pcDNA5/FRT/TO expression vector for 
use with the Flp-In™ T-REx™ stable, inducible mammalian cell expression system 
(see Figure 5.4 and 2.9 Molecular Cloning for expanded methods). 
pcDNA5/FRT/TO was linearised by restriction digest at the KpnI site (5’) and NotI 
site (3’) in the multiple cloning site (MCS) of the vector. The linear vector was 
dephosphorylated and gel purified prior to ligation with the insert. KpnI and NotI 
restriction sites were introduced onto the 5’ and 3’ ends of the NDI1 cDNA in the 
pWPI donor plasmid by PCR. The linear PCR product was gel purified and 
digested by KpnI-HF and NotI-HF enzymes to generate 5’ and 3’ compatible ends 
for ligation with the linear vector. The new insert was again gel purified prior to 
ligation with the linear vector. XL1-Blue electrocompetant E. coli were transformed 
with ligation mix to isolate and amplify the novel vector. Selection was performed in 
the presence of 100 μg/ml ampicillin.  Colonies arising from transformation were 
selected and grown overnight at 37°C in LB broth containing 100 μg/ml ampicillin. 
Vector DNA was isolated using a QIAGEN® Mini-prep kit and diagnostic restriction 
digests were performed to assess the presence of insert DNA of the desired size 
(approx. 1.55 kb). Vectors with inserts of the desired size were sent for Sanger 
sequencing analysis (Source Bioscience) to confirm the identity of the inserts (see 
Appendix A). E. coli were then retransformed with the correct vector in order to 
amplify and isolate endotoxin-free vector for mammalian cell transfection, 
performed using the QIAGEN® Mini-prep kit.  
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Figure 5.4. Scale map of the pcDNA5/FRT/TO-NDI1 expression vector highlighting key 
features. NDI1 cDNA was subcloned into the pcDNA5/FRT/TO expression vector by restriction 
digest and ligation at 5’ KpnI and 3’NotI restriction sites. The NDI1 sequence was engineered to 
contain a Kozak consensus sequence before the start codon to aid initiation of protein translation in 
cells (see 2.9 Molecular Cloning and Appendix B). The expression vector contained a number of 
key features: the CMV promoter to enable high level expression of NDI1; the Ampicillin resistance 
gene and its respective promoter to enable selection of positive bacterial colonies; the Tetracycline 
(TET) operator, which when bound by the TET repressor protein (expressed by the host cell line) in 
the absence of Tetracycline in the culture media inhibits NDI1 gene expression; the FRT site which 
allows site-specific vector integration into the whole cell genome at a corresponding FRT site by 
homologous recombination; the Hygromycin resistance gene (lacking a start codon) which when 
integrated into the correct site of the host cell genome will confer hygromycin resistance to the cell 
and enable selection of positive clones. The scale map was created using SerialCloner 2-6-1. The 
pcDNA5/FRT/TO DNA sequence was imported from the manufacturer’s online resource 
(https://tools.thermofisher.com/content/sfs/vectors/pcdna5frtto_seq.txt). The NDI1 vector and 
sequence map were a gift from Dr. Alberto Sanz (Institute for Cell and Molecular Biosciences & 
Newcastle University Institute for Ageing, Newcastle University, Newcastle, UK). See Appendix A 
for sequences.  
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5.3.3 Inducing NDI1 protein expression in the Flp-In™ T-REx™ 
293-NDI1 stable cell line 
Following transfection and selection of a stable Flp-In™ T-REx™ 293-NDI1 cell line 
(see 2.2.6 Exogenous gene expression in mammalian cell lines), expression of 
NDI1 was induced by addition of Dox to the cell culture medium. NDI1 protein 
expression was confirmed by performing a Western blot on cell lysates (uninduced 
and induced) using a primary antibody raised against NDI1 (see 2.1.2.1.1 Primary 
antibodies). A Dox titration was performed to optimise and titrate protein 
expression (Figure 5.5). NDI1 protein was first detectable after treatment (24 h) 
with 1 ng Dox/ml and peaked upon treatment with 10 - 100 ng Dox/ml. NDI1 protein 
expression was maintained at higher concentrations of Dox, but at a lower level. A 
consistent gradation of NDI1 protein expression in cells was achieved within the 
range of 1 – 100 ng/ml Dox, which was one of the aims of the experiment.  
	  
A       B
	  
 
Figure 5.5. NDI1 protein expression in Flp-In™ T-REx™ 293 - NDI1 cells in response to Dox 
induction. (A) Cells were plated on 6-well plates at a density of 20,000 cells/cm2 in Tet-free 
medium (4.5 g/l glucose)	   (see 2.2. Mammalian cell culture)	   supplemented with blasticidin and 
hygromycin. When cells reached 70 – 80% confluency, NDI1 gene expression was induced with 
serially diluted Dox in Tet-free medium for 24 h.	  Cells were then washed in ice-cold PBS and lysed 
in ice-cold RIPA buffer (150 mM sodium chloride, 1.0 % (v/v) Triton X-100, 0.5 % (w/v) sodium 
deoxycholate, 0.1 % (w/v) SDS, 50 mM Tris, pH 8.0 at 4°C, supplemented with DTT and protease 
inhibitors. Cells were scraped from the plate surface, transferred to 1.5 ml Eppendorf tubes on ice, 
sonicated and then centrifuged (17,000 X g for 10 min at 4°C). Supernatants were stored on ice for 
immediate use or snap-frozen on dry ice and stored at - 20°C. SDS-PAGE (25 μg protein) and 
Western blotting was performed as standard. Post blocking, PVDF membranes were cut 
horizontally with a razor blade (as indicated by the grey dotted line) and each section was 
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individually incubated with the appropriate primary antibody (rabbit) for the Mw range of that 
section, indicated by band descriptions (see 2.1.2.1.1 Primary antibodies). All rabbit primary 
antibodies were labeled with the same fluorescent secondary antibody (see 2.1.2.1.2 Secondary 
antibodies). Western blots were imaged using the Odyssey® CLx Infrared Imaging System 
(fluorescence emission at 800 nm); (B) The Western blot signal intensity of NDI1 (quantified with LI-
COR Biosciences Image Studio™ Lite software) from (A) was normalized to that of VDAC as a 
loading control. Graphed data is mean ± SEM of n ≥ 3 biological replicates. Statistical analysis was 
performed by one-way ANOVA with Dunnett’s Multiple Comparison post-test comparing all 
treatments to UT control. Means were considered significantly different when P < 0.05. *P < 0.05, 
**P < 0.01. UT, untreated.  
 
5.3.4 Preliminary characterization of the effects of NDI1 protein 
expression in cells  
Having confirmed Dox- inducible, titratable NDI1 protein expression, I next 
investigated the functionality of NDI1. NDI1 is an NADH dehydrogenase, as is 
complex I, so the same NADH-linked substrates can be used to measure complex 
I- or NDI1- mediated respiration in whole cells (e.g. pyruvate or glutamate). As both 
complex I and NDI1 (Dox induced) are expressed in the cell model, the challenge 
was to differentiate between the contributions of both enzymes to NADH-linked 
respiration. Unlike complex I, NDI1 is insensitive to the inhibitor rotenone (Rustin 
and Jacobs, 2009, Seo et al., 1999). In the presence of NADH-linked substrates, 
cell respiration in cells containing complex I but not NDI1 will cease in the presence 
of rotenone. However, if both complex I and NDI1 are functionally expressed in 
cells, upon addition of rotenone to the system respiration should be only partially 
decreased, with NDI1-driven respiration remaining uninhibited. The difference 
between rotenone-sensitive and rotenone-insensitive respiration can thus be used 
as a measure of functional NDI1 expression in mammalian cells. I used the 
Seahorse Bioscience XF96 analyzer to measure the oxygen consumption rate 
(OCR) of unpermeabilised cells in the presence of pyruvate: a measure of NADH-
linked respiration (see Figure 5.6 and 2.8 Seahorse XF96 Respirometry). Dox-
induced cells exhibited 62.3 ± 8.6 % rotenone-insensitive respiration (mean ± SEM, 
whereas uninduced cells exhibited 8.0 ± 1.3 % rotenone-insensitive respiration, 
confirming the presence of functional NDI1 in the Dox-induced cells.  
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Figure 5.6. Oxygen consumption rate comparison of Dox-induced and uninduced cells, 
measured using the Seahorse Bioscience XF96 analyzer, showing the partial rotenone 
insensitivity of NDI1-expressing cells. (A) Flp-In™ T-REx™ 293 - NDI1 cells were plated at a 
density of 50,000 cells/ well of a 96 well plate in low glucose (1 g/l) Tet-free medium supplemented 
with blasticidin and hygromycin. Cells were plated ± Dox (1 μg/ml). 24 h later, cell medium was 
replaced with low glucose Seahorse assay medium (180 μl/well), following a cell wash in the same 
medium. The cell plate was incubated in a CO2-free incubator for 1 h prior to assay.  Compound 
injections (final concentrations) were the following: oligomycin (1 μM), FCCP (1 μM), rotenone (2 
μM), antimycin A (AA) (50 μM). Graphed data represents mean ± SEM of n ≥ 6 technical replicates; 
(B) quantification of rotenone-insensitive mitochondrial respiration in Dox-induced versus uninduced 
cells, expressed as %  max. mitochondrial respiration (mean ± SEM of n ≥ 6 technical replicates).  	  
Having confirmed functional NDI1 expression in the cell model, another question to 
be addressed was the effect of NDI1 expression on mitochondrial ROS production. 
Mitochondrial ROS production in whole cells can be measured in a number of 
ways, e.g. using mitochondria-targeted redox-responsive probes for analysis by 
mass-spectrometry or fluorescent probes for visualization by confocal microscopy 
(Dikalov and Harrison, 2014, Cocheme et al., 2012). These approaches can be 
time-consuming, particularly when applied to a new and untested system, and 
sensitivity can also be a limiting factor.  In order to gain a preliminary insight into 
the effects of NDI1 on mitochondrial ROS production, I investigated the protein 
expression of a biological marker, manganese superoxide dismutase (MnSOD), 
which is located in the mitochondrial matrix and is involved in the detoxification of 
superoxide in cells (Murphy, 2009). MnSOD catalyses the rapid dismutation of 
superoxide to H2O2, which can then be metabolized to H2O by peroxidases, GSH 
and catalase. There is evidence that increased mitochondrial superoxide levels 
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induce upregulation of MnSOD protein expression in cells (Hart et al., 2015, Kim et 
al., 2005). Thus, I investigated the expression of MnSOD in uninduced and induced 
cell lysates, 24 h post-Dox addition (Figure 5.7). There was no significant increase 
in MnSOD protein expression, although the trend appeared to follow that of NDI1 
protein expression between the titratable [Dox] range (1 – 100 ng/ml Dox). 
However, this should be considered cautiously as levels then appeared to 
decrease. A Dox-induction time-course has not yet been performed. If NDI1 protein 
expression is not detectable before the 24 h time-point, it is conceivable that an 
adaptive response to increased mitochondrial ROS production (if occurring) may 
take longer to occur.  
 
A       B 	  
	  
 
Figure 5.7. MnSOD protein expression in Dox-induced NDI1 cells, measured by Western 
blotting. (A) Cell lysates were prepared and SDS-PAGE and Western blot performed as described 
in Figure 5.5. PVDF membranes sections were individually incubated with the appropriate primary 
antibody (rabbit) for the Mw range of that section (indicated by band descriptions). Western blots 
were imaged using the Odyssey® CLx Infrared Imaging System (fluorescence emission at 800 nm); 
(B) The Western blot signal intensity of MnSOD from (A) was normalized to that of VDAC as a 
loading control. Graphed data is mean ± SEM of n ≥ 3 biological replicates. UT, untreated.	  
 
To investigate longer-term effects of NDI1 protein expression on MnSOD protein 
expression as a marker of increased mitochondrial ROS production, cells were 
treated with Dox for 72 h. However, it appears that Dox is unstable in cell culture 
media for that time duration as NDI1 protein expression was greatly decreased 
(Figure 5.8). There is anecdotal evidence to suggest that Dox is unstable after 48 
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h in cell culture media, so future experiments will require Dox replacement every 24 
– 48 h to maintain stable NDI1 expression for longer time-points. To summarise, 
the effects of NDI1 protein expression on mitochondrial ROS production in this cell 
line are currently unknown and will require future experiments.  
 
A 
 
B      C 
	   	  	  
Figure 5.8. NDI1 and MnSOD protein expression in Dox-induced NDI1 cells 72 h post Dox 
addition, measured by Western blotting. (A) Cells were plated on 6-well plates at a density of 
10,000 cells/cm2 in Tet-free medium (4.5 g/l glucose)	  supplemented with blasticidin and hygromycin. 
When cells reached approx. 30% confluency, NDI1 gene expression was induced with serially 
diluted Dox in Tet-free medium for 72 h.	   Cell lysis, SDS-PAGE and Western blotting were all 
performed as previously described. Western blots were imaged using the Odyssey® CLx Infrared 
Imaging System (fluorescence emission at 800 nm); (B) The Western blot signal intensities of NDI1 
or MnSOD from (A) were normalized to that of VDAC as a loading control. Graphed data is n = 1 or 
mean ± range of n = 2 biological replicates. UT, untreated.  
 
In parallel, I investigated the effects of NDI1 protein expression on AMPK activity. 
As discussed in Chapter 4, AMPK redox-regulation independent of changes to the 
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cell ATP/ADP ratio has been reported by a number of groups (Emerling et al., 
2009, Hart et al., 2015, Mungai et al., 2011, Shao et al., 2014, Zmijewski et al., 
2010). However, I did not observe conclusive evidence of redox-regulation of 
AMPK in a previous cell line (terminally differentiated C2C12 mouse myotubes) in 
response to either cytosolic or mitochondrially-derived ROS, instead showing that 
AMPK activity was only increased when ATP/ADP ratios were decreased. Working 
with the hypothesis that co-expression of NDI1 and complex I in a mammalian cell 
line (in this case by using a human, HEK 293 background) might increase 
mitochondrial ROS production by RET, I investigated if any changes occurred to 
AMPK activity upon expression of NDI1 (Figure 5.9 & 5.10).  
 
AMPK phosphorylation was increased in Dox-induced cells (24 h post-induction) at 
concentrations previously shown to induce NDI1 protein expression (≥ 1 ng 
Dox/ml) and not at lower concentrations. ACC phosphorylation also appeared to 
increase dose-dependently between 0.1 and 10 ng Dox/ml, but this did not reach 
statistical significance. Levels decreased at higher concentrations of Dox. In cells 
lysed 72 h post-induction (previously shown to have greatly decreased or 
undetectable NDI1 protein expression levels), AMPK phosphorylation followed a 
dose-dependent trend but to a lesser extent (preliminary data, n = 1). ACC 
phosphorylation appeared to be unchanged from untreated cells. AMPK is primarily 
activated by decreases in the cell ATP/ADP or ATP/AMP ratios. Thus, using the 
respirometry data presented in Figure 5.6, I also calculated ADP-linked respiration 
(basal – oligomycin-treated OCR) to test if NDI1 expression (or Dox treatment) was 
affecting ATP synthesis by FOF1 - ATP synthase (Figure 5.9). Dox-induced cells 
exhibited 60.3 ± 3.4 % ADP-linked respiration, and uninduced cells exhibited 71.8 ± 
4.3 % ADP-linked respiration, suggesting that the NDI1 protein expression or Dox 
treatment may affect ATP synthesis by FOF1 - ATP synthase. This data is 
preliminary, as it was from technical replicates from one biological experiment, and 
so further experiments will be required to expand the result. ATP/ADP assays will 
be also be required to test for any small changes in ATP/ADP ratios caused by 
protein expression or Dox treatment that could affect AMPK activity. Similarly, the 
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effects of Dox on AMPK activity in WT cells will need to be tested. As observed in 
Figure 5.10, it is currently difficult to confirm or exclude any off-target effects of 
Dox on AMPK activity in NDI1 stable cells. Although I have not observed any 
published reports that suggest Dox treatment basally induces AMPK activation, 
Dox has been reported to alter cell metabolism in different cell lines (Ahler et al., 
2013). Thus, the effects of Dox on AMPK activity in untransfected cells will need to 
be investigated in future work. 
 
The preliminary data confirms that this cell line expresses a gradation of Dox-
induced, functional, NDI1, within a range of 1 – 100 ng/ml Dox. NDI1 expression 
coincides with increased AMPK phosphorylation within this range. Dox-induced 
cells exhibit a potential decrease in ADP-linked respiration (although it should be 
noted that the cells in the Seahorse experiment were induced with 1 μg/ml Dox, a 
10-fold higher concentration than the [Dox] that induced peak NDI1 expression). 
Increased ROS production in the cells remains undetermined. The preliminary data 
suggests that NDI1 protein expression may be having a biological effect in the 
cells. However, the mechanism behind the AMPK activation is currently unclear 
and the preliminary data should be interpreted cautiously with the above points in 
mind. In future experiments (if off-target effects of NDI1 protein expression and Dox 
treatment are ruled out), NDI1-dependent hypotheses can be investigated, e.g. 
does NDI1 protein expression increase ROS production in cells by RET? And if so, 
is this ROS production capable of altering the redox-state of the cytosol and also of 
AMPK?  
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A      B 
 
 
 
C	        D 
 
 
E 
	  
Figure 5.9. AMPK and ACC phosphorylation in Dox-induced NDI1 cells 24 h or 72 h post Dox 
addition (measured by Western blotting) and a comparison of ADP-linked respiration in 24h-
Dox-induced and uninduced cells (measured by Seahorse XF96 respirometry). (A – D) Cells 
were plated and induced for 24 h (A) or 72 h (B) as described in Figures 5.5 and 5.8, respectively. 
Cells were lysed in Hepes lysis buffer, supplemented with DTT and protease inhibitors, and SDS-
PAGE and Western blotting was performed as described in 2.4 AMPK assays. Western blots were 
imaged using the Odyssey® CLx Infrared Imaging System (fluorescence emission at 800 nm); (C) 
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The Western blot signal intensities of AMPKα1/2-phosphoT172 bands from (A & B) were 
normalized to the signal intensity of AMPKβ1 a loading control. (D) The Western blot signal 
intensities of ACC1/2-phosphoS79 bands from (A & B) were also normalized to the signal intensity 
of AMPKβ1 a loading control. (C & D) Graphed data is mean ± SEM of n ≥ 3 biological replicates 
from (A) or n = 1 from (B); Statistical analysis was performed by one-way ANOVA with Dunnett’s 
Multiple Comparison post-test comparing all treatments to UT control. Means were considered 
significantly different when P < 0.05. *P < 0.05. (E) Quantification of ADP-linked mitochondrial 
respiration in Dox-induced versus uninduced cells (from Figure 5.6), expressed as % basal 
respiration (mean ± SEM of n ≥ 6 technical replicates).  UT, untreated. 
 
 
 
 
 
A      B 
 
  
 
Figure 5.10. Comparison of the effects of Dox on NDI1 protein expression and AMPK or ACC 
phosphorylation. (A) AMPK phosphorylation and (B) ACC phosphorylation versus NDI1 protein 
expression. 	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5.3.5 AOX expression vector preparation, amplification and 
purification 
An AOX stable cell line was created in parallel to the NDI1 stable cell line, using 
host cells from the same stock. Molecular cloning of AOX was perfomed by 
Aonghus McCarthy (MRC Mitochondrial Biology Unit, University of Cambridge, 
Wellcome Trust/MRC Building, Cambridge Biomedical Campus, Hills Road, 
Cambridge CB2 0XY, UK) in the course of a summer studentship sponsored by the 
Amgen Scholars programme, Cambridge 2016. The cDNA insert coding for AOX (~ 
1.1 kb) was PCR amplified from the pWPI donor plasmid and subcloned into the 
pcDNA5/FRT/TO expression vector for use with the Flp-In™ T-REx™ stable, 
inducible mammalian cell expression system, as previously described (see Figure 
5.11). The pcDNA5/FRT/TO was linearised by restriction digest at the BamHI site 
(5’) and XhoI site (3’) in the MCS. The linear vector was dephosphorylated and gel 
purified prior to ligation with the insert. BamHI and XhoI restriction sites were 
introduced onto the 5’ and 3’ ends of the NDI1 cDNA in the pWPI donor plasmid by 
PCR. The linear PCR product was gel purified and digested by BamHI-HF and 
XhoI enzymes to generate 5’ and 3’ compatible ends. The new insert was again gel 
purified prior to ligation with the linear vector. XL1-Blue electrocompetant E.coli 
were transformed, selected and grown as previously described. Vector DNA was 
isolated (QIAGEN® Mini-prep kit) and diagnostic restriction digests were performed 
to assess the presence of insert DNA of the desired size (~ 1.1 kb). Vectors with 
inserts of the desired size were sent for Sanger sequencing analysis (Source 
Bioscience) to confirm the identity of the inserts (see Appendix A). The correct 
vector was then amplified for mammalian cell transfection as previously described.   
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Figure 5.11. Scale map of the pcDNA5/FRT/TO-AOX expression vector highlighting key 
features. AOX cDNA was subcloned into the pcDNA5/FRT/TO expression vector by restriction 
digest and ligation at 5’ BamHI and 3’XhoI restriction sites. Key features highlighted are as 
described above. The scale map was created using SerialCloner 2-6-1, using the pcDNA5/FRT/TO 
DNA backbone sequence as previously described. The AOX vector and sequence map were a gift 
from Dr. Alberto Sanz (Institute for Cell and Molecular Biosciences & Newcastle University Institute 
for Ageing, Newcastle University, Newcastle, UK). 
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5.3.6 Inducing AOX protein expression in the Flp-In™ T-REx™ 
293-AOX stable cell line 
Following transfection and selection of a stable Flp-In™ T-REx™ 293-AOX cell line 
(as described for NDI1), expression of AOX was induced by addition of Dox to the 
cell culture medium. AOX protein expression was confirmed by performing a 
Western blot on cell lysates (uninduced and induced) using a primary antibody 
raised against AOX (see 2.1.2.1.1 Primary antibodies). A Dox titration was 
performed to optimise and titrate protein expression (Figure 5.12). AOX protein 
was first detectable after treatment (24 h) with 10 ng Dox/ml and peaked upon 
treatment with 100 ng  Dox/ml, with a high level of AOX protein expression 
maintained at higher concentrations of Dox. Dox concentrations between 1 – 10 
ng/ml will be investigated in future experiments to see if lower but still detectable 
levels of NDI1 protein can be observed. 
  
A       B     	  
	  
 
 
 
 
Figure 5.12.	  AOX protein expression in Flp-In™ T-REx™ 293 - AOX cells in response to Dox 
induction. (A) Cell lysates were prepared and SDS-PAGE and Western blotting performed as 
described in Figure 5.5. PVDF membranes were dual incubated with primary antibodies: rabbit-α-
AOX and mouse-α-VDAC. Rabbit and mouse primary antibodies were differentially labeled with 
fluorescent secondary antibodies (see 2.1.2.1.2 Secondary antibodies). Western blots were 
imaged using the Odyssey® CLx Infrared Imaging System (fluorescence emission at 800 nm for 
AOX and 680 nm for VDAC); (B) The Western blot signal intensity of AOX from (A) was normalized 
to that of VDAC as a loading control. Graphed data is n = 1 or mean ± range of n = 2 biological 
replicates.	  
0 10
1
10
2
10
3
10
4
10
0
[Dox
.] (ng
/ml)
0 10
-1
10
-2
10
-3
[Dox.]
 (ng/m
l)
M
w
 la
dd
er
30
40 AOX (~ 35 kDa)
30
40
Mw
(kDa)
24 h
VDAC (~ 31 kDa)
AOX protein expression
0
10
-3
10
-2
10
-1
10
0
10
1
10
2
10
3
10
4
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
[Doxycycline] (ng/ml)
Si
gn
al
 In
te
ns
ity
(A
O
X/
VD
AC
)
Chapter 5 – Alternative respiratory enzymes  
	   226	  
5.3.7 Preliminary characterization of the effects of AOX protein 
expression in cells 
Although respirometry analysis of AOX protein expression in cells has not yet been 
tested, I did have opportunity to begin to characterize AMPK activation in the cells 
(Figure 5.13 and 5.14) and compare the results to those of NDI1 expressing cells. 
I found that AMPK phosphorylation in AOX cells increased dose-dependently in 
response to Dox treatment (n = 1 or 2). ACC phosphorylation was less clear. The 
preliminary results show that it is currently impossible to distinguish between the 
effects of individual protein expression and [Dox] on AMPK activity in these NDI1 
and AOX stable cell lines and control experiments on untransfected cells are 
required before investigating any potential protein-specific effects.  	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B      C 
	   	  	  
D	   	   	   	   	   	   E	  
	  	  
Figure 5.13.	   AMPK and ACC phosphorylation in Dox-induced AOX cells 24 h post Dox 
addition, measured by Western blotting. (A) Cell lysates were prepared and SDS-PAGE and 
Western blotting performed as described in Figure 5.9; (B) The Western blot signal intensity of 
AMPKα1/2-phosphoT172 from (A) was normalized to the signal intensity of AMPKβ1 a loading 
control. The lanes marked by the red asterisks were excluded from the quantification due to transfer 
flaws; (C) The Western blot signal intensity of ACC1/2-phosphoS79 from (A) was also normalized to 
the signal intensity of AMPKβ1 a loading control; (D) AMPK phosphorylation increases as AOX 
protein expression increases, however, the effects on (E) ACC phosphorylation are less clear. 
Graphed data is n = 1 or mean ± range of n = 2 biological replicates. UT, untreated.  
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Figure 5.14. Comparison of the effects of Dox on NDI1 or AOX protein expression and on 
AMPK phosphorylation. (A) [Dox] has similar effects on NDI1 or AOX expression in the respective 
stable cell lines; (B) Preliminary data shows that [Dox] increases AMPK phosphorylation in both 
NDI1 and AOX stable cell lines; (A & B) Graphed NDI1 data is mean ± SEM of n ≥ 3 biological 
replicates, graphed AOX data is n = 1 or mean ± range of n = 2 biological replicates. UT, untreated.  	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5.4 Discussion and future work 
This chapter describes the preliminary data on this project obtained to date. The 
goal of this project is to create stable cell lines expressing the alternative 
respiratory enzymes, NDI1 and AOX, so that the biological effects of RET in cells 
can be investigated. NDI1 and AOX have previously been shown to increase or 
decrease mitochondrial ROS production by RET by reducing or oxidizing the Q 
pool, respectively. Stable cell lines in which expression of the alternative 
respiratory enzymes can be acutely controlled is favourable, as it should enable 
ROS production by RET to be turned on or off, or increased gradually. Although 
progress has been made in characterising the cell lines, a number of questions 
remain unaddressed and will require future experiments.  
 
I have confirmed that both the NDI1 and AOX cell lines express proteins under the 
control of Dox. A gradation of NDI1 protein expression can be achieved between 1 
– 100 ng Dox/ml and AOX between 10 – 100 ng Dox/ml. High protein expression 
levels are beneficial for characterising enzymatic activity, however, high levels of 
expression of matrix or IMM associated proteins may have a negative effect on the 
ΔP. For testing the effects of NDI1 and AOX on ROS production (which is also 
dependent on the magnitude of the ΔP) it is favourable to be able to titrate the 
protein expression, from low to high. While functional NDI1 protein expression was 
confirmed by Seahorse XF96 respirometry (measured as rotenone-insensitive 
mitochondrial respiration), the functionality of AOX has not yet been confirmed. 
AOX is cyanide-resistant (unlike complex IV, which is cyanide sensitive) but is 
inhibited by propyl gallate (Fernandez-Ayala et al., 2009). My aim is to perform a 
similar respiration experiment as in NDI1 cells, utilising sensitivity to propyl gallate 
as a measure of functional AOX expression. 
 
In response to induction with a high [Dox] (1 μg/ml), ADP-linked respiration in NDI1 
cells appeared to be slightly decreased (preliminary data, n = 1). Similarly, it is 
currently unclear if Dox is having off-target effects on the cell, as AMPK 
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phosphorylation may be increased in both NDI1 and AOX cell lines in response to 
Dox. While there may be biological reasons for the increased AMPK 
phosphorylation (relating to the activities of the alternative respiratory enzymes or 
their effects on ROS production) an important control that needs to be performed is 
to test the effects of Dox on untransfected host cells. This experiment will quickly 
confirm or exclude any effects of the Dox treatment on AMPK activity. Furthermore, 
ATP/ADP assays on Dox-treated untransfected host cells will identify if Dox has 
mild cytotoxic effects that may induce mild AMPK activation. If these results are 
negative, then ATP/ADP assays on Dox-induced NDI1 and AOX cell lines will tell 
us if the AMPK phosphorylation is caused by the NDI1 or AOX enzymes affecting 
ATP levels in the cell, or if there are other potential ways in which the enzymes are 
signalling to AMPK, e.g. via ROS production. 
 
ROS production in Dox-induced NDI1 cells has not yet been confirmed. This will be 
tested in a number of ways. My aim is utilise the redox-sensitive mito-roGFP-ORP1 
and cyto-roGFP-ORP1 probes (Gutscher et al., 2009, Albrecht et al., 2011) 
previously discussed (2.7 Live cell confocal microscopy and imaging). The 
probes are targeted to the mitochondrial matrix and the cytosol, respectively, so 
can detect H2O2 in both compartments. This approach will be particularly useful in 
determining the source of ROS production (if it occurs) and if the ROS can cross 
the mitochondrial membranes to the cytosol and affect processes there. Similarly, 
Prx 3 (mitochondrial) and Prx2 (cytosolic) dimerisation assays (2.6 Peroxiredoxin 
dimerisation assays) can be performed as a biologically relevant readout of 
increased ROS production. Prior to the ROS measurements, it will be necessary to 
perform a Dox induction time-course to identify the minimum incubation time 
required to detect NDI1 protein expression.  ROS measurements can then be 
performed at regular intervals after NDI1 expression, as detection of increased 
ROS production may be time-sensitive.  The same induction time-course and ROS 
measurements can also be performed on the AOX cell line.  
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Finally, when characterisation of the cell lines has been completed, the goal of this 
project is to investigate ROS production by RET in greater detail. RET is emerging 
as a physiologically relevant phenomenon that may play a role in cell signalling 
pathways, as a way in which mitochondria communicate with the rest of the cell. 
The cell models may be useful in investigating potential redox-regulated proteins, 
e.g. AMPK, as well as the response of known ROS scavenging proteins to a form 
of ROS production that can be technically difficult to induce in cell lines without 
mitochondrial inhibitors. Although the AOX cell line may (as was the case in the 
AOX mouse (El-Khoury et al., 2013)) require a blockade of electron transfer in 
order for activation, the evidence in the literature to date suggests that expression 
of functional NDI1 is sufficient to promote hyper-reduction of the Q pool and 
increase ROS production. Thus, creating a cell system that allows us to recreate 
RET conditions will be useful for further investigations by our lab and others in the 
field.  
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The focus of this thesis has been to work towards characterising the effects of 
primarily mitochondrially-derived ROS on AMPK activity in cells. In Chapter 4, I 
described the effects of both exogenous H2O2 (delivered as external boluses) and 
mitochondrially-derived ROS (produced by MPQ) on AMPK activity, cell ATP/ADP 
ratios and cellular redox state. Following these experiments, I arrived at the 
conclusion that, at least in this cell model, ROS primarily activates AMPK indirectly, 
by an AMP/ADP-dependent mechanism. However, regarding the H2O2 
experiments, the magnitude of the AMPK activity markers (AMPK specific activity, 
and AMPK and ACC phosphorylation) were time-dependent, and did not correlate 
perfectly with changes in the cell’s ATP/ADP ratio in response to H2O2. These 
results somewhat mirror other published results in the field (Auciello et al., 2014), 
which have been attributed to possible upstream effects of ROS, such as the 
response of phosphatases to H2O2, or to a direct mechanism possibly playing a 
minor role in the extent of AMPK activation in response to ROS (Zmijewski et al., 
2010). Although this remains an intriguing possibility, AMPK activation in response 
to H2O2 in my experiments was only observed in response to supra-physiological 
concentrations of H2O2 (750 μM). At these concentrations, the evidence of Prx 2 
hyperoxidation suggests that there is extensive oxidative damage, so any minor 
effects on AMPK activity at this concentration are unlikely to be physiologically 
relevant.  
The results of selective, mitochondrially-derived ROS on AMPK activity were 
clearer. The first conclusion that can be made from these experiments is that 
although MPQ generated ROS rapidly and cumulatively within the mitochondrial 
matrix, there was no evidence that this ROS was transferring to the cytosol 
(undetectable Prx 2 dimerisation). This itself raises important questions in the 
redox-signalling field, relating to the threshold of mitochondrial matrix oxidation that 
needs to be reached before H2O2 can potentially diffuse from the matrix to the rest 
of the cell. As previously described, the mitochondrial matrix contains many 
antioxidant defence systems, including Prx, Trx and GSH systems. While it is 
conceivable that cell lines may have greater expression levels of these systems 
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than primary cells and tissues, going forward, it will be important to monitor the flux 
of ROS from mitochondria before implicating mitochondrial ROS in cytosolic, 
nuclear or other cellular signalling pathways that occur outside of the mitochondria. 
Of course, it may be that redox signals originate as elevated H2O2 within 
mitochondria, but that these signals are converted to a thiol redox relay in the IMS 
that passes on the signal to the rest of the cell . In this scenario, H2O2 may not be 
detected leaving the organelle. A second conclusion that can be made is that there 
was no significant change in AMPK activity in response to high levels of oxidation 
to the matrix caused by mitochondrially-derived ROS. Thirdly, any slight (not 
statistically significant) change in AMPK activity only occurred when the cell 
ATP/ADP ratios appeared to decrease slightly, indicating that any effects were due 
to mitochondrial ROS affecting ATP/ADP ratios, possibly by inhibiting mitochondrial 
ATP production. However, as neither the AMPK activation nor the decrease in 
ATP/ADP ratios was statistically significant, this conclusion is a tentative one at the 
moment.  
Regarding the concept of compartmentalisation of mitochondrial ROS, a number of 
experiments could be performed in the future to confirm and build on my results. 
The conclusion would benefit from real-time data in live cells, possibly by utilising 
the cyto-roGFP-ORP1 or mito-roGFP-ORP1 probes, which allow visualisation of 
cytosolic or mitochondrial H2O2 (Gutscher et al., 2009, Sobotta et al., 2013). If a 
threshold of mitochondrial oxidation needs to be reached before H2O2 can diffuse 
from mitochondria, then it is likely that this threshold can be modulated by factors 
that affect the redox state of the mitochondrial matrix or H2O2 metabolism. An 
obvious candidate is Trx 2, which recharges Prx 3 in the mitochondrial matrix using 
the NADPH pool. Modulating the protein expression of Trx 2 (by overexpression or 
by knock-down/knock-out experiments) may help to clarify the spatiotemporal 
dynamics of ROS generation in the matrix. Furthermore, AMPK was identified as a 
target of Trx 1 in the cytosol (Shao et al., 2014), suggesting that cytosolic 
expression levels of antioxidant defence proteins play a role in how AMPK 
responds to ROS. Thus, modulating the expression of Trx 1 may also alter the 
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results of both the H2O2 and MPQ experiments, and thus clarify the biological 
mechanisms. Overexpressing the AMP/ADP-insensitive RG AMPK mutant (Hawley 
et al., 2010) in these cells would also offer further clarification of whether AMPK is 
directly in response to mitochondrial ROS.  
The results from Chapter 4 were observed in parallel with the development of an 
approach to analyse the redox state of candidate proteins in cells, Click-PEGylation 
(Chapter 3). The goal was to adapt this method to analysing the redox state of 
AMPK in cell lysates in response to ROS, specifically mitochondrially-derived ROS. 
As the results from Chapter 4 indicated that direct redox-regulation of AMPK was 
unlikely to be a main mechanism of activation in this cell model, the Click-
PEGylation experiments on AMPK were halted after a few preliminary 
investigations of purified AMPK and AMPK in cell lysates. Prior to this, however, 
collaborator Lucie A.G. van Leeuwen and I performed a series of proof of principle 
experiments on the redox exemplar, GAPDH, and established the method as a 
useful alternative tool in the redox biology field (van Leeuwen et al., 2017). In Click-
PEGylation, cysteine residues are differentially labelled according to thiol redox 
state, which is then assessed by mobility shift electrophoresis. The thiol-labelling 
step by maleimide derivatisation is separated from the PEG labelling (which 
confers mobility shifts), and linked using Click chemistry. This approach offers 
greater flexibility compared to existing single-step strategies. While broad redox-
dependent mobility shifts were observable in purified AMPK α in response to 
differential pre-treatments with reductant (TCEP) or oxidant (diamide), detecting 
AMPK α in cell lysates proved more challenging. The reasons for the poor 
detection in cell lysates were likely technical issues which can be optimized in 
future experiments on AMPK or other proteins of interest, including: 1) the starting 
protein concentration of the cell lysate can be increased from 500 μg protein/ml. 
The various steps in the Click-PEGylation protocol, including spin column and 
protein purification steps, can lead to sample loss. While this is not a problem for 
highly expressed metabolic proteins, such as GAPDH, AMPK is less highly 
expressed in cells and so sample loss greatly dimished AMPK protein detection by 
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Western blotting. Thus, increasing the starting protein concentration should 
minimise this problem; 2) some protein degradation may have occurred during the 
catalyst incubation. This may have occurred if any of the reagents had become 
oxidised during preparation, with the formation of small amounts of H2O2. This can 
lead to Fenton-like chemistry (due to the presence of Cu1+) and the formation of 
hydroxyl radical, which can lead to protein degradation (Finney and O'Halloran, 
2003). Thus, adding antioxidants to the catalyst incubation (e.g. butylated 
hydroxyanisole (Verhagen et al., 1991))	  may inhibit protein degradation if it remains 
an issue.  
Although the AMPK α catalytic subunit has previously been the focus of 
experiments searching for redox-sensitive cysteine residues that may play a role in 
AMPK regulation (Zmijewski et al., 2010, Shao et al., 2014), the β subunit also 
plays a vital role in AMPK regulation, particularly by AMP/ADP-independent 
activation by small molecules that bind the ADaM site. This mode of activation 
appears to be affected by post-translational modifications to the β subunit (Hardie, 
2016). It is also reported that the β1 and β2 isoforms have different affinities for 
glycogen (Koay et al., 2010), differential expression in different cell types (Birk and 
Wojtaszewski, 2006, Hardie, 2017), and are differentially activated by ADaM-site 
activators (Hardie, 2017). The human β1 isoform contains three cysteine residues 
and the β2 isoform contains two. Thus, the response of the β subunit to oxidation 
could in principle confer differential effects on AMPK activity in an isoform-
dependent manner. As no published paper to date (nor this body of work) have 
explicitly excluded ROS from having a minor role in AMPK regulation, focusing on 
the β subunit may help to clarify some of the interesting differences observed in the 
magnitude of AMPK activation in response to different stimuli. Due to the relatively 
low molecular weights of the AMPK β subunit isoforms (30 or 38 kDa), the small 
number of cysteine residues and the availability of sensitive primary antibodies, it 
should be possible to assess the redox state of the β subunit isoforms by Click-
PEGylation.  
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Chapter 5 described the preliminary data of a project that is of interest to other 
work in the lab as well as my own. The goal of this project is to create stable cell 
lines expressing the alternative respiratory enzymes, NDI1 and AOX, so that the 
biological effects of RET in cells can be investigated. NDI1 and AOX have 
previously been shown to increase or decrease mitochondrial ROS production by 
RET by reducing or oxidizing the Q pool, respectively. Stable cell lines in which 
expression of the alternative respiratory enzymes can be controlled and preferably 
titrated is favourable, as it should enable ROS production by RET to be turned on 
or off, or increased gradually. The results presented are very much preliminary but 
I confirmed that both the NDI1 and AOX cell lines express proteins under the 
control of Dox. A gradation of NDI1 protein expression was achieved between 1 – 
100 ng Dox/ml and AOX between 10 – 100 ng Dox/ml. Functional NDI1 protein 
expression was confirmed by Seahorse XF96 respirometry (measured as 
rotenone-insensitive mitochondrial respiration). However, the functionality of AOX 
has not yet been confirmed. AOX is cyanide-resistant (unlike complex IV, which is 
cyanide sensitive) but is inhibited by propyl gallate (Fernandez-Ayala et al., 2009). 
Thus, sensitivity to propyl gallate can be used as a measure of functional AOX 
expression. ROS production in Dox-induced NDI1 or AOX cells has not yet been 
measured and will be a key focus of experiments in the immediate future, tested by 
previously described or other methods. If NDI1 and AOX have opposing effects on 
ROS production, then the nature of the ROS production will need to be confirmed, 
i.e. is it the result of forward or reverse electron transfer. RET is characterised by a 
hyper-reduced Q pool, high ΔP, and superoxide production from complex I that is 
inhibited by rotenone (which binds the Q-binding site, blocking electron flow to the 
complex I FMN) and FCCP (which dissipates the ΔP). Q redox state, likely to be 
the key determinant of RET in these cell lines, can be assessed by HPLC 
separation followed by identification by differential UV/Vis absorption spectra 
(Scialo et al., 2016).   If the results from the single-gene expressing cell lines are 
promising, a future experiment may involve co-expressing AOX and NDI1 in the 
same cell model. Previous papers have found that AOX is most functional when 
there is a blockade of the ETC (El-Khoury et al., 2013) or when there is increased 
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electron donation to the Q pool, such as from NDI1 co-expression (Scialo et al., 
2016).  	  
Finally, as discussed in Chapter 5, the effects of NDI1 or AOX expression on 
AMPK activity are currently complicated by possible off-target effects of Dox on 
AMPK activity. This can be easily addressed with appropriate control experiments. 
However, whether AMPK will still be seen as a potential target of mitochondrial 
ROS signalling by RET is debatable, although the expansion of the results 
discussed in Chapter 4 would be vital to completely address this hypothesis. Even 
so, a cell model of RET will be a valuable tool for our and other labs in studying the 
downstream targets of ROS production by RET, be that AMPK or other proteins.  
 
Together, the work in this thesis offers further understanding into the role of ROS 
and mitochondrial ROS in AMPK activity, has resulted in the generation of a new 
method for easily assessing the redox state of candidate proteins and will 
potentially result in a cell model of mitochondrial ROS production of RET, with a 
wide scope for future work that can follow.  However, at this stage my view is that 
the redox regulation of AMPK activity seems unlikely to be a significant aspect of 
its natural regulation, a conclusion that is in agreement with other published results 
that have emerged during the course of this project (Auciello et al., 2014).
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8 - Appendices 
8. Appendices 	  
Appendix A. Gene and plasmid sequences  	  
AMPKα2-CT-FLAG (pcDNA3 vector backbone) 
Gifted by Professor David Carling (MRC Clinical Sciences Centre, Hammersmith 
Hospital Campus, London, UK). 	  
> [AMPKα2-CT-FLAG (rattus norvegicus) 1689 bp]  
ATGGCTGAGAAGCAGAAGCACGACGGGCGTGTGAAGATCGGACACTACGTGCTGGGGGACAC
CCTGGGCGTCGGCACCTTCGGCAAAGTGAAGATTGGAGAACATCAATTGACAGGCCATAAAGT
GGCAGTTAAGATCTTAAATAGACAGAAGATTCGCAGTTTAGATGTTGTTGGAAAAATAAAACGA
GAAATTCAAAATCTTAAACTCTTTCGTCATCCTCATATTATCAAACTCTACCAAGTGATCAGCACT
CCAACAGACTTTTTTATGGTAATGGAATATGTGTCTGGAGGTGAATTGTTCGACTACATCTGTAA
ACACGGGAGGGTTGAAGAGGTGGAAGCTCGCCGGCTCTTCCAGCAGATTCTGTCTGCCGTGG
ACTACTGTCACAGGCACATGGTTGTCCACAGGGACCTGAAGCCAGAGAACGTGTTGCTGGACG
CCCAGATGAATGCTAAGATAGCTGACTTCGGACTCTCTAATATGATGTCAGATGGTGAATTTCT
ACGAACTAGCTGTGGATCGCCAAATTATGCAGCACCGGAGGTCATCTCAGGAAGGCTGTATGC
GGGTCCTGAGGTTGATATCTGGAGCTGTGGTGTTATCCTGTATGCCCTTCTCTGTGGCACCCTC
CCGTTCGACGATGAGCACGTGCCTACGCTCTTTAAGAAGATCCGAGGGGGTGTGTTCTACATC
CCGGAGTATCTCAACCGTTCTATTGCCACTCTGCTGATGCACATGCTGCAGGTGGACCCCTTG
AAGCGAGCAACTATCAAAGACATACGAGAGCATGAATGGTTTAAACAGGATTTGCCCAGTTACC
TCTTTCCTGAAGACCCCTCCTATGATGCTAACGTCATTGATGATGAGGCTGTGAAAGAAGTATG
TGAAAAATTTGAGTGTACAGAATCAGAAGTGATGAACAGTTTATACAGTGGTGACCCTCAAGAC
CAGCTCGCAGTGGCTTATCATCTCATCATTGACAATCGGAGAATAATGAACCAAGCCAGTGAGT
TCTACCTCGCCTCCAGTCCTCCAACGGGTTCCTTCATGGACGATATGGCCATGCACATTCCCCC
CGGCCTGAAACCACATCCTGAAAGGATGCCACCTCTCATAGCAGACAGCCCCAAAGCACGCTG
TCCACTGGATGCACTCAACACAACTAAGCCCAAATCTTTAGCTGTGAAAAAAGCCAAGTGGCAC
CTTGGGATCCGAAGCCAGAGCAAACCATACGACATTATGGCGGAGGTGTACCGAGCTATGAAG
CAGCTGGACTTTGAATGGAAGGTAGTGAATGCATACCATCTTCGAGTAAGAAGAAAAAACCCAG
TGACTGGCAATTACGTGAAAATGAGCTTACAGCTTTACCTGGTTGACAATCGGAGCTATCTTCT
AGACTTTAAAAGCATCGATGATGAGGTGGTGGAGCAGAGGTCTGGTTCTTCAACACCTCAGCG
CTCCTGTTCTGCTGCCGGCCTCCACAGACCTCGGTCAAGTGTCGATTCCAGCACAGCCGAGAA
CCATTCACTGTCTGGCTCTCTCACTGGTTCTTTGACTGGCAGCACTTTGTCCTCCGCTTCCCCG
CGCCTGGGCAGTCATACCATGGATTTTTTTGAAATGTGCGCCAGTCTTATCACTGCTTTAGCCC
GTGGCGGCGATTATAAAGACGACGACGACAAGTGA 
 
Features : 
Start: [1 : 3] 
Linker: [1657 : 1662] 
FLAG: [1663 : 1686] 
Stop: [1687 : 1689] 	  
Translation: [562 aa] 
MAEKQKHDGRVKIGHYVLGDTLGVGTFGKVKIGEHQLTGHKVAVKILNRQKIRSLDVVGKIKREIQN
LKLFRHPHIIKLYQVISTPTDFFMVMEYVSGGELFDYICKHGRVEEVEARRLFQQILSAVDYCHRHMV
VHRDLKPENVLLDAQMNAKIADFGLSNMMSDGEFLRTSCGSPNYAAPEVISGRLYAGPEVDIWSCG
VILYALLCGTLPFDDEHVPTLFKKIRGGVFYIPEYLNRSIATLLMHMLQVDPLKRATIKDIREHEWFKQ
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DLPSYLFPEDPSYDANVIDDEAVKEVCEKFECTESEVMNSLYSGDPQDQLAVAYHLIIDNRRIMNQA
SEFYLASSPPTGSFMDDMAMHIPPGLKPHPERMPPLIADSPKARCPLDALNTTKPKSLAVKKAKWH
LGIRSQSKPYDIMAEVYRAMKQLDFEWKVVNAYHLRVRRKNPVTGNYVKMSLQLYLVDNRSYLLDF
KSIDDEVVEQRSGSSTPQRSCSAAGLHRPRSSVDSSTAENHSLSGSLTGSLTGSTLSSASPRLGSH
TMDFFEMCASLITALARGGDYKDDDDK* 	  
AMPKβ1 (from pcDNA3 vector backbone) 
Gifted by Professor David Carling (MRC Clinical Sciences Centre, Hammersmith 
Hospital Campus, London, UK). 	  
> [AMPKβ1 (rattus norvegicus) 813 bp]  
ATGGGCAATACGAGCAGCGAGCGCGCCGCGCTGGAGCGGCAGGCTGGCCATAAGACGCCGC
GGAGGGACAGCTCGGAGGGCACCAAGGATGGGGACAGGCCCAAGATCCTGATGGACAGCCC
CGAAGACGCCGACATCTTCCACACCGAGGAAATGAAGGCTCCAGAGAAGGAGGAGTTCCTGG
CGTGGCAGCACGACCTCGAGGTGAATGAGAAAGCCCCCGCCCAGGCTCGGCCCACCGTATTT
CGATGGACAGGGGGTGGAAAGGAGGTCTACTTGTCTGGATCCTTCAACAACTGGAGCAAATTG
CCCCTCACTAGAAGCCAAAACAACTTCGTAGCCATCCTGGACCTACCGGAAGGAGAGCATCAG
TACAAGTTCTTTGTGGATGGCCAGTGGACCCACGATCCTTCCGAGCCAATAGTAACCAGCCAG
CTTGGCACAGTTAACAACATCATTCAAGTGAAGAAAACTGACTTTGAAGTATTTGATGCTTTAAT
GGTGGATTCCCAAAAGTGCTCCGATGTATCTGAGCTGTCCAGTTCCCCCCCAGGACCCTACCA
CCAGGAGCCTTACATCTCTAAACCAGAGGAGCGGTTCAAGGCCCCGCCCATCCTCCCGCCTCA
CCTGCTGCAGGTCATCTTGAACAAGGACACGGGCATCTCTTGTGATCCAGCGCTGCTTCCGGA
GCCCAACCACGTCATGCTGAACCACCTCTATGCACTCTCTATCAAGGATGGAGTGATGGTGCT
CAGTGCGACCCATCGGTACAAGAAAAAGTACGTCACCACCCTCCTCTACAAGCCCATATGA 
 
Features: 
Start: [1 : 3] 
Stop: [811 : 813] 	  
Translation: [270 aa] 
MGNTSSERAALERQAGHKTPRRDSSEGTKDGDRPKILMDSPEDADIFHTEEMKAPEKEEFLAWQH
DLEVNEKAPAQARPTVFRWTGGGKEVYLSGSFNNWSKLPLTRSQNNFVAILDLPEGEHQYKFFVD
GQWTHDPSEPIVTSQLGTVNNIIQVKKTDFEVFDALMVDSQKCSDVSELSSSPPGPYHQEPYISKPE
ERFKAPPILPPHLLQVILNKDTGISCDPALLPEPNHVMLNHLYALSIKDGVMVLSATHRYKKKYVTTLL
YKPI* 	  
AMPKγ1-NT-Myc (pcDNA3 vector backbone) 
Gifted by Professor David Carling (MRC Clinical Sciences Centre, Hammersmith 
Hospital Campus, London, UK). 	  
> [AMPKγ1-NT-Myc (rattus norvegicus) 1029 bp]  
ATGGAGCAGAAGCTTATCTCCGAGGAGGACCTCGGTGGCGAGTCGGTTGCTGCAGAGAGCGC
TCCAGCTCCGGAGAATGAACACTCTCAAGAGACCCCGGAATCGAACAGTAGTGTGTACACCAC
CTTCATGAAGTCTCATCGCTGCTATGACCTGATCCCCACAAGCTCCAAGCTGGTGGTATTTGAT
ACTTCGCTGCAGGTAAAGAAAGCCTTCTTTGCCCTGGTGACTAACGGTGTTCGTGCTGCCCCTT
TGTGGGATAGTAAGAAGCAGAGCTTTGTGGGCATGCTGACCATCACTGACTTCATCAATATTCT
GCACCGATACTACAAGTCAGCCCTGGTGCAGATCTATGAACTGGAGGAGCACAAGATAGAGAC
TTGGAGAGAGGTCTACCTGCAAGACTCCTTTAAGCCACTTGTCTGCATTTCTCCAAATGCCAGC
TTGTTCGATGCTGTCTCTTCATTAATTCGAAATAAGATCCACAGGCTTCCAGTTATTGACCCGGA
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GTCAGGCAACACCTTGTACATTCTTACTCACAAGCGGATCCTCAAGTTCCTCAAGTTGTTTATCA
CTGAGTTCCCCAAGCCGGAATTCATGTCTAAGTCTCTGGAAGAGCTACAGATTGGCACCTACG
CCAATATTGCCATGGTCCGTACCACTACACCTGTCTATGTGGCTCTGGGCATCTTTGTACAGCA
CCGAGTCTCCGCCTTGCCTGTGGTGGATGAGAAAGGGCGTGTGGTGGACATCTACTCCAAGTT
TGATGTGATTAATTTGGCAGCAGAAAAGACATACAACAACCTAGATGTGTCTGTGACAAAAGCC
CTACAGCACCGGTCACACTACTTCGAGGGTGTTCTCAAGTGCTACCTACATGAGACTCTAGAAG
CAATCATCAATAGACTGGTGGAAGCAGAGGTTCACCGTCTGGTGGTGGTGGATGAACATGACG
TGGTCAAGGGCATTGTATCGCTGTCTGACATCTTACAGGCTCTGGTGCTCACAGGTGGAGAGA
AGAAGCCCTGA 
 
Features: 
Start: [1 : 3] 
Myc: [4 : 33] 
Linker: [34 : 39] 
Stop: [1027 : 1029] 
 
Translation: [342 aa] 
MEQKLISEEDLGGESVAAESAPAPENEHSQETPESNSSVYTTFMKSHRCYDLIPSSKLVVFDTSLQV
KKAFFALVTNGVRAAPLWDSKKQSFVGMLTITDFINILHRYYKSALVQIYELEEHKIETWREVYLQDS
FKPLVCISPNASLFDAVSSLIRNKIHRLPVIDPESGNTLYILTHKRILKFLKLFITEFPKPEFMSKSLEEL
QIGTYANIAMVRTTTPVYVALGIFVQHRVSALPVVDEKGRVVDIYSKFDVINLAAEKTYNNLDVSVTK
ALQHRSHYFEGVLKCYLHETLEAIINRLVEAEVHRLVVVDEHDVVKGIVSLSDILQALVLTGGEKKP* 
NDI1 (pcDNA5/FRT/T0 vector backbone) 
pWPI-NDI1 vector gifted by Dr. Alberto Sanz (Institute for Cell and Molecular 
Biosciences & Newcastle University Institute for Ageing, Newcastle University, 
Newcastle, UK) (Scialo et al., 2016). 
> [NDI1 (Saccharomyces cerevisiae S288C) 1541 bp]  
ATGCTATCGAAGAATTTGTATAGTAACAAGAGGTTGCTCACCTCGACGAATACGCTAGTCAGAT
TCGCTTCCACCAGATCCACAGGGGTGGAAAACTCCGGAGCAGGTCCTACATCTTTTAAGACCA
TGAAAGTCATTGACCCTCAGCACAGCGACAAACCAAACGTGCTGATACTGGGTTCGGGGTGGG
GAGCTATTTCGTTTTTAAAGCACATTGACACCAAGAAGTACAACGTTTCCATCATCTCTCCTAGA
AGCTATTTCTTATTTACGCCTTTGTTACCTTCTGCACCAGTTGGGACAGTAGACGAAAAGTCAAT
TATTGAGCCCATCGTTAATTTTGCTCTCAAGAAAAAGGGGAACGTTACCTACTATGAGGCAGAA
GCCACCTCTATCAATCCCGACAGGAATACCGTTACCATAAAATCATTATCTGCCGTTAGCCAGC
TATACCAACCTGAAAACCATCTAGGGCTGCATCAAGCAGAACCTGCTGAAATTAAGTACGATTA
TTTAATCAGTGCTGTAGGTGCGGAACCTAACACATTTGGTATTCCTGGGGTCACTGATTACGGT
CATTTCCTGAAGGAAATTCCCAACTCTTTGGAAATAAGAAGAACTTTTGCCGCCAATCTAGAGA
AGGCTAACTTATTGCCAAAGGGTGATCCCGAAAGAAGAAGACTACTGTCCATTGTCGTGGTTG
GTGGTGGGCCTACTGGTGTAGAGGCCGCTGGTGAACTACAGGATTATGTTCACCAGGACCTGA
GAAAGTTTCTCCCTGCATTGGCCGAAGAAGTCCAAATTCACTTGGTCGAAGCTCTGCCCATCGT
TTTGAATATGTTTGAGAAAAAGCTTTCATCATACGCGCAATCACATTTAGAAAACACTTCGATCA
AAGTACATCTGAGAACGGCTGTCGCCAAAGTTGAAGAAAAGCAATTGTTGGCAAAGACCAAACA
CGAAGACGGTAAAATAACCGAAGAAACTATTCCATACGGTACTTTGATTTGGGCCACGGGTAAC
AAGGCAAGACCGGTAATCACTGACCTTTTCAAGAAAATTCCTGAGCAAAACTCGTCCAAGAGAG
GATTGGCAGTGAATGACTTTTTGCAGGTGAAAGGCAGCAACAACATTTTCGCCATTGGTGACAA
TGCATTTGCTGGGTTGCCACCAACCGCCCAAGTAGCGCACCAAGAGGCCGAATATTTGGCCAA
GAATTTTGATAAAATGGCTCAAATACCAAATTTCCAAAAGAATCTATCTTCAAGAAAGGATAAAA
TTGATCTCTTGTTCGAGGAGAACAACTTTAAACCTTTCAAATACAACGATTTAGGTGCCTTAGCA
TACCTGGGATCCGAAAGGGCCATTGCAACCATACGTTCCGGTAAGAGAACATTTTACACCGGT
GGTGGCTTAATGACCTTCTACTTATGGAGAATTTTGTACTTGTCCATGATTCTATCTGCAAGATC
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GAGATTAAAGGTCTTTTTCGACTGGATTAAATTAGCATTTTTCAAAAGAGACTTTTTTAAAGGAT
TATAG 
 
 
Features: 
Start: [1 : 3] 
Stop: [1539 : 1541] 
Primer annealing sites (extension/amplification): [1 : 21] [1541 : 1516] 
 
Translation: [513 aa] 
MLSKNLYSNKRLLTSTNTLVRFASTRSTGVENSGAGPTSFKTMKVIDPQHSDKPNVLILGSGWGAIS
FLKHIDTKKYNVSIISPRSYFLFTPLLPSAPVGTVDEKSIIEPIVNFALKKKGNVTYYEAEATSINPDRN
TVTIKSLSAVSQLYQPENHLGLHQAEPAEIKYDYLISAVGAEPNTFGIPGVTDYGHFLKEIPNSLEIRR
TFAANLEKANLLPKGDPERRRLLSIVVVGGGPTGVEAAGELQDYVHQDLRKFLPALAEEVQIHLVEA
LPIVLNMFEKKLSSYAQSHLENTSIKVHLRTAVAKVEEKQLLAKTKHEDGKITEETIPYGTLIWATGNK
ARPVITDLFKKIPEQNSSKRGLAVNDFLQVKGSNNIFAIGDNAFAGLPPTAQVAHQEAEYLAKNFDK
MAQIPNFQKNLSSRKDKIDLLFEENNFKPFKYNDLGALAYLGSERAIATIRSGKRTFYTGGGLMTFYL
WRILYLSMILSARSRLKVFFDWIKLAFFKRDFFKGL* 	  
AOX (from pcDNA5/FRT/T0 vector) 	  
pWPI-AOX vector gifted by Dr. Alberto Sanz (Institute for Cell and Molecular 
Biosciences & Newcastle University Institute for Ageing, Newcastle University, 
Newcastle, UK) (Scialo et al., 2016). 
> [AOX (Ciona intestinalis) 1110 bp]  
ATGTTGTCTACCGGAAGTAAAACTTTCCTATTTCGACCGTTCCTGGGCTCATGCCATGCACTAC
AAAGTGGAAAACTACCATGTTCAAATCTTCATACAACTCCCACGAAAATCACAGTGAAAAGATAT
TTGGTTGGATATAGTTGGTCAACTCAGCCACATTCCAGATTACTTCATTCATGTCAACAATTAAA
GATAGATGACAAAAATAAATCCGAGCATTTTAAAATTGAAACAAACGATTCAACCGATGAACCCA
ATATAGAAGTGGAAAACTTCCCTCACTTTAGAGAAGCAAAAAAAGCAAAAGAGACACAAAAAGG
AAGCTCTCTTGCTGAAGCTGAGGAGCATCCGGATGTAGAAGAAGGAAGAGCGATGCAAGATGG
AGGGTATAGACTTCCTCATCCTATCTGGCACAAACAAGAATTAGAATCAGTGCGGATATCACAT
AGACCTCCTGTTGGGAAAGTAGACAAATTGGCTTATTACAGTGTACAGTTACTTCGGACTGGCT
TTGATGTTTTTTCTGGTTATACTCTCGGTACCTACACTGGACGGCTAGATGAGAAACAGTGGGT
CAAGAGAATTATATTTTTAGAAACCATTGCTGGTGTACCAGGAATGGTCGGTGCCATGGTTCGT
CACCTGGTTTCCTTACGTAGATTAAAGCGAGACCACGGTTGGATTCACACATTGCTTGAGGAAG
CTGAAAATGAGAGAATGCACTTAATGACTGCGATGAGAATTGCTAACCCTGGTATTATCATGAG
GACGAGTATTGTGGTTGCACAAGGAATCTTTGTGTCTGGATTTTCTTTGGCTTACTTAATCTCAC
CACGATTTTGTCATCGTTTTGTCGGCTATCTGGAAGAGGAAGCAGTTAAGACTTACACGCATTG
TTTAGAAGAACTTGACAGTGGAAACCTAAAAATGTGGTGcCGAATGAAAGCGCCAGAAATTGCT
GTTGAATATTGGAAACTCCCTGACGATGCAATGATGCGAGACGTTATCCTGGCAATCCGAGCT
GATGAAGCACATCACAGATCAGTCAACCATGACTTGGGATCGAGAAAACCAGACGAGCAGAAT
CCTTATCCACCTGGACAATAG 
 
Features : 
Start: [1 : 3] 
Sequencing error in AOX: [939 : 939] (from previous gifted vector) 
Stop: [1108 : 1110] 
Primer annealing sites (extension/amplification): [1 : 21] [1110 : 1089] 
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Translation: [369 aa] 
MLSTGSKTFLFRPFLGSCHALQSGKLPCSNLHTTPTKITVKRYLVGYSWSTQPHSRLLHSCQQLKID
DKNKSEHFKIETNDSTDEPNIEVENFPHFREAKKAKETQKGSSLAEAEEHPDVEEGRAMQDGGYR
LPHPIWHKQELESVRISHRPPVGKVDKLAYYSVQLLRTGFDVFSGYTLGTYTGRLDEKQWVKRIIFL
ETIAGVPGMVGAMVRHLVSLRRLKRDHGWIHTLLEEAENERMHLMTAMRIANPGIIMRTSIVVAQGI
FVSGFSLAYLISPRFCHRFVGYLEEEAVKTYTHCLEELDSGNLKMWCRMKAPEIAVEYWKLPDDAM
MRDVILAIRADEAHHRSVNHDLGSRKPDEQNPYPPGQ* 
pcDNA3 vector backbone 
Thermo Fisher Scientific (Invitrogen): V79020 
>  [5446 bp] 
GACGGATCGGGAGATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTG 
ATGCCGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCG
CGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAG
GGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATCGCGTTGACATTGATTATTGA
CTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTT
ACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCA
ATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGACT
ATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTAT
TGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTT
CCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGT
ACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACG
TCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGC
CCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCT
GGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGAC
CCAAGCTTGGTACCGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATTCTGCAGA
TATCCATCACACTGGCGGCCGCTCGAGCATGCATCTAGAGGGCCCTATTCTATAGTGTCACCTA
AATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCC
CCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGA
GGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGA
CAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGG
CTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGC
GCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCT
AGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAA
GCTCTAAATCGGGGCATCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAA
AACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTT
GACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCT
ATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGGGGATTTCGGCCTATTGGTTAAAAAATGA
GCTGATTTAACAAAAATTTAACGCGAATTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAA
AGTCCCCAGGCTCCCCAGGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACC
AGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAG
TCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCC
CATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCT
CTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCC
GGGAGCTTGTATATCCATTTTCGGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATT
GAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGAC
TGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCG
CCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGC
GCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTG
AAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCAC
CTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGAT
CCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATG
GAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGA
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ACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCG
ATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCG
GCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCT
TGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGC
GCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGAC
CGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAG
GTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCAT
GCTGGAGTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATA
GCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCA
TCAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCA
TAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCA
TAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACT
GCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGG
GGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGG
TCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAAT
CAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAA
AAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGA
CGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGA
AGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTC
CCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTC
GTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCC
GGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACT
GGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCT
AACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCG
GAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGT
TTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACG
GGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAA
GGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGT
AAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTT
CGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCAT
CTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAA
TAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCC
AGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGT
TGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCC
GGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCC
TTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAG
CACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCA
ACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGG
GATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGC
GAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAA
CTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAAT
GCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAAT
ATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAA
AATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTC 
 
 
Features: 
Primer annealing sites (sequencing): [769 : 789] [1053 : 1036] 
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pcDNA5/FRT/T0 vector backbone 
Thermo Fisher Scientific (Invitrogen): V652020 
>  [5137 bp] 
GACGGATCGGGAGATCTCCCGATCCCCTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCG
CATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCA
AAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAG
GCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGT
TATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATA
ACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAAT
GACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTA
CGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACG
TCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTAC
TTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATC
AATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAAT
GGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCAT
TGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCCCTATC
AGTGATAGAGATCTCCCTATCAGTGATAGAGATCGTCGACGAGCTCGTTTAGTGAACCGTCAGA
TCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCC
TCCGGACTCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGATCCACTAGTCCAGTGTGGTG
GAATTCTGCAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGCCCGTTTAAACCCGC
TGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTT
CCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCA
TTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGG
ATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAA
AGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCATTAAGCGCGGC
GGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTT
TCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGG
GCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGT
GATGGTTCACGTACCTAGAAGTTCCTATTCCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTC
CTTGGCCAAAAAGCCTGAACTCACCGCGACGTCTGTCGAGAAGTTTCTGATCGAAAAGTTCGA
CAGCGTCTCCGACCTGATGCAGCTCTCGGAGGGCGAAGAATCTCGTGCTTTCAGCTTCGATGT
AGGAGGGCGTGGATATGTCCTGCGGGTAAATAGCTGCGCCGATGGTTTCTACAAAGATCGTTA
TGTTTATCGGCACTTTGCATCGGCCGCGCTCCCGATTCCGGAAGTGCTTGACATTGGGGAATT
CAGCGAGAGCCTGACCTATTGCATCTCCCGCCGTGCACAGGGTGTCACGTTGCAAGACCTGCC
TGAAACCGAACTGCCCGCTGTTCTGCAGCCGGTCGCGGAGGCCATGGATGCGATCGCTGCGG
CCGATCTTAGCCAGACGAGCGGGTTCGGCCCATTCGGACCGCAAGGAATCGGTCAATACACTA
CATGGCGTGATTTCATATGCGCGATTGCTGATCCCCATGTGTATCACTGGCAAACTGTGATGGA
CGACACCGTCAGTGCGTCCGTCGCGCAGGCTCTCGATGAGCTGATGCTTTGGGCCGAGGACT
GCCCCGAAGTCCGGCACCTCGTGCACGCGGATTTCGGCTCCAACAATGTCCTGACGGACAATG
GCCGCATAACAGCGGTCATTGACTGGAGCGAGGCGATGTTCGGGGATTCCCAATACGAGGTC
GCCAACATCTTCTTCTGGAGGCCGTGGTTGGCTTGTATGGAGCAGCAGACGCGCTACTTCGAG
CGGAGGCATCCGGAGCTTGCAGGATCGCCGCGGCTCCGGGCGTATATGCTCCGCATTGGTCT
TGACCAACTCTATCAGAGCTTGGTTGACGGCAATTTCGATGATGCAGCTTGGGCGCAGGGTCG
ATGCGACGCAATCGTCCGATCCGGAGCCGGGACTGTCGGGCGTACACAAATCGCCCGCAGAA
GCGCGGCCGTCTGGACCGATGGCTGTGTAGAAGTACTCGCCGATAGTGGAAACCGACGCCCC
AGCACTCGTCCGAGGGCAAAGGAATAGCACGTACTACGAGATTTCGATTCCACCGCCGCCTTC
TATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGG
GGATCTCATGCTGGAGTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAAT
AAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGT
CCAAACTCATCAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGGCGTAA
TCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGC
CGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTG
CGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAA
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CGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCT
GCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATC
CACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGA
ACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACA
AAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTC
CCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCG
CCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGT
GTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCG
CCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGC
AGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTG
GTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTT
ACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGT
TTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTT
TTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTA
TCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATA
TATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCT
GTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGG
CTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTT
ATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGC
CTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTG
CGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCAT
TCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGG
TTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGT
TATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGT
GAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCG
TCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTT
CTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCG
TGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGA
AGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTC
CTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGT
ATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTC 
 
Features : 
Primer annealing sites (sequencing): [769 : 789] [1106 : 1089] 	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pWPI vector backbone 	  
Dr. Alberto Sanz (Institute for Cell and Molecular Biosciences & Newcastle 
University Institute for Ageing, Newcastle University, Newcastle, UK).                                    	  
> [11101 bp]  
 
TTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATATCCTTGATCTGTGGATCTACCACACAC
AAGGCTACTTCCCTGATTAGCAGAACTACACACCAGGGCCAGGGGTCAGATATCCACTGACCT
TTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGAGGCCAATAAAGGAG
AGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGGATGGATGACCCGGAGAGAGAAGTGT
TAGAGTGGAGGTTTGACAGCCGCCTAGCATTTCATCACGTGGCCCGAGAGCTGCATCCGGAGT
ACTTCAAGAACTGCTGATATCGAGCTTGCTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGA
GGCGTGGCCTGGGCGGGACTGGGGAGTGGCGAGCCCTCAGATCCTGCATATAAGCAGCTGCT
TTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTA
GGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTC
TGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAG
CAGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAG
GACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCA
AAAATTTTGACTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGG
GGGAGAATTAGATCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAA
TTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAG
AAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAG
AAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAGATA
AAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGACCACCGCA
CAGCAAGCGGCCGCTGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTG
AATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAG
AAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGG
AGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATT
GTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTT
GCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCT
AAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGT
GCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATG
GAGTGGGACAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAA
ACCAGCAAGAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTG
GTTTAACATAACAAATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAG
GTTTAAGAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTA
TCGTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGA
AGGTGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGATG
TCGACGATAAGCTTTGCAAAGATGGATAAAGTTTTAAACAGAGAGGAATCTTTGCAGCTAATGG
ACCTTCTAGGTCTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCAC
ATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAA
GGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGT
GGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGG
CCCTTGCGTGCCTTGAATTACTTCCACTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGG
TTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGA
GTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCT
GTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTT
TTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGG
CCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGC
GAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCT
GGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAG
TTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACG
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CGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTC
AGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTC
GAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCA
CACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTT
GCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCT
TCCATTTCAGGTGTCGTGAGGAATTTCGACATTTAAATTTAATTAATCTCGACGGTATCGGTTAA
CTTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAG
CAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCCGATCACG
AGACTAGCCTCGAGGTTTAAACTACGGGCTGCAGGAATTCCGCCCCCCCCCCCCTAACGTTAC
TGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTG
CCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGG
GGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCT
CTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCA
CCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGC
ACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAG
CGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGG
GCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAACGTCTAGGCCCCCCGAACC
ACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAATACCATGGTGAGCAAGGGCGAGGAG
CTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT
CAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCT
GCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTG
CAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCC
GAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGC
CGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCA
AGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATA
TCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGG
ACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTG
CTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAA
GCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACG
AGCTGTACAAGTCCGGACTCAGATCTCGACTAGCTAGTAGCTAGCTAGCTAGTCGAGCTCAAC
TTCGAATTCGATATCAAGCTTATCGCGATACCGTCGACCTCGAGGGAATTCCGATAATCAACCT
CTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATG
TGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCT
CCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGG
CGTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCA
GCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTG
CCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGG
GGAAGCTGACGTCCTTTCCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGT
CCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGG
CTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCG
CCTCCCCGCATCGGGAATTCGCTCAAGCTTCGAATTAATTCTGCAGAGCTCGGTACCTTTAAGA
CCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAG
GGCTAATTCACTCCCAACGAAGACAAGATGGGATCAATTCACCATGGGAATAACTTCGTATAGC
ATACATTATACGAAGTTATGCTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTAGACCAGATCTGA
GCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGA
GTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCT
TTTAGTCAGTGTGGAAAATCTCTAGCAGCATCTAGAATTAATTCCGTGTATTCTATAGTGTCACC
TAAATCGTATGTGTATGATACATAAGGTTATGTATTAATTGTAGCCGCGTTCTAACGACAATATG
TACAAGCCTAATTGTGTAGCATCTGGCTTACTGAAGCAGACCCTATCATCTCTCTCGTAAACTG
CCGTCAGAGTCGGTTTGGTTGGACGAACCTTCTGAGTTTCTGGTAACGCCGTCCCGCACCCGG
AAATGGTCAGCGAACCAATCAGCAGGGTCATCGCTAGCCAGATCCTCTACGCCGGACGCATCG
TGGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTGGCGCCTATATCGCCGACATCACCGAT
GGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTTCGGCGTGGGTATGGTGGC
AGGCCCCGTGGCCGGGGGACTGTTGGGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGG
CGGTGCTCAACGGCCTCAACCTACTACTGGGCTGCTTCCTAATGCAGGAGTCGCATAAGGGAG
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AGCGTCGAATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGA
CACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAG
ACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACG
CGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTT
TCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCT
AAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGA
AAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTG
CCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGT
GCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCC
GAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTA
TTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGT
ACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGC
CATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGA
GCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGA
GCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAAC
GTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGG
ATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATT
GCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGA
TGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACG
AAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTT
TACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATC
CTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCC
CGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAA
CAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCC
GAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTA
GGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAG
TGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGG
ATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAAC
GACCTACACCGAACTGAGATACCTACAGCGTGAGCATTGAGAAAGCGCCACGCTTCCCGAAGG
GAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAG
CTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAG
CGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGC
CTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTG
ATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGA
CCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTC
CCCGCGCGTTGGCCGATTCATTAATGCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGT
CCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGT
GTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAG
CAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATT
CTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGA
GCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTGGACAC
AAGACAGGCTTGCGAGATATGTTTGAGAATACCACTTTATCCCGCGTCAGGGAGAGGCAGTGC
GTAAAAAGACGCGGACTCATGTGAAATACTGGTTTTTAGTGCGCCAGATCTCTATAATCTCGCG
CAACCTATTTTCCCCTCGAACACTTTTTAAGCCGTAGATAAACAGGCTGGGACACTTCACATGA
GCGAAAAATACATCGTCACCTGGGACATGTTGCAGATCCATGCACGTAAACTCGCAAGCCGAC
TGATGCCTTCTGAACAATGGAAAGGCATTATTGCCGTAAGCCGTGGCGGTCTGTACCGGGTGC
GTTACTGGCGCGTGAACTGGGTATTCGTCATGTCGATACCGTTTGTATTTCCAGCTACGATCAC
GACAACCAGCGCGAGCTTAAAGTGCTGAAACGCGCAGAAGGCGATGGCGAAGGCTTCATCGT
TATTGATGACCTGGTGGATACCGGTGGTACTGCGGTTGCGATTCGTGAAATGTATCCAAAAGC
GCACTTTGTCACCATCTTCGCAAAACCGGCTGGTCGTCCGCTGGTTGATGACTATGTTGTTGAT
ATCCCGCAAGATACCTGGATTGAACAGCCGTGGGATATGGGCGTCGTATTCGTCCCGCCAATC
TCCGGTCGCTAATCTTTTCAACGCCTGGCACTGCCGGGCGTTGTTCTTTTTAACTTCAGGCGGG
TTACAATAGTTTCCAGTAAGTATTCTGGAGGCTGCATCCATGACACAGGCAAACCTGAGCGAAA
CCCTGTTCAAACCCCGCTTTAAACATCCTGAAACCTCGACGCTAGTCCGCCGCTTTAATCACGG
CGCACAACCGCCTGTGCAGTCGGCCCTTGATGGTAAAACCATCCCTCACTGGTATCGCATGAT
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TAACCGTCTGATGTGGATCTGGCGCGGCATTGACCCACGCGAAATCCTCGACGTCCAGGCACG
TATTGTGATGAGCGATGCCGAACGTACCGACGATGATTTATACGATACGGTGATTGGCTACCGT
GGCGGCAACTGGATTTATGAGTGGGCCCCGGATCTTTGTGAAGGAACCTTACTTCTGTGGTGT
GACATAATTGGACAAACTACCTACAGAGATTTAAAGCTCTAAGGTAAATATAAAATTTTTAAGTG
TATAATGTGTTAAACTACTGATTCTAATTGTTTGTGTATTTTAGATTCCAACCTATGGAACTGATG
AATGGGAGCAGTGGTGGAATGCCTTTAATGAGGAAAACCTGTTTTGCTCAGAAGAAATGCCATC
TAGTGATGATGAGGCTACTGCTGACTCTCAACATTCTACTCCTCCAAAAAAGAAGAGAAAGGTA
GAAGACCCCAAGGACTTTCCTTCAGAATTGCTAAGTTTTTTGAGTCATGCTGTGTTTAGTAATAG
AACTCTTGCTTGCTTTGCTATTTACACCACAAAGGAAAAAGCTGCACTGCTATACAAGAAAATTA
TGGAAAAATATTCTGTAACCTTTATAAGTAGGCATAACAGTTATAATCATAACATACTGTTTTTTC
TTACTCCACACAGGCATAGAGTGTCTGCTATTAATAACTATGCTCAAAAATTGTGTACCTTTAGC
TTTTTAATTTGTAAAGGGGTTAATAAGGAATATTTGATGTATAGTGCCTTGACTAGAGATCATAAT
CAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAAC
CTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAA
TAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTG
TCCAAACTCATCAATGTATCTTATCATGTCTGGATCAACTGGATAACTCAAGCTAACCAAAATCA
TCCCAAACTTCCCACCCCATACCCTATTACCACTGCCAATTACCTAGTGGTTTCATTTACTCTAA
ACCTGTGATTCCTCTGAATTATTTTCATTTTAAAGAAATTGTATTTGTTAAATATGTACTACAAAC
TTAGTAG 
 
pOG44 vector  	  
Thermo Fisher Scientific (Invitrogen): V600520 	  >[5785	  bp]	  
 
CCGCGGTCTTTCGGACTTTTGAAAGTGATGGTGGTGGGGGAAGGATTCGAACCTTCGAAGTCG
ATGACGGCAGATTTAGAGTCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAG
CAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTT
AGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTA
GTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACA
TAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATA
ATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATT
TACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGA
CGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCT
ACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACA
TCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCA
ATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCC
ATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCT
AACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAA
GCTTCTAGAATTCGCTGTCTGCGAGGGCCAGCTGTTGGGGTGAGTACTCCCTCTCAAAAGCGG
GCATGACTTCTGCGCTAAGATTGTCAGTTTCCAAAAACGAGGAGGATTTGATATTCACCTGGCC
CGCGGTGATGCCTTTGAGGGTGGCCGCGTCCATCTGGTCAGAAAAGACAATCTTTTTGTTGTC
AAGCTTGAGGTGTGGCAGGCTTGAGATCTGGCCATACACTTGAGTGACAATGACATCCACTTT
GCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACTGCAGCCCAAGCTTCCACCATGCCAC
AATTTGATATATTATGTAAAACACCACCTAAGGTGCTTGTTCGTCAGTTTGTGGAAAGGTTTGAA
AGACCTTCAGGTGAGAAAATAGCATTATGTGCTGCTGAACTAACCTATTTATGTTGGATGATTAC
ACATAACGGAACAGCAATCAAGAGAGCCACATTCATGAGCTATAATACTATCATAAGCAATTCG
CTGAGTTTGGATATTGTCAACAAGTCACTGCAGTTTAAATACAAGACGCAAAAAGCAACAATTCT
GGAAGCCTCATTAAAGAAATTGATTCCTGCTTGGGAATTTACAATTATTCCTTACTATGGACAAA
AACATCAATCTGATATCACTGATATTGTAAGTAGTTTGCAATTACAGTTCGAATCATCGGAAGAA
GCAGATAAGGGAAATAGCCACAGTAAAAAAATGCTTAAAGCACTTCTAAGTGAGGGTGAAAGCA
TCTGGGAGATCACTGAGAAAATACTAAATTCGTTTGAGTATACTTCGAGATTTACAAAAACAAAA
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ACTTTATACCAATTCCTCTTCCTAGCTACTTTCATCAATTGTGGAAGATTCAGCGATATTAAGAA
CGTTGATCCGAAATCATTTAAATTAGTCCAAAATAAGTATCTGGGAGTAATAATCCAGTGTTTAG
TGACAGAGACAAAGACAAGCGTTAGTAGGCACATATACTTCTTTAGCGCAAGGGGTAGGATCG
ATCCACTTGTATATTTGGATGAATTTTTGAGGAATTCTGAACCAGTCCTAAAACGAGTAAATAGG
ACCGGCAATTCTTCAAGCAACAAGCAGGAATACCAATTATTAAAAGATAACTTAGTCAGATCGTA
CAACAAAGCTTTGAAGAAAAATGCGCCTTATTCAATCTTTGCTATAAAAAATGGCCCAAAATCTC
ACATTGGAAGACATTTGATGACCTCATTTCTTTCAATGAAGGGCCTAACGGAGTTGACTAATGTT
GTGGGAAATTGGAGCGATAAGCGTGCTTCTGCCGTGGCCAGGACAACGTATACTCATCAGATA
ACAGCAATACCTGATCACTACTTCGCACTAGTTTCTCGGTACTATGCATATGATCCAATATCAAA
GGAAATGATAGCATTGAAGGATGAGACTAATCCAATTGAGGAGTGGCAGCATATAGAACAGCTA
AAGGGTAGTGCTGAAGGAAGCATACGATACCCCGCATGGAATGGGATAATATCACAGGAGGTA
CTAGACTACCTTTCATCCTACATAAATAGACGCATATAAGTACGCATTTAAGCATAAACACGCAC
TATGCCGTTCTTCTCATGTATATATATATACAGGCAACACGCAGATATAGGTGCGACGTGAACA
GTGAGCTGTATGTGCGGGTACCGAGCTCCTCGAGGATCAGACATGATAAGATACATTGATGAG
TTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTAT
TGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTATCCTCGAGGAGCTCATGAGCGCTT
GTTTCGGCGTGGGTATGGTGGCAGGCCCGTGGCCGGGGGACTGTTGGGCGCCATCTCCTTGC
ATGCACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTCAACCTACTACTGGGCTGCTTCCTAA
TGCAGGAGTCGCATAAGGGAGAGCGTCGACCTCGAGGGGGGGCCCGGTACCCAGCTTTTGTT
CCCTTTAGTGAGGGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAA
TTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGGAGCATAAAGTGTAAAGCCTGGGG
TGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGA
AACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATT
GGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGC
GGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAA
GAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGT
TTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGC
GAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTC
CTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCTTCGGGAAGCGTGGCGCTT
TCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGT
GTGCACGAACCCCCCGTTCAGCCCGACCCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCA
ACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGA
GGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAA
CAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACTTCGGAAAAAGAGTTGGTAGCTCTTGA
TCCGGCAAACAAACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGA
AAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAA
ACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAAT
TAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATG
CTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCC
CCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATAC
CGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCC
GAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAG
CTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGT
GGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGT
TACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGA
AGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCA
TGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTG
TATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAG
AACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCG
CTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTT
CACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGC
GACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTA
TTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCA
CATTTCCCCGAAAAGTGCCACTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTT
TGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGA
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ATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTG
GACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCA
CCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGC
CCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGC
GAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACAC
CCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCATTCGCCATTCAGGCTGCGCAACTGTT
GGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCT
GCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCC
AGTGAGCGCGCGTAATACGACTCACTATAGGGCGAATTGGAGCTCCA  	  
pLPCX mito roGFP2-Orp1 	  
Dr. Tobias P. Dick (Redox Regulation (A160), Deutsches Krebsforschungszentrum, 
Im Neuenheimer Feld 280, 69120 Heidelberg) via Addgene (plasmid # 64992) 
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TTTGAAAGACCCCACCCGTAGGTGGCAAGCTAGCTTAAGTAACGCCACTTTGCAAGGCATGGA
AAAATACATAACTGAGAATAGAAAAGTTCAGATCAAGGTCAGGAACAAAGAAACAGCTGAATAC
CAAACAGGATATCTGTGGTAAGCGGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGAGACAG
CTGAGTGATGGGCCAAACAGGATATCTGTGGTAAGCAGTTCCTGCCCCGGCTCGGGGCCAAG
AACAGATGGTCCCCAGATGCGGTCCAGCCCTCAGCAGTTTCTAGTGAATCATCAGATGTTTCCA
GGGTGCCCCAAGGACCTGAAAATGACCCTGTACCTTATTTGAACTAACCAATCAGTTCGCTTCT
CGCTTCTGTTCGCGCGCTTCCGCTCTCCGAGCTCAATAAAAGAGCCCACAACCCCTCACTCGG
CGCGCCAGTCTTCCGATAGACTGCGTCGCCCGGGTACCCGTATTCCCAATAAAGCCTCTTGCT
GTTTGCATCCGAATCGTGGTCTCGCTGTTCCTTGGGAGGGTCTCCTCTGAGTGATTGACTACCC
ACGACGGGGGTCTTTCATTTGGGGGCTCGTCCGGGATTTGGAGACCCCTGCCCAGGGACCAC
CGACCCACCACCGGGAGGTAAGCTGGCCAGCAACTTATCTGTGTCTGTCCGATTGTCTAGTGT
CTATGTTTGATGTTATGCGCCTGCGTCTGTACTAGTTAGCTAACTAGCTCTGTATCTGGCGGAC
CCGTGGTGGAACTGACGAGTTCTGAACACCCGGCCGCAACCCTGGGAGACGTCCCAGGGACT
TTGGGGGCCGTTTTTGTGGCCCGACCTGAGGAAGGGAGTCGATGTGGAATCCGACCCCGTCA
GGATATGTGGTTCTGGTAGGAGACGAGAACCTAAAACAGTTCCCGCCTCCGTCTGAATTTTTGC
TTTCGGTTTGGAACCGAAGCCGCGCGTCTTGTCTGCTGCAGCGCTGCAGCATCGTTCTGTGTT
GTCTCTGTCTGACTGTGTTTCTGTATTTGTCTGAAAATTAGGGCCAGACTGTTACCACTCCCTTA
AGTTTGACCTTAGGTCACTGGAAAGATGTCGAGCGGATCGCTCACAACCAGTCGGTAGATGTC
AAGAAGAGACGTTGGGTTACCTTCTGCTCTGCAGAATGGCCAACCTTTAACGTCGGATGGCCG
CGAGACGGCACCTTTAACCGAGACCTCATCACCCAGGTTAAGATCAAGGTCTTTTCACCTGGC
CCGCATGGACACCCAGACCAGGTCCCCTACATCGTGACCTGGGAAGCCTTGGCTTTTGACCCC
CCTCCCTGGGTCAAGCCCTTTGTACACCCTAAGCCTCCGCCTCCTCTTCCTCCATCCGCCCCG
TCTCTCCCCCTTGAACCTCCTCGTTCGACCCCGCCTCGATCCTCCCTTTATCCAGCCCTCACTC
CTTCTCTAGGCGCCGGAATTGATCCCCCGGGCTGCAGGTCGGCCGCCACGACCGGTGCCGCC
ACCATCCCCTGACCCACGCCCCTGACCCCTCACAAGGAGACGACCTTCCATGACCGAGTACAA
GCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCCGGGCCGTACGCACCCTCGCCGCC
GCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGACCCGGACCGCCACATCGAGCGGGT
CACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTGTGGGTCG
CGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGCGGGGGCGG
TGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCCGCGCAGCAA
CAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTCCTGGCCACCG
TCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGCCGTCGTGCTCCCCGGAGT
GGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGCGCCCCGCAACCTC
CCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGAGTGCCCGAAGGACCGCGC
GACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACGCCCGCCCCACGACCCGCAGCGCCCG
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ACCGAAAGGAGCGCACGACCCCATGGCTCCGACCGAAGCCGACCCGGGCGGCCCCGCCGAC
CCCGCACCCGCCCCCGAGGCCCACCGACTCTAGTAATAGTAATCAATTACGGGGTCATTAGTT
CATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCG
CCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGG
ACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAG
TGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTA
TGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCT
ATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGG
GGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGG
ACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGT
GGGAGGTCTATATAAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGCTACCGGACTC
AGATCTCGAGATGGCCTCCACTCGTGTCCTCGCCTCTCGCCTGGCCTCCCAGATGGCTGCTTC
CGCCAAGGTTGCCCGCCCTGCTGTCCGCGTTGCTCAGGTCAGCAAGCGCACCATCCAGACTG
GCTCCCCCCTCCAGACCCTCAAGCGCACCCAGATGACCTCCATCGTCAACGCCACCACCCGCC
AGGCTTTCCAGAAGCGCGCCTACTCTTCCGGATCCGTGAGCAAGGGCGAGGAGCTGTTCACC
GGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTC
CGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTCCACCACCG
GCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTC
AGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTAC
GTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAA
GTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACG
GCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACTGCCACAACGTCTATATCATGGCCG
ACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGC
GTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCC
CGACAACCACTACCTGAGCACCTGCTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATC
ACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTAC
AAGACTAGTGGTGGTTCAGGTGGTGGTGGTTCAGGTGGTGGTGGTTCAGGTGGAGGAGGATC
AGGAGGAGGAGGATCAGGAGGAGGAGGATCAGGAGGAGAATTCGATATCTCAGAATTCTATAA
GCTAGCACCTGTTGACAAGAAAGGCCAACCATTCCCCTTCGACCAATTAAAGGGAAAAGTGGT
GCTTATCGTTAATGTTGCCTCCAAATGTGGATTCACTCCTCAATACAAAGAACTAGAGGCCTTGT
ACAAACGTTATAAGGACGAAGGATTTACCATCATCGGGTTCCCATGCAACCAGTTTGGCCACCA
AGAACCTGGCTCTGATGAAGAAATTGCCCAGTTCTGCCAACTGAACTATGGCGTGACTTTCCCC
ATTATGAAAAAAATTGACGTTAATGGTGGCAATGAGGACCCTGTTTACAAGTTTTTGAAGAGCC
AAAAATCCGGTATGTTGGGCTTGAGAGGTATCAAATGGAATTTTGAAAAATTCTTAGTCGATAAA
AAGGGTAAAGTGTACGAAAGATACTCTTCACTAACCAAACCTTCTTCGTTGTCCGAAACCATCG
AAGAACTTTTGAAAGAGGTGGAATAGATCGATAAAATAAAAGATTTTATTTAGTCTCCAGAAAAA
GGGGGGAATGAAAGACCCCACCTGTAGGTTTGGCAAGCTAGCTTAAGTAACGCCATTTTGCAA
GGCATGGAAAAATACATAACTGAGAATAGAGAAGTTCAGATCAAGGTCAGGAACAGATGGAAC
AGCTGAATATGGGCCAAACAGGATATCTGTGGTAAGCAGTTCCTGCCCCGGCTCAGGGCCAAG
AACAGATGGAACAGCTGAATATGGGCCAAACAGGATATCTGTGGTAAGCAGTTCCTGCCCCGG
CTCAGGGCCAAGAACAGATGGTCCCCAGATGCGGTCCAGCCCTCAGCAGTTTCTAGAGAACCA
TCAGATGTTTCCAGGGTGCCCCAAGGACCTGAAATGACCCTGTGCCTTATTTGAACTAACCAAT
CAGTTCGCTTCTCGCTTCTGTTCGCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCACAAC
CCCTCACTCGGGGCGCCAGTCCTCCGATTGACTGAGTCGCCCGGGTACCCGTGTATCCAATAA
ACCCTCTTGCAGTTGCATCCGACTTGTGGTCTCGCTGTTCCTTGGGAGGGTCTCCTCTGAGTG
ATTGACTACCCGTCAGCGGGGGTCTTTCATTTGGGGGCTCGTCCGGGATCGGGAGACCCCTG
CCCAGGGACCACCGACCCACCACCGGGAGGTAAGCTGGCTGCCTCGCGCGTTTCGGTGATGA
CGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGC
CGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCGCAGCC
ATGACCCAGTCACGTAGCGATAGCGGAGTGTACTGATAACTTCGTATAATGTATGCTATACGAA
GTTATTAGGTCTGAAGAGGAGTTTACGTCCAGCCAAGCTAGGGCCGCGATCCGGAACCCTTAA
TATAACTTCGTATAATGTATGCTATACGAAGTTATCAGTACTGGCTTAACTATGCGGCATCAGAG
CAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAA
TACCGCATCAGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTG
CGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAAC
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GCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTT
GCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCA
GAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGT
GCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAG
CGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAA
GCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCG
TCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGAT
TAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTA
CACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTT
GGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAG
CAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACG
CTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCAC
CTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTC
TGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCA
TAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCA
GTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGC
CAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTA
ATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCAT
TGCTGCAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCA
ACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCT
CCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATA
ATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCA
TTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAACACGGGATAATACC
GCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCT
CAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTC
AGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAA
AAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAG
CATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAA
TAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCAT
GACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAAGAATTGCTAGCAATT
GCTAGCAATTGCTAGCAATTCATACCAGATCACCGAAAACTGTCCTCCAAATGTGTCCCCCTCA
CACTCCCAAATTCGCGGGCTTCTGCCTCTTAGACCACTCTACCCTATTCCCCACACTCACCGGA
GCCAAAGCCGCGGCCCTTCCGTTTCTTTGCT 
pLPCX cyto roGFP2-Orp1 
Dr. Tobias P. Dick (Redox Regulation (A160), Deutsches Krebsforschungszentrum, 
Im Neuenheimer Feld 280, 69120 Heidelberg) via Addgene (plasmid # 
64991)(Gutscher et al., 2009). 
> [7518 bp] 
TTTGAAAGACCCCACCCGTAGGTGGCAAGCTAGCTTAAGTAACGCCACTTTGCAAGGCATGGA
AAAATACATAACTGAGAATAGAAAAGTTCAGATCAAGGTCAGGAACAAAGAAACAGCTGAATAC
CAAACAGGATATCTGTGGTAAGCGGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGAGACAG
CTGAGTGATGGGCCAAACAGGATATCTGTGGTAAGCAGTTCCTGCCCCGGCTCGGGGCCAAG
AACAGATGGTCCCCAGATGCGGTCCAGCCCTCAGCAGTTTCTAGTGAATCATCAGATGTTTCCA
GGGTGCCCCAAGGACCTGAAAATGACCCTGTACCTTATTTGAACTAACCAATCAGTTCGCTTCT
CGCTTCTGTTCGCGCGCTTCCGCTCTCCGAGCTCAATAAAAGAGCCCACAACCCCTCACTCGG
CGCGCCAGTCTTCCGATAGACTGCGTCGCCCGGGTACCCGTATTCCCAATAAAGCCTCTTGCT
GTTTGCATCCGAATCGTGGTCTCGCTGTTCCTTGGGAGGGTCTCCTCTGAGTGATTGACTACCC
ACGACGGGGGTCTTTCATTTGGGGGCTCGTCCGGGATTTGGAGACCCCTGCCCAGGGACCAC
CGACCCACCACCGGGAGGTAAGCTGGCCAGCAACTTATCTGTGTCTGTCCGATTGTCTAGTGT
CTATGTTTGATGTTATGCGCCTGCGTCTGTACTAGTTAGCTAACTAGCTCTGTATCTGGCGGAC
CCGTGGTGGAACTGACGAGTTCTGAACACCCGGCCGCAACCCTGGGAGACGTCCCAGGGACT
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TTGGGGGCCGTTTTTGTGGCCCGACCTGAGGAAGGGAGTCGATGTGGAATCCGACCCCGTCA
GGATATGTGGTTCTGGTAGGAGACGAGAACCTAAAACAGTTCCCGCCTCCGTCTGAATTTTTGC
TTTCGGTTTGGAACCGAAGCCGCGCGTCTTGTCTGCTGCAGCGCTGCAGCATCGTTCTGTGTT
GTCTCTGTCTGACTGTGTTTCTGTATTTGTCTGAAAATTAGGGCCAGACTGTTACCACTCCCTTA
AGTTTGACCTTAGGTCACTGGAAAGATGTCGAGCGGATCGCTCACAACCAGTCGGTAGATGTC
AAGAAGAGACGTTGGGTTACCTTCTGCTCTGCAGAATGGCCAACCTTTAACGTCGGATGGCCG
CGAGACGGCACCTTTAACCGAGACCTCATCACCCAGGTTAAGATCAAGGTCTTTTCACCTGGC
CCGCATGGACACCCAGACCAGGTCCCCTACATCGTGACCTGGGAAGCCTTGGCTTTTGACCCC
CCTCCCTGGGTCAAGCCCTTTGTACACCCTAAGCCTCCGCCTCCTCTTCCTCCATCCGCCCCG
TCTCTCCCCCTTGAACCTCCTCGTTCGACCCCGCCTCGATCCTCCCTTTATCCAGCCCTCACTC
CTTCTCTAGGCGCCGGAATTGATCCCCCGGGCTGCAGGTCGGCCGCCACGACCGGTGCCGCC
ACCATCCCCTGACCCACGCCCCTGACCCCTCACAAGGAGACGACCTTCCATGACCGAGTACAA
GCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCCGGGCCGTACGCACCCTCGCCGCC
GCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGACCCGGACCGCCACATCGAGCGGGT
CACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTGTGGGTCG
CGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGCGGGGGCGG
TGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCCGCGCAGCAA
CAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTCCTGGCCACCG
TCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGCCGTCGTGCTCCCCGGAGT
GGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGCGCCCCGCAACCTC
CCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGAGTGCCCGAAGGACCGCGC
GACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACGCCCGCCCCACGACCCGCAGCGCCCG
ACCGAAAGGAGCGCACGACCCCATGGCTCCGACCGAAGCCGACCCGGGCGGCCCCGCCGAC
CCCGCACCCGCCCCCGAGGCCCACCGACTCTAGTAATAGTAATCAATTACGGGGTCATTAGTT
CATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCG
CCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGG
ACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAG
TGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTA
TGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCT
ATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGG
GGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGG
ACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGT
GGGAGGTCTATATAAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGCTACCGGACTC
AGATCTCGAGATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCG
AGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGC
CACCTACGGCAAGCTGACCCTGAAGTTCATCTCCACCACCGGCAAGCTGCCCGTGCCCTGGCC
CACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAA
GCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTT
CAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGA
ACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTG
GAGTACAACTACAACTGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAG
GTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCA
GCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCT
GCTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTG
ACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGACTAGTGGTGGTTCAGGTGG
TGGTGGTTCAGGTGGTGGTGGTTCAGGTGGAGGAGGATCAGGAGGAGGAGGATCAGGAGGA
GGAGGATCAGGAGGAGAATTCGATATCTCAGAATTCTATAAGCTAGCACCTGTTGACAAGAAAG
GCCAACCATTCCCCTTCGACCAATTAAAGGGAAAAGTGGTGCTTATCGTTAATGTTGCCTCCAA
ATGTGGATTCACTCCTCAATACAAAGAACTAGAGGCCTTGTACAAACGTTATAAGGACGAAGGA
TTTACCATCATCGGGTTCCCATGCAACCAGTTTGGCCACCAAGAACCTGGCTCTGATGAAGAAA
TTGCCCAGTTCTGCCAACTGAACTATGGCGTGACTTTCCCCATTATGAAAAAAATTGACGTTAAT
GGTGGCAATGAGGACCCTGTTTACAAGTTTTTGAAGAGCCAAAAATCCGGTATGTTGGGCTTGA
GAGGTATCAAATGGAATTTTGAAAAATTCTTAGTCGATAAAAAGGGTAAAGTGTACGAAAGATAC
TCTTCACTAACCAAACCTTCTTCGTTGTCCGAAACCATCGAAGAACTTTTGAAAGAGGTGGAAT
AGATCGATAAAATAAAAGATTTTATTTAGTCTCCAGAAAAAGGGGGGAATGAAAGACCCCACCT
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GTAGGTTTGGCAAGCTAGCTTAAGTAACGCCATTTTGCAAGGCATGGAAAAATACATAACTGAG
AATAGAGAAGTTCAGATCAAGGTCAGGAACAGATGGAACAGCTGAATATGGGCCAAACAGGAT
ATCTGTGGTAAGCAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGAACAGCTGAATATGG
GCCAAACAGGATATCTGTGGTAAGCAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGTCC
CCAGATGCGGTCCAGCCCTCAGCAGTTTCTAGAGAACCATCAGATGTTTCCAGGGTGCCCCAA
GGACCTGAAATGACCCTGTGCCTTATTTGAACTAACCAATCAGTTCGCTTCTCGCTTCTGTTCG
CGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCACAACCCCTCACTCGGGGCGCCAGTCCT
CCGATTGACTGAGTCGCCCGGGTACCCGTGTATCCAATAAACCCTCTTGCAGTTGCATCCGAC
TTGTGGTCTCGCTGTTCCTTGGGAGGGTCTCCTCTGAGTGATTGACTACCCGTCAGCGGGGGT
CTTTCATTTGGGGGCTCGTCCGGGATCGGGAGACCCCTGCCCAGGGACCACCGACCCACCAC
CGGGAGGTAAGCTGGCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGC
AGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAG
GGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCGCAGCCATGACCCAGTCACGTAGCGATA
GCGGAGTGTACTGATAACTTCGTATAATGTATGCTATACGAAGTTATTAGGTCTGAAGAGGAGT
TTACGTCCAGCCAAGCTAGGGCCGCGATCCGGAACCCTTAATATAACTTCGTATAATGTATGCT
ATACGAAGTTATCAGTACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACC
ATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCTCTTCCG
CTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACT
CAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAA
AAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCC
GCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGA
CTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTG
CCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCA
CGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCC
CCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGA
CACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGC
GGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGT
ATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAC
AAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAG
GATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACG
TTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAAT
GAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATC
AGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCG
TGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAG
ACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGC
AGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAG
TAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTGCAGGCATCGTGGTGTC
ACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGA
TCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGT
TGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATC
CGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGG
CGACCGAGTTGCTCTTGCCCGGCGTCAACACGGGATAATACCGCGCCACATAGCAGAACTTTA
AAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGA
GATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAG
CGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACAC
GGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTC
TCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTT
CCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAG
GCGTATCACGAGGCCCTTTCGTCTTCAAGAATTGCTAGCAATTGCTAGCAATTGCTAGCAATTC
ATACCAGATCACCGAAAACTGTCCTCCAAATGTGTCCCCCTCACACTCCCAAATTCGCGGGCTT
CTGCCTCTTAGACCACTCTACCCTATTCCCCACACTCACCGGAGCCAAAGCCGCGGCCCTTCC
GTTTCTTTGCT 	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Appendix B. Primer sequences 
 
Sequencing primers 
Gene of 
interest 
Plasmid Forward sequencing primer 
(5’ – 3’) 
Reverse sequencing primer 
(5’ – 3’) 
AMPKα2-
CT-FLAG 
pcDNA3 CMV-F: 
CGCAAATGGGCGGTAGGCGTGT 
BGH-R: 
TAGAAGGCACAGTCGAGG 
AMPKβ1  
 
pcDNA3 CMV-F: 
CGCAAATGGGCGGTAGGCGTGT 
BGH-R: 
TAGAAGGCACAGTCGAGG 
AMPKγ1-
NT-Myc 
pcDNA3 CMV-F: 
CGCAAATGGGCGGTAGGCGTGT 
BGH-R: 
TAGAAGGCACAGTCGAGG 
NDI1 pcDNA5/
FRT/T0 
CMV-F: 
CGCAAATGGGCGGTAGGCGTGT 
BGH-R: 
TAGAAGGCACAGTCGAGG 
AOX pcDNA5/
FRT/T0 
CMV-F: 
CGCAAATGGGCGGTAGGCGTGT 
BGH-R: 
TAGAAGGCACAGTCGAGG 
 
Extension/Amplification primers 
Gene 
of 
interest 
Plasmid Forward primer 
(5’ – 3’) 
Reverse primer 
(5’ – 3’) 
NDI1 pWPI TTA ATC GGT ACC GCC ACC 
ATG CTA TCG AAG AAT TTG 
TAT 
 
Description: 
5’-Flank-KpnI-Kozak-Start-NDI1-3’ 
CG GGT AGC GGC GCG CTA TAA 
TCC TTT AAA AAA GTC TCT T 
 
Description: 
5’-Flank-NotI-Stop-NDI1-3’ 
AOX pWPI GTC ACC GGA TCC GCC ACC 
ATG TTG TCT ACC GGA AGT 
AAA 
 
Description: 
5’-Flank-BamHI-Kozak-Start-
AOX-3’ 
CG GGT CTC GAG TGT CTA TTG TCC 
AGG TGG ATA AGG 
 
Description: 
5’-Flank-Xho1-linker-Stop-AOX-3’ 
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